

[illegible]

risks, uncertainties and assumptions relating to our business, results of operations, industry and future growth. Given these uncertainties, you should not place undue reliance on these forward-looking statements. No forward-looking statement is a guarantee of future performance. You should read this Quarterly Report on Form 10-Q and the documents that we reference herein and have filed with the SEC as exhibits thereto completely and with the understanding that our actual future results may be materially different from any future results expressed or implied by these forward-looking statements. Except as required by law, we assume no, and specifically decline any, obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future. This Quarterly Report on Form 10-Q also contains or may contain estimates, projections and other information concerning our industry, our business and the markets for certain therapeutics, including data regarding the estimated size of those markets, their projected growth rates and the incidence of certain medical conditions. Information that is based on estimates, forecasts, projections or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained these industry, business, market and other data from reports, research surveys, studies and similar data prepared by third parties, industry, medical and general publications, government data and similar sources. In some cases, we do not expressly refer to the sources from which these data are derived. Except where the context otherwise requires, in this Quarterly Report on Form 10-Q, the æœCompany,æœ æœExcure,æœ æœewe,æœ æœousæœ and æœouræœ refers to Excure, Inc., a Delaware corporation, and, where appropriate, our subsidiary. 4Table of ContentsPART I - FINANCIAL INFORMATIONItem 1. Financial Statements.EXCURE, INC.UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share data)June 30, 2024December 31, 2023ASSETSCurrent assets:Cash and cash equivalents\$528Â \$816Â Other receivable\$559Â 15Â Prepaid expenses and other current assets\$92Â 1, 193Â Total current assets\$2,079Â 2,024Â Property and equipment, net40Â 54Â Right-of-use asset\$6, 126Â 6, 517Â Other noncurrent assets\$2, 443Â 2, 985Â Total assets\$10, 688Â \$11, 580Â LIABILITIES AND STOCKHOLDERSâ€™ EQUITYCurrent liabilities:Accounts payable\$1, 585Â 1, 631Â Accrued expenses and other current liabilities\$46Â 879Â Short-term debt\$1, 000Â â€”Â Total current liabilities\$3, 431Â 2, 510Â Lease liability, noncurrent\$5, 644Â 6, 039Â Total liabilities\$9, 075Â 8, 549Â Commitments and Contingencies (Note 12) Stockholdersâ€™ equity:Preferred stock, \$0.0001 par value per share; 10,000,000 shares authorized, no shares issued and outstanding, JuneÂ 30, 2024 and DecemberÂ 31, 2023â€”Â â€”Â Common stock, \$0.0001 par value per share; 200,000,000 shares authorized, 8,651,148 issued and outstanding, JuneÂ 30, 2024; 8,650,753 issued and outstanding, DecemberÂ 31, 20231Â 1Â Additional paid-in capital\$192, 604Â 192, 593Â Accumulated deficit\$(190, 992)\$(189, 563)Total stockholdersâ€™ equity\$1, 613Â 3, 031Â Total liabilities and stockholdersâ€™ equity\$10, 688Â \$11, 580Â See accompanying notes to the unaudited condensed consolidated financial statements.5Table of ContentsEXCURE, INC.UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(in thousands, except share and per share data)Three Months EndedJune 30, Six Months EndedJune 30, 2024202320242023Revenue:Â Â Â Â Â Revenue\$â€”Â â€”Â \$500Â â€”Â Â Â Â Â Â Â Â Â Â Â Total revenueâ€”Â â€”Â \$500Â â€”Â Operating expenses:1Â 235Â 5, 642Â 2, 571Â 10, 181Â Operating loss\$(1, 235)\$(5, 642)\$(2, 071)\$(10, 181)Other (expense) income, net:Â Â Â Â Â Dividend income1Â 15Â 5Â 32Â Â Â Â Â Â Interest income3Â 13Â 6Â 24Â Â Â Â Â Interest expense(6)â€”(6)â€”Â Other income\$637Â â€”Â 637Â â€”Â Â Â Â Â Â Â Â Â Â Â Other expenseâ€”(150)â€”(46)â€”Â Â Â Â Â Â Â Â Â Â Â Total other (expense) income, net\$35Â 63Â \$(22)\$(42)10Â Net loss before provision for income taxes\$(600)\$(5, 764)\$(1, 429)\$(10, 171)Provision for income taxesâ€”(15)â€”(15)â€”Â â€”Â Net loss\$(600)\$(5, 764)\$(1, 429)\$(10, 171)Basic and diluted loss per common share\$(0.07)\$(0.68)\$(0.17)\$(1.38)Weighted-average basic and diluted common shares outstanding8, 651, 078Â 8, 432, 394Â 8, 650, 878Â 7, 366, 594Â See accompanying notes to the unaudited condensed consolidated financial statements.6Table of ContentsEXCURE, INC.UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERSâ€™ EQUITY(in thousands, except shares)Common StockSharesAdditional Paid-in CapitalAccumulated DeficitTotal Stockholders' EquityBalance at January 1, 20248, 650, 753Â 1Â \$192, 593Â \$(189, 563)\$3, 031Â Equity-based compensationÂ Â Â Â Â 5Â 5Â Vesting of restricted stock units and related repurchases197Â â€”Â â€”Â â€”Â Net lossâ€”(829)Balance at March 31, 20248, 650, 950Â 1Â \$192, 598Â \$(190, 392)\$2, 207Â Equity-based compensationÂ Â Â Â Â 6Â 6Â Vesting of restricted stock units and related repurchases198Â â€”Â â€”Â â€”Â Net lossâ€”(600)Balance at June 30, 20248, 651, 148Â 1Â \$192, 604Â \$(190, 992)\$1, 613Â See accompanying notes to the unaudited condensed consolidated financial statements.7Table of ContentsEXCURE, INC.UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERSâ€™ EQUITY(in thousands, except shares)Common StockSharesAdditional Paid-in CapitalAccumulated DeficitTotal Stockholders' EquityBalance at January 1, 20234, 965, 901Â 1Â \$187, 571Â \$(172, 649)\$14, 922Â Equity-based compensationÂ Â Â Â Â 308Â 308Â Reclassification of common stock warrants to liabilityÂ Â Â Â Â (800)â€”(800)Vesting of restricted stock units and related repurchases5, 561Â 1Â (2)â€”(1)Issuance of common stock, net3, 400, 000Â â€”Â 4, 597Â â€”Â 4, 597Â Net lossâ€”(4, 407)Balance at March 31, 20233, 371, 462Â 1Â \$191, 674Â \$(177, 056)\$14, 619Â Equity-based compensationÂ Â Â Â Â 969Â â€”Â 969Â Vesting of restricted stock units and related repurchases276, 845Â â€”Â (119)â€”(119)Net loss\$(5, 764)Balance at June 30, 20233, 648, 307Â 1Â \$192, 524Â \$(182, 820)\$9, 705Â See accompanying notes to the unaudited condensed consolidated financial statements.8Table of ContentsEXCURE, INC.UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(in thousands)Six Months Ended June 30, 20242023Cash flows from operating activities:Net loss\$(1, 429)\$(10, 171)Adjustments to reconcile net loss to cash used in operating activities:Depreciation and amortization14 479Â Equity-based compensation11Â 1, 277Â Amortization of right-of-use asset390Â 364Â Otherâ€”(44)Changes in operating assets and liabilities:Other receivable(544)â€”(4)Prepaid expenses and other current assets15 145Â Other noncurrent assetsâ€”(288)Accounts payable(46)(18)Accrued expenses(32)(190)Other liabilities(395)(347)Net cash used in operating activities(1, 616)(8, 129)Cash flows from investing activities:Purchase of available-for-sale securitiesâ€”(2, 000)Proceeds from sale of property and equipmentâ€”(211)Net cash used in investing activitiesâ€”(1, 789)Cash flows from financing activities:Proceeds from short-term borrowing1, 000Â â€”Â Proceeds from common stock offeringâ€”(5, 440)Payment of common stock financing costsâ€”(843)Payment of exercise of common stock warrantsâ€”(800)Payments for minimum statutory tax withholding related to net share settlement of equity awardsâ€”(121)Net cash provided by provided by financing activities1, 000Â 3, 676Â Net (decrease) in cash, cash equivalents, and restricted cash(616)(6, 242)Cash, cash equivalents, and restricted cash - beginning of period2, 016Â 9, 777Â Cash, cash equivalents, and restricted cash - end of period\$1, 400Â \$3, 535Â See accompanying notes to the unaudited condensed consolidated financial statements.9EXCURE, INC.UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (continued)(in thousands)The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the unaudited condensed consolidated balance sheets that sum to the total of the amounts shown in the unaudited condensed consolidated statements of cash flows:June 30, 2024December 31, 2023Cash and cash equivalents\$528Â \$816Â Restricted cash included in other noncurrent assets\$872Â 1, 200Â Total cash, cash equivalents, and restricted cash shown in the unaudited condensed consolidated statements of cash flows\$1, 400Â \$2, 016Â See accompanying notes to the unaudited condensed consolidated financial statements.10Table of ContentsEXCURE, INC.NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(in thousands, except share and per share data)1. Description of Business, Basis of Presentation and Going ConcernDescription of BusinessExcure, Inc. has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that the Company was exploring strategic alternatives to maximize stockholder value. The Company is attempting to license its intellectual property to generate value for stockholders. In addition, the Company is engaging in a broader exploration of strategic alternatives. This effort involves exploring growth through transactions with potential partners that see opportunity in joining an existing, publicly-traded organization. Throughout these unaudited condensed consolidated financial statements, the terms the æœCompany,æœ and æœExcureæœ refer to Excure, Inc. and where appropriate, its wholly owned subsidiary, Excure Operating Company. Excure Operating Company holds all material assets and conducts all business activities and operations of Excure, Inc.Â Basis of PresentationThe accompanying unaudited condensed consolidated financial statements as of JuneÂ 30, 2024 and December 31, 2023, and for the three and six months ended JuneÂ 30, 2024 and 2023, have been presented in conformity with accounting principles generally accepted in the United States of America (æœGAAPæœ) and with instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934, as amended. Principles of ConsolidationThe accompanying unaudited condensed consolidated financial statements include the accounts of Excure and its wholly owned subsidiary, Excure Operating Company. All intercompany transactions and accounts are eliminated in consolidation.Unaudited Interim Financial InformationThe accompanying interim condensed consolidated balance sheet as of JuneÂ 30, 2024, the interim condensed consolidated statements of operations for the three and six months ended JuneÂ 30, 2024 and 2023, the interim condensed consolidated statements of changes in stockholdersâ€™ equity for the three and six months ended JuneÂ 30, 2024 and 2023, and the interim condensed consolidated statements of cash flows for the six months ended JuneÂ 30, 2024 and 2023 are unaudited. The interim unaudited condensed consolidated financial statements have been prepared on the same basis as the annual audited financial statements and with instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934, as amended; and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the Companyâ€™s financial position as of JuneÂ 30, 2024, the results of its operations for the three and six months ended JuneÂ 30, 2024 and 2023, and the results of its cash flows for the six months ended JuneÂ 30, 2024 and 2023. The financial data and other information disclosed in these notes related to the three and six months ended JuneÂ 30, 2024 and 2023 are unaudited. The results for the six months ended JuneÂ 30, 2024 are not necessarily indicative of results to be expected for the year ending DecemberÂ 31, 2024, or any other interim periods, or any future year or period. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes for the year ended December 31, 2023, included in the Companyâ€™s Annual Report on Form 10-K filed with the Securities and Exchange Commission (æœSECæœ) on June 6, 2024. 11Table of ContentsEXCURE, INC.NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(in thousands, except share and per share data)Going ConcernAt each reporting period, the Company evaluates whether there are conditions or events that raise substantial doubt about the Companyâ€™s ability to continue as a going concern for a period of one year after the date that the financial statements are issued. The Company is required to make certain additional disclosures if it concludes substantial doubt exists and it is not alleviated by the Companyâ€™s plans or when its plans alleviate substantial doubt about the Companyâ€™s ability to continue as a going concern. The accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern for a period of one year after the date that the financial statements are issued. As of JuneÂ 30, 2024, the Company expects to incur significant expenses and negative cash flows for the foreseeable future. As of JuneÂ 30, 2024, the Companyâ€™s cash and cash equivalents were \$528. Management believes that, given the Companyâ€™s current cash position, operating plans and forecasted negative cash flows from operating activities over the next twelve months, there is substantial doubt about the Companyâ€™s ability to continue as a going concern within one year after the date these financial statements are issued. Substantial additional financing will be needed by the Company to fund its operations.Management believes that the Companyâ€™s existing cash and cash equivalents are insufficient to continue to fund its operating expenses and additional funding is needed in the very near term. The Company has already engaged in significant cost reductions, so our ability to further cut costs and extend the Companyâ€™s operating runway is limited. As a result, substantial additional financing will be needed by the Company in the very near term to pay expenses, fund the ongoing exploration of strategic alternatives and pursue any alternatives that may be identified. There can be no assurance that such additional financing will be available and, if available, can be obtained on acceptable terms.The accompanying unaudited condensed consolidated financial statements have been prepared as though the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.2. Significant Accounting PoliciesThe Companyâ€™s significant accounting policies are disclosed in the audited consolidated financial statements and the notes thereto, which are included in the in the Companyâ€™s Annual Report on Form 10-K (the æœAnnual Reportæœ) for the year ended DecemberÂ 31, 2023 filed with the SEC on June 6, 2024. Since the date of those audited consolidated financial statements, there have been no material changes to the Companyâ€™s significant accounting policies.Use of EstimatesThe preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases its estimates on certain assumptions which it believes are reasonable in the circumstances and while actual results could differ from those estimates, management does not believe that any change in those assumptions in the near term would have a significant effect on the Companyâ€™s financial position, results of operations or cash flows. Actual results in future periods could differ from those estimates. 12Table of ContentsEXCURE, INC.NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(in thousands, except share and per share data)3. Supplemental Balance Sheet InformationPrepaid expenses and other current assetsJune 30, 2024December 31, 2023Prepaid insurance\$476Â \$508Â Prepaid franchise tax\$61Â 259Â Lease costs\$255Â 235Â Prepaid professional fees\$70Â 95Â Prepaid software 62Â 72Â Other\$84 24Â Â Â Â Â Prepaid expenses and other current assets\$92Â 1, 193Â Other noncurrent assetsJune 30, 2024December 31, 2023Restricted cash\$872Â 1, 200Â Prepaid insurance\$571Â 1, 785Â Â Â Â Â Other noncurrent assets\$2, 443Â \$2, 985Â Property and equipment, netJune 30, 2024December 31, 2023Scientific equipment\$246Â \$246Â Computers and software\$3Â 34Â Furniture and fixtures\$30Â 30Â Property and equipment, gross\$279Â 279Â Less: accumulated depreciation and amortization(239) (225)Property and equipment, net\$40Â 54Â Depreciation and amortization expense was \$14 and \$479 for the six months ended JuneÂ 30, 2024 and 2023, respectively. Accrued expenses and other current liabilitiesJune 30, 2024December 31, 2023Current lease liability\$671Â \$626Â Accrued payroll-related expensesâ€”(71) Accrued other expenses\$175Â 182Â Â Â Â Â Accrued expenses and other current liabilities\$846Â \$879Â 4. LeasesThe Companyâ€™s lease arrangements at JuneÂ 30, 2024 consist of (i) a lease for office space at its headquarters in Chicago, Illinois that commenced in July 2020 (the æœChicago Leaseæœ) and (ii) a lease for office equipment (the æœOffice Equipment Leaseæœ). The Chicago Lease and the Office Equipment Lease are classified as operating leases.13Table of ContentsEXCURE, INC.NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(in thousands, except share and per share data)Chicago LeaseThe Company has approximately thirty thousand square feet of office space in Chicago, Illinois. The original term (the æœOriginal Termæœ) of the Chicago Lease is 10 years, commencing on July 1, 2020 (the æœCommencement Dateæœ), which is the date the premises were ready for occupancy under the terms of the Chicago Lease. The Company has options to extend the term of the Chicago Lease for two additional successive periods of five years each (the æœExtension Periodsæœ) at the then prevailing effective market rental rate.The initial annual base rent during the Original Term is approximately \$1,113 for the first 12-month period of the Original Term, payable in monthly installments beginning on the Commencement Date. Base rent thereafter is subject to annual increases of 3%, for an aggregate amount of \$12,761 over the Original Term. The Company must also pay its proportionate share of certain operating expenses and taxes for each calendar year during the term. During the first 12-month period of the Original Term, the base rent and the Company's proportionate share of operating expenses and taxes were subject to certain abatements. The following table summarizes lease costs in the Companyâ€™s unaudited condensed consolidated statement of operations:Three Months EndedJune 30, Six Months EndedJune 30, 2024202320242023Operating lease costs\$142Â \$326Â \$285Â \$652Â Variable lease costs(117) (193) 313Â Short term lease costs\$9Â â€”Â 20Â â€”Â Total lease costs\$34Â \$307Â \$308Â \$965Â The Company made cash payments for operating leases \$327 and \$860 during the six months ended JuneÂ 30, 2024 and 2023, respectively. On June 11, 2024, the Company received a formal notice from its landlord indicating the landlord will draw on the restricted cash account designated for the lease as a result of past due rent for December 2023 through June 2024. The landlord also withdrew the July 2024 payment from the restricted cash account. These draws are within the terms and conditions of the lease and the related restricted cash account. Sublease of Office SpaceThe Company entered into a sublease agreement with Cyclopure, Inc. (the æœSubtenantæœ) to sublease approximately 57% of its office space pursuant to that certain sublease agreement (the æœSublease Agreementæœ), dated as of May 4, 2023. The term of the Sublease Agreement began on May 15, 2023 and ends on June 30, 2030, the expiration date of the Chicago Lease. The first three months under the Sublease Agreement are rent free. Beginning August 15, 2023, the Company began charging the Subtenant for 57% of the base rent under the Chicago Lease, and the subtenant is responsible for its pro rata share of operating expenses and taxes payable. In 2024, the Company does not receive payment from the Subtenant as the Subtenant pays the Companyâ€™s landlord directly. The following table summarizes sublease receipts in the Companyâ€™s condensed consolidated statement of

14Table of ContentsEXICURE, INC.NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(in thousands, except share and per share data)5. Investment in Convertible Notes ReceivableIn May 2023, the Company entered into two subscription agreements to purchase non-guaranteed private placement convertible notes receivable (the "Notes Receivable") for a subscription amount of \$1A million each. The Notes Receivable mature in May 2026 and the yield to maturity is 4.5% per annum. The Company has the option to request that the issuer redeem part or the entire principal amount of the Notes Receivable on the first anniversary after the issue date and every three months thereafter before the maturity date. The redemption price will be one hundred percent (100%) of the Notes Receivable's face value, plus accrued interest. The Company also has the ability to convert the debt into shares based on the number of shares computed by dividing the face value of each security by a calculated conversion price, which is subject to adjustment provisions, determined at the time of issuance. The securities may be converted from May 3, 2024, the first anniversary of the issue date of the first agreement, to April 15, 2026, one month prior to the maturity date to the second agreement. In March 2024, the Company notified the issuer of the Notes Receivable that it was exercising its redemption right with respect to the entire principal amount of the Notes Receivable after the first anniversary of their issue dates (May 3 and May 16, 2024, respectively) for an aggregate redemption price of \$2.090A million (representing the principal amount plus 4.5% per annum yield to the redemption date). The issuer has taken the position that the Notes Receivable are not redeemable until August 3, 2024 and August 16, 2024, and as a result that redemption notice submitted in March were premature. We have attempted to redeem the \$2A million aggregate principal amount of the convertible Notes Receivable in June 2024, but have not received a response to our most recent request. The Company's debt securities are classified as available-for-sale (AFS) pursuant to Accounting Standards Codification (ASC) 320 - Investments - Debt Securities. AFS securities are recorded at fair value. As of JuneA 30, 2024 and December 31, 2023, management does not believe these AFS investments are recoverable and recorded them at a fair value of \$0.6. DebtOn May 3, 2024, the Company executed a promissory note (NoteA) and subsequently received a loan in the amount of \$300 from an individual investor. All principal and accrued interest will be due and payable on the earlier of (i) May 3, 2025 or (ii) upon an event of default, at such time, such amounts declared by the investor will become due and payable by Company. Interest will accrue on this Note at 6.0% and is payable at maturity. On June 3, 2024, the Company executed another promissory note (NoteB) and subsequently received a loan in the amount of \$700 from DGP, a related party. All principal and accrued interest will be due and payable on the earlier of (i) March 25, 2025 or (ii) upon an event of default, at such time, such amounts declared by the investor will become due and payable by Company. Interest will accrue on this DGP Note at 6.0% and is payable at maturity.7. Stockholders' EquityPreferred StockAs of JuneA 30, 2024 and DecemberA 31, 2023, the Company had 10,000,000 shares of preferred stock, par value \$0.0001 authorized and no shares issued and outstanding. Common StockAs of JuneA 30, 2024 and DecemberA 31, 2023, the Company had authorized 200,000,000 shares of common stock, par value \$0.0001. As of JuneA 30, 2024 and DecemberA 31, 2023, the Company had 8,651,148 shares and 8,650,753 shares issued and outstanding, respectively. The holders of shares of the Company's common stock are entitled to one vote per share on all matters to be voted upon by the Company's stockholders and there are no cumulative rights. Subject to preferences that may be applicable to any outstanding preferred stock, the holders of shares of the Company's common stock are entitled to receive ratably any dividends that may be declared from time to time by the Board of Directors (the "Board") out of 15Table of ContentsEXICURE, INC.NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(in thousands, except share and per share data)funds legally available for that purpose. In the event of the Company's liquidation, dissolution or winding up, the holders of shares of the Company's common stock are entitled to share ratably in all assets remaining after payment of liabilities, subject to prior distribution rights of preferred stock then outstanding. The Company's common stock has no preemptive or conversion rights or other subscription rights. There are no redemption or sinking fund provisions applicable to the Company's common stock. The outstanding shares of the Company's common stock are fully paid and non-assessable. September 2022 PIPE (Private Investment in Public Equity) Securities Purchase AgreementOn September 26, 2022, the Company entered into a securities purchase agreement (the "Securities Purchase Agreement") with CBI USA, Inc. (CBI USA), pursuant to which the Company agreed to issue and sell to CBI USA in a private placement an aggregate of 3,400,000 shares of Common Stock, at a purchase price of \$1.60 per share. The private placement closed on February 24, 2023 (the "Closing Date"). The Company received gross proceeds of \$5,440 from the September 2022 PIPE (or net proceeds of \$4,597 after transaction expenses). CBI USA funded the acquisition pursuant to the Securities Purchase Agreement through a loan from its affiliate, DGP Co., Ltd. (DGP). On June 23, 2023, DGP exercised its option pursuant to the loan and acquired the 3,400,000 shares of Common Stock initially acquired by CBI USA pursuant to the Securities Purchase Agreement. DGP subsequently agreed to sell its shares to a third party, with the closing of 10% (340,000 shares) occurring in February 2024 and the remainder to close by or on September 30, 2024. The Securities Purchase Agreement, as confirmed and clarified by that certain letter agreement, dated October 31, 2022, between the Company and CBI USA, provided CBI USA together with its affiliates and any group of which it or they are a member with the right to designate directors to the Company's board of directors in proportion to the ownership of CBI USA and its affiliates and any such group. CBI USA and DGP have announced they expect to exercise such rights as a group. Together, they beneficially own 45% of the outstanding shares of Common Stock based on their most recent Schedule 13D amendment. As noted above, DGP has entered into an agreement to sell its remaining shares to a third party by or on September 30, 2024. September 2022 Registration Rights AgreementIn connection with the Securities Purchase Agreement, the Company entered into a registration rights agreement with CBI USA (the "Registration Rights Agreement"). CBI USA assigned its rights under the Registration Rights Agreement to DGP when DGP acquired the 3,400,000 shares of Common Stock initially sold to CBI USA. Pursuant to the Registration Rights Agreement, the Company agreed to file a registration statement covering the resale of the shares of Common Stock sold pursuant to the Securities Purchase Agreement, to use reasonable best efforts to cause such registration statement to become effective as promptly as practicable, and to keep such registration statement continuously effective until the earlier of (i) the date the shares covered by such registration statement have been sold or may be resold pursuant to Rule 144 without restriction, or (ii) the date that is two (2) years following the Closing Date. In the event the registration statement was not filed within 90 days following the Closing Date, subject to certain limited exceptions, the Company agreed to make payments as liquidated damages in an amount equal to 0.5% of the aggregate amount invested in the shares of Common Stock pursuant to the Securities Purchase Agreement per 30-day period or pro rata for any portion thereof for each such month during which such event continues, subject to certain caps set forth in the Registration Rights Agreement. We have paid \$27 to CBI USA and accrued \$191 to DGP pursuant to this provision.16Table of ContentsEXICURE, INC.NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(in thousands, except share and per share data)Registered Direct OfferingOn December 16, 2021, the Company completed a securities purchase agreement (the "Purchase Agreement") with certain institutional purchasers (the "Purchasers") entered into on December 14, 2021, pursuant to which the Company offered to the Purchasers, in a registered direct offering priced at the market consistent with the rules of Nasdaq (the "Registered Direct Offering"), (i) an aggregate of 433,553 shares (the "Shares") of the Company's common stock, \$0.0001 par value per share, (ii) pre-funded warrants to purchase up to an aggregate of 718,981 shares of Common Stock (the "Pre-Funded Warrants"), and (iii) warrants to purchase up to 576,261 shares of Common Stock (the "Warrants"). The combined purchase price of each share of Common Stock and accompanying Warrant is \$9.9780 per share. The combined purchase price of each Pre-Funded Warrant and accompanying Warrant is \$9.9480 (equal to the combined purchase price per share of Common Stock and accompanying Warrant, minus \$0.03). The per share exercise price for the Warrants is \$8.1031, the closing bid price of the Company's Common Stock on December 13, 2021 (and as adjusted for the reverse stock split referenced in Note 1). The Warrants will be exercisable immediately from the closing December 16, 2021, and will expire on the five-year anniversary of the date of issuance, or December 16, 2026. The Pre-Funded Warrants and Warrants, which met equity classification, were recognized as a component of permanent stockholders' equity within additional paid-in-capital together with the net proceeds from the Registered Direct Offering. The gross proceeds to the Company from the Registered Direct Offering (excluding effect of subsequent exercises of pre-funded warrants) were \$11,478 and net proceeds after deducting the placement agent's fees and other offering expenses paid or payable by the Company were \$10,226. The securities were offered by the Company pursuant to an effective shelf registration statement on Form S-3 (File No. 333-251555) previously filed with the Securities and Exchange Commission (the "SEC") on December 21, 2020, and which was declared effective by the SEC on January 7, 2021 (the "Registration Statement"). Each Warrant is exercisable for one share of Common Stock at an exercise price of \$8.1031 per share. The Warrants are immediately exercisable as of the date of issuance of December 16, 2021 and will expire on the five-year anniversary of the date of issuance, or December 16, 2026. The Pre-Funded Warrants were offered in lieu of shares of Common Stock to one of the Purchasers whose purchase of shares of Common Stock in the Registered Direct Offering would otherwise result in said Purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the Purchaser, 9.99%) of the Company's outstanding Common Stock immediately following the consummation of the Registered Direct Offering. Each Pre-Funded Warrant is exercisable for one share of Common Stock at an exercise price of \$0.030 per share. The Pre-Funded Warrants are immediately exercisable and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. A holder (together with its affiliates) of the Warrant or Pre-Funded Warrant may not exercise any portion of the Warrant or Pre-Funded Warrant, as applicable, to the extent that the holder would own more than 4.99% (or, at the holder's option upon issuance, 9.99%) of the Company's outstanding Common Stock immediately after exercise, as such percentage ownership is determined in accordance with the terms of the Warrant or Pre-Funded Warrant, as applicable. In lieu of making the cash payment otherwise contemplated to be made to the Company upon exercise of a Warrant in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of Common Stock determined according to a formula set forth in the Warrants, provided that such cashless exercise shall only be permitted if the Registration Statement is not effective at the time of such exercise or if the prospectus to which the Registration Statement is a part is not available for the issuance of shares of Common Stock to the Warrant holder. In lieu of making the cash payment otherwise contemplated to be made to the Company upon exercise of a Pre-Funded Warrant in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of Common Stock determined according to a formula set forth in the Pre-Funded Warrants.17Table of ContentsEXICURE, INC.NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(in thousands, except share and per share data)Common Stock WarrantsWarrants to purchase 576,261 shares of common stock at a price of \$8.1031 per share were acquired in the December 2021 registered-direct offering transaction. The warrants were classified as equity. As a result of the closing of the September 2022 PIPE, a warrant holder elected to exercise their option within 30 days of the closing of the September 2022 PIPE (February 24, 2023) to receive a cash payout for the outstanding warrants in the amount of the Black-Scholes value of each warrant as prescribed in the warrant agreement. The Company paid \$800 to this warrant holder on June 23, 2023 and 526,151 were settled as a result. As of JuneA 30, 2024, warrants to purchase 50,110 shares of common stock at a price of \$8.1031 per share that were acquired in the December 2021 registered-direct offering transaction remain outstanding.8. Equity-Based Compensation2017 Equity Incentive PlanOn SeptemberA 22, 2017, the Company's stockholders approved the Excure, Inc. 2017 Equity Incentive Plan (the "2017 Plan"), which became effective on November 15, 2017. The 2017 Plan provides for the issuance of incentive awards of up to 194,750 shares of Excure common stock, which includes 72,330 shares of Excure common stock to be issued to officers, employees, consultants and directors, plus a number of shares not to exceed 122,793 that are subject to issued and outstanding awards under the Excure OpCo 2015 Equity Incentive Plan (the "2015 Plan") and were assumed in the merger transaction on September 26, 2017. Awards that may be awarded under the 2017 Equity Incentive Plan include non-qualified and incentive stock options, stock appreciation rights, bonus shares, restricted stock, restricted stock units, performance units and cash-based awards. The number of shares of common stock reserved for issuance under the 2017 Equity Incentive Plan automatically increases on January 1 of each year, beginning on January 1, 2020, by the lesser of (i) 153,333 shares, (ii) 5% of the total number of shares of its capital stock outstanding on December 31 of the preceding calendar year, or (iii) a lesser number of shares determined by the Compensation Committee of the Board (the "Compensation Committee"). No future awards will be made under the 2015 Plan upon the effectiveness of the 2017 Plan. On January 1, 2024, pursuant to the terms of the 2017 Plan, the number of awards that are reserved and may be awarded under the 2017 Plan was automatically increased by 153,333 awards. A A A A A A As of JuneA 30, 2024, the aggregate number of equity awards available for grant under the 2017 Equity Incentive Plan was 455,292. Awards granted under the 2017 Plan are contingent on the participants' continued employment or provision of non-employee services and are subject to forfeiture if employment or continued service terminates for any reason. The initial award granted to an employee or consultant generally vests 25% on the first 12-month anniversary of the grant date and vests 1/48th monthly thereafter until fully vested at the end of 48 months. Subsequent awards granted to employees or consultants generally vest 1/48th monthly until fully vested at the end of 48 months. The initial stock option grant to a non-employee director vests 1/36th monthly until fully vested at the end of 36 months. Subsequent stock option grants to a non-employee director vests 1/12th monthly until fully vested at the end of 12 months. The term of common stock option grants is 10 years unless terminated earlier as described above.18Table of ContentsEXICURE, INC.NOTES TO UNAUDITED

PriceWeighted-Average Remaining Contractual Terms (years)Aggregate Aggregate Intrinsic Value (thousands)Outstanding - December 31, 202312,115A \$4.28A 5.4Sâ€¢A Grantadâ€¢A A Exercisedâ€¢A â€¢A A Forfeited(416)5.51A Outstanding - June 30, 202411,699A \$5.51A 4.9Sâ€¢A Exercisable - June 30, 202411,699A \$5.51A 4.9Sâ€¢A Vested and Expected to Vest - June 30, 202411,699A \$5.51A 4.9Sâ€¢A A 20Table of ContentsEXICURE, INC.NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(in thousands, except share and per share data)A summary of restricted stock unit activity of the periods indicated is as follows: Restricted Stock UnitsWeighted-Average Grant Date Fair ValueUnvested balance - December 31, 2023,043A \$10.41A Grantadâ€¢A â€¢A A Vested(592)18.47A Forfeited(417)3.45A Unvested balance - June 30, 2024,034A \$12.24A The grant date fair value of restricted stock units is based on the Company's closing stock price at the date of grant. At vesting, each outstanding restricted stock unit will be exchanged for one share of the Company's common stock. Restricted stock units generally vest evenly on a quarterly basis over a period of 4 years in exchange for continued service provided by the restricted stock unit recipient during that vesting period.9. Income TaxesThe Company incurred a pretax loss in each of the six months ended June 30, 2024 and 2023, which consists entirely of loss in the United States and resulted in no provision for income tax expense during the periods then ended. The effective tax rate is 0% in each of the six months ended June 30, 2024 and 2023 because the Company has generated tax losses and has provided a full valuation allowance against its deferred tax assets. 10. Loss Per Common ShareBasic loss per common share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per common share is calculated using the treasury share method by giving effect to all potentially dilutive securities that were outstanding. Potentially dilutive options, restricted stock units and warrants to purchase common stock that were outstanding during the periods presented were excluded from the diluted loss per share calculation for the periods presented because such shares had an anti-dilutive effect due to the net loss reported in those periods. Therefore, basic and diluted loss per common share is the same for each of the six months ended June 30, 2024 and 2023. The following is the computation of loss per common share for the three and six months ended June 30, 2024 and 2023: Three Months EndedJune 30,Six Months EndedJune 30,2024202320242023Net loss\$(600)\$(5,764)\$(1,429)\$(10,171)Weighted-average basic and diluted common shares outstanding8,651,078A 8,432,394A 8,650,878A 7,366,594A Loss per share - basic and diluted\$(0.07)\$(0.68)\$(0.17)\$(1.38)21Table of ContentsEXICURE, INC.NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(in thousands, except share and per share data)The outstanding securities presented below were excluded from the calculation of loss per common share, for the periods presented, because such securities would have been anti-dilutive due to the Company's loss per share during that period:As of June 30,20242023Options to purchase common stock11,699A 166,906A Restricted stock units2,034A 7,700A Warrants to purchase common stock50,110A 50,110A 11. Fair Value MeasurementsASC Topic 820, Fair Value Measurement, establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value, as follows: Level 1 Inputs - unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date; Level 2 Inputs - other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability; and Level 3 Inputs - unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date. Assets measured at fair value on a recurring basis as of June 30, 2024 are as follows:TotalLevel 1Level 2Level 3AssetsShort-term investments:Investment in convertible notes receivable\$â€¢A â€¢A â€¢A â€¢A Total financial assets\$â€¢A â€¢A â€¢A â€¢A Assets measured at fair value on a recurring basis as of December 31, 2023 are as follows: TotalLevel 1Level 2Level 3AssetsCash equivalents:Money market funds\$1,629A \$1,629A \$â€¢A â€¢A Short-term investments:Investment in convertible notes receivable\$â€¢A â€¢A â€¢A â€¢A Total financial assets\$1,629A \$1,629A \$â€¢A â€¢A The Company uses the market approach and Level 1 and Level 2 inputs to value its cash equivalents and Level 2 inputs to value its short-term investments. The Company uses the market approach and Level 3 inputs to value its liabilities. There were no liabilities measured at fair value on a recurring basis as of as of December 31, 2023 nor June 30, 2024. There were no transfers between Level 1, 2, or 3, during the six months ended June 30, 2024, and 2023. Both observable and unobservable inputs were used to determine fair value of the positions that the Company classified within the Level 3 category. Unrealized gains and losses associated within the Level 3 category include changes in fair value that were attributable to both observable and unobservable inputs.22Table of ContentsEXICURE, INC.NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(in thousands, except share and per share data)12. Commitments and ContingenciesLegal ProceedingsOn December 13, 2021, Mark Colwell filed a putative securities class action lawsuit against the Company, David A. Giljohann and Brian C. Bock in the United States District Court for the Northern District of Illinois, captioned Colwell v. Exicure, Inc. et al., Case No. 1:21-cv-0663. On February 4, 2021, plaintiff filed an amended putative securities class action complaint. On March 20, 2023, the court entered an order appointing James Mathew as lead plaintiff and Bleichmar Fonti & Auld LLP as lead counsel in the action pursuant to the Private Securities Litigation Reform Act of 1995. On May 26, 2023, lead plaintiff filed a second amended complaint against the Company, Dr. Giljohann, Mr. Bock, and Grant Corbett. The second amended complaint alleges that Dr. Giljohann, Mr. Bock, and Dr. Corbett made materially false and/or misleading statements related to the Company's clinical programs purportedly causing losses to investors who acquired Company securities between January 7, 2021 and December 10, 2021. The second amended complaint does not quantify any alleged damages but, in addition to attorneys' fees and costs, lead plaintiff seeks to recover damages on behalf of himself and others who acquired the Company's stock during the putative class period at allegedly inflated prices and purportedly suffered financial harm as a result. On or around August 6, 2024, the parties reached an agreement in principle to settle the litigation, subject to executing a definitive settlement agreement and approval of the court. A status hearing with the court is set for August 30, 2024. The Company believes that any liability as a result of the settlement will be covered by insurance. On March 1, 2022, Kapil Puri filed a shareholder derivative lawsuit on behalf of the Company in the United States District Court for the Northern District of Illinois, against Dr. Giljohann and Mr. Bock, Jeffrey L. Cleland, Elizabeth Garofalo, Bosun Hau, Bali Muralidhar, Andrew Sassine, Matthias Schroff, James Sulat and Timothy Walbert, captioned Puri v. Giljohann, et al., Case No. 1:22-cv-01083. On March 8, 2022, Yixin Sim filed a similar shareholder derivative lawsuit in the same court against the same individuals, captioned Sim v. Giljohann, et al., Case No. 1:22-cv-01217. On April 25, 2022, Stourbridge Investments LLC filed a similar shareholder derivative lawsuit against the same individuals in the United States District Court for the District of Delaware, captioned Stourbridge Investments LLC v. Exicure, Inc. et al., Case No. 1:22-cv-00526. Based on similar factual allegations presented in the Colwell complaint, described above, the Puri, Sim, and Stourbridge complaints (collectively, the "Derivative Complaints") allege that the defendants caused the Company to issue false and/or misleading statements in the proxy statement for its 2021 Annual Meeting of Stockholders regarding risk oversight, code of conduct, clinical program and compensation matters, among other things, in violation of federal securities law, and committed breaches of fiduciary duties. The Derivative Complaints also assert that Dr. Giljohann and Mr. Bock are liable for contribution under the federal securities laws. The Puri and Stourbridge complaints further assert state law claims for unjust enrichment, and the Puri complaint additionally asserts state law claims for abuse of control, gross mismanagement and corporate waste. The plaintiffs do not quantify any alleged damages in the Derivative Complaints, but seek restitution for damages to the Company, attorneys' fees, costs, and expenses, as well as an order directing that certain proposals for strengthening board oversight be put to a vote of the Company's shareholders. On March 18, 2022, James McNabb, through counsel, sent a written demand to the Company (the "Demand Letter") demanding that the Board of Directors investigate certain allegations and commence proceedings on the Company's behalf against certain of the Company's officers and directors for alleged breaches of fiduciary duties and corporate waste. All of the Derivative Cases have been stayed pending a decision on any motion to dismiss that may be filed in the Colwell case. Further, pursuant to agreement, the Demand Letter is being held in abeyance and any related statute of limitations tolled pending such motion and decision. On October 3, 2023, a former employee filed a complaint against the Company and its executives related to the former employee's separation from the Company. The parties proceeded with paper discovery and this matter did not settle at an in-person settlement conference on July 17, 2024. As a result, we are entering the discovery phase of this litigation.23Table of ContentsEXICURE, INC.NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(in thousands, except share and per share data)Northwestern University License Agreements On December 12, 2011, (1) AuraSense, LLC, the Company's former parent, assigned to the Company all of its worldwide rights and interests under AuraSense, LLC's 2009 license agreement with Northwestern University ("AuraSense License") in the field of the use of nanoparticles, nanotechnology, microtechnology or nanomaterial-based constructs as therapeutics or accompanying therapeutics as a means of delivery, but expressly excluding diagnostics (the "assigned field"); (2) in accordance with the terms and conditions of this assignment, the Company assumed all liabilities and obligations of AuraSense, LLC as set forth in its license agreement in the assigned field; and (3) in order to secure this assignment and the patent rights from NU, the Company agreed (i) to pay NU an annual license fee, which may be credited against any royalties due to NU in the same year, (ii) to reimburse NU for expenses associated with the prosecution and maintenance of the license patent rights, (iii) to pay NU royalties based on any net revenue generated by the Company's sale or transfer of any licensed product, (iv) to pay NU, in the event the Company grants a sublicense under the licensed patent rights, the greater of a percentage of all sublicense royalties or a percentage of any net revenue generated by a sublicensee's sale or transfer of any licensed product, and (v) to pay NU a percentage of all other sublicense payments received by the Company. In August 2015, the Company entered into a restated license agreement with NU (the "Restated License Agreement"). In February 2016, the Company obtained exclusive license as to NU's rights in certain SNA technology it jointly owns with NU (the "Co-owned Technology License"). The Company's license to NU's rights is limited to the assigned field, however the Company has no such limitation as to its own rights in this jointly owned technology. The Company's rights and obligations in the Co-owned Technology License agreement is substantially the same as in the Restated License Agreement from August 2015 (collectively referred to as "the Northwestern University License Agreements"). As of June 30, 2024, the Company has paid to NU an aggregate of \$11,567 in consideration of each of the obligations described above. On August 3, 2023, the company received a notice letter (the "Letter") from counsel for NU alleging the Company breached the Northwestern University License Agreements. The Letter alleges that a lack of development required under the Northwestern University License Agreements is a breach. The Northwestern University License Agreements were subsequently terminated on September 10, 2023 and October 3, 2023, respectively. LeasesRefer to Note 4.A Leases, for a discussion of the commitments associated with the Company's lease agreements.13. Related-Party TransactionsPursuant to a Consulting Agreement, effective as of September 25, 2022, between the Company and Alta Companies LTD ("Alta"), the Company paid Alta \$218 on February 27, 2023 for a consulting fee earned as a result of the September 2022 PIPE closing. Paul Kang, a director of the Company since February 2023 and the CEO of the Company since August 2023, is the President of Alta. Also, refer to the DGP Note in Footnote 6.14. License AgreementOn February 5, 2024, the Company entered into a patent license agreement to develop cavitrolimod for potential treatment for hepatitis with a private clinical stage biopharmaceutical company. Under the terms of the agreement, this biopharmaceutical company will receive an exclusive license in the field of hepatitis to all of the Company's relevant patents. An initial payment of \$500 was paid to the Company after the execution of this agreement. This payment was recognized as revenue in accordance with ASC 606, Revenue from Contracts with Customers. The Company will also be entitled to modest royalties on future net sales on all licensed technology during the term of the licensed patents. The Company will be responsible for, and make all decisions concerning, the preparation, filing, prosecution, and maintenance for each patent and patent application included within the licensed patents. 24Table of ContentsItem 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.The following information should be read in conjunction with our unaudited condensed consolidated financial statements and the notes thereto included in this Quarterly Report on Form 10-Q and the audited financial information and the notes thereto included in our Annual Report on Form 10-K (the "Annual Report") for the year ended December 31, 2023, which was filed with the Securities and Exchange Commission, or SEC, on June 6, 2024. This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, that involve significant risks and uncertainties. Our actual results, performance or experience could differ materially from what is indicated by any forward-looking statement due to various important factors, risks, uncertainties, assumptions and other factors including, but not limited to, those identified in this Quarterly Report on Form 10-Q and those set forth under the section titled "Risk Factors" in Part II, Item 1A of this Quarterly Report on Form 10-Q and in our other SEC filings. OverviewHistorically, we have been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, we announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that we were exploring strategic alternatives to maximize stockholder value. The Company is attempting to license its intellectual property to generate value for stockholders. In February 2024, the Company received an upfront payment of \$500 from executed a licensing agreement for patents related to one of our historical drug candidates, and received a small, one-time payment and an entitlement to only modest royalties on future sales of the licensed technology that we do not believe will be material. In the second

deficiencies pursuant to the decision of the Nasdaq Hearings Panel. The Company intends to attempt to cure the bid price deficiency by effecting another reverse stock split, subject to stockholder approval. A special meeting of stockholders has been called for August 15, 2024, at which stockholders will vote on a proposal to approve a reverse stock split at a ratio in the range of 1-for-2 to 1-for-15, with such ratio to be determined at the discretion of the Board of Directors. Compliance with Nasdaq's rule requiring stockholders' equity of at least \$2,500,000 based on the Company's balance sheet as of June 30, 2024. The Company is not in compliance with this requirement based on its June 30, 2024 balance sheet. Compliance with Nasdaq's corporate governance requirements with respect to board and committee composition. The Company has received numerous deficiency notifications with respect to these requirements in the past year. Although the Company believes it is currently in compliance, there can be no assurance it will remain in compliance. Compliance with Nasdaq's requirement to hold an annual meeting. On January 11, 2024, Nasdaq notified the Company that it did not comply with listing requirements by not holding an annual meeting in 2023. The Company held its combined 2023 and 2024 annual meeting on June 28, 2024. On April 17, 2024, the Company received a delinquency notification as it had not filed its Annual Report Form 10-K for the year ended December 31, 2023. The extended deadline for compliance was established by Nasdaq at May 20, 2024, the same deadline for our Form 10-Q for the quarter ended September 30, 2023. The Annual Report Form 10-K was filed on June 6, 2024. Although the Company filed its Form 10-Q for the quarter ended September 30, 2023 prior to the extended deadline of May 20, 2024, on May 21, 2024, the Company received a delisting determination from the Nasdaq staff as a result of not filing its Annual Report Form 10-K by the May 20, 2024 deadline and failure to timely file its Form 10-Q for the quarter ended March 31, 2024 (which was subsequently filed on June 17, 2024). The staff's delisting determination also noted the failure to hold its 2023 annual meeting as another basis of the delisting determination. On May 28, 2024, the Company requested an appeal of the delisting determination to Nasdaq's hearings panel, the hearing took place on July 9, 2024. On July 31, 2024, the Company received formal notice that the Nasdaq Hearings Panel determined to continue the Company's listing subject to the Company evidencing compliance with all applicable criteria for continued listing on The Nasdaq Capital Market by September 16, 2024. The Company is diligently working to timely satisfy the terms of the Panel's decision and to ensure the Company's continued listing on Nasdaq. Even if the Company regains compliance with Nasdaq's listing requirements and addresses the outstanding deficiency notices to Nasdaq's satisfaction, there can be no assurance that the Company will remain in compliance with Nasdaq's requirements and will not be delisted. Critical Accounting Estimates We prepare our condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States of America, which require our management to make estimates that affect the reported amounts of assets, liabilities and disclosures of contingent assets and liabilities at the balance sheet dates, as well as the reported amounts of revenues and expenses during the reporting periods. To the extent that there are material differences between these estimates and actual results, our financial condition or results of operations would be affected. We base our estimates on our own historical experience and other assumptions that we believe are reasonable after taking account of our circumstances and expectations for the future based on available information. We evaluate these estimates on an ongoing basis. We consider an accounting estimate to be critical if: (1) the accounting estimate requires us to make assumptions about matters that were highly uncertain at the time the accounting estimate was made, and (2) changes in the estimate that are reasonably likely to occur from period to period, or use of different estimates that we reasonably could have used in the current period, would have a material impact on our financial condition or results of operations. Management has discussed the development and selection of these critical accounting estimates with the Audit Committee of our Board of Directors. In addition, there are other items within our financial statements that require estimation, but are not deemed critical as defined above. Changes in estimates used in these and other items could have a material impact on our financial statements. This includes estimates where the nature of the estimate is material due to the levels of subjectivity and judgment necessary to account for highly uncertain matters or the susceptibility of such matters to change, and the impact of the estimate on financial condition or operating performance is material. Recent accounting pronouncements not yet adopted There are no recent accounting pronouncements that the Company has not yet adopted. Results of Operations Comparison of the Three Months Ended June 30, 2024 and 2023 The following table summarizes the results of our operations for the three months ended June 30, 2024 and 2023. Three Months Ended June 30, (dollars in thousands) 2024 2023 Change Revenue: Revenue \$6,424,407 (78)% Operating expenses: General and administrative expense \$1,235.5 (14)% Total operating expenses \$5,188.9 (78)% Operating loss \$(1,235.5) (78)% Other (expense) income, net: Dividend income \$15.4 (14)% Interest income \$13.1 (100)% Total other income \$28.5 (62)% Net loss before provision for income taxes \$(1,207.0) (78)% Provision for income taxes \$5.7 (60)% Net loss \$(1,212.7) (78)% General and administrative expense Three Months Ended June 30, (dollars in thousands) 2024 2023 Change General and administrative expense \$1,235.5 (14)% Full-time employees 57 (2)% General and administrative expense was \$1.2 million for the three months ended June 30, 2024, representing a decrease of \$4.4 million or 78%, from \$5.6 million for the three months ended June 30, 2023. The decrease for the three months ended June 30, 2024 was mostly due to higher costs in 2023 due to separation pay for executives and related stock based compensation expense, and consulting fees, partially offset by lower bonus, retention, and insurance expense. In addition, \$0.9 million of expenses, primarily facilities, depreciation and other expense and platform and discovery-related expense, no longer met the criteria to be classified as research and development expenses due to the shift in our historical operations suspending all research and development activities as discussed above. Other Income The Company sold samples of its clinical products to a private clinical stage biopharmaceutical company. Comparison of the Six Months Ended June 30, 2024 and 2023 The following table summarizes the results of our operations for the six months ended June 30, 2024 and 2023. Six Months Ended June 30, (dollars in thousands) 2024 2023 Change Revenue: Revenue \$5,000.0 (50)% Total Revenue \$5,000.0 (50)% Operating expenses: Research and development expense \$1,423.1 (100)% General and administrative expense \$2,571.8 (71)% Total operating expenses \$3,994.9 (75)% Operating loss \$(1,423.1) (100)% Other income, net: Dividend income \$32.2 (84)% Interest income \$24.1 (75)% Total other income \$56.3 (63)% Net loss before provision for income taxes \$(1,366.8) (71)% Provision for income taxes \$1.4 (86)% Net loss \$(1,368.2) (71)% Revenue On February 5, 2024, the Company entered into a patent license agreement to develop a rotavirus vaccine for potential treatment for hepatitis with a private clinical stage biopharmaceutical company. Under the terms of the agreement, this biopharmaceutical company received an exclusive license in the field of hepatitis to all of the Company's relevant patents. An initial payment of \$500 was paid to the Company after the execution of this agreement. Research and development expense The following table summarizes our research and development expenses incurred during the periods indicated. Six Months Ended June 30, (dollars in thousands) 2024 2023 Change Employee-related expense \$511.4 (51)% Facilities, depreciation, and other expenses \$755.4 (100)% Platform and discovery-related expense \$93.9 (100)% Clinical development programs expense \$64.6 (64)% Total research and development expense \$1,423.1 (100)% Research and development expense was \$0.9 million for the six months ended June 30, 2024, reflecting a decrease of \$1.4 million, or 100% from research and development expense of \$1.4 million for six months ended June 30, 2023. In 2022, the Company suspended its clinical, preclinical, and discovery program activities and reduced headcount as it began exploring strategic alternatives in April 2023. As a result, after the first quarter of 2023, the Company determined it was no longer appropriate to record any research and development expenses. General and administrative expense Six Months Ended June 30, (dollars in thousands) 2024 2023 Change General and administrative expense \$2,571.8 (71)% Full-time employees 57 (2)% General and administrative expense was \$2.6 million for the six months ended June 30, 2024, representing a decrease of \$6.2 million or 71%, from \$8.8 million for the six months ended June 30, 2023. The decrease for the six months ended June 30, 2024 was mostly due to lower professional fees as a result of reduced operations and higher costs in 2023 from the separation pay of former executives and related stock based compensation expense. Other Income The Company sold samples of its clinical products during the second quarter to a private clinical stage biopharmaceutical company. Liquidity and Capital Resources Since our inception, we have incurred significant operating losses. We generated limited revenue from our collaboration agreements, which have since been terminated. We have funded our operations to date with proceeds received from equity financings and payments received in connection with collaboration agreements, which have since been terminated. Currently we are exploring strategic alternatives and generating limited revenue. As of June 30, 2024, our cash and cash equivalents were \$0.5 million as compared to \$0.8 million as of December 31, 2023. To date, we have funded our operations primarily with proceeds received from equity financings and to a lesser extent, payments received in connection with collaboration agreements. We attempted to redeem the \$24 million aggregate principal amount of the convertible Notes Receivable in March and again in May, but have not received a response to our most recent request. Management does not believe the Notes Receivable are recoverable and they have been written down to \$0 on our balance sheet. See "Risk Factors" We do not expect to be able to redeem the investment in convertible Notes Receivable. We incurred net losses of approximately \$1.4 million and \$10.2 million for the six months ended June 30, 2024 and 2023, respectively. We expect to incur significant expenses and negative cash flows for the foreseeable future. Our current liquidity is not sufficient to continue to fund operations. As a result, there is substantial doubt about our ability to continue as a going concern. Substantial additional financing will be needed in the very near term to fund our operations and there is no certainty we will obtain such financing. If we are unable to raise capital, we will 30 Table of Contents be unable to continue operations. We may need to seek bankruptcy protection and/or cease operations in the near term, which may result in our stockholders receiving no or very little value in respect of their shares of our common stock. See "Funding Requirements" below for additional information on our future capital needs. Cash Flows The following table shows a summary of our cash flows for the six months ended June 30, 2024 and 2023. Six Months Ended June 30, (in thousands) 2024 2023 (unaudited) Net cash used in operating activities \$(1,616) (8,129) Net cash used in investing activities \$(1,789) Net cash provided by financing activities \$1,000.4 (6,242) Operating activities Net cash used in operating activities was \$1.6 million and \$8.1 million for the six months ended June 30, 2024 and 2023, respectively. The decrease in cash used in operating activities for the six months ended June 30, 2024 of \$6.5 million was due to the reduction of operating activities and lower headcount, and revenue received related to the patent license agreement. Investing activities Net cash used in investing activities was \$0.0 million and \$1.8 million for the six months ended June 30, 2024 and 2023, respectively. The decrease in cash provided by investing activities of \$1.8 million was primarily due to purchase of the convertible Notes Receivable. Financing activities Net cash provided by financing activities was \$1.0 million and \$3.7 million for six months ended June 30, 2024 and 2023, respectively. The decrease of \$2.7 million is due to the funds received from the Private Placement in February 2023. Funding Requirements We will need to obtain substantial additional funding in the very near term to continue operations. If we are unable to raise capital at all or on acceptable terms, we would be unable to continue operations. Our existing cash and cash equivalents are not sufficient to enable us to fund our operating expenses. Our future capital requirements are difficult to forecast and will depend on many factors, including: the results of our exploration of strategic alternatives, including any potential transactions; the results of any future or pending litigation against the Company; the extent to which we encounter increased costs as a result of global and macroeconomic conditions, including rising inflation and interest rates, supply chain disruptions, fluctuating exchange rates, and increases in commodity, energy and fuel prices; and unknown legal, administrative, regulatory, accounting, and information technology costs as well as additional costs associated with operating as a public company. 31 Table of Contents Until such time, if ever, as we can generate substantial revenue, we expect to finance our cash needs primarily through equity offerings. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders may be materially diluted, and the terms of such securities could include liquidation or other preferences that adversely affect the rights of our stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include restrictive covenants that limit our ability to take specified actions, such as incurring additional debt, making capital expenditures or declaring dividends. Further, the global financial markets have experienced significant disruptions over the past couple of years due to the COVID-19 pandemic, the ongoing conflict between Russia and Ukraine, and worsening global macroeconomic conditions, including actions taken by central banks to counter inflation, volatility in the capital markets and related market uncertainty, may impact our ability to obtain additional financing when needed on favorable terms or at all. Any further disruption or slowdown in the global financial markets and economy may negatively affect our ability to raise funding through equity or debt financings on attractive terms or at all, which could in the future negatively affect our operations. Going Concern In accordance with Accounting Standards Codification 205-40, Going Concern, we have evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about our ability to continue as a going concern within one year after the date that the unaudited condensed consolidated financial statements are issued. In the absence of a significant source of recurring revenue, our continued viability is dependent on our ability to continue to raise additional capital to finance our operations. As discussed above, there are substantial uncertainties about our ability to raise such financing. Contractual Obligations and Commitments There have been no material changes to our contractual obligations and commitments from those described in our Annual Report. Item 3. Quantitative and Qualitative Disclosures about Market Risk As a smaller reporting company, as defined by Rule 12b-2 of the Exchange Act and in Item 10(f)(1) of Regulation S-K, we are electing scaled disclosure reporting obligations and therefore are not required to provide the information requested by this Item. Item 4. Controls and Procedures Limitations on Effectiveness of Controls In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs. Evaluation of Disclosure Controls and Procedures We maintain disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, that are designed to ensure that information required to be disclosed in our periodic and current reports that we file with the SEC under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. 32

captioned Colwell v. Exicure, Inc. et al., Case No. 1:21-cv-0663, On February 4, 2021, plaintiff filed an amended putative securities class action complaint. On March 20, 2023, the court entered an order appointing James Mathew as lead plaintiff and Bleichmar Fonti & Auld LLP as lead counsel in the action pursuant to the Private Securities Litigation Reform Act of 1995. On May 26, 2023, lead plaintiff filed a second amended complaint against the Company, Dr. Giljohann, Mr. Bock, and Grant Corbett. The second amended complaint alleges that Dr. Giljohann, Mr. Bock, and Dr. Corbett made materially false and/or misleading statements related to the Company’s clinical programs purportedly causing losses to investors who acquired Company securities between January 7, 2021 and December 10, 2021. The second amended complaint does not quantify any alleged damages but, in addition to attorneys’ fees and costs, lead plaintiff seeks to recover damages on behalf of himself and others who acquired the Company’s stock during the putative class period at allegedly inflated prices and purportedly suffered financial harm as a result. On or around August 6, 2024, the parties reached an agreement in principle to settle the litigation, subject to executing a definitive settlement agreement and approval of the court. A status hearing with the court is set for August 30, 2024. The Company believes that any liability as a result of the settlement will be covered by insurance. On March 1, 2022, Kapil Puri filed a shareholder derivative lawsuit on behalf of the Company in the United States District Court for the Northern District of Illinois, against Messrs. Giljohann and Bock, Jeffrey L. Cleland, Elizabeth Garofalo, Bosun Hau, Bali Muralidhar, Andrew Sassine, Matthias Schroff, James Sulat and Timothy Walbert, captioned Puri v. Giljohann, et al., Case No. 1:22-cv-01083. On March 8, 2022, Yixin Sim filed a similar shareholder derivative lawsuit in the same court against the same individuals, captioned Sim v. Giljohann, et al., Case No. 1:22-cv-01217. On April 25, 2022, Stourbridge Investments LLC filed a similar shareholder derivative lawsuit against the same individuals in the United States District Court for the District of Delaware, captioned Stourbridge Investments LLC v. Exicure, Inc. et al., Case No. 1:22-cv-00526. Based on similar factual allegations presented in the Colwell complaint, described above, the Puri, Sim, and Stourbridge complaints, or collectively, the Derivative Complaints, allege that the defendants caused the Company to issue false and/or misleading statements in its 2021 proxy statement regarding risk oversight, code of conduct, clinical program and compensation matters, among other things, in violation of federal securities law, and committed breaches of fiduciary duties. The Derivative Complaints also assert that Dr. Giljohann and Mr. Bock are liable for contribution under the federal securities laws. The Puri and Stourbridge complaints further assert state law claims for unjust enrichment, and the Puri complaint additionally asserts state law claims for abuse of control, gross mismanagement and corporate waste. The plaintiffs do not quantify any alleged damages in the Derivative Complaints, but seek restitution for damages to the Company, attorneys’ fees, costs, and expenses, as well as an order directing that certain proposals for strengthening board oversight be put to a vote of the Company’s shareholders. On March 18, 2022, James McNabb, through counsel, sent a written demand to the Company (the “Demand Letter”) demanding that the Board of Directors investigate certain allegations and commence proceedings on the Company’s behalf against certain of the Company’s current officers and directors for alleged breaches of fiduciary duties and corporate waste. All of the Derivative Cases have been stayed pending a decision on any motion to dismiss that may be filed in the Colwell case. Further, pursuant to agreement, the Demand Letter is being held in abeyance and any related statute of limitations tolled pending such motion and decision. On October 3, 2023, a former employee filed a complaint against the Company and its executives related to the former employee’s separation from the Company. The parties proceeded with paper discovery and this matter did not settle at an in-person settlement conference on July 17, 2024. As a result, we are entering the discovery phase of this litigation. Table of Contents We may also be a party to litigation and subject to claims incident to the ordinary course of business. Although the results of litigation and claims cannot be predicted with certainty, we currently believe that the final outcome of these ordinary course matters will not have a material adverse effect on our business. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors. Table of Contents Item 1A. Risk Factors. In addition to other information contained in this Quarterly Report on Form 10-Q, the following risks should be considered in evaluating our business and future prospects and an investment in our common stock. The risks and uncertainties described below are not the only ones we face. If any of the following risks and uncertainties develops into actual events, our business, financial condition, results of operations and cash flows could be materially adversely affected. In that case, the price of our common stock could decline and you may lose all or part of your investment. Risks Related to Our Business Our exploration of strategic alternatives may not be successful. Given the Company’s current focus to explore growth through strategic transactions with potential partners, the Company’s ability to execute its current business plan depends on its ability to obtain additional funding via a strategic transaction or a series of strategic transactions, or to obtain funding to support such a transaction. We currently have no source of significant, ongoing revenues or committed financing, and our financial resources are limited to our cash and cash equivalents. Substantial additional funding is needed in the very near term. The Company plans to continue pursuing strategic alternatives, however, there can be no assurance that the Company will have sufficient resources or obtain additional financing necessary to complete this effort. Even if we can obtain financing, we may not be able to consummate such a transaction in a timely manner or at all or in a manner that would not adversely impact our business. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty. Strategic transactions are complex and time-consuming to identify, evaluate, negotiate and consummate in compliance with applicable laws and Nasdaq requirements. Our board and management do not have meaningful experience executing this type of endeavor in the U.S. public markets. Even if we are successful in entering into a strategic transaction, the terms and conditions of that transaction may restrict us from entering into future agreements with other potential collaborators. Additionally, such strategic transactions may not be favorable to investors nor deliver any anticipated benefits by the time of business integration. We need to obtain substantial funding in the very near term in order to continue operations and our exploration of strategic alternatives. We require significant capital resources in order to continue to operate our business and conduct our exploration of strategic alternatives, and our very limited liquidity could materially and adversely affect our business operations. Because we have no current source of significant, ongoing revenue or committed financing, our current available cash and cash equivalents provide us with very limited liquidity. Our existing cash and cash equivalents are not sufficient for us to continue to fund our business operations. Substantial additional funding is needed in the very near term. Any such required additional capital may not be available on reasonable terms, if at all, due to a variety of factors, including uncertainty about the future direction of the Company and investor reaction to our controlling stockholders and board and management composition, as well as broader conditions in the economy and capital markets, including recent volatility caused by inflation and other factors. The Company has already engaged in significant cost reductions, so our ability to further cut costs and extend our operating runway is limited. Without sufficient additional capital funding in the very near term, we may be required, among other things, to seek bankruptcy protection and/or cease operations. We do not expect to be able to redeem the investment in convertible Notes Receivable. In March 2024, the Company notified the issuer of the investment in convertible Notes Receivable that it was exercising its redemption right with respect to the entire principal amount of the investment in convertible Notes Receivable after the first anniversary of their issue dates (May 3 and May 16, 2024, respectively) for an aggregate redemption price of \$2.090 million (representing the principal amount plus 4.5% per annum yield to the redemption date). In response, the issuer took the position that the investment in convertible Notes Receivable were not redeemable until August 3, 2024 and August 16, 2024. We again attempted to redeem the entire principal amount of the convertible Notes Receivable in May, but have not received a response to our most recent request. As a result, management does not believe the Notes Receivable are recoverable and they have been written down to \$0 on our balance sheet. Table of Contents Our controlling stockholders, executive officers and members of our board, have limited experience controlling or governing a public company operating in the United States. Our controlling stockholders have not previously controlled a U.S. public company. In addition, no members of the board or our chief executive officer or chief financial officer have experience serving as directors or management of a U.S. publicly traded company. This could make it difficult to ensure that the Company complies with all applicable laws and stock exchange requirements, maintains adequate internal and disclosure controls and appropriately assesses and manages risk. This concern is exacerbated by the limited resources the Company has following recent reductions in force, and if there are further reductions in force or members of management leave the Company, it may be very difficult to manage this risk. The transitional state of the Company and ongoing exploration of strategic alternatives also exacerbates the challenging environment in this respect. If the board of directors does not successfully or efficiently manage their roles and responsibilities, including the significant regulatory oversight and reporting obligations under the federal securities laws and the continuous scrutiny of investors, our prospects may be adversely impacted. In addition, against this backdrop, it may be difficult to earn the confidence of prospective investors or strategic partners, threatening our ability to obtain much needed financing and hindering our exploration of strategic alternatives. Turnover of our board and senior management, and any inability to attract and retain qualified management and other key personnel, could impair our ability to implement our business plan. As we continue our exploration of strategic alternatives, and potentially pursue transactions involving new business lines or industries, we may experience additional turnover in our board and senior management. Departures of members of our senior management team and board members have created, and will create if they continue, significant continuity risks and challenges to our ability to operate our business, assess and manage risks and comply with applicable laws. If key members of our senior management team depart, it will be important that we attract and retain qualified managers promptly and develop and implement an effective succession plan. We expect to face significant competition in attracting experienced executives and other key personnel, and there can be no assurance that we will be able to do so. In addition, there are significant uncertainties as to how our transitional state of operations, financial condition and related matters will impact our ability to attract the necessary personnel and manage these succession risks. Our urgent need to raise capital and engage with potential partners in strategic transactions magnify these risks. If we are unable to adequately address these concerns in the near term, and earn the confidence of potential investors and/or business partners, our prospects and financial condition would be adversely impacted. Our consolidated financial statements have been prepared assuming that we will continue as a going concern. Our ability to continue as a going concern will require us to obtain additional funding. Based on our current operating plans and existing working capital at June 30, 2024, our current liquidity is not sufficient to continue to fund operations. As a result, there is substantial doubt about our ability to continue as a going concern. Substantial additional financing will be needed by us in the very near term to fund our operations and exploration of strategic alternatives. The perception of our ability to continue as a going concern may make it more difficult for us to obtain financing for the continuation of our operations and could result in the loss of confidence by investors and employees. Obtaining additional financing contains risks, including: additional equity financing may not be available to us on satisfactory terms and any equity we are able to issue could lead to dilution for current stockholders; loans or other debt instruments may have terms and/or conditions, such as interest rate, restrictive covenants and control or revocation provisions; the current environment in capital markets combined with our capital constraints may prevent us from being able to obtain adequate debt financing; and if we fail to obtain required additional financing to grow our business we may need to seek bankruptcy protection in the near term. We currently do not comply with the Nasdaq continued listing requirements and have received a delisting determination notice from the Nasdaq staff. Our common stock may be delisted from Nasdaq which could negatively impact the price of our common stock, liquidity and our ability to access the capital markets. Our common stock is currently listed on Nasdaq under the symbol “XCUR.” As previously disclosed, the Company has received numerous deficiency notices with respect to various Nasdaq listing requirements in the past year and recently received a delisting determination from the Nasdaq staff. These related to, or may in the future relate to: Table of Contents Compliance with Nasdaq’s minimum bid price rule due to the Company’s stock trading below \$1.00 for a sustained period of time. The Company effected a one-for-thirty reverse stock split on June 29, 2022 in order to attempt to raise the stock price. On September 13, 2023, the Company received a delinquency notification that the closing bid price of the Company’s stock traded below \$1.00 for the previous 30 consecutive business days. The Company’s stock price has remained below \$1.00 since receipt of the notification, which must be cured by September 9, 2024, per the March 12, 2024 extension letter received from Nasdaq. As described below, the Company now has until September 16, 2024 to cure all outstanding deficiencies pursuant to the decision of the Nasdaq Hearings Panel. The Company intends to attempt to cure the bid price deficiency by effecting another reverse stock split, subject to stockholder approval. A special meeting of stockholders has been called for August 15, 2024, at which stockholders will vote on a proposal to approve a reverse stock split at a ratio in the range of 1-for-2 to 1-for-15, with such ratio to be determined at the discretion of the Board of Directors. Compliance with Nasdaq’s rule requiring stockholders’ equity of at least \$2,500,000 based on the Company’s balance sheet as of June 30, 2024. The Company is not in compliance with this requirement based on its June 30, 2024 balance sheet. Compliance with Nasdaq’s corporate governance requirements with respect to board and committee composition. The Company has received numerous deficiency notifications with respect to these requirements in the past year. Although the Company believes it is currently in compliance, there can be no assurance it will remain in compliance. Compliance with Nasdaq’s requirement to hold an annual meeting. On January 11, 2024, Nasdaq notified the Company that it did not comply with listing requirements by not holding an annual meeting in 2023. The Company held its combined 2023 and 2024 annual meeting on June 28, 2024. On April 17, 2024, the Company received a delinquency notification as it had not filed its Annual Report Form 10-K for the year ended December 31, 2023. The extended deadline for compliance was established by Nasdaq at May 20, 2024, the same deadline for our Form 10-Q for the quarter ended September 30, 2023. The Annual Report Form 10-K was filed on June 6, 2024. Although the Company filed its Form 10-Q for the quarter ended September 30, 2023 prior to the extended deadline of May 20, 2024, on May 21, 2024, the Company received a delisting determination from the Nasdaq staff as a result of not filing its Annual Report Form 10-K by the May 20, 2024 deadline and failure to timely file its Form 10-Q for the quarter ended March 31, 2024 (which was subsequently filed on June 17, 2024). The staff’s delisting determination also noted the failure to hold its 2023 annual meeting as another basis of the delisting determination. On May 28, 2024, the Company requested an appeal of the delisting determination to Nasdaq’s hearings panel. A hearing has been scheduled for July 9, 2024. On July 31, 2024, the Company received formal notice that the Nasdaq Hearings Panel determined to continue the Company’s listing subject to the Company evidencing compliance with all applicable criteria for continued listing on The Nasdaq Capital Market by September 16, 2024. The Company is diligently working to timely satisfy the terms of the Panel’s decision and to ensure the Company’s continued listing on Nasdaq. We may not be successful in our appeal or be able to regain compliance with Nasdaq’s listing requirements and our failure to do so may result in the delisting of our Common Stock by Nasdaq. Even if the Company is successful in our appeal and regains compliance with Nasdaq’s listing requirements and addresses the outstanding deficiency notices to Nasdaq’s satisfaction, there can be no assurance that the Company will remain in compliance with Nasdaq’s requirements and will not be delisted. If Nasdaq suspends or delists our securities from trading on its exchange for failure to meet the listing standards, we and our stockholders could face significant negative consequences including: limited availability of market quotations and liquidity for our securities; a determination that the common stock is a “penny stock” which would require brokers trading in the common stock to adhere to more stringent rules, possibly resulting in a reduced level of trading activity in the secondary trading market for shares of common stock; a limited amount of analyst coverage, if any; a decreased ability to issue additional securities or obtain additional financing in the future. Table of Contents Suspension or delisting from Nasdaq could also result in other negative consequences, including the potential loss of institutional investor interest and make obtaining new financing much more challenging. In addition, fewer strategic opportunities may be available, particularly from counterparties that are interested in combining with a listed company. We have a history of losses. We expect to continue to incur significant losses for the foreseeable future and may never achieve or maintain profitability, which could result in a decline in the market value of our common stock. Between our inception in June 2011 and the Company’s decision to engage in a broader exploration of strategic alternatives, we devoted our resources to the development of SNA technology, and are currently exploring out-licensing opportunities and strategic alternatives to maximize stockholder value. We have had significant operating losses since our inception. As of June 30, 2024, we have generated an accumulated deficit of \$209.8 million, including \$18,837 of additional paid-in capital reclassified to accumulated deficit upon C-corporation conversion. For the six months ended June 30, 2024 and 2023, our net loss was \$1.4 million and \$10.2 million, respectively. Substantially all of our losses have resulted from expenses incurred in connection with our research programs and from general and administrative costs associated with our operations. Although we have generated a limited amount of revenues from licensing and sales of supplies, we have not generated, and do not expect to generate, any product revenue for the foreseeable future and currently have no source of significant, ongoing revenue or committed financing, and we expect to continue to incur significant operating losses for the foreseeable future. The amount of future losses is uncertain. Our future financial performance and condition are substantially dependent on the results of our ongoing exploration of strategic alternatives, and we cannot predict whether we will be successful. We are pursuing asset out-licenses, asset sales and similar strategic transactions with respect to our historical assets. There can be no assurance that we will be successful in executing such a strategic transactions. Our internal computer systems, or those of contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our business operations. Despite the implementation of security measures, our internal computer systems and those of our contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. Such

events could cause interruptions of our operations. For instance, theft or other exposure of data may interfere with our ability to protect our intellectual property, trade secrets, and other information critical to our operations. We can provide no assurances that certain sensitive and proprietary information relating to one or more of our therapeutic candidates has not been, or will not in the future e, compromised. Although we have invested resources to enhance the security of our computer systems, there can be no assurances we will not experience additional unauthorized intrusions into our computer systems, or those of our contractors and consultants, that we will successfully detect future unauthorized intrusions in a timely manner, or that future unauthorized intrusions will not result in material adverse effects on our financial condition, reputation, or business prospects. Payments related to the elimination of ransomware may materially affect our financial condition and results of operations. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the development of our therapeutic candidates could be delayed. Our information technology systems could face serious disruptions that could adversely affect our business. Our information technology and other internal infrastructure systems, including corporate firewalls, servers, documents storage systems, backup systems, leased lines and connection to the Internet, face the risk of systemic failure that could disrupt our operations. A significant disruption in the availability of our information technology and other internal infrastructure systems could cause interruptions and delays in our operations. Our business and operations could suffer in the event of system failures or unauthorized or inappropriate use of or access to our information technology systems. We are increasingly dependent on our information technology systems and infrastructure for our business. We collect, store and transmit sensitive information including intellectual property, proprietary business information and personal information in connection with business operations. The secure maintenance of this information is critical to our operations and business strategy. Some of this information could be an attractive target of criminal attack or unauthorized access and use by third parties with a wide range of motives and expertise, including organized criminal groups, hackers, patient groups, disgruntled current or former employees and others. Cyber-attacks are of ever-increasing sophistication and complexity, and despite our security measures, our information technology systems and infrastructure may be vulnerable to such attacks or may be breached, including due to employee error or malfeasance. The pervasiveness of cybersecurity incidents in general and the risks of cyber-crime are complex and continue to evolve. Although we are making significant efforts to maintain the security and integrity of our information systems and are exploring various measures to manage the risk of a security breach or disruption, there can be no assurance that our security efforts and measures will be effective or that attempted security breaches or disruptions would not be successful or damaging. Despite the implementation of security measures, our internal computer systems and those of our employees, contractors and consultants are vulnerable to damage or interruption from computer viruses, unauthorized or inappropriate access or use, natural disasters, pandemics (including COVID-19), terrorism, war, and telecommunication and electrical failures. Such events could cause interruption of our operations. For example, the loss or compromise of preclinical data for our therapeutic candidates could result in delays in our regulatory filings and development efforts, as well as delays in the commercialization of our products, and significantly increase our costs. To the extent that any disruption, security breach or unauthorized or inappropriate use or access to our systems were to result in a loss of or damage to our data, or inappropriate disclosure of confidential or proprietary information, including but not limited to patient, employee or vendor information, we could incur notification obligations to affected individuals and government agencies, liability, including potential lawsuits from patients, collaborators, employees, stockholders or other third parties and liability under foreign, federal and state laws that protect the privacy and security of personal information, and the development and potential commercialization of our therapeutic candidates could be delayed. Existing insurance arrangements may not provide protection for the costs that may arise from such loss or damage. Any long-term disruption in our ability to access our information technology systems could have a material adverse effect on our operations, our business, results of operations and stock price. Our current operations are concentrated in one location and any events affecting this location may have material adverse consequences. Our current operations are located in our facilities situated in Chicago, Illinois. Any unplanned event, such as flood, fire, explosion, earthquake, extreme weather condition, medical epidemics, power shortage, telecommunication failure or other natural or man-made accidents or incidents that result in us being unable to fully utilize the facilities, may have a material adverse effect on our ability to operate our business, particularly on a daily basis, and have significant negative consequences on our financial and operating conditions. Loss of access to these facilities may result in increased costs, or interruption of our business operations. As part of our risk management policy, we maintain insurance coverage at levels that we believe are appropriate for our business. However, in the event of an accident or incident at these facilities, we cannot assure you that the amounts of insurance will be sufficient to satisfy any damages and losses. If our facilities are unable to operate because of an accident or incident or for any other reason, even for a short period of time, any or all of our research and development programs may be harmed. Any business interruption may have a material adverse effect on our business, financial position, results of operations and prospects. If we continue to fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired. We are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act of 2002, or Sarbanes-Oxley Act, and the rules and regulations of Nasdaq. Pursuant to Section 404 of the Sarbanes-Oxley Act, or Section 404, we are required to perform system and process evaluation and testing of our internal control over financial reporting to allow our management to report on the effectiveness of our internal control over financial reporting. However, while we remain a non-accelerated filer or an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. During the evaluation and testing process, we identified material weaknesses as described under Part I, Item 4 of this Form 10-Q. If we fail to remediate that material weakness, or if we identify one or more material weaknesses in our internal control over financial reporting, we will be unable to assert that our internal control over financial reporting is effective. Further, we may in the future discover additional weaknesses in our system of internal financial and accounting controls and procedures that could result in additional material misstatement of our financial statements. Moreover, our internal controls over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system's objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected. Moreover, we are aware that the remote working arrangements implemented in connection with the COVID-19 pandemic potentially present new areas of risk, and we continue to carefully monitor any impact to our internal controls and procedures. Our limited resources and recent reductions in force, as well as the turnover in our board of directors and the potential for future management changes, present significant continuity risk and could impact our ability to remediate our material weaknesses and maintain effective internal control over financial reporting in the future. If we are unable to remedy our material weaknesses and assert that our internal control over financial reporting is effective, investors could lose confidence in the reliability of our financial statements, the market price of our stock could decline and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities. The restatement of our prior quarterly financial statements may affect stockholder and investor confidence in us or harm our reputation, and may subject us to additional risks and uncertainties, including increased costs and the increased possibility of legal proceedings and regulatory inquiries, sanctions or investigations. Management identified material weaknesses in the Company's internal control over financial reporting and restated its 2023 first quarter and second quarter unaudited interim condensed consolidated financial statements via Form 10-Q/A's. As a result of the restatement, we have incurred, and may continue to incur, unanticipated costs for accounting and legal fees in connection with, or related to, such restatement. In addition, such restatement could subject us to a number of additional risks and uncertainties, including the increased possibility of legal proceedings and inquiries, sanctions or investigations by the SEC or other regulatory authorities. Any of the foregoing may adversely affect our reputation, the accuracy and timing of our financial reporting, or our business, results of operations, liquidity and financial condition, or cause stockholders, investors, members and customers to lose confidence in the accuracy and completeness of our financial reports or cause the market price of our common stock to decline. Risks Related to Ownership of Our Common Stock The influence of our significant stockholders could make our Common Stock less attractive to some investors or otherwise harm the trading price of our Common Stock. CBI USA and DGP collectively own approximately 45% of outstanding Common Stock and exercise significant influence over us. We previously had been a controlled company under the corporate governance rules for Nasdaq-listed companies and still do not have a majority independent board. Members of our board and management are directly affiliated with CBI and DGP. Investors may be hesitant to invest in the Company given the influence of CBI and DGP. In addition, should the interest or interests of our controlling stockholders differ from those of other stockholders, the other stockholders may not have the same protections afforded to stockholders of companies that are subject to all of the corporate governance rules for Nasdaq-listed companies. Additionally, it is possible we could pursue strategic or financing transactions with our controlling stockholders or their affiliates. The interests of the controlling stockholders and other stockholders would diverge in this case, and the lack of an independent board to evaluate such a transaction could adversely impact other stockholders. These conflicts of interest (or the perception that they could occur) might adversely affect our business and prospects for obtaining financing or completing a strategic transaction. For so long as CBI USA and DGP own a significant stake, they (and/or their transferees) will have substantial control over the elections of our directors and to approve any other corporate action requiring the affirmative vote of holders of a majority of the outstanding shares of our Common Stock. This could deter investment in the Company and adversely impact our stock price and ability to obtain financing. These impacts may be more pronounced in the near term as investors assess the direction of the Company under the control of CBI USA and DGP and the impact of the new board and management. DGP's recently announced agreement to sell its shares to a third party could also deter investment as it creates uncertainty as to the transferee's intentions with respect to the Company. If DGP's sale is completed, the third party transferee would become the Company's largest stockholder. Potential partners considering engaging in a strategic transaction with the Company could have similar concerns. Given our urgent need for additional funding and/or to complete a strategic transaction, it is imperative that our controlling stockholders and our board and management earn the confidence of investors and potential partners in the near term and there is no assurance this will occur. The market price of our common stock has been, and is likely to continue to be, highly volatile, and you may not be able to resell your shares at or above the price you paid for them. Our stock price will continue to be volatile. As a result of this volatility, investors may not be able to sell their common stock at or above the price paid for the shares. The market price for our common stock may be influenced by a variety of factors, including the other risks described in this section titled "Risk Factors" and the following: (1) our ability or inability to raise additional capital and the terms on which we raise it; (2) the development, execution and announcement of any proposed strategic alternative; (3) investors may react negatively to our controlled company status and the influence of our controlling stockholder or our reconstituted board and/or our uncertain business strategy; (4) strategic decisions by us or our competitors, such as acquisitions, divestitures, spin-offs, joint ventures, strategic investments or changes in business strategy; (5) we are unable to achieve the perceived benefits of our Company as rapidly or to the extent anticipated by financial or industry analysts; and (6) changes in general economic, industry, political and market conditions, including, but not limited to, the ongoing impact of the COVID-19 pandemic. In addition, the stock markets in general, and the markets for pharmaceutical and biotechnology stocks in particular, have experienced extreme volatility that has been often unrelated to the operating performance of the issuer. These broad market and industry factors, such as those related to the COVID-19 pandemic, Russia's invasion of Ukraine, and the Israel/Hamas war and retaliatory actions taken by the United States, NATO and others, may seriously harm the market price of our common stock, regardless of our operating performance. Raising additional funds by issuing securities may cause dilution to existing stockholders and raising funds through lending and licensing arrangements may restrict our operations or require us to relinquish proprietary rights. Until such time, if ever, as we can generate substantial revenues, we expect to attempt to finance our cash needs through a combination of equity offerings and debt financings. As discussed elsewhere, it may be very challenging to obtain equity or debt financing given the current transitional state of the Company. However, to the extent that we raise additional capital through the issuance of shares or other securities convertible into shares, our stockholders will be diluted. Future issuances of our common stock or other equity securities, or the perception that such sales may occur, could adversely affect the prevailing market price of our common stock and impair our ability to raise capital through future offerings of equity or equity-linked securities. We cannot be certain if the reduced reporting requirements applicable to us will make our common stock less attractive to investors. We were an emerging growth company as defined in the JOBS Act until December 31, 2023. As such, we took advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including (1) not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, (2) reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and (3) exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. In addition, as an emerging growth company, we were only required to provide two years of audited financial statements. Even though we no longer qualify as an emerging growth company as of 2024, we still qualify as a smaller reporting company and a non-accelerated filer which allows us to continue to take advantage of many of the same exemptions from disclosure requirements including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our share price may be more volatile. Anti-takeover provisions in our charter documents and under the General Corporation Law of the State of Delaware could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our management. Provisions in our amended and restated certificate of incorporation and our bylaws may delay or prevent an acquisition of us or a change in our management. These provisions include a classified board of directors, a prohibition on actions by written consent of our stockholders, and the ability of the Board of Directors of the Company, or the Board, to issue preferred stock without stockholder approval. In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, or DGCL, which prohibits stockholders owning in excess of 15% of the outstanding combined organization voting stock from merging or combining with the combined organization. Although we believe these provisions collectively will provide for an opportunity to receive higher bids by requiring potential acquirers to negotiate with our Board, they would apply even if the offer may be considered beneficial by some stockholders. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove then-current management by making it more difficult for stockholders to replace members of the Board, which is responsible for appointing the members of management. Our amended and restated certificate of incorporation designates the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders' ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees or agents. Our amended and restated certificate of incorporation provides that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for any of the following types of actions or proceedings under Delaware statutory or common law: derivative action or proceeding brought on our behalf, any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, employees or agents to us or our stockholders, any action asserting a claim arising pursuant to any provision of the DGCL, our amended and restated certificate of incorporation or our amended and restated bylaws or any action asserting a claim that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein. This provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act, or any other claims for which a court or forum other than the Court of Chancery has exclusive jurisdiction or for which the Court of Chancery does not have subject matter jurisdiction. Furthermore, Section 22 of the Securities Act, creates concurrent jurisdiction for federal and state courts over all Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. Our amended and restated certificate of incorporation also provides that any person purchasing or otherwise acquiring any interest in any shares of our common stock shall be deemed to have notice of and to have consented to this provision of our amended and restated certificate of incorporation. This choice of forum provision may limit our stockholders' ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, employees or agents, which may discourage such lawsuits against us and our directors, officers, employees and agents even though an action, if successful, might benefit our stockholders. Stockholders who do bring a claim in the Court of Chancery could face additional litigation costs in pursuing any such claim, particularly if they do not reside in or near Delaware. The Court of Chancery may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments or results may be more favorable to us than to our stockholders. If a court were to find this exclusive forum provision in our

amended and restated certificate of incorporation to be applicable or unenforceable in any action, we may incur further significant additional costs associated with resolving the dispute in other jurisdictions, all of which could have a material adverse effect on our business, financial condition or results of operations. Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited. We have incurred substantial losses during our history and do not expect to be profitable in the near future, if ever. Our net operating loss, or NOL, carryforwards generated in tax years beginning on or before December 31, 2017, are only permitted to be carried forward for 20 years under applicable U.S. tax law. Under the Tax Cuts and Jobs Act, as modified by the CARES Act, our federal NOLs generated in tax years beginning after December 31, 2017, may be carried forward indefinitely, but the deductibility of such federal NOLs is limited to 80% of taxable income. In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an “ownership change,” generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period, the corporation’s ability to use its pre-change NOL, and other pre-change tax attributes (such as research tax credits) to offset its post-change income or taxes may be limited. We have experienced ownership changes in the past. We completed a review of our changes in ownership through December 31, 2022 and determined that we experienced an “ownership change” within the meaning of Section 382(g) during the fourth quarter of 2022. This ownership change has and will continue to subject our net operating loss carryforwards to an annual limitation, which will significantly restrict our ability to use them to offset our taxable income in periods following the ownership change. We determined that at the date of the 2022 ownership change, we had a net unrealized built-in loss (“NUBIL”). The NUBIL was determined based on the difference between the fair market value of our assets and their tax basis at the ownership change date. Because of the NUBIL, certain deductions recognized during the five-year period beginning on 43Table of Contents the date of the IRC Section 382 ownership change (the “recognition period”) are subject to the same limitation as the net operating loss carryforwards or certain other deductions.As of December 31, 2023, we determined that we ceased operations of our historical business enterprise which subjects us to a zero limitation as defined under IRC Section 382(c). Therefore, we are restricted in our ability to use any of the historical net operating losses that occurred before the most recent ownership change in the 4th quarter of 2022. General Risk FactorsFINRA sales practice requirements may limit a stockholder’s ability to buy and sell our stock due to our low stock price.The Financial Industry Regulatory Authority, or FINRA, has adopted rules requiring that, in recommending an investment to a customer, a broker-dealer must have reasonable grounds for believing that the investment is suitable for that customer. Prior to recommending speculative or low-priced securities to their non-institutional customers, broker-dealers must make reasonable efforts to obtain information about the customer’s financial status, tax status, investment objectives and other information. Under interpretations of these rules, FINRA has indicated its belief that there is a high probability that speculative or low-priced securities will not be suitable for at least some customers. If these FINRA requirements are applicable to us or our securities, which we believe they are, they may make it more difficult for broker-dealers to recommend that at least some of their customers buy our common stock, which may limit the ability of our stockholders to buy and sell our common stock and could have an adverse effect on the market for and price of our common stock.If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline. The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business. Our research coverage by securities and industry analysts is currently limited. In addition, because we did not become a reporting company by conducting an underwritten initial public offering of our common stock, security analysts of brokerage firms may not provide wider coverage of our Company. In addition, investment banks may be less likely to agree to underwrite secondary offerings on our behalf than they might if we became a public reporting company by means of an underwritten initial public offering, because they may be less familiar with our Company as a result of more limited coverage by analysts and the media, and because we became public at an early stage in our development. The failure to receive wider research coverage or support in the market for our shares will have an adverse effect on our ability to develop a liquid market for our common stock and the trading price for our stock would be negatively impacted.In the event we obtain wider securities or industry analyst coverage, if any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if our target studies and operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. 44Table of ContentsItem 2. Unregistered Sales of Equity Securities and Use of Proceeds. None.Item 3. Defaults Upon Senior Securities.None.Item 4. Mine Safety Disclosures.Not applicable.Item 5. Other Information.During the quarter ended June 30, 2024, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.45Table of ContentsItem 6. ExhibitsIncorporated by Reference ExhibitNo.Exhibit DescriptionFormExhibit No.Filing DateFile No.3.1Certificate of Amendment to Certificate of Incorporation, filed with the Secretary of State of the State of Delaware on September 26, 2017.8-K3.210/02/17A 000-557643.2Amended and Restated Certificate of Incorporation, as filed with the Secretary of State of the State of Delaware on November 15, 2017.10-K3.33/11/21001-390113.3Certificate of Amendment to Amended and Restated Certificate of Incorporation of Excure, Inc., effective June 29, 2022.8-K3.106/29/22001-390113.4Amended and Restated Bylaws, as currently in effect.8-K3.410/02/17000-557643.1.*Certification of Principal Executive Officer Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, As Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.31.2*Certification of Principal Financial Officer Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, As Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.32.1*Certifications of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.101.INS*Inline XBRL Instance Document “a” the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document101.SCH*Inline XBRL Taxonomy Extension Schema Document101.CAL*Inline XBRL Taxonomy Extension Calculation Linkbase Document101.DEF*Inline XBRL Taxonomy Extension Definition Linkbase Document101.LAB*Inline XBRL Taxonomy Extension Label Linkbase Document101.PRE*Inline XBRL Taxonomy Extension Presentation Linkbase Document104*Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)* Filed herewith.46Table of Contents** The certification attached as Exhibit 32.1 that accompanies this Quarterly Report on Form 10-Q is not deemed filed with the SEC and is not to be incorporated by reference into any filing of Excure, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of such Form 10-Q), irrespective of any general incorporation language contained in such filing.47Table of ContentsSIGNATURESPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.Date: August 13, 2024EXICURE, INC.By:/s/ Paul KangPaul KangChief Executive OfficerBy:/s/ Jiyoung HwangJiyoung HwangChief Financial OfficerBy:/s/ Joshua MillerJoshua MillerChief Accounting Officer48 EX-31.1 2 excureexhibit311-63024.htm EX-31.1 DocumentExhibit 31.1 CERTIFICATIONS I, Paul Kang, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Excure, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and 5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and 5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. Date: August 13, 2024/s/ Paul KangPaul KangChief Executive Officer(Principal Executive Officer) EX-31.2 3 excureexhibit312-63024.htm EX-31.2 DocumentExhibit 31.2 CERTIFICATIONS I, Jiyoung Hwang, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Excure, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and 5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. Date: August 13, 2024/s/ Jiyoung HwangJiyoung HwangChief Financial Officer(Principal Financial Officer) EX-32.1 4 excureexhibit321-63024.htm EX-32.1 DocumentExhibit 32.1 SECTION 1350 CERTIFICATIONS* Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. § 1350), Paul Kang, Chief Executive Officer of Excure, Inc. (the “Company”), and Jiyoung Hwang, Chief Financial Officer of the Company, each hereby certifies that, to the best of his or her knowledge:1. The Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2024, to which this Certification is attached as Exhibit 32.1 (the “Periodic Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and 2. The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: August 13, 2024IN WITNESS WHEREOF, the undersigned have set their hands hereto as of the 13th day of August, 2024./s/ Paul Kang/s/ Jiyoung HwangPaul KangJiyoung HwangChief Executive OfficerChief Financial Officer(Principal Executive Officer)(Principal Financial Officer)A *This certification accompanies the Quarterly Report on Form 10-Q, to which it relates is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Excure, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Quarterly Report on Form 10-Q), irrespective of any general incorporation language contained in such filing. EX-101.SCH 5 xcure-20240630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 9952151 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 9952152 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952153 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 9952154 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY link:presentationLink link:calculationLink link:definitionLink 9952155 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 9952156 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952157 - Disclosure - Description of Business, Basis of Presentation and Going Concern link:presentationLink link:calculationLink link:definitionLink 9952158 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 9952159 - Disclosure - Supplemental Balance Sheet Information link:presentationLink link:calculationLink link:definitionLink 9952160 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 9952161 - Disclosure - Investment in Convertible Notes Receivable link:presentationLink link:calculationLink link:definitionLink 9952162 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 9952163 - Disclosure - Stockholders’ Equity link:presentationLink link:calculationLink link:definitionLink 9952164 - Disclosure - Equity-Based Compensation link:presentationLink link:calculationLink link:definitionLink 9952165 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 9952166 - Disclosure - Loss Per Common Share link:presentationLink link:calculationLink link:definitionLink 9952167 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 9952168 - Disclosure - Commitment and Contingencies link:presentationLink link:calculationLink link:definitionLink 9952169 - Disclosure - Related-Party Transactions link:presentationLink link:calculationLink link:definitionLink 9952170 - Disclosure - License Agreement link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Supplemental Balance Sheet Information (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Equity-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Loss Per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Description of Business, Basis of Presentation and Going Concern (Details) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Supplemental Balance Sheet Information - Schedule of Prepaid and Other Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Supplemental Balance Sheet Information - Schedule of Other Noncurrent Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Supplemental Balance Sheet Information - Schedule of Property and Equipment, Net (Details) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Supplemental Balance Sheet Information - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Supplemental Balance Sheet Information - Schedule of Accrued expenses and other current liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Leases - Lease Costs (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Leases - Sublease Receipts (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Investment in Convertible Notes Receivable - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure -

Debt - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Stockholders' Equity - Preferred and Common Stock (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Stockholders' Equity - Securities Purchase Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Stockholders' Equity - Common Stock Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Equity-Based Compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Equity-Based Compensation - Schedule of Equity-Based Compensation Expense Classification in Statement of Operations (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Equity-Based Compensation - Schedule of Assumptions Used to Determine Fair Value of Common Stock Option Grants (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Equity-Based Compensation - Schedule of Fair Value of Underlying Common Stock and Exercise Price of Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Equity-Based Compensation - Schedule of Stock Options Rollforward (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Equity-Based Compensation - Schedule of Restricted Stock Unit Awards Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Income Taxes - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Loss Per Common Share - Schedule of Computation of loss per common share (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Loss Per Common Share - Schedule of Antidilutive Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Commitment and Contingencies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Related-Party Transactions - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - License Agreement (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 xcur-20240630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 xcur-20240630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 xcur-20240630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Maximum ESPP contribution rate as a percentage of compensation (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate Adjustments to reconcile net loss to cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Statistical Measurement [Domain] Statistical Measurement [Domain] Related-Party Transactions Related Party Transactions Disclosure [Text Block] Schedule of Lease Costs Lease, Cost [Table Text Block] Schedule of Prepaid and Other Current Assets Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Maximum contribution amount Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount Other income Other Nonoperating Income Cover [Abstract] Net (decrease) in cash, cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Trading Symbol All Trading Arrangements All Trading Arrangements [Member] Third Party Sale of Company Stock Third Party Sale Of Company Stock [Member] Third Party Sale Of Company Stock Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Non-NEOs Non-NEOs [Member] Schedule of Computation of Loss per Common Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Schedule of Equity-Based Compensation Expense Classification in Statement of Operations Share-Based Payment Arrangement, Cost by Plan [Table Text Block] Promissory Note Promissory Note [Member] Promissory Note Pay vs Performance Disclosure [Line Items] Prepaid insurance Prepaid Insurance, Noncurrent Prepaid Insurance, Noncurrent Prepaid software Prepaid Software, Current Prepaid Software, Current Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Loss Per Common Share Earnings Per Share, Policy [Policy Text Block] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Vesting of restricted stock units and related repurchases (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Fair Value Measurements Fair Value Disclosures [Text Block] Award Timing Disclosures [Line Items] Other Performance Measure, Amount Other Performance Measure, Amount Leases Lessee, Operating Leases [Text Block] Common stock, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Operating lease costs Operating Lease, Cost Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Number of shares available for grant (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Lease liability, noncurrent Operating Lease, Liability, Noncurrent Common Stock And Accompanying Warrant Common Stock And Accompanying Warrant [Member] Common Stock And Accompanying Warrant Warrant liability, measurement input, term Warrants and Rights Outstanding, Term Plan Name [Domain] Plan Name [Domain] Sales price of shares issued in transaction (in dollars per share) Sale of Stock, Price Per Share Other noncurrent assets Other noncurrent assets Other Assets, Noncurrent Entity Tax Identification Number Entity Tax Identification Number Leases [Abstract] Leases [Abstract] Schedule of Finite-Lived Intangible Assets [Table] Intangible Asset, Finite-Lived [Table] Pro rata accrual Registration Rights Agreement, Pro Rata Accrual Registration Rights Agreement, Pro Rata Accrual Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Money market funds Money Market Funds [Member] Proceeds from patent license agreement Proceeds From Patent License Agreement Proceeds From Patent License Agreement Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Consideration for stock transaction Sale of Stock, Consideration Received on Transaction Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Plan Name [Axis] Plan Name [Axis] Equity Components [Axis] Equity Components [Axis] Award Timing Method Award Timing Method [Text Block] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Available-for-sale securities Investment in convertible notes receivable Debt Securities, Available-for-Sale Measurement Frequency [Axis] Measurement Frequency [Axis] Warrants settled (in shares) Class Of Warrant Or Right, Number Of Securities Settled In Period Class Of Warrant Or Right, Number Of Securities Settled In Period Entity Common Stock, Shares Outstanding (in shares) Entity Common Stock, Shares Outstanding Redemption price percentage Debt Securities, Available-for-Sale, Redemption Price, Percentage Debt Securities, Available-for-Sale, Redemption Price, Percentage Non-employee Director Non-employee Director [Member] Non-employee Director [Member] Insider Trading Policies and Procedures [Line Items] Use of Estimates Use of Estimates, Policy [Policy Text Block] Adjustment to Compensation, Amount Adjustment to Compensation Amount Compensation Amount Outstanding Recovery Compensation Amount Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Entity Small Business Entity Small Business Company Selected Measure Amount Company Selected Measure Amount Geographical [Axis] Geographical [Axis] Tabular List, Table Tabular List [Table Text Block] Level 3 Fair Value, Inputs, Level 3 [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Weighted Average Weighted Average [Member] Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Schedule of Other Noncurrent Assets Schedule of Other Assets, Noncurrent [Table Text Block] Number of shares called by warrants (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Accrued expenses and other current liabilities Accrued expenses and other current liabilities Accrued Liabilities, Current Potentially dilutive shares excluded from computation of weighted-average diluted common shares outstanding (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Period One Share-Based Payment Arrangement, Tranche One [Member] Warrants issued in sale of stock (in shares) Sale Of Stock, Number Of Warrants Issued In Transaction Sale Of Stock, Number Of Warrants Issued In Transaction Cash, cash equivalents, and restricted cash - beginning of period Cash, cash equivalents, and restricted cash - end of period Total cash, cash equivalents, and restricted cash shown in the unaudited condensed consolidated statements of cash flows Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Common stock, voting rights for each share Common Stock, Voting Rights For Each Share Common Stock, Voting Rights For Each Share Compensation cost not yet recognized Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Current assets: Assets, Current [Abstract] Payments for minimum statutory tax withholding related to net share settlement of equity awards Payment, Tax Withholding, Share-Based Payment Arrangement Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Monthly vesting percentage (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Monthly Percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Monthly Percentage Operating lease, estimated rental payment over lease term Lessee, Operating Lease, Estimated Rental Payment Over Original Term Lessee, Operating Lease, Estimated Rental Payment Over Original Term Share-based Payment Arrangement, Option Options to purchase common stock Share-Based Payment Arrangement, Option [Member] Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Short term lease costs Short-Term Lease, Cost Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Warrant Warrants to purchase common stock Warrant [Member] Other receivable Increase (Decrease) in Other Receivables Security Exchange Name Security Exchange Name Award Type [Axis] Award Type [Axis] Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Total liabilities Liabilities Registration rights agreement, liquidation damages payable as a percent of amount invested, if filed late (as a percent) Registration Rights Agreement, Liquidation Damages Payable As A Percent Of Amount Invested, If Filed Late Registration Rights Agreement, Liquidation Damages Payable If Filed Late, As A Percent Of Amount Invested Exercisable, weighted-average exercise price (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Number of shares issued for each vested restricted stock unit (in shares) Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Of Common Stock Issuable Upon Vesting Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Of Common Stock Issuable Upon Vesting Notes Receivable, One Notes Receivable, One [Member] Notes Receivable, One Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Third Party Third Party [Member] Third Party Research and development expense Research and Development Expense Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Expiration Date Trading Arrangement Expiration Date Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Restricted Stock Units Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Goodwill and Intangible Assets Disclosure [Abstract] Number of shares exercisable for each warrant (in shares) Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Current lease liability Operating Lease, Liability, Current Total Shareholder Return Amount Total Shareholder Return Amount Common stock, shares issued (in shares) Common Stock, Shares, Issued Entity [Domain] Entity [Domain] CBI USA, Inc CBI USA, Inc [Member] CBI USA, Inc Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Purchase price (in dollars per share) Sale Of Stock And Warrants, Price Per Share Sale Of Stock And Warrants, Price Per Share Scientific equipment Equipment [Member] Pro rata payment Registration Rights Agreement, Pro Rata Payment Registration Rights Agreement, Pro Rata Payment Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Less: accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property and equipment, gross Property, Plant and Equipment, Gross Prepaid insurance Prepaid Insurance Exercise (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Debt Instrument [Line Items] Debt Instrument [Line Items] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Weighted-Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Research and development expense Research and Development Expense [Member] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Weighted-average diluted common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Total stockholders' equity Beginning balance Ending balance Equity, Attributable to Parent Related Party Related Party [Member] Operating lease, renewal term Lessee, Operating Lease, Renewal Term Interest expense Interest Expense, Nonoperating DGP Co. Ltd DGP Co. Ltd [Member] DGP Co. Ltd Fair Value, Recurring Fair Value, Recurring [Member] Number of additional shares allowable annually under the plan (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Allowable Under The Plan Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Allowable Under The Plan Maximum number of shares per employee in purchase period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Shares Per Employee Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Prepaid franchise tax Prepaid Franchise Tax Prepaid Franchise Tax Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Number of shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Sale of Stock [Domain] Sale of Stock [Domain] Other liabilities Increase (Decrease) in Other Operating Liabilities Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Document Fiscal Period Focus Document Fiscal Period Focus All Executive Categories All Executive Categories [Member] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Weighted-Average Remaining Contractual Term (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term ASSETS Assets [Abstract] Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Document Type Document Type Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Exercisable, weighted-average remaining contractual term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Initial Employee Stock Option Initial Employee Stock Option [Member] Initial Employee Stock Option [Member] Depreciation and amortization Depreciation, Amortization and Accretion, Net Exercise price of common stock option (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Maximum Maximum [Member] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Furniture and fixtures Furniture and Fixtures [Member] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Accounts payable Accounts Payable, Current Accounting Policies [Abstract] Accounting Policies [Abstract] Revenue: Revenues [Abstract] Schedule of Assumptions Used to Determine Fair Value of Common Stock Option Grants Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Current Fiscal Year End Date Current Fiscal Year End Date Amount of transaction Related Party Transaction, Amounts of Transaction Total lease costs Lease, Cost Dividend income Investment Income, Dividend Statistical Measurement [Axis] Statistical Measurement [Axis] PEO Name PEO Name Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Net loss before provision for income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Vesting [Axis] Vesting [Axis] Award Type [Domain] Award Type [Domain] Name Outstanding Recovery, Individual Name Operating lease, number of extensions Lessee, Operating Lease, Number of Extensions Lessee, Operating Lease, Number of Extensions Prepaid professional fees Prepaid Professional Fees, Current Prepaid Professional Fees, Current Schedule of Antidilutive Securities Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Non-PEO NEO Non-PEO NEO [Member] Title of Individual [Axis] Title and Position [Axis] Additional Paid-in Capital Additional Paid-in Capital [Member] Stated yield Debt

Securities, Available-for-Sale, Stated Yield Debt Securities, Available-for-Sale, Stated Yield Award Timing Predetermined Award Timing Predetermined [Flag] Restricted cash Restricted Cash, Noncurrent Registration rights agreement, required filing term Registration Rights Agreement, Required Filing Term Registration Rights Agreement, Required Filing Term Class of Stock [Axis] Class of Stock [Axis] Diluted loss per common share (in dollars per share) Loss per share - diluted (in dollars per share) Earnings Per Share, Diluted Title of Individual [Domain] Title and Position [Domain] Counterparty Name [Domain] Counterparty Name [Domain] Amortization of right-of-use asset Operating Lease, Right-of-Use Asset, Periodic Reduction Name Measure Name Entity Interactive Data Current Entity Interactive Data Current Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Vested and expected to vest, weighted average remaining contractual term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Vesting percentage (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Equity-based compensation Share-Based Payment Arrangement, Noncash Expense Proceeds from sale of property and equipment Proceeds from Sale of Property, Plant, and Equipment Provision for income taxes Income Tax Expense (Benefit) Aggregate consideration paid to NU for agreement obligations Aggregate Payments Made To Date For License Agreements Aggregate Payments Made To Date For License Agreements Other (expense) income, net: Nonoperating Income (Expense) [Abstract] Interest rate Debt Instrument, Interest Rate, Stated Percentage Compensation expense recognition period Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Revenue Revenue from Contract with Customer, Excluding Assessed Tax Chicago Chicago [Member] Chicago Total other (expense) income, net Nonoperating Income (Expense) Effective tax rate (as a percent) Effective Income Tax Rate Reconciliation, Percent Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Operating loss Operating Income (Loss) Total liabilities and stockholdersâ€™ equity Liabilities and Equity Pre-Funded Warrants Pre-Funded Warrants [Member] Pre-Funded Warrants Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] All Adjustments to Compensation All Adjustments to Compensation [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Accrued payroll-related expenses Employee-related Liabilities, Current Percentage of ownership after transaction (as a percent) Sale of Stock, Percentage of Ownership after Transaction Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Additional paid-in capital Additional Paid in Capital Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Legal Entity [Axis] Legal Entity [Axis] Payment of common stock financing costs Payments Of Common Stock Financing Costs Payments Of Common Stock Financing Costs Interest income Investment Income, Interest Schedule of Restricted Stock Unit Awards Activity Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Individual: Individual [Axis] Number of additional shares authorized, potential maximum additional shares (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Potential Maximum Additional Shares Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Potential Maximum Additional Shares Vesting of restricted stock units and related repurchases Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Payment of exercise of common stock warrants Payment For Exercise Of Common Stock Warrant Payment For Exercise Of Common Stock Warrant Forfeited (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Expected term Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Entity Address, State or Province Entity Address, State or Province Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Statement [Line Items] Statement [Line Items] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Operating expenses: Operating Expenses [Abstract] Schedule of Property and Equipment, Net Property, Plant and Equipment [Table Text Block] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Financial Instruments [Domain] Financial Instruments [Domain] Sublease amounts paid to landlord Sublease Income Vesting [Domain] Vesting [Domain] Unvested balance - beginning of period (in dollars per share) Unvested balance - end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value LIABILITIES AND STOCKHOLDERSâ€™ EQUITY Liabilities and Equity [Abstract] Registration rights agreement, liquidation damages payable if filed late, measurement term Registration Rights Agreement, Liquidation Damages Payable If Filed Late, Measurement Term Registration Rights Agreement, Liquidation Damages Payable If Filed Late, Measurement Term Minimum Minimum [Member] Restatement Determination Date Restatement Determination Date Vested and expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Adoption Date Trading Arrangement Adoption Date Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Related Party Transactions [Abstract] Related Party Transactions [Abstract] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Outstanding beginning balance (in dollars per share) Outstanding ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Right-of-use asset Operating Lease, Right-of-Use Asset Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Shares outstanding, beginning period (in shares) Shares outstanding, ending period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Exercise Price Award Exercise Price Forfeiture rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate Percentage of shares subsequently sold at closing Sale Of Stock, Number Of Shares Issued In Transaction, Percentage Subsequently Sold Sale Of Stock, Number Of Shares Issued In Transaction, Percentage Subsequently Sold Loss Per Common Share Earnings Per Share [Text Block] Arrangement Duration Trading Arrangement Duration Stockholdersâ€™ equity: Equity, Attributable to Parent [Abstract] Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Consideration received, gross Sale Of Stock, Consideration Received On Transaction, Gross Sale Of Stock, Consideration Received On Transaction, Gross Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] All Individuals All Individuals [Member] Excure OpCo 2015 Equity Incentive Plan Excure OpCo 2015 Equity Incentive Plan [Member] Excure OpCo 2015 Equity Incentive Plan [Member] Notes Receivable Notes Receivable [Member] PEO PEO [Member] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Name Trading Arrangement, Individual Name Other expense Other Nonoperating Income (Expense) Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Other noncurrent assets Increase (Decrease) in Other Noncurrent Assets Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Net proceeds Proceeds from Issuance of Common Stock And Warrants Net of Placement Agent Fee and Other Offering Expenses Payable Proceeds from Issuance of Common Stock And Warrants Net of Placement Agent Fee and Other Offering Expenses Payable Assets Assets, Fair Value Disclosure [Abstract] Sublease percentage of office space subtenant (as a percent) Lessee, Operating Sublease, Percentage Of Office Space Subleased Lessee, Operating Sublease, Percentage Of Office Space Subleased Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Related Party [Domain] Related and Nonrelated Parties [Domain] Cash equivalents: Cash and Cash Equivalents, Fair Value Disclosure Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Local Phone Number Local Phone Number Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Total operating expenses Operating Expenses Risk-free interest rate, maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] PEO Total Compensation Amount PEO Total Compensation Amount ESPP purchase price as a percentage of market price (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Schedule of Accrued expenses and other current liabilities Schedule of Accrued Liabilities [Table Text Block] Income Statement Location [Axis] Statement of Income Location, Balance [Axis] Vested and expected to vest, weighted-average exercise price (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Proceeds from sale or maturity of available-for-sale securities Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Common Stock Common Stock [Member] Measure: Measure [Axis] Fair value of underlying common stock (in dollars per share) Share Price Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Issuance of common stock, net (in shares) Stock Issued During Period, Shares, New Issues Operating lease area Lessee, Operating Lease, Lease Area Lessee, Operating Lease, Lease Area Entity Emerging Growth Company Entity Emerging Growth Company Entity Central Index Key Entity Central Index Key General and administrative expense General and Administrative Expense [Member] CBI USA & DGP Co. Ltd CBI USA & DGP Co. Ltd [Member] CBI USA & DGP Co. Ltd Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Expected volatility, minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Stockholders' Equity Equity [Text Block] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Equity Component [Domain] Equity Component [Domain] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Financial Instrument [Axis] Financial Instrument [Axis] Short-term debt Long-Term Debt, Current Maturities Other receivable Other Receivables, Gross, Current Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Equity-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Entity Shell Company Entity Shell Company Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Supplemental Balance Sheet Information [Abstract] Supplemental Balance Sheet Information [Abstract] Title Trading Arrangement, Individual Title Statement [Table] Statement [Table] Measurement Frequency [Domain] Measurement Frequency [Domain] Counterparty Name [Axis] Counterparty Name [Axis] Significant Accounting Policies Significant Accounting Policies [Text Block] City Area Code City Area Code Current liabilities: Liabilities, Current [Abstract] Number of additional shares authorized, percentage of common stock outstanding (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Percentage of Common Stock Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Percentage of Common Stock Outstanding Increase in number of shares available for grant (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Available for Grant Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Available for Grant Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Level 1 Fair Value, Inputs, Level 1 [Member] Total current assets Assets, Current Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Operating lease, base rent annual percentage increase (as a percent) Lessee, Operating Lease, Base Rent Annual Percentage Increase Lessee, Operating Lease, Base Rent Annual Percentage Increase Accrued expenses Increase (Decrease) in Accrued Liabilities Exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Operating lease, annual rent payment Lessee, Operating Lease, Annual Rent Payment Initial Twelve Months Lessee, Operating Lease, Annual Rent Payment Initial Twelve Months Weighted-Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Weighted-average grant date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Income Taxes Income Tax Disclosure [Text Block] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Equity [Abstract] Equity [Abstract] Accumulated deficit Retained Earnings (Accumulated Deficit) Class of Stock [Domain] Class of Stock [Domain] Notes Receivable, Two Notes Receivable, Two [Member] Notes Receivable, Two Related Party Transaction [Line Items] Related Party Transaction [Line Items] General and administrative expense General and Administrative Expense Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Net cash provided by provided by financing activities Net Cash Provided by (Used in) Financing Activities Underlying Securities Award Underlying Securities Amount Investment in Convertible Notes Receivable Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Payment for warrant liability Class Of Warrant Or Right, Payment For Liability Class Of Warrant Or Right, Payment For Liability Amendment Flag Amendment Flag Entity Registrant Name Entity Registrant Name Other Gain (Loss) on Disposition of Property Plant Equipment Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] License Agreement Intangible Assets Disclosure [Text Block] Fair Value as of Grant Date Award Grant Date Fair Value Subsequent Employee Stock Option Subsequent Employee Stock Option [Member] Subsequent Employee Stock Option [Member] Period in between reoccurring put option Debt Securities, Available-for-Sale, Period In Between Reoccurring Put Option Debt Securities, Available-for-Sale, Period In Between Reoccurring Put Option Lease costs Lease, Cost, Current Lease, Cost, Current Level 2 Fair Value, Inputs, Level 2 [Member] Aggregate Intrinsic Value (thousands) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Number of shares issued in transaction (in shares) Sale of Stock, Number of Shares Issued in Transaction Debt Debt Disclosure [Text Block] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Geographical [Domain] Geographical [Domain] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Debt instrument, face amount Debt Instrument, Face Amount Issuance of common stock, net Stock Issued During Period, Value, New Issues Proceeds from short-term borrowing Proceeds from Short-Term Debt Entity Address, Postal Zip Code Entity Address, Postal Zip Code Principles of Consolidation Consolidation, Policy [Policy Text Block] Restatement Determination Date: Restatement Determination Date [Axis] Title of 12(b) Security Title of 12(b) Security Common stock, \$0.0001 par value per share; 200,000,000 shares authorized, 8,651,148 issued and outstanding, JuneÂ 30, 2024; 8,650,753 issued and outstanding, DecemberÂ 31, 2023 Common Stock, Value, Issued Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Ownership percentage limitation at election of purchaser (as a percent) Class Of Warrant Or Right, Ownership Percentage Limitation At Election Of Purchaser Class Of Warrant Or Right, Ownership Percentage Limitation At Election Of Purchaser Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Vested and expected to vest, aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Preferred stock, \$0.0001 par value per share; 10,000,000 shares authorized, no shares issued and outstanding, JuneÂ 30, 2024 and DecemberÂ 31, 2023 Preferred Stock, Value, Issued Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Employee Stock Employee Stock [Member] Reclassification of common stock warrants to liability Adjustments To Additional Paid in Capital, Decrease Related To Reclassification Adjustments To Additional Paid in Capital, Decrease Related To Reclassification Basic loss per common share (in dollars per share) Loss per share - basic (in dollars per share) Earnings Per Share, Basic Accounts payable Increase (Decrease) in Accounts Payable Computers and software Computers and Software [Member] Computers and Software [Member] Proceeds from common

stock offering Proceeds from Issuance of Common Stock Operating lease, cash payments Operating Lease, Payments Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Expiration period Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Other Other Prepaid Expense, Current Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Ownership percentage limitation (as a percent) Class Of Warrant Or Right, Ownership Percentage Limitation Class Of Warrant Or Right, Ownership Percentage Limitation Total current liabilities Liabilities, Current Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Total assets Assets Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Percentage of outstanding shares allowable as annual increase (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Commitments and Contingencies (Note 12) Commitments and Contingencies Risk-free interest rate, minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Termination Date Trading Arrangement Termination Date Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Expected volatility, maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Description of Business, Basis of Presentation and Going Concern Business Description and Basis of Presentation [Text Block] Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Table] Exercise price (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Equity-Based Compensation Share-Based Payment Arrangement [Text Block] Entity Address, City or Town Entity Address, City or Town Pre-Funded Warrants And Accompanying Warrant Pre-Funded Warrants And Accompanying Warrant [Member] Pre-Funded Warrants And Accompanying Warrant Debt Instrument [Axis] Debt Instrument [Axis] Schedule of Common Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Share-based compensation expense Share-Based Payment Arrangement, Expense Net loss Net loss Net Income (Loss) Attributable to Parent Trading Arrangement: Trading Arrangement [Axis] Investments, Debt and Equity Securities [Abstract] Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Period of no rental cost Lessee, Operating Sublease, Period Of No Rental Cost Lessee, Operating Sublease, Period Of No Rental Cost Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Biopharmaceutical Company Biopharmaceutical Company [Member] Biopharmaceutical Company Entity File Number Entity File Number Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Document Fiscal Year Focus Document Fiscal Year Focus Income Statement [Abstract] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Total financial assets Assets, Fair Value Disclosure Operating lease, contract term Lessee, Operating Lease, Term of Contract Accrued other expenses Other Accrued Liabilities, Current Name Forgone Recovery, Individual Name Exercisable, aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Document Period End Date Document Period End Date Sale of Stock [Axis] Sale of Stock [Axis] Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Unvested balance - beginning of period (in shares) Unvested balance - end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Insider Trading Arrangements [Line Items] Supplemental Balance Sheet Information Supplemental Balance Sheet Disclosures [Text Block] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Variable lease costs Variable Lease, Cost, Net Variable Lease, Cost, Net PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Number of subscription agreements entered into Number Of Subscription Agreements Entered Number Of Subscription Agreements Entered Adjustment to Compensation: Adjustment to Compensation [Axis] Prepaid expenses and other current assets Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary or Equity Method Investee, Sale of Stock, Type [Table] Document Transition Report Document Transition Report Document Quarterly Report Document Quarterly Report Gross proceeds Proceeds From Issuance Of Common Stock And Warrants Proceeds From Issuance Of Common Stock And Warrants Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Entity Current Reporting Status Entity Current Reporting Status Accumulated Deficit Retained Earnings [Member] Restricted cash included in other noncurrent assets Restricted Cash and Cash Equivalents Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Related Party [Axis] Related and Nonrelated Parties [Axis] Weighted-average basic common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Subsidiary, Sale of Stock [Line Items] Subsidiary, Sale of Stock [Line Items] Restricted stock units Restricted Stock Units (RSUs) [Member] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Executive Category: Executive Category [Axis] Name Awards Close in Time to MNPI Disclosures, Individual Name Excicure, Inc. 2017 Equity Incentive Plan Excicure, Inc. 2017 Equity Incentive Plan [Member] Excicure, Inc. 2017 Equity Incentive Plan [Member] Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Entity Filer Category Entity Filer Category Income Statement Location [Domain] Statement of Income Location, Balance [Domain] Purchase of available-for-sale securities Payments to Acquire Debt Securities, Available-for-Sale Company Selected Measure Name Company Selected Measure Name Private Placement Private Placement [Member] EX-101.PRE 9 xcur-20240630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Cover Page - shares 6 Months Ended Jun. 30, 2024 Aug. 06, 2024 Cover [Abstract] Á Á Document Type 10-Q Á Document Quarterly Report true Á Document Period End Date Jun. 30, 2024 Á Document Transition Report false Á Entity File Number 001-39011 Á Entity Registrant Name EXICURE, INC. Á Entity Incorporation, State or Country Code DE Á Entity Tax Identification Number 81-5333008 Á Entity Address, Address Line One 2430 N. Halsted St. Á Entity Address, City or Town Chicago Á Entity Address, State or Province IL Á Entity Address, Postal Zip Code 60614 Á City Area Code (847) Á Local Phone Number 673-1700 Á Title of 12(b) Security Common Stock, par value \$0.0001 per share Á Trading Symbol XCUR Á Security Exchange Name NASDAQ Á Entity Current Reporting Status Yes Á Entity Interactive Data Current Yes Á Entity Filer Category Non-accelerated Filer Á Entity Small Business true Á Entity Emerging Growth Company false Á Entity Shell Company false Á Entity Common Stock, Shares Outstanding (in shares) Á 8,651,204 Entity Central Index Key 0001698530 Á Current Fiscal Year End Date --12-31 Á Document Fiscal Year Focus 2024 Á Document Fiscal Period Focus Q2 Á Amendment Flag false Á X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a-1> + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13-Subsection a-1> + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12-Subsection b-2> + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12-Subsection b-2> + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12-Subsection b-2> + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Regulation S-T -Number 232 -Section 405> + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12-Subsection b-2> + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12-Subsection b-2> + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12-Subsection b-2> + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12-Subsection b-2> + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12-Subsection b> + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12-Subsection d1-1> + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 12 R2.htm IDEA: XBRL DOCUMENT v3.24.2.u1 UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD (\$) in Thousands Jun. 30, 2024 Dec. 31, 2023 Current assets: Á Á Cash and cash equivalents \$ 528 \$ 816 Other receivable 559 15 Prepaid expenses and other current assets 992 1,193 Total current assets 2,079 2,024 Property and equipment, net 40 54 Right-of-use asset 6,126 6,517 Other noncurrent assets 2,443 2,985 Total assets 10,688 11,580 Current liabilities: Á Á Accounts payable 1,585 1,631 Accrued expenses and other current liabilities 846 879 Short-term debt 1,000 0 Total current liabilities 3,431 2,510 Lease liability, noncurrent 5,644 6,039 Total liabilities 9,075 8,549 Commitments and Contingencies (Note 12) Stockholders' equity: Á Á Preferred stock, \$0.0001 par value per share; 10,000,000 shares authorized, no shares issued and outstanding, JuneÁ 30, 2024 and DecemberÁ 31, 2023 0 0 Common stock, \$0.0001 par value per share; 200,000,000 shares authorized, 8,651,148 issued and outstanding, JuneÁ 30, 2024; 8,650,753 issued and outstanding, DecemberÁ 31, 2023 1 1 Additional paid-in capital 192,604 192,593 Accumulated deficit (190,992) (189,563) Total stockholders' equity 1,613 3,031 Total liabilities and stockholders' equity \$ 10,688 \$ 11,580 X - DefinitionCarrying value as of the balance

data-bbox="112 10 889 990" data-label="Text">

date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1:

1Reference 4:

units outstanding during the reporting period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/exampleRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 52-Publisher FASB-URI https://asc.fasb.org/1943274/2147482635/260-10-55-52>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(g\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (g)-Publisher FASB-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph \(g\)\(3\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph (g)(3)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 15-Publisher FASB-URI https://asc.fasb.org/1943274/2147482635/260-10-55-15>Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(e\)\(4\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (e)(4)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-7](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-7)Reference 12: <http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-2>Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 60B-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 60B-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B)Reference 14: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.5-03\(25\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03(25))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.9-04\(27\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-04(27))-Publisher FASB-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-04\(23\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-04(23))-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 19: <http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 7-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-7> + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.5-03\(4\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03(4))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-07\(2\)\(a\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-07(2)(a))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1) + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - Definition Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 2: <http://www.xbrl.org/2003/role/exampleRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 48-Publisher FASB-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 30-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 30-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30)Reference 5: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 270-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 270-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1)Reference 6: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(ee\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (ee)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 7: [http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-04\(11\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-04(11))-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 9: <http://www.xbrl.org/2003/role/exampleRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 31-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31>Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 235-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.9-05\(b\)\(2\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 235-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-05(b)(2))-Publisher FASB-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1)Reference 11: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.5-03\(10\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03(10))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 12: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.9-04\(15\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-04(15))-Publisher FASB-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1) + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 270-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 270-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(ee\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (ee)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 12-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12>Reference 4: <http://www.xbrl.org/2003/role/exampleRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 231-Publisher FASB-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 9-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SAB Topic 6.1.7\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SAB Topic 6.1.7)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1)Reference 7: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 8-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-10>Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22)Reference 10: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.5-03\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2) + Details Name: us-gaap_InvestmentIncomeDividend Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - Definition Amount of dividend income on nonoperating securities. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.5-03\(7\)\(a\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03(7)(a))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2) + Details Name: us-gaap_InvestmentIncomeDividend Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - Definition Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22)Reference 2: <http://www.xbrl.org/2003/role/exampleRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 48-Publisher FASB-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.5-03\(7\)\(b\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03(7)(b))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 270-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 270-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(ee\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (ee)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32) + Details Name: us-gaap_InvestmentIncomeInterest Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 9-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(g\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (g)-Publisher FASB-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph \(g\)\(3\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph (g)(3)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.5-03\(20\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03(20))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 9: <http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6>Reference 10:

https://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 - Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference

Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482913/230-10-50-8>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4> + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1> + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(b\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap_DepreciationAmortizationAndAccretionNet Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(b\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap_IncreaseDecreaseInAccruedLiabilities Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in noncurrent assets classified as other. + ReferencesReference 1: [http://www.xbrl.org/2003/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://www.xbrl.org/2003/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap_IncreaseDecreaseInOtherNoncurrentAssets Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in operating liabilities classified as other. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap_IncreaseDecreaseInOtherOperatingLiabilities Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in receivables classified as other. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap_IncreaseDecreaseInOtherReceivables Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24> + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24> + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25> + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 9: <http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 13: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 16: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 17: <http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7>Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(18\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(1\)\(d\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 23: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 24: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 26: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 27: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 28: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 29: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 30: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 31: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 32: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B)Reference 33: <http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 34: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 35: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A)Reference 36: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B)Reference 37: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1)

gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-14> + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-12> + Details Name: us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-14> + Details Name: us-gaap_ProceedsFromShortTermDebt Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPayment For Exercise Of Common Stock Warrant + ReferencesNo definition available. + Details Name: xcur_PaymentForExerciseOfCommonStockWarrant Namespace Prefix: xcur_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPayments Of Common Stock Financing Costs + ReferencesNo definition available. + Details Name: xcur_PaymentsOfCommonStockFinancingCosts Namespace Prefix: xcur_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 17 R7.htm IDEA: XBRL DOCUMENT v3.24.2.u1 UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) - USD (\$) \$ in Thousands Jun. 30, 2024 Dec. 31, 2023 Statement of Cash Flows [Abstract] Â Â Cash and cash equivalents \$ 528 \$ 816 Restricted cash included in other noncurrent assets 872 1,200 Total cash, cash equivalents, and restricted cash shown in the unaudited condensed consolidated statements of cash flows \$ 1,406 \$ 2,016 X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483467/210-10-45-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-4> + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482913/230-10-50-8>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-4> + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482913/230-10-50-8>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478546/942-210-S99-1>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-4> + Details Name: us-gaap_RestrictedCashAndCashEquivalents Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfCashFlowsAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 18 R8.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Description of Business, Basis of Presentation and Going Concern 6 Months Ended Jun. 30, 2024 Accounting Policies [Abstract] Â Description of Business, Basis of Presentation and Going Concern Description of Business, Basis of Presentation and Going ConcernDescription of BusinessExcicure, Inc. has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that the Company was exploring strategic alternatives to maximize stockholder value. The Company is attempting to license its intellectual property to generate value for stockholders. In addition, the Company is engaging in a broader exploration of strategic alternatives. This effort involves exploring growth through transactions with potential partners that see opportunity in joining an existing, publicly-traded organization. Throughout these unaudited condensed consolidated financial statements, the terms the “Company,” “we,” and “Excicure” refer to Excicure, Inc. and where appropriate, its wholly owned subsidiary, Excicure Operating Company. Excicure Operating Company holds all material assets and conducts all business activities and operations of Excicure, Inc.Â Basis of PresentationThe accompanying unaudited condensed consolidated financial statements as of JuneÂ 30, 2024 and December 31, 2023, and for the three and six months ended JuneÂ 30, 2024 and 2023, have been presented in conformity with accounting principles generally accepted in the United States of America (the “GAAP”) and with instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934, as amended. Principles of ConsolidationThe accompanying unaudited condensed consolidated financial statements include the accounts of Excicure and its wholly owned subsidiary, Excicure Operating Company. All intercompany transactions and accounts are eliminated in consolidation.Unaudited Interim Financial InformationThe accompanying interim condensed consolidated balance sheet as of JuneÂ 30, 2024, the interim condensed consolidated statements of operations for the three and six months ended JuneÂ 30, 2024 and 2023, the interim condensed consolidated statements of changes in stockholders’ equity for the three and six months ended JuneÂ 30, 2024 and 2023, and the interim condensed consolidated statements of cash flows for the six months ended JuneÂ 30, 2024 and 2023 are unaudited. The interim unaudited condensed consolidated financial statements have been prepared on the same basis as the annual audited financial statements and with instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934, as amended; and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the Company’s financial position as of JuneÂ 30, 2024, the results of its operations for the three and six months ended JuneÂ 30, 2024 and 2023, and the results of its cash flows for the six months ended JuneÂ 30, 2024 and 2023. The financial data and other information disclosed in these notes related to the three and six months ended JuneÂ 30, 2024 and 2023 are unaudited. The results for the six months ended JuneÂ 30, 2024 are not necessarily indicative of results to be expected for the year ending DecemberÂ 31, 2024, or any other interim periods, or any future year or period. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes for the year ended December 31, 2023, included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on June 6, 2024. Going ConcernAt each reporting period, the Company evaluates whether there are conditions or events that raise substantial doubt about the Company’s ability to continue as a going concern for a period of one year after the date that the financial statements are issued. The Company is required to make certain additional disclosures if it concludes substantial doubt exists and it is not alleviated by the Company’s plans or when its plans alleviate substantial doubt about the Company’s ability to continue as a going concern.The accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern for a period of one year after the date that the financial statements are issued. As of JuneÂ 30, 2024, the Company expects to incur significant expenses and negative cash flows for the foreseeable future. As of JuneÂ 30, 2024, the Company’s cash and cash equivalents were \$528. Management believes that, given the Company’s current cash position, operating plans and forecasted negative cash flows from operating activities over the next twelve months, there is substantial doubt about the Company’s ability to continue as a going concern within one year after the date these financial statements are issued. Substantial additional financing will be needed by the Company to fund its operations.Management believes that the Company’s existing cash and cash equivalents are insufficient to continue to fund its operating expenses and additional funding is needed in the very near term. The Company has already engaged in significant cost reductions, so our ability to further cut costs and extend the Company’s operating runway is limited. As a result, substantial additional financing will be needed by the Company in the very near term to pay expenses, fund the ongoing exploration of strategic alternatives and pursue any alternatives that may be identified. There can be no assurance that such additional financing will be available and, if available, can be obtained on acceptable terms.The accompanying unaudited condensed consolidated financial statements have been prepared as though the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI <https://asc.fasb.org/235/tableOfContent>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI <https://asc.fasb.org/275/tableOfContent>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI <https://asc.fasb.org/205/tableOfContent> + Details Name: us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 19 R9.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Significant Accounting Policies 6 Months Ended Jun. 30, 2024 Accounting Policies [Abstract] Â Significant Accounting Policies Significant Accounting PoliciesThe Company’s significant accounting policies are disclosed in the audited consolidated financial statements and the notes thereto, which are included in the in the Company’s Annual Report on Form 10-K (the “Annual Report”) for the year ended DecemberÂ 31, 2023 filed with the SEC on June 6, 2024. Since the date of those audited consolidated financial statements, there have been no material changes to the Company’s significant accounting policies.Use of EstimatesThe preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases its estimates on certain assumptions which it believes are reasonable in the circumstances and while actual results could differ from those estimates, management does not believe that any change in those assumptions in the near term would have a significant effect on the Company’s financial position, results of operations or cash flows. Actual results in future periods could differ from those estimates. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483426/235-10-50-1>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI <https://asc.fasb.org/235/tableOfContent> + Details Name: us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 20 R10.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Supplemental Balance Sheet Information 6 Months Ended Jun. 30, 2024 Supplemental Balance Sheet Information [Abstract] Â Supplemental Balance Sheet Information Supplemental Balance Sheet InformationPrepaid expenses and other current assetsJune 30, 2024December 31, 2023Prepaid insurance\$476A \$508A Prepaid franchise tax61A 259A Lease costs255A 235A Prepaid professional fees70A 95A Prepaid software 62A 72A Other68A 24A A A A A Prepaid expenses and other current assets\$992A \$1,193A Other noncurrent assetsJune 30, 2024December 31, 2023Restricted cash\$872A \$1,200A Prepaid insurance1,571A 1,785A A A A A Other noncurrent assets\$2,443A \$2,985A Property and equipment, netJune 30, 2024December 31, 2023Scientific equipment\$246A \$246A Computers and software3A 3A Furniture and fixtures30A 30A Property and equipment, gross\$279A 279A Less: accumulated depreciation and amortization(239)(225)Property and equipment, net\$40A \$54A Depreciation and amortization expense was \$14 and \$479 for the six months ended JuneÂ 30, 2024 and 2023, respectively. Accrued expenses and other current liabilitiesJune 30, 2024December 31, 2023Current lease liabilities\$671A \$626A Accrued payroll-related expensesÂ 71A Accrued other expenses175A 182A A A A A Accrued expenses and other current liabilities\$846A \$879A X - DefinitionThe entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 210 -Name Accounting Standards Codification -Publisher FASB -URI <https://asc.fasb.org/210/tableOfContent> + Details Name: us-gaap_SupplementalBalanceSheetDisclosuresTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionSupplemental Balance Sheet Information [Abstract] + ReferencesNo definition available. + Details Name: xcur_SupplementalBalanceSheetInformationAbstract Namespace Prefix: xcur_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 21 R11.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Leases 6 Months Ended Jun. 30, 2024 Leases [Abstract] Â Leases LeasesThe Company’s lease arrangements at JuneÂ 30, 2024 consist of (i) a lease for office space at its headquarters in Chicago, Illinois that commenced in July 2020 (the “Chicago Lease”) and (ii) a lease for office equipment (the “Office Equipment Lease”). The Chicago Lease and the Office Equipment Lease are classified as operating leases.Chicago LeaseThe Company has approximately thirty thousand square feet of office space in Chicago, Illinois. The original term (the “Original Term”) of the Chicago Lease is 10 years, commencing on July 1, 2020 (the “Commencement Date”), which is the date the premises were ready for occupancy under the terms of the Chicago Lease. The Company has options to extend the term of the Chicago Lease for two additional successive periods of five years each (the “Extension Periods”) at the then prevailing effective market rental rate. The initial annual base rent during the Original Term is approximately \$1,113 for the first 12-month period of the Original Term, payable in monthly installments beginning on the Commencement Date. Base rent

thereafter is subject to annual increases of 3%, for an aggregate amount of \$12,761 over the Original Term. The Company must also pay its proportionate share of certain operating expenses and taxes for each calendar year during the term. During the first 12-month period of the Original Term, the base rent and the Company's proportionate share of operating expenses and taxes were subject to certain abatements. The following table summarizes lease costs in the Company's unaudited condensed consolidated statement of operations: Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Operating lease costs \$142A \$326A \$285A \$652A Variable lease costs (117)(19) 3A 313A Short term lease costs 9A 6A 20A 6A Total lease costs \$34A \$307A \$308A \$965A The Company made cash payments for operating leases \$327 and \$860 during the six months ended June 30, 2024 and 2023, respectively. On June 11, 2024, the Company received a formal notice from its landlord indicating the landlord will draw on the restricted cash account designated for the lease as a result of past due rent for December 2023 through June 2024. The landlord also withdrew the July 2024 payment from the restricted cash account. These draws are within the terms and conditions of the lease and the related restricted cash account. Sublease of Office Space The Company entered into a sublease agreement with Cyclopure, Inc. (the Subtenant) to sublease approximately 57% of its office space pursuant to that certain sublease agreement (the Sublease Agreement), dated as of May 4, 2023. The term of the Sublease Agreement began on May 15, 2023 and ends on June 30, 2030, the expiration date of the Chicago Lease. The first three months under the Sublease Agreement are rent free. Beginning August 15, 2023, the Company began charging the Subtenant for 57% of the base rent under the Chicago Lease, and the Subtenant is responsible for its pro rata share of operating expenses and taxes payable. In 2024, the Company does not receive payment from the Subtenant as the Subtenant pays the Company's landlord directly. The following table summarizes sublease receipts in the Company's condensed consolidated statement of operations: Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Sublease amounts paid to landlord \$173A \$6A \$346A \$6A Totals \$173A \$6A \$346A \$6A X - References No definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability. + References Reference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/842-20/tableOfContent> + Details Name: us-gaap_LesseeOperatingLeasesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 22 R12.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Investment in Convertible Notes Receivable 6 Months Ended Jun. 30, 2024 Investments, Debt and Equity Securities [Abstract] A Investment in Convertible Notes Receivable Investment in Convertible Notes Receivable In May 2023, the Company entered into two subscription agreements to purchase non-guaranteed private placement convertible notes receivable (the Notes Receivable) for a subscription amount of \$1A million each. The Notes Receivable mature in May 2026 and the yield to maturity is 4.5% per annum. The Company has the option to request that the issuer redeem part or the entire principal amount of the Notes Receivable on the first anniversary after the issue date and every three months thereafter before the maturity date. The redemption price will be one hundred percent (100%) of the Notes Receivable's face value, plus accrued interest. The Company also has the ability to convert the debt into shares based on the number of shares computed by dividing the face value of each security by a calculated conversion price, which is subject to adjustment provisions, determined at the time of issuance. The securities may be converted from May 3, 2024, the first anniversary of the issue date of the first agreement, to April 15, 2026, one month prior to the maturity date to the second agreement. In March 2024, the Company notified the issuer of the Notes Receivable that it was exercising its redemption right with respect to the entire principal amount of the Notes Receivable after the first anniversary of their issue dates (May 3 and May 16, 2024, respectively) for an aggregate redemption price of \$2.090A million (representing the principal amount plus 4.5% per annum yield to the redemption date). The issuer has taken the position that the Notes Receivable are not redeemable until August 3, 2024 and August 16, 2024, and as a result that redemption notice submitted in March were premature. We have attempted to redeem the \$2A million aggregate principal amount of the convertible Notes Receivable in June 2024, but have not received a response to our most recent request. The Company's debt securities are classified as available-for-sale (AFS) pursuant to Accounting Standards Codification (ASC) 320 - Investments - Debt Securities. AFS securities are recorded at fair value. As of June 30, 2024 and December 31, 2023, management does not believe these AFS investments are recoverable and recorded them at a fair value of \$0. X - References No definition available. + Details Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The entire disclosure for investments in certain debt and equity securities. + References Reference 1: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 940 -SubTopic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/940-320/tableOfContent> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/320/tableOfContent](http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-K (SK) -Number 229 -Section 1403 -Paragraph b -Publisher SEC Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/320/tableOfContent) Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-10](http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-10) Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6B -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B) Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6B -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B) Reference 7: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/942-320/tableOfContent> + Details Name: us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R13.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Debt 6 Months Ended Jun. 30, 2024 Debt Disclosure [Abstract] A Debt Debt On May 3, 2024, the Company executed a promissory note (Note) and subsequently received a loan in the amount of \$300 from an individual investor. All principal and accrued interest will be due and payable on the earlier of (i) May 3, 2025 or (ii) upon an event of default, at such time, such amounts declared by the investor will become due and payable by Company. Interest will accrue on this Note at 6.0% and is payable at maturity. On June 3, 2024, the Company executed another promissory note (DGP Note) and subsequently received a loan in the amount of \$700 from DGP, a related party. All principal and accrued interest will be due and payable on the earlier of (i) March 25, 2025 or (ii) upon an event of default, at such time, such amounts declared by the investor will become due and payable by Company. Interest will accrue on this DGP Note at 6.0% and is payable at maturity. X - References No definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. + References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6B) Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6B) Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1B) Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1B) Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1B) Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1B) Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1B) Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph \(h\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B) Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SX 210.4-08\(c\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-599-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.4-08(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-599-1B) Reference 10: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/470/tableOfContent> Reference 11: <http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2B> Reference 12: <http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B> Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B) Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B) Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C) Reference 16: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C) Reference 17: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C) Reference 18: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B) Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B) Reference 20: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B) Reference 21: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B) + Details Name: us-gaap_DebtDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 24 R14.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stockholders' Equity 6 Months Ended Jun. 30, 2024 Equity [Abstract] A Stockholders' Equity Stockholders' Equity Preferred Stock As of June 30, 2024 and December 31, 2023, the Company had 10,000,000 shares of preferred stock, par value \$0.0001 authorized and no shares issued and outstanding. Common Stock As of June 30, 2024 and December 31, 2023, the Company had authorized 200,000,000 shares of common stock, par value \$0.0001. As of June 30, 2024 and December 31, 2023, the Company had 8,651,148 shares and 8,650,753 shares issued and outstanding, respectively. The holders of shares of the Company's common stock are entitled to one vote per share on all matters to be voted upon by the Company's stockholders and there are no cumulative rights. Subject to preferences that may be applicable to any outstanding preferred stock, the holders of shares of the Company's common stock are entitled to receive ratably any dividends that may be declared from time to time by the Board of Directors (the Board) out of funds legally available for that purpose. In the event of the Company's liquidation, dissolution or winding up, the holders of shares of the Company's common stock are entitled to share ratably in all assets remaining after payment of liabilities, subject to prior distribution rights of preferred stock then outstanding. The Company's common stock has no preemptive or conversion rights or other subscription rights. There are no redemption or sinking fund provisions applicable to the Company's common stock. The outstanding shares of the Company's common stock are fully paid and non-assessable. September 2022 PIPE (Private Investment in Public Equity) Securities Purchase Agreement On September 26, 2022, the Company entered into a securities purchase agreement (the Securities Purchase Agreement) with CBI USA, Inc. (CBI USA), pursuant to which the Company agreed to issue and sell to CBI USA in a private placement an aggregate of 3,400,000 shares of Common Stock, at a purchase price of \$1.60 per share. The private placement closed on February 24, 2023 (the Closing Date). The Company received gross proceeds of \$5,440 from the September 2022 PIPE (or net proceeds of \$4,597 after transaction expenses). CBI USA funded the acquisition pursuant to the Securities Purchase Agreement through a loan from its affiliate, DGP Co., Ltd. (DGP). On June 23, 2023, DGP exercised its option pursuant to the loan and acquired the 3,400,000 shares of Common Stock initially acquired by CBI USA pursuant to the Securities Purchase Agreement. DGP subsequently agreed to sell its shares to a third party, with the closing of 10% (340,000 shares) occurring in February 2024 and the remainder to close by or on September 30, 2024. The Securities Purchase Agreement, as confirmed and clarified by that certain letter agreement, dated October 31, 2022, between the Company and CBI USA, provided CBI USA together with its affiliates and any group of which it or they are a member with the right to designate directors to the Company's board of directors in proportion to the ownership of CBI USA and its affiliates and any such group. CBI USA and DGP have announced they expect to exercise such rights as a group. Together, they beneficially own 45% of the outstanding shares of Common Stock based on their most recent Schedule 13D amendment. As noted above, DGP has entered into an agreement to sell its remaining shares to a third party by or on September 30, 2024. September 2022 Registration Rights Agreement In connection with the Securities Purchase Agreement, the Company entered into a registration rights agreement with CBI USA (the Registration Rights Agreement). CBI USA assigned its rights under the Registration Rights Agreement to DGP when DGP acquired the 3,400,000 shares of Common Stock initially sold to CBI USA. Pursuant to the Registration Rights Agreement, the Company agreed to file a registration statement covering the resale of the shares of Common Stock sold pursuant to the Securities Purchase Agreement, to use reasonable best efforts to cause such registration statement to become effective as promptly as practicable, and to keep such registration statement continuously effective until the earlier of (i) the date the shares covered by such registration statement have been sold or may be resold pursuant to Rule 144 without restriction, or (ii) the date that is two (2) years following the Closing Date. In the event the registration statement was not filed within 90 days following the Closing Date, subject to certain limited exceptions, the Company agreed to make payments as liquidated damages in an amount equal to 0.5% of the aggregate amount invested in the shares of Common Stock pursuant to the Securities Purchase Agreement per 30-day period or pro rata for any portion thereof for each such month during which such event continues, subject to certain caps set forth in the Registration Rights Agreement. We have paid \$27 to CBI USA and accrued \$191 to DGP pursuant to this provision. Registered Direct Offering On December 16, 2021, the Company completed a securities purchase agreement (the Purchase Agreement) with certain institutional purchasers (the Purchasers) entered into on December 14, 2021, pursuant to which the Company offered to the Purchasers, in a registered direct offering priced at-the-market consistent with the rules of Nasdaq (the Registered Direct Offering), (i) an aggregate of 433,553 shares (the Funded Shares) of the Company's common stock, \$0.0001 par value per share, (ii) pre-funded warrants to purchase up to an aggregate of 718,981 shares of Common Stock (the Pre-Funded Warrants), and (iii) warrants to purchase up to 576,261 shares of Common Stock (the Warrants). The combined purchase price of each share of Common Stock and accompanying Warrant is \$9.9780 per share. The combined purchase price of each Pre-Funded Warrant and accompanying Warrant is \$9.9480 (equal to the combined purchase price per share of Common Stock and accompanying Warrant, minus \$0.03). The per share exercise price for the Warrants is \$8.1031, the closing bid price of the Company's Common Stock on December 13, 2021 (and as adjusted for the reverse stock split referenced in Note 1). The Warrants will be exercisable immediately from the closing December 16, 2021, and will expire on the five-year anniversary of the date of issuance, or December 16, 2026. The Pre-Funded Warrants and Warrants, which met equity classification, were recognized as a component of permanent stockholders' equity within additional paid-in-capital together with the net proceeds from the Registered Direct Offering. The gross proceeds to the Company from the Registered Direct Offering (excluding effect of subsequent exercises of pre-funded warrants) were \$11,478 and net proceeds after deducting the placement agent's fees and other offering expenses paid or payable by the Company were \$10,226. The securities were offered by the Company pursuant to an effective shelf registration statement on Form S-3 (File No. 333-251555) previously filed with the Securities and Exchange Commission (the SEC) on December 21, 2020, and which was declared effective by the SEC on January 7, 2021 (the Registration Statement). Each Warrant is exercisable for one share of Common Stock at an exercise price of \$8.1031

per Share. The Warrants are immediately exercisable as of the date of issuance of December 16, 2021 and will expire on the five-year anniversary of the date of issuance, or December 16, 2026. The Pre-Funded Warrants were offered in lieu of shares of Common Stock to one of the Purchasers whose purchase of shares of Common Stock in the Registered Direct Offering would otherwise result in said Purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the Purchaser, 9.99%) of the Company’s outstanding Common Stock immediately following the consummation of the Registered Direct Offering. Each Pre-Funded Warrant is exercisable for one share of Common Stock at an exercise price of \$0.030 per share. The Pre-Funded Warrants are immediately exercisable and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. A holder (together with its affiliates) of the Warrant or Pre-Funded Warrant may not exercise any portion of the Warrant or Pre-Funded Warrant, as applicable, to the extent that the holder would own more than 4.99% (or, at the holder’s option upon issuance, 9.99%) of the Company’s outstanding Common Stock immediately after exercise, as such percentage ownership is determined in accordance with the terms of the Warrant or Pre-Funded Warrant, as applicable. In lieu of making the cash payment otherwise contemplated to be made to the Company upon exercise of a Warrant in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of Common Stock determined according to a formula set forth in the Pre-Funded Warrants. Common Stock Warrants to purchase 576,261 shares of common stock at a price of \$8.1031 per share were acquired in the December 2021 registered-direct offering transaction. The warrants were classified as equity. As a result of the closing of the September 2022 PIPE, a warrant holder elected to exercise their option within 30 days of the closing of the September 2022 PIPE (February 24, 2023) to receive a cash payout for the outstanding warrants in the amount of the Black-Scholes value of each warrant as prescribed in the warrant agreement. The Company paid \$800 to this warrant holder on June 23, 2023 and 526,151 were settled as a result. As of June 30, 2024, warrants to purchase 50,110 shares of common stock at a price of \$8.1031 per share that were acquired in the December 2021 registered-direct offering transaction remain outstanding. X - References No definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The entire disclosure for equity. + References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(h\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2)Reference 6: <http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6>Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6](http://www.xbrl.org/2003/role/disclosureRef-Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.3-04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\)\(e\)\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08)(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 10: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13>Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18) + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R15.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Equity-Based Compensation 6 Months Ended June 30, 2024 Share-Based Payment Arrangement [Abstract] A Equity-Based Compensation Equity-Based Compensation 2017 Equity Incentive Plan On September 22, 2017, the Company’s stockholders approved the Excure, Inc. 2017 Equity Incentive Plan (the “2017 Plan”), which became effective on November 15, 2017. The 2017 Plan provides for the issuance of incentive awards of up to 194,750 shares of Excure common stock, which includes 72,330 shares of Excure common stock to be issued to officers, employees, consultants and directors, plus a number of shares not to exceed 122,793 that are subject to issued and outstanding awards under the Excure OpCo 2015 Equity Incentive Plan (the “2015 Plan”) and were assumed in the merger transaction on September 26, 2017. Awards that may be awarded under the 2017 Equity Incentive Plan include non-qualified and incentive stock options, stock appreciation rights, bonus shares, restricted stock, restricted stock units, performance units and cash-based awards. The number of shares of common stock reserved for issuance under the 2017 Equity Incentive Plan automatically increases on January 1 of each year, beginning on January 1, 2020, by the lesser of (i) 153,333 shares, (ii) 5% of the total number of shares of its capital stock outstanding on December 31 of the preceding calendar year, or (iii) a lesser number of shares determined by the Compensation Committee of the Board (the “Compensation Committee”). No future awards will be made under the 2015 Plan upon the effectiveness of the 2017 Plan. On January 1, 2024, pursuant to the terms of the 2017 Plan, the number of awards that are reserved and may be awarded under the 2017 Plan was automatically increased by 153,333 awards. As of June 30, 2024, the aggregate number of equity awards available for grant under the 2017 Equity Incentive Plan was 455,292. Awards granted under the 2017 Plan are contingent on the participants’ continued employment or provision of non-employee services and are subject to forfeiture if employment or continued service terminates for any reason. The initial award granted to an employee or consultant generally vests 25% on the first 12-month anniversary of the grant date and vests 1/48th monthly thereafter until fully vested at the end of 48 months. Subsequent awards granted to employees or consultants generally vest 1/48th monthly until fully vested at the end of 48 months. The initial stock option grant to a non-employee director vests 1/36th monthly until fully vested at the end of 36 months. Subsequent stock option grants to a non-employee director vests 1/12th monthly until fully vested at the end of 12 months. The term of common stock option grants is 10 years unless terminated earlier as described above. Employee Stock Purchase Plan The 2017 Employee Stock Purchase Plan (the “ESPP”) was adopted by the Board in September 2017 and approved by the Company’s stockholders in September 2017. Through the ESPP, eligible employees may authorize payroll deductions of up to 15% of their compensation to purchase common stock. The maximum number of shares that an employee may purchase on any exercise date in an offer period will be the smaller of (i) 250 shares or (ii) such number of shares as has a fair market value (determined as of the offering date for such offer period) equal to \$25,000 within one calendar year minus the fair market value of any other shares of common stock that are attributed to such calendar year. The purchase price per share at each purchase date is equal to 85% of the lower of (i) the closing market price per share of Excure common stock on the employee’s offering date or (ii) the closing market price per share of Excure common stock on the exercise date. The ESPP provides that the number of shares reserved and available for issuance will automatically increase each January 1, beginning on January 1, 2018 and each January 1 thereafter through January 1, 2027, by the least of (i) 10,000 shares; (ii) 0.3% of the outstanding shares of common stock on the last day of the immediately preceding calendar year; or (iii) a lesser number of shares determined by the Board. On January 1, 2024, the number of shares of common stock available for issuance under the ESPP increased by 10,000 shares. As of June 30, 2024, there were 61,971 shares available for issuance under the ESPP. Equity-based compensation expense is classified in the statements of operations as follows: Three Months Ended June 30, 2023 \$1.58; Six Months Ended June 30, 2023 \$3.15; weighted avg. \$1.58; 5.8 years Risk-free interest rate 3.83%; expense \$4.28. As of June 30, 2024, the Company’s General and administrative expense \$6.969A, 11.23A, 6.6A, 9.699A, 11.1A, 1.277A Unamortized equity-based compensation expense at June 30, 2024 was \$21, which is expected to be amortized over a weighted-average period of 1.4 years. The Company utilizes the Black-Scholes option-pricing model to determine the fair value of common stock option grants. The Black-Scholes option-pricing model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable. The model also requires the input of highly subjective assumptions. No options were granted during the six months ended June 30, 2024. The following table presents the assumptions used in the Black-Scholes option-pricing model for stock options granted during the six months ended June 30, 2023: Six Months Ended June 30, 2023 Expected term 5.8 to 5.8 years Risk-free interest rate 3.83% to 3.83%; weighted avg. 3.83% Expected volatility 101.0% to 101.0%; weighted avg. 101.0% Forfeiture rate 5A % Expected dividend yield 0A % The expected term is based upon the “simplified method” as described in Staff Accounting Bulletin Topic 14.D.2. Currently, the Company does not have sufficient experience to provide a reasonable estimate of an expected term of its common stock options. The Company will continue to use the “simplified method” until there is sufficient experience to provide a more reasonable estimate in conformance with ASC 718-10-30-25 through 30-26. The risk-free interest rate assumptions were based on the U.S. Treasury bond rate appropriate for the expected term in effect at the time of grant. For stock options granted after December 31, 2021, the expected volatility is based on the volatility of shares of the Company. For stock options granted prior to January 1, 2022, the expected volatility is based on calculated enterprise value volatilities for publicly traded companies in the same industry and general stage of development. The estimated forfeiture rates were based on historical experience for similar classes of employees. The dividend yield was based on expected dividends at the time of grant. The fair value of the underlying common stock and the exercise price for the common stock options granted during the six months ended June 30, 2023 are summarized in the table below. No options were granted during the six months ended June 30, 2024. Fair Value of Underlying Common Stock Exercise Price of Common Stock Option Six months ended June 30, 2023 \$1.58; weighted avg. \$1.58; 5.8 years Risk-free interest rate 3.83%; weighted avg. \$1.58 The weighted-average grant date fair value of common stock options granted in the six months ended June 30, 2023 was \$1.26 per common stock option. A summary of common stock option activity as of the periods indicated is as follows: Options Weighted-Average Exercise Price Weighted-Average Remaining Contractual Term (years) Aggregate Intrinsic Value (thousands) Outstanding - December 31, 2023 115A \$4.28A 5.4 \$4.28A Granted 6A \$4.28A Exercised 416A \$5.1A Forfeited (416)A \$5.1A Outstanding - June 30, 2024 115A \$4.28A 5.4 \$4.28A Exercised - June 30, 2024 115A \$4.28A Vested and Expected to Vest - June 30, 2024 115A \$4.28A A summary of restricted stock unit activity of the periods indicated is as follows: Restricted Stock Units Weighted-Average Grant Date Fair Value Unvested balance - December 31, 2023 0.43A \$10.41A Granted 6A \$4.28A Vested (592)A \$18.47A Forfeited (417)A \$3.45A Unvested balance - June 30, 2024 0.34A \$12.24A The grant date fair value of restricted stock units is based on the Company’s closing stock price at the date of grant. At vesting, each outstanding restricted stock unit will be exchanged for one share of the Company’s common stock. Restricted stock units generally vest evenly on a quarterly basis over a period of 4 years in exchange for continued service provided by the restricted stock unit recipient during that vesting period. X - Definition The entire disclosure for share-based payment arrangement. + References Reference 1: [http://www.xbrl.org/2003/role/exampleRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/exampleRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(h\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(h\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(l\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - References No definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 26 R16.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Income Taxes 6 Months Ended June 30, 2024 Income Tax Disclosure [Abstract] A Income Taxes Income Taxes The Company incurred a pretax loss in each of the six months ended June 30, 2024 and 2023, which consists entirely of loss in the United States and resulted in no provision for income tax expense during the periods then ended. The effective tax rate is 0% in each of the six months ended June 30, 2024 and 2023 because the Company has generated tax losses and has provided a full valuation allowance against its deferred tax assets. X - References No definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The entire disclosure for income tax. + References Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12>Reference 2: <http://www.xbrl.org/2003/role/exampleRef-Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef-Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SAB Topic 6.1.5.Q1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.1.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1)Reference 7: <http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13>Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\)\(e\)\(2\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08)(e)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 9: <http://www.xbrl.org/2003/role/disclosureRef-Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef-Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14>Reference 11:

disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(2\)\(g\)\(3\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(2\)\(c\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(2\)\(e\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(e)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1)Reference 10: <http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/850/tableOfContent>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6>Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1) + Details Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 31 R21.htm IDEA: XBRL DOCUMENT v3.24.2.u1 License Agreement 6 Months Ended Jun. 30, 2024 Goodwill and Intangible Assets Disclosure [Abstract] Â License Agreement License AgreementOn February 5, 2024, the Company entered into a patent license agreement to develop cavrotolimid for potential treatment for hepatitis with a private clinical stage biopharmaceutical company. Under the terms of the agreement, this biopharmaceutical company will receive an exclusive license in the field of hepatitis to all of the Companyâ€™s relevant patents. An initial payment of \$500 was paid to the Company after the execution of this agreement. This payment was recognized as revenue in accordance with ASC 606, Revenue from Contracts with Customers. The Company will also be entitled to modest royalties on future net sales on all licensed technology during the term of the licensed patents. The Company will be responsible for, and make all decisions concerning, the preparation, filing, prosecution, and maintenance for each patent and patent application included within the licensed patents. X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all or part of the information related to intangible assets. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContent>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3)Reference 4: <http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/985-20/tableOfContent> + Details Name: us-gaap_IntangibleAssetsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 32 R22.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Pay vs Performance Disclosure - USD (\$) \$ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Mar. 31, 2024 Jun. 30, 2023 Mar. 31, 2023 Jun. 30, 2024 Jun. 30, 2023 Pay vs Performance Disclosure Â Â Â Â Â Net loss \$ (600) \$ (829) \$ (5,764) \$ (4,407) \$ (1,429) X - ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6](http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: <a href=)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 9: <http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 13: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 16: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 17: <http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7>Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(18\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(1\)\(d\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 23: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 24: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 26: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 27: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 28: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 29: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 30: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 31: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 32: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B)Reference 33: <http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 34: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 35: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1)Reference 36: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1)Reference 37: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(22\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1) + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration XML 33 R23.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Insider Trading Arrangements 3 Months Ended Jun. 30, 2024 Trading Arrangements, by Individual Â Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false X - ReferencesReference 1:

interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary. + ReferencesReference 1: [http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4](http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1 + Details Name: us-gaap ConsolidationPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 + Details Name: us-gaap EarningsPerSharePolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9)Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(c\) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1)Reference 5: <http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12>Reference 7: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 35 R25.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Supplemental Balance Sheet Information (Tables) 6 Months Ended Jun. 30, 2024 Supplemental Balance Sheet Information [Abstract] A Schedule of Prepaid and Other Current Assets Prepaid expenses and other current assetsJune 30, 2023Prepaid insurance$476A $508A Prepaid franchise tax61A 259A Lease costs255A 235A Prepaid professional fees70A 95A Prepaid software 62A 72A Other68A 24A A A A A Prepaid expenses and other current assets$992A $1,193A Schedule of Other Noncurrent Assets Other noncurrent assetsJune 30, 2024December 31, 2023Restricted cash$872A $1,200A Prepaid insurance1,571A 1,785A A A A A Other noncurrent assets$2,443A $2,985A Schedule of Property and Equipment, Net Property and equipment, netJune 30, 2024December 31, 2023Scientific equipments$246A $246A Computers and software3A 3A Furniture and fixtures30A 30A Property and equipment, gross279A 279A Less: accumulated depreciation and amortization(239)(225)Property and equipment, net$40A $54A Schedule of Accrued expenses and other current liabilities Accrued expenses and other current liabilitiesJune 30, 2024December 31, 2023Current lease liability$671A $626A Accrued payroll-related expenses$A 71A Accrued other expenses175A 182A A A A A Accrued expenses and other current liabilities$846A $879A X - DefinitionTabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs. + ReferencesNo definition available. + Details Name: us-gaap DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap PropertyPlantAndEquipmentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of accrued liabilities. + ReferencesNo definition available. + Details Name: us-gaap ScheduleOfAccruedLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of noncurrent assets. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap ScheduleOfOtherAssetsNoncurrentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionSupplemental Balance Sheet Information [Abstract] + ReferencesNo definition available. + Details Name: xcur SupplementalBalanceSheetInformationAbstract Namespace Prefix: xcur_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 36 R26.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Leases (Tables) 6 Months Ended Jun. 30, 2024 Leases [Abstract] A Schedule of Lease Costs The following table summarizes lease costs in the Companyâ€™s unaudited condensed consolidated statement of operations:Three Months EndedJune 30,Six Months EndedJune 30,2024202320242023Operating lease costs$142A $326A $285A $652A Variable lease costs(117)(19)3A 313A Short term lease costs9A â€”A 20A â€”A Total lease costs$34A $307A $308A $965A The following table summarizes sublease receipts in the Companyâ€™s condensed consolidated statement of operations:Three Months EndedJune 30,Six Months EndedJune 30,2024202320242023Sublease amounts paid to landlord$173A $â€”A A $346A $â€”A Total$173A $â€”A A $346A $â€”A X - DefinitionTabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap LeaseCostTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 37 R27.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Equity-Based Compensation (Tables) 6 Months Ended Jun. 30, 2024 Share-Based Payment Arrangement [Abstract] A Schedule of Equity-Based Compensation Expense Classification in Statement of Operations Equity-based compensation expense is classified in the statements of operations as follows:Three Months EndedJune 30,Six Months EndedJune 30,2024202320242023Research and development expenses$â€”A $â€”A A $â€”A A $154A General and administrative expense6A 969A 11A 1,123A 6A $969A $11A $1,277A Schedule of Assumptions Used to Determine Fair Value of Common Stock Option Grants The following table presents the assumptions used in the Black-Scholes option-pricing model for stock options granted during the six months ended June 30, 2023:Six Months EndedJune 30,2023Expected term5.8 to 5.8 yearsRisk-free interest rate3.83% to 3.83%; weighted avg. 3.83%Expected volatility101.0% to 101.0%; weighted avg. 101.0%Forfeiture rate5A %Expected dividend yieldâ€”A %The fair value of the underlying common stock and the exercise price for the common stock options granted during the six months ended June 30, 2023 are summarized in the table below. No options were granted during the six months ended JuneA 30, 2024.Fair Value of Underlying Common StockExercise Price of Common Stock OptionSix months ended June 30, 2023$1.58; weighted avg. $1.58$1.58; weighted avg. $1.58 Schedule of Common Stock Option Activity A summary of common stock option activity as of the periods indicated is as follows:OptionsWeighted-Average Exercise PriceWeighted-Average Remaining Contractual Term (years)Aggregate Intrinsic Value (thousands)Outstanding - December 31, 202311,115A $4.28A 5.4$â€”A A Grantedâ€”A A A Exercisedâ€”A A A Forfeited(416)5.51A Outstanding - June 30, 202411,699A $5.51A 4.9$â€”A A Vested and Expected to Vest - June 30, 202411,699A $5.51A 4.9$â€”A A Schedule of Restricted Stock Unit Awards Activity A summary of restricted stock unit activity of the periods indicated is as follows: Restricted Stock UnitsWeighted-Average Grant Date Fair ValueUnvested balance - December 31, 20233,043A $10.41A Grantedâ€”A A A Vested(592)18.47A Forfeited(417)3.45A Unvested balance - June 30, 20242,034A $12.24A X - ReferencesNo definition available. + Details Name: us-gaap DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: <a href=)Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 40 R30.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Description of Business, Basis of Presentation and Going Concern (Details) - USD ($) in Thousands Jun. 30, 2024 Dec. 31, 2023 Accounting Policies [Abstract] A A Cash and cash equivalents $ 528 $ 816 X - ReferencesNo definition available. + Details Name: us-gaap AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: <a href=)

Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 10 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 41 R31.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Supplemental Balance Sheet Information - Schedule of Prepaid and Other Current Assets (Details) - USD (\$) in Thousands Jun. 30, 2024 Dec. 31, 2023 Supplemental Balance Sheet Information [Abstract] A A Prepaid insurance \$ 476 \$ 508 Prepaid franchise tax 61 259 Lease costs 255 235 Prepaid professional fees 70 95 Prepaid software 62 72 Other 68 24 Prepaid expenses and other current assets \$ 992 \$ 1,193 X - DefinitionAmount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1 + Details Name: us-gaap OtherPrepaidExpenseCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5 + Details Name: us-gaap PrepaidInsurance Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLease, Cost, Current + ReferencesNo definition available. + Details Name: xcur LeaseCostCurrent Namespace Prefix: xcur Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPrepaid Franchise Tax + ReferencesNo definition available. + Details Name: xcur PrepaidFranchiseTax Namespace Prefix: xcur Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPrepaid Professional Fees, Current + ReferencesNo definition available. + Details Name: xcur PrepaidProfessionalFeesCurrent Namespace Prefix: xcur Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPrepaid Software, Current + ReferencesNo definition available. + Details Name: xcur PrepaidSoftwareCurrent Namespace Prefix: xcur Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSupplemental Balance Sheet Information [Abstract] + ReferencesNo definition available. + Details Name: xcur SupplementalBalanceSheetInformationAbstract Namespace Prefix: xcur Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 42 R32.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Supplemental Balance Sheet Information - Schedule of Other Noncurrent Assets (Details) - USD (\$) in Thousands Jun. 30, 2024 Dec. 31, 2023 Supplemental Balance Sheet Information [Abstract] A A Restricted cash \$ 872 \$ 1,200 Prepaid insurance 1,571 1,785 Other noncurrent assets \$ 2,443 \$ 2,985 X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap OtherAssetsNoncurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 5 -SubTopic 210 -Topic 954 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 + Details Name: us-gaap RestrictedCashNoncurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPrepaid Insurance, Noncurrent + ReferencesNo definition available. + Details Name: xcur PrepaidInsuranceNoncurrent Namespace Prefix: xcur Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSupplemental Balance Sheet Information [Abstract] + ReferencesNo definition available. + Details Name: xcur SupplementalBalanceSheetInformationAbstract Namespace Prefix: xcur Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 43 R33.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Supplemental Balance Sheet Information - Schedule of Property and Equipment, Net (Details) - USD (\$) in Thousands Jun. 30, 2024 Dec. 31, 2023 Property, Plant and Equipment [Line Items] A A Property and equipment, gross \$ 279 \$ 279 Less: accumulated depreciation and amortization (239) (225) Property and equipment, net 40 54 Scientific equipment A A Property, Plant and Equipment [Line Items] A A Property and equipment, gross 246 246 Computers and software A A Property, Plant and Equipment [Line Items] A A Property and equipment, gross 3 3 Furniture and fixtures A A Property, Plant and Equipment [Line Items] A A Property and equipment, gross \$ 30 \$ 30 X - DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap PropertyPlantAndEquipmentGross Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A + Details Name: us-gaap PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 44 R34.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Supplemental Balance Sheet Information - Narrative (Details) - USD (\$) in Thousands 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Supplemental Balance Sheet Information [Abstract] A A Depreciation and amortization \$ 14 \$ 479 X - DefinitionThe aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap DepreciationAmortizationAndAccretionNet Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionSupplemental Balance Sheet Information [Abstract] + ReferencesNo definition available. + Details Name: xcur SupplementalBalanceSheetInformationAbstract Namespace Prefix: xcur Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 45 R35.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Supplemental Balance Sheet Information - Schedule of Accrued expenses and other current liabilities (Details) - USD (\$) in Thousands Jun. 30, 2024 Dec. 31, 2023 Supplemental Balance Sheet Information [Abstract] A A Current lease liability \$ 671 \$ 626 Accrued payroll-related expenses 0 71 Accrued other expenses 175 182 Accrued expenses and other current liabilities \$ 846 \$ 879 X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap AccruedLiabilitiesCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap OtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionSupplemental Balance Sheet Information [Abstract] + ReferencesNo definition available. + Details Name: xcur SupplementalBalanceSheetInformationAbstract Namespace Prefix: xcur Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 46 R36.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Leases - Narrative (Details) ftA² in Thousands, \$ in Thousands 6 Months Ended May 04, 2023 Jul. 01, 2020 USD (\$) ftA² extension period Jun. 30, 2024 USD (\$) Jun. 30, 2023 USD (\$) Lessee, Lease, Description [Line Items] A A A Operating lease, cash payments A A \$ 327 \$ 860 Chicago A A A Lessee, Lease, Description [Line Items] A A A Operating lease area | ftA² A 30 A Operating lease, contract term A 10 years A A Operating lease, number of extensions | extension period A 2 A A Operating lease, renewal term A 5 years A A Operating lease, annual rent payment A \$ 1,113 A A Operating lease, base rent annual percentage increase (as a percent) A 3.00% A A Operating lease, estimated rental payment over lease term A \$ 12,761 A A Sublease percentage of office space subtenant (as a percent) 57.00% A A Period of no rental cost 3 months A A X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap LesseeLeaseDescriptionLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTerm of lessee's operating lease renewal, in 'PnYmMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap LesseeOperatingLeaseRenewalTerm Namespace Prefix: us-gaap Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionTerm of lessee's operating lease, in 'PnYmMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap LesseeOperatingLeaseTermOfContract Namespace Prefix: us-gaap Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap OperatingLeasePayments Namespace

Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - Definition: Lessee, Operating Lease, Annual Rent Payment Initial Twelve Months + ReferencesNo definition available. + Details Name: xcur_LesseeOperatingLeaseAnnualRentPaymentInitialTwelveMonths Namespace Prefix: xcur_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - Definition: Lessee, Operating Lease, Base Rent Annual Percentage Increase + ReferencesNo definition available. + Details Name: xcur_LesseeOperatingLeaseBaseRentAnnualPercentageIncrease Namespace Prefix: xcur_ Data Type: dtr-types1:percentItem Type Balance Type: na Period Type: instant X - Definition: Lessee, Operating Lease, Estimated Rental Payment Over Original Term + ReferencesNo definition available. + Details Name: xcur_LesseeOperatingLeaseEstimatedRentalPaymentOverOriginalTerm Namespace Prefix: xcur_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - Definition: Lessee, Operating Lease, Lease Area + ReferencesNo definition available. + Details Name: xcur_LesseeOperatingLeaseLeaseArea Namespace Prefix: xcur_ Data Type: dtr-types1:arealtem Type Balance Type: na Period Type: duration X - Definition: Lessee, Operating Lease, Number of Extensions + ReferencesNo definition available. + Details Name: xcur_LesseeOperatingLeaseNumberOfExtensions Namespace Prefix: xcur_ Data Type: xbrli:integerItem Type Balance Type: na Period Type: duration X - Definition: Lessee, Operating Sublease, Percentage Of Office Space Subleased + ReferencesNo definition available. + Details Name: xcur_LesseeOperatingSubleasePercentageOfOfficeSpaceSubleased Namespace Prefix: xcur_ Data Type: dtr-types1:percentItem Type Balance Type: na Period Type: duration X - Definition: Lessee, Operating Sublease, Period Of No Rent Cost + ReferencesNo definition available. + Details Name: xcur_LesseeOperatingSubleasePeriodOfNoRentCost Namespace Prefix: xcur_ Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - Details Name: srt.StatementGeographicalAxis=xcur_ChicagoMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 47 R37.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Leases - Lease Costs (Details) - USD (\$) in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Leases [Abstract] A A A A Operating lease costs \$ 142 \$ 326 \$ 285 \$ 652 Variable lease costs (117) (19) 3 313 Short term lease costs 9 0 20 0 Total lease costs \$ 34 \$ 307 \$ 308 \$ 965 X - Definition: Amount of lease cost recognized by lessee for lease contract. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4> + Details Name: us-gaap_LeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - Definition: Amount of short-term lease cost, excluding expense for lease with term of one month or less. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4](http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4) + Details Name: us-gaap_ShortTermLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - Definition: Variable Lease, Cost, Net + ReferencesNo definition available. + Details Name: xcur_VariableLeaseCostNet Namespace Prefix: xcur_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration XML 48 R38.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Leases - Sublease Receipts (Details) - USD (\$) in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Leases [Abstract] A A A A Sublease amounts paid to landlord \$ 173 \$ 0 \$ 346 \$ 0 X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Definition: Amount of sublease income excluding finance and operating lease expense. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4](http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4) + Details Name: us-gaap_SubleaseIncome Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration XML 49 R39.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Investment in Convertible Notes Receivable - Narrative (Details) 1 Months Ended Mar. 31, 2024 USD (\$) May 31, 2023 USD (\$) agreement Jun. 30, 2024 USD (\$) Dec. 31, 2023 USD (\$) Debt Securities, Available-for-sale [Line Items] A A A A Available-for-sale securities A A \$ 0 \$ 0 Notes Receivable A A A A Debt Securities, Available-for-sale [Line Items] A A A A Number of subscription agreements entered into [agreement] 2 A A A Available-for-sale securities A A \$ 2,000,000 A Stated yield 4.50% A A Period in between reoccurring put option 4 3 months A A Redemption price percentage A 100.00% A A Proceeds from sale or maturity of available-for-sale securities \$ 2,090,000.00 A A Notes Receivable, One A A A A Debt Securities, Available-for-sale [Line Items] A A A A Available-for-sale securities A \$ 1,000,000 A A Notes Receivable, Two A A A A Debt Securities, Available-for-sale [Line Items] A A A A Available-for-sale securities A \$ 1,000,000 A X - Definition: Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103>Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100>Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(bbb\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(bbb\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 5: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(bbb\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(aa\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2)Reference 8: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-03\(f\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1)Reference 10: <http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1> + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - Definition: Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12> + Details Name: us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - Definition: Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(aa\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(aaa\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aaa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2)Reference 8: <http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3>Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3) + Details Name: us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Definition: Debt Securities, Available-for-Sale, Period In Between Reoccurring Put Option + ReferencesNo definition available. + Details Name: xcur_DebtSecuritiesAvailableForSalePeriodInBetweenReoccurringPutOption Namespace Prefix: xcur_ Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - Definition: Debt Securities, Available-for-Sale, Redemption Price, Percentage + ReferencesNo definition available. + Details Name: xcur_DebtSecuritiesAvailableForSaleRedemptionPricePercentage Namespace Prefix: xcur_ Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - Definition: Debt Securities, Available-for-Sale, Stated Yield + ReferencesNo definition available. + Details Name: xcur_DebtSecuritiesAvailableForSaleStatedYield Namespace Prefix: xcur_ Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - Definition: Number Of Subscription Agreements Entered + ReferencesNo definition available. + Details Name: xcur_NumberOfSubscriptionAgreementsEntered Namespace Prefix: xcur_ Data Type: xbrli:integerItem Type Balance Type: na Period Type: duration X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_NotesReceivableMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=xcur_NotesReceivableOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=xcur_NotesReceivableTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R40.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Debt - Narrative (Details) - Promissory Note - USD (\$) in Thousands Jun. 30, 2024 May 03, 2024 Debt Instrument [Line Items] A A Debt instrument, face amount \$ 300 Interest rate 4.600% DGP Co. Ltd [Related Party] A A Debt Instrument [Line Items] A A Debt instrument, face amount \$ 700 A Interest rate 6.000% X - Definition: Face (par) amount of debt instrument at time of issuance. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B)Reference 3: <http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B>Reference 4: <http://www.xbrl.org/1943274/2147481568/470-20-55-69C>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2> + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - Definition: Contractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(22\)\(a\)\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B) + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItem Type Balance Type: na Period Type: instant X - Definition: Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8>Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(f\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.12-04\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B)Reference 5: <http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B>Reference 6: <http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C>Reference 7: <http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E>Reference 8: <http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F>Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B)Reference 11: <http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F>Reference 12: <http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69G -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69G>Reference 13: [http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69H -Publisher FASB](http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69H -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69H)

-Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap DebtInstrumentAxis=xcur PromissoryNoteMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt CounterpartyNameAxis=xcur DGCPoLdMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap RelatedPartyTransactionsByRelatedPartyAxis=us-gaap RelatedPartyMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R41.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stockholders' Equity - Preferred and Common Stock (Details) Jun. 30, 2024 vote \$ / shares shares Dec. 31, 2023 \$ / shares shares Equity [Abstract] Å Å Preferred stock, shares authorized (in shares) 10,000,000 10,000,000 Preferred stock, par value (in dollars per share) | \$ / shares \$ 0.0001 \$ 0.0001 Preferred stock, shares issued (in shares) 0 0 Preferred stock, shares outstanding (in shares) 0 0 Common stock, shares authorized (in shares) 200,000,000 200,000,000 Common stock, par value (in dollars per share) | \$ / shares \$ 0.0001 Common stock, shares issued (in shares) 8,651,148 8,650,753 Common stock, shares outstanding (in shares) 8,651,148 8,650,753 Common stock, voting rights for each share | vote 1 Å X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionCommon Stock, Voting Rights For Each Share + ReferencesNo definition available. + Details Name: xcur CommonStockVotingRightsForEachShare Namespace Prefix: xcur_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant XML 52 R42.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stockholders' Equity - Securities Purchase Agreement (Details) - USD (\$) \$ / shares in Units, \$ in Thousands 1 Months Ended 6 Months Ended Jun. 23, 2023 Feb. 24, 2023 Sep. 26, 2022 Dec. 16, 2021 Feb. 29, 2024 Jun. 30, 2024 Dec. 31, 2023 Dec. 31, 2021 Subsidiary, Sale of Stock [Line Items] Å Å Å Å Å Å Å Å Registration rights agreement, required filing term Å Å 90 days Å Å Å Å Å Å Å Å Registration rights agreement, liquidation damages payable as a percent of amount invested, if filed late (as a percent) Å Å 0.50% Å Å Å Å Å Å Å Å Registration rights agreement, liquidation damages payable if filed late, measurement term Å Å 30 days Å Å Å Å Å Å Å Å Common stock, par value (in dollars per share) Å Å Å \$ 0.0001 \$ 0.0001 Å Exercise price (in dollars per share) Å Å Å Å Å Å Å Å 8.1031 Å Å Å Å 8.1031 Warrant liability, measurement input, term Å Å Å 5 years Å Å Å Å Å Å Å Å Gross proceeds Å Å Å \$ 11,478 Å Å Å Å Net proceeds Å Å Å \$ 1,226 Å Å Å Å Ownership percentage limitation (as a percent) Å Å Å 4.99% Å Å Å Å Å Å Å Å Ownership percentage limitation at election of purchaser (as a percent) Å Å Å 9.99% Å Å Å Å DGP Co. Ltd Å Å Å Å Å Å Å Å Subsidiary, Sale of Stock [Line Items] Å Å Å Å Å Å Å Å Pro rata accrual Å Å Å Å Å Å Å \$ 191 Å Å Å CBI USA, Inc Å Å Å Å Å Å Å Å Subsidiary, Sale of Stock [Line Items] Å Å Å Å Å Å Å Å Pro rata payment Å Å Å Å \$ 27 Å Å Å Pre-Funded Warrants Å Å Å Å Å Å Å Å Subsidiary, Sale of Stock [Line Items] Å Å Å Å Å Å Å Å Warrants issued in sale of stock (in shares) Å Å Å Å 718,981 Å Å Å Å Exercise price (in dollars per share) Å Å Å Å \$ 0.030 Å Å Å Å Å Å Å Å Number of shares exercisable for each warrant (in shares) Å Å Å 1 Å Å Å Å Warrant Å Å Å Å Å Å Å Å Subsidiary, Sale of Stock [Line Items] Å Å Å Å Å Å Å Å Warrants issued in sale of stock (in shares) Å Å Å 576,261 Å Å Å Å Exercise price (in dollars per share) Å Å Å Å 8.1031 Å Å Å Å Å Å Å Å Number of shares exercisable for each warrant (in shares) Å Å Å 1 Å Å Å Å Å Å Å Å Common Stock And Accompanying Warrant Å Å Å Å Å Å Å Å Subsidiary, Sale of Stock [Line Items] Å Å Å Å Å Å Å Å Purchase price (in dollars per share) Å Å Å Å 9.9780 Å Å Å Å Å Å Å Å Pre-Funded Warrants And Accompanying Warrant Å Å Å Å Å Å Å Å Subsidiary, Sale of Stock [Line Items] Å Å Å Å Å Å Å Å Purchase price (in dollars per share) Å Å Å Å 9.9480 Å Å Å Å Å Å Å Å Common Stock Å Å Å Å Å Å Å Å Subsidiary, Sale of Stock [Line Items] Å Å Å Å Å Å Å Å Number of shares issued in transaction (in shares) Å Å Å Å 433,553 Å Å Å Å Å Å Å Å Common stock, par value (in dollars per share) Å Å Å Å \$ 0.0001 Å Å Å Å Private Placement Å Å Å Å Å Å Å Å Subsidiary, Sale of Stock [Line Items] Å Å Å Å Å Å Å Å Number of shares issued in transaction (in shares) Å Å Å 3,400,000 Å Å Å Å Å Å Å Å Sales price of shares issued in transaction (in dollars per share) Å Å Å Å 1.60 Å Å Å Å Å Å Å Å Consideration received, gross Å Å Å 5,440 Å Å Å Å Å Å Å Å Consideration for stock transaction Å Å 4,597 Å Å Å Å Private Placement | CBI USA & DGP Co. Ltd Å Å Å Å Å Å Å Å Subsidiary, Sale of Stock [Line Items] Å Å Å Å Å Å Å Å Percentage of ownership after transaction (as a percent) Å Å Å Å 45.00% Å Å Å Third Party Sale of Company Stock | CBI USA, Inc | DGP Co. Ltd Å Å Å Å Å Å Å Å Subsidiary, Sale of Stock [Line Items] Å Å Å Å Å Å Å Å Number of shares issued in transaction (in shares) 3,400,000 Å Å Å Å Å Å Å Å Third Party Sale of Company Stock | DGP Co. Ltd | Third Party Å Å Å Å Å Å Å Å Subsidiary, Sale of Stock [Line Items] Å Å Å Å Å Å Å Å Number of shares issued in transaction (in shares) Å Å Å 340,000 Å Å Å Å Percentage of shares subsequently sold at closing Å Å Å Å 10.00% Å Å Å X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares. + ReferencesNo definition available. + Details Name: us-gaap ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionCash received on stock transaction after deduction of issuance costs. + ReferencesNo definition available. + Details Name: us-gaap SaleOfStockConsiderationReceivedOnTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe number of shares issued or sold by the subsidiary or equity method investee per stock transaction. + ReferencesNo definition available. + Details Name: us-gaap SaleOfStockNumberOfSharesIssuedInTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPercentage of subsidiary's or equity investee's stock owned by parent company after stock transaction. + ReferencesNo definition available. + Details Name: us-gaap SaleOfStockPercentageOfOwnershipAfterTransaction Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPer share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + ReferencesNo definition available. + Details Name: us-gaap SaleOfStockPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap SubsidiarySaleOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPeriod between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

+ Details Name: us-gaap_WarrantsAndRightsOutstandingTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionClass Of Warrant Or Right, Ownership Percentage Limitation + ReferencesNo definition available. + Details Name: xcur_ClassOfWarrantOrRightOwnershipPercentageLimitation Namespace Prefix: xcur_ Data Type: dtr-types1:percentItem Type Balance Type: na Period Type: instant X - DefinitionClass Of Warrant Or Right, Ownership Percentage Limitation At Election Of Purchaser + ReferencesNo definition available. + Details Name: xcur_ClassOfWarrantOrRightOwnershipPercentageLimitationAtElectionOfPurchaser Namespace Prefix: xcur_ Data Type: dtr-types1:percentItem Type Balance Type: na Period Type: instant X - DefinitionProceeds From Issuance Of Common Stock And Warrants + ReferencesNo definition available. + Details Name: xcur_ProceedsFromIssuanceOfCommonStockAndWarrants Namespace Prefix: xcur_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionProceeds from Issuance Of Common Stock And Warrants Net of Placement Agent Fee and Other Offering Expenses Payable + ReferencesNo definition available. + Details Name: xcur_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfPlacementAgentFeeAndOtherOfferingExpensesPayable Namespace Prefix: xcur_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRegistration Rights Agreement, Liquidation Damages Payable If Filed Late, As A Percent Of Amount Invested + ReferencesNo definition available. + Details Name: xcur_RegistrationRightsAgreementLiquidationDamagesPayableAsAPercentOfAmountInvestedIfFiledLate Namespace Prefix: xcur_ Data Type: dtr-types1:percentItem Type Balance Type: na Period Type: duration X - DefinitionRegistration Rights Agreement, Liquidation Damages Payable If Filed Late, Measurement Term + ReferencesNo definition available. + Details Name: xcur_RegistrationRightsAgreementLiquidationDamagesPayableIfFiledLateMeasurementTerm Namespace Prefix: xcur_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionRegistration Rights Agreement, Pro Rata Accrual + ReferencesNo definition available. + Details Name: xcur_RegistrationRightsAgreementProRataAccrual Namespace Prefix: xcur_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionRegistration Rights Agreement, Pro Rata Payment + ReferencesNo definition available. + Details Name: xcur_RegistrationRightsAgreementProRataPayment Namespace Prefix: xcur_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRegistration Rights Agreement, Required Filing Term + ReferencesNo definition available. + Details Name: xcur_RegistrationRightsAgreementRequiredFilingTerm Namespace Prefix: xcur_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionSale Of Stock And Warrants, Price Per Share + ReferencesNo definition available. + Details Name: xcur_SaleOfStockAndWarrantsPricePerShare Namespace Prefix: xcur_ Data Type: dtr-types1:perShareItemType Balance Type: na Period Type: duration X - DefinitionSale Of Stock, Consideration Received On Transaction, Gross + ReferencesNo definition available. + Details Name: xcur_SaleOfStockConsiderationReceivedOnTransactionGross Namespace Prefix: xcur_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionSale Of Stock, Number Of Shares Issued In Transaction, Percentage Subsequently Sold + ReferencesNo definition available. + Details Name: xcur_SaleOfStockNumberOfSharesIssuedInTransactionPercentageSubsequentlySold Namespace Prefix: xcur_ Data Type: dtr-types:percentItem Type Balance Type: na Period Type: instant X - DefinitionSale Of Stock, Number Of Warrants Issued In Transaction + ReferencesNo definition available. + Details Name: xcur_SaleOfStockNumberOfWarrantsIssuedInTransaction Namespace Prefix: xcur_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - Details Name: srt_CounterpartyNameAxis=xcur_DGPCoLtdMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=xcur_PreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=xcur_CommonStockAndAccompanyingWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=xcur_PreFundedWarrantsAndAccompanyingWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidarySaleOfStockAxis=us-gaap_PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=xcur_CBIUSADGPCoLtdMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidarySaleOfStockAxis=xcur_ThirdPartySaleOfCommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=xcur_CBIUSALnMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=xcur_ThirdPartyMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 53 R43.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stockholders' Equity - Common Stock Warrants (Details) - USD (\$) \$ / shares in Units, \$ in Thousands Jun. 23, 2023 Jun. 30, 2024 Dec. 31, 2021 Equity [Abstract] A A A Number of shares called by warrants (in shares) A 50,110 576,261 Exercise price (in dollars per share) A \$ 8.1031 \$ 8.1031 Payment for warrant liability \$ 800 A A Warrants settled (in shares) 526,151 A A X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: <http://www.xbrli.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3> + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: <http://www.xbrli.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3> + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionClass Of Warrant Or Right, Number Of Securities Settled In Period + ReferencesNo definition available. + Details Name: xcur_ClassOfWarrantOrRightNumberOfSecuritiesSettledInPeriod Namespace Prefix: xcur_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionClass Of Warrant Or Right, Payment For Liability + ReferencesNo definition available. + Details Name: xcur_ClassOfWarrantOrRightPaymentForLiability Namespace Prefix: xcur_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 54 R44.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Equity-Based Compensation - Narrative (Details) - USD (\$) \$ / shares in Units, \$ in Thousands 1 Months Ended 6 Months Ended Jan. 01, 2024 Jan. 01, 2020 Sep. 30, 2017 Jun. 30, 2024 Jun. 30, 2023 Sep. 22, 2017 Share-based Compensation Arrangement by Share-based Payment Award [Line Items] A A A A Compensation cost not yet recognized A A A \$ 21 A A Compensation expense recognition period A A A 1 year 4 months 24 days A A Granted (in shares) A A A 0 A A Weighted-average grant date fair value (in dollars per share) A A A \$ 1.26 A Employee Stock A A A A Share-based Compensation Arrangement by Share-based Payment Award [Line Items] A A A A Number of shares available for grant (in shares) A A A 61,971 A A Maximum ESPP contribution rate as a percentage of compensation (as a percent) A A 15.00% A A Maximum number of shares per employee in purchase period (in shares) A A 250 A A Maximum contribution amount A A \$ 25 A A ESPP purchase price as a percentage of market price (as a percent) A A 85.00% A A Number of additional shares allowable annually under the plan (in shares) A A 10,000 A A Percentage of outstanding shares allowable as annual increase (as a percent) A A 0.30% A A Increase in number of shares available for grant (in shares) 10,000 A A A A Restricted stock units A A A A Share-based Compensation Arrangement by Share-based Payment Award [Line Items] A A A A Vesting period A A A 4 years A A Number of shares issued for each vested restricted stock unit (in shares) A A 1 A A Exicure, Inc. 2017 Equity Incentive Plan A A A A Share-based Compensation Arrangement by Share-based Payment Award [Line Items] A A A A Number of shares authorized (in shares) A A A 194,750 Number of shares available for grant (in shares) A A 455,292 A 72,330 Number of additional shares authorized, potential maximum additional shares (in shares) A 153,333 A A A Number of additional shares authorized, percentage of common stock outstanding (as a percent) A 5.00% A A A Exicure, Inc. 2017 Equity Incentive Plan | Share-based Payment Arrangement, Option A A A A Share-based Compensation Arrangement by Share-based Payment Award [Line Items] A A A A Number of shares available for grant (in shares) 153,333 A A A A Expiration period A A A 10 years A A Exicure, Inc. 2017 Equity Incentive Plan | Initial Employee Stock Option A A A A Share-based Compensation Arrangement by Share-based Payment Award [Line Items] A A A A Monthly vesting percentage (as a percent) A A 2.08% A A Vesting period A A A 48 months A A Exicure, Inc. 2017 Equity Incentive Plan | Initial Employee Stock Option | Non-employee Director A A A A Share-based Compensation Arrangement by Share-based Payment Award [Line Items] A A A A Monthly vesting percentage (as a percent) A A 2.78% A A Vesting period A A A 36 months A A Exicure, Inc. 2017 Equity Incentive Plan | Initial Employee Stock Option | Period One A A A A Share-based Compensation Arrangement by Share-based Payment Award [Line Items] A A A A Vesting percentage (as a percent) A A 25.00% A A Exicure, Inc. 2017 Equity Incentive Plan | Subsequent Employee Stock Option A A A A Share-based Compensation Arrangement by Share-based Payment Award [Line Items] A A A A Monthly vesting percentage (as a percent) A A 2.08% A A Vesting period A A A 48 months A A Exicure, Inc. 2017 Equity Incentive Plan | Subsequent Employee Stock Option | Non-employee Director A A A A Share-based Compensation Arrangement by Share-based Payment Award [Line Items] A A A A Monthly vesting percentage (as a percent) A A 8.33% A A Vesting period A A A 12 months A A Exicure OpCo 2015 Equity Incentive Plan A A A A Share-based Compensation Arrangement by Share-based Payment Award [Line Items] A A A A Number of shares available for grant (in shares) A A A 122,793 X - DefinitionAmount of cost not yet recognized for nonvested award under share-based payment arrangement. + ReferencesReference 1: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDnHnMnS' format, for example, 'PIY5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionPeriod over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDnHnMnS' format, for example, 'PIY5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. + ReferencesReference 1: [http://www.xbrli.org/2003/role/exampleRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/exampleRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: <http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D>Reference 2: <http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3>Reference 3: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 4: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 5: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 6: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(4\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 7: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 8: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 9: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 10: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 11: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(v\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 12: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(vi\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(vi) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 13: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(vii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(vii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 14: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(viii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(viii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 15: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 16: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 17: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 18: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iv\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 19: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(v\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 20: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 21: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 22: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(e\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 23: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(e\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 24: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 25: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 26: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 27: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(iv\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)

https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28:

XML 58 R48.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Equity-Based Compensation - Schedule of Stock Options Rollforward (Details) - USD (\$) \$ / shares in Units, \$ in Thousands 6 Months Ended 12 months Ended Jun. 30, 2024 Dec. 31, 2023 Options A Shares outstanding, beginning period (in shares) 12,115 A Granted (in shares) 0 A Exercise (in shares) 0 A Forfeited (in shares) (416) A Shares outstanding, ending period (in shares) 11,699 12,115 Exercisable (in shares) 11,699 A Vested and expected to vest (in shares) 11,699 A Weighted-Average Exercise Price A Outstanding beginning balance (in dollars per share) \$ 4.28 A Granted (in dollars per share) 0 A Exercised (in dollars per share) 0 A Forfeited (in dollars per share) 5.51 A Outstanding ending balance (in dollars per share) 5.51 \$ 4.28 Exercisable, weighted-average exercise price (in dollars per share) 5.51 A Vested and expected to vest, weighted-average exercise price (in dollars per share) \$ 5.51 A Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] A Weighted-Average Remaining Contractual Term (years) 4 years 10 months 24 days 5 years 4 months 24 days Exercisable, weighted-average remaining contractual term 4 years 10 months 24 days A Vested and expected to vest, weighted average remaining contractual term 4 years 10 months 24 days A Aggregate Intrinsic Value (thousands) \$ 0 \$ 0 Exercisable, aggregate intrinsic value 0 A Vested and expected to vest, aggregate intrinsic value \$ 0 A X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) (iii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionAmount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionAmount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionNumber of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionWeighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionAmount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionWeighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYmNdTnHmMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYmNdTnHmMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYmNdTnHmMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2> + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-599-1> + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-599-1> + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-599-1> + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration XML 59 R48.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Equity-Based Compensation - Schedule of Restricted Stock Unit Awards Activity (Details) - Restricted stock units 6 Months Ended Jun. 30, 2024 \$ / shares shares Restricted Stock Units A Unvested balance - beginning of period (in shares) | shares 3,043 Granted (in shares) | shares 0 Vested (in shares) | shares (592) Forfeited (in shares) | shares (417) Unvested balance - end of period (in shares) | shares 2,034 Weighted-Average Grant Date Fair Value A Unvested balance - beginning of period (in dollars per share) | \$ / shares 10.41 Granted (in dollars per share) | \$ / shares 0 Vested (in dollars per share) | \$ / shares 18.47 Forfeited (in dollars per share) | \$ / shares 3.45 Unvested balance - end of period (in dollars per share) | \$ / shares \$ 12.24 X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionWeighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit)

https://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionPer share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 60 R50.htm IDEA: XBRL DOCUMENT V3.24.2.u1 Income Taxes - Narrative (Details) - USD \$(3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Income Tax Disclosure [Abstract] \$ \$ \$ \$ Provision for income taxes \$ 0 \$ 0 \$ 0 Effective tax rate (as a percent) \$ \$ 0.00% 0.00% X - DefinitionPercentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231 + Details Name: us-gaap_EffectiveIncomeTaxRateContinuingOperations Namespace Prefix: us-gaap_Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SAB Topic 6.1.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-599-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-599-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-599-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration XML 61 R51.htm IDEA: XBRL DOCUMENT V3.24.2.u1 Loss Per Common Share - Schedule of Computation of loss per common share (Details) - USD \$(/ shares in Units, \$ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Mar. 31, 2024 Jun. 30, 2023 Mar. 31, 2023 Jun. 30, 2024 Jun. 30, 2023 Earnings Per Share [Abstract] \$ \$ \$ \$ Net loss \$ (600) \$ (829) \$ (5,764) \$ (4,407) \$ (1,429) \$ (10,171) Weighted-average basic common shares outstanding (in shares) 8,651,078 \$ 8,432,394 \$ 8,650,878 7,366,594 Weighted-average diluted common shares outstanding (in shares) 8,651,078 \$ 8,432,394 \$ 8,650,878 7,366,594 Loss per share - basic (in dollars per share) \$ (0.07) \$ (0.68) \$ (0.17) \$ (1.38) Loss per share - diluted (in dollars per share) \$ (0.07) \$ (0.68) \$ (0.17) \$ (1.38) X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 5

S99-1Reference 7:

```
https://asc.fasb.org/1943274/214748326/850-150-3 + Details Name: us-gaap_RelatedPartyTransactionAmountsOffTransaction Namespace Prefix: us-gaap_Data Type: xbrli:itemItemSize  
Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07)(c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07)(c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07)(g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_RelatedPartyTransactionLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis-us-gaap_RelatedPartyMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 66 R56.htm IDEA: XBRL DOCUMENT v3.24.2.u1 License Agreement (Details) $ in Thousands Feb. 05, 2024 USD ($) Biopharmaceutical Company A Finite-Lived Intangible Assets [Line Items] A Proceeds from patent license agreement $ 500 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionProceeds From Patent License Agreement + ReferencesNo definition available. + Details Name: xcpr_ProceedsFromPatentLicenseAgreement Namespace Prefix: xcpr_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: srt_CounterpartyNameAxisxcpr_BiopharmaceuticalCompanyMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 67 Financial Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial Report.xlsx M4SL#110 (.##5D'04UB@<+O 9%KJCA'0<,O8TPI+GAM M;$V,.0/L'.1!$ _I|QO;>=IP4BJ0-<I2L+U?>LOQOD&1#LD)>OCGI;CVX>;QA&SWPGM*N#H#BV&S' C(I|/14TBK9.Y?-N')=HI6-Y #OGDK7A.YNJQ[C=F+W]AE6'4GPZ4AIOW ]=OU|RJUEA<C#MBITE1+ P04 M'# <C@PU9FMJ.B) K J+& O1OIUR.WIS+W+U&OLS9+/ M3LP.# =?>7>.FT9DE'7").('$Q">O'MWKPMOHFQC'C=W].6K1.'! " 8 Y'T / MGR6W .H=<SCZGS#g&(Q7)PSN.YGH>.:8FB.CZBS[EDT/M=M=H".#AAZZ.(43)L4.<'>#6XES]<MM2Q3P0H9|JN |LF.FW+A#6|CR.SNH7U MF937.|*5M IXIL|=KI)V'=OLF.UJ<OR'X'>F'?'Q6KU/KC.LK(N&+NW M.JCX(BA:<'47@>M02P.$% @XX.-69E&UL5|-CJHX%'[OK]IX9_9M'8v@:.TSw:I-MNTF83M M3A'%5B;-EDDB1 OTV23J;/ OLZ2'O.14VCZ#@AY\^XN8NB&B)3R MV+=>|J06N|I3+>MUES6QH0QIJ.M-O=5H1I';*$81V!@? %CL:#%05%;>U/@.M.47.,@5RU9-2.I MS$U>=I.KF(M+Y);7VMXM<9< L.ATR@eXPxU@o?>YoI^1.6HCA5,+SP&IG/U9K MQJ'22("R7V4:I)/j3%0@>R3GLZGS<=>GSVQ.V7 CK:=#1M&N#C7/>XMLE0 MBW A(5M+5 TR M6'IUVLS ZY y>?IUeIKr;O=005SP6.XYB1'^QL4$UFUG2.98RT1G+D 4..#?5 MT4Q07?|MHK(H#P1+27)#SRFUAI#H(FLB1)4>"(<7K;YH|M5ZY2=<6%?$ !&N#<?>'9ST6G|I25&'T95O-RCEU= 9<-8WSZJ T'-25LU GDB5P/M MG#P=Q+<E L&08:7'82J3E'34@3 BNEVOZRTD.FJW'ZF/(F9 M-AIRM1:M2G&IA&S:L1>2%M16:PUDSY@R.S-D7T.Ut$.9$)=>{BLZ+&MB' H8X2JKMHG#H(V>?>P'B>RB'>L'>U3-L+(WIJ07RN0)/< 23(T MI.Z-.60FA)%9GJZ'|>ZH'C(*!&'Y'CIE-C*>.Y'<O?>N@<GLI '|>*K'<+A M.7N?>=<E|GT|:2MSAD6R4)R033R%' MSfY|<VLJ4_5'D=>?EK[DHN.Q;Y.FOH7O+<+.Y/Y GM,T+,T.WF)<Y'>M0-M-2D< #'>%>@>IKB.D5N78V5WG-V-1'<'4';'CIRS'>=<(|)[A|F]&#.F MOX>=<[V'>Y'89Y7'>LM4'6RL)'Q&MVXU.L5* ID8'V@<U+AO+RAE5Y.O.50& RN0 MHGO.C$7H<?>.77Y CT9+CVZNEGMEZO7'<9.2|>IF1-GJk-K9-'151W/55OR ML+Y]/.053L -6-W(GPPI3AR&A+SDACE)+F2J+S&S._YRMQYQ4XOTASMA*7&+<SC MYL=Q3E.XS.G#V#P(RNLYJ7IE,6-FMMBM DL6XA9S/N)-7-W5YYNTB42%(JP# 4A MW5W+Cl'+<3>G>U./HL@6V5$#DU1'?OXG|3-ROJA)?>.NVB&+A=A=OB5,VJ&KXF M8SO#>FZ=>? VUI4/+D7;SHYG@<K.M.YLA,Z0Z1'P7V*BH IJV+'NJJ'/>26<+|1|8$>F S6VZ3MW>.?>2K6J5D*Q$ M2P=>U|(H&8XQ)|#1?CQIBK::QK<~.;OOY@CS#%F<."19H;.J6+k#F'.FJ| MU4#E|JO4#6CV30.9FV/JD3@HWW/O#>#>C|Q(AI8N_5+ P04 M'# <C@PU9Z2))MD6' #0#@< &'AL/W=O7UT/G-ZD>TH4OFCS&49)->+|> UVZF '%# M6W(IS&KDRSKF&DX5)ONE>!!'A1':>8XO7?,PZQQ,'<OC'7@>7&8Z&A,Q5B3- MXBKITLLTR?>5%<S9V9'/'<4>#>wW1'<9+Q43HA+NQG&VH-I'$LC24'$9SB=E% M8TC?>2XS ?D3OX=BG3X])@9EN*6&.1D#PMW'SPA&PM=<@<L E.P!'#$IDE,<.. M6%)&9LFWGQ30TFAP-8*4'%>Z_PD_O+AKJ|<G&S<C>10I/KJV(+<USOSHSZ M '"9,YJURL<OLQU3+<|L+<8C9;?/V?YQ+> 3EA VP.P5P&TA4'Q@/<@/<3% MLASKBFLL' =>R391Y&M3,O?>YNVB6|1.3OHE6<+<#>WPYSHH.H.D29J)GM |+<RMCO=<C;OM.DQK>A046KVNSYEPP5_5+6LI1U M#<AS6_72'<V/V';S%G&ZMO 757&+<E'<3F>B|JDOX.3E.MH-|:7JM#<X&6.7<,$ MQQ?>IDOOBH<@<C+15J)1#GWZ/>/->G&|J_/8'ME/<C=CUP97T.QBGFM+<86_M%<G3O_S#OF-JHG4+<9'ZAR%ISKZC0D5Y/$XL1=(V%Q*)JSVACPTJB9>K|K M'88W%B|J4@1F%|1#8:_.JP16+<50X|-+<XVFYVQ|>7I@S04#8#7Q...J.'"KB5 MO<#NQNPITBTBD9J; UCZZI?<?KR/MR='WU'1K=>RP.)AM>$I$YZGCJ8(X27RKH MFMSTTA.RT3>B53$DUFBU1A#ZSL>|>2OKFW$>%=Y&<6@AZ"?>?R2B |G.M0C_GICKQ?>79=UW6==CO,A/3W9/9 AISYE-CSBDNR MCNNOVQ9Y%|.2%>T'>V07QE7@>J@>S'>L+1+$3QJT&+YC)=AXMM3C&N/A,EIAC'+<+&F;GYG7H..9YIY/X MEJ
```

P]>]]HP&+T=TL7L1,1&(EY M3NK=<J\$;V,Q?>M?4:G>7%LF/DXJ?>M%*A*%C\$-L8J,3)2EIMO=<2F:QT)XB&B9,U5 MR4KG26F?7B9N%=<Y:Y?>8ESR9^[[F7;KU:
 2P]]HP&+T=TL7L1,1&(EY M3NK=<J\$;V,Q?>M?4:G>7%LF/DXJ?>M%*A*%C\$-L8J,3)2EIMO=<2F:QT)XB&B9,U5 MR4KG26F?7B9N%=<Y:Y?>8ESR9^[[F7;KU:
 MWM4&O0007:==E9S9T)XH^ H++E,Q0^B/?>SHP64LCV=I^D^JX MOJZ\$&^<@<X:ZXW9P,PS\$4)G:~)ARH;6^Y7L77ZQDBR&FZJ&A?2F#<5VCUOQZ^J^PH-8<^Q 2/I<K
 JI5AAS3R7+<Q,S,D2;R1^X0H+>RTB7P) MD Z02RT^<Q&S9DGBH^R^2<=E.L6G7R-SMK4F^<N4>P^M53:~VVS[[A92Q^1. M% A>|<|
 VU+Q95X\$=J4RAB20H+3&EGV^I[M(65.Q08DW57%,-=RZT=V M Q?M^M(BGT,NW2."TO>Q>51-2M2M,61VU1KC,"75-DU,(.6V3+V7" M^N^20A(Y5;>#<\$.C\$25TS(>X.960X2+Y-
 WMFL=+>OXG7\$2) MUC\$=<9R=F>?>BJOCSTQW/TEW.TJ8&128;FJVW.5.W4T17?>GV20HWWXYT62? M^9SA:3DU.E5HT6NB(63KB>:=#3:1 V KUW^78/K^A+H9J]^EGGD,0:~3
 M17O) FYAZC=>Y>@<ND:YDG^&J((O>=)Q)=XY=<6 ZY+1A,AV8 5HHNRD[FVFLWO7TA0X8?P]^RJO M2P,\$%< X,-63:~L9C> @ N@8 @ I^X;WJWQKJ|<S+QJ2R1\$M|);~3
),M|Z:~%>VD21?>DJFST60:6>~91&4Q3*2R9D,1J|UWQ|QZ^VA9^X&M&JLF32 M:8ZB~B9J|@<X:D666<<I^<9^>U<^<Q%8XBA(Q^),J@>Z8^|ZPW| M^Y(Y);F1A:~^>82FT^>P 23%E=<V%O57,
 NGU^QU5A 1..-G80N|KH8U79 M@<E4163|9H|=78 Y|UW|Q^>Q%Y^W^Y17>>4<LFXZU.D:|<^&S^Y^J^X|<U^ M65E-NX)P=KH2F12IXQ^L&N^FF&S%<1%<L%FG6GHZ 178O<.<XQ2J|OCN1^&
 M29L,N8)B) Q(8G;^HPW^N^Q0<~<M>S!(J!^J! @<VXP^GF P^M^>+~[M;VLI@|YL2 AEF^<XG^ =F@M3,8Z3<^%Z0?V P23XJ^*~*~@<H'615#<@<Q^OW M^2^~^<^<C+>19?>
 ET?>O>|JN^9#<@<=O5!1,TPB>+Q0!A,OSBR1L^H1EDRN JM^A(DC9%N)~>E@<QI^<K^<K=6DA=U&S=0727 M.9.RJN9;KJ2V0%>?>W50H1^<^>PQL7P^<VZJ^F?>U+|J^S3=~H1, [K>A20D
 M6*Y1PZ<ONV| @OR+<F/GPU07^4<4IRT M8^WB>+YDYJ|DJM^>@<Y^J|W?&|VH5C.A.LZ|P^YUAY^< M. -OTX-G^<U^<?>7SKJ)U^S^M^+J5.AJ20(\$10>+67D NIV4K6%5?>736E1.
 M=7Z9T^%MON@ 5115W2.VX^|NYNK^E+ P04 ~#<@CPUN9;6X|<#~! M^&0^<A1^+W=07+3 @GJ^K?>=E>EPTC?>R E.A4IEH MF0^<E%KROS8^<W^<J7Y|Y|R>~<V<?>G\$70VX|IG<=<#%["UEO?>
 FD+>+ZKJQ| MD2@<55VQB^> JNTU1,\$\$6~<W^C1ZD?>8&1@V+!<^A75L&2DEQK-IHHG3BF5Y^>Y^<CLV&F+0540CDFAUKYUR^XBG M^5;D(VK5VJA&8P?>
 J|~>RVP60>D70JYU&2&0JFPF1\$5.B5+U0Y\$3(%)<3 M & <ZJUGJ61<50LIR N1S1W^<@<^N^VJ^>LQ.L^<N^<U^<LOS^>~<TB^<W^<M^> M1>1>5X2730+4.G#<Q^>+>
 <0.0VF66<M^M<DCB/WG676;3K=E3XD7^ I+S^J; MX&FTE>0<5OG@F1^?>?>30LTAM2VYU^>?>+>159EV^<A^?>+>M^J|6W<9S0U.8|>=>3&BVS075XLLUKPC:B%?>CU^KH|Z;A<=<
 (M(PUD,9)=F 2H331;~?2J|JFE7+AG%|<R1 MZ#<^Y^V146W=|J;K?>6N<VZ<^5(MV%~^<^~^<N^ZU,TRD^E16B|E^*~<U^<L05A^<M^%XKX.R9.V.L2W:CF=NB13A7034ZD2;)&
 M^M+CT6ZFZFK^|OL4Y^X-EM."ZG+T^4EG[VWUY>F]KDNUTY67K^T4TNYN56ZV M5Z-HU|<K^<#>9IX|J64E^<~<^>~>JQJ9Y^T^Y^<M^5.FU^8=7Z:G030;Q=<#T3 M^*K5U0JN15FR,N8C;Q)KT8S
 J1RE7B2|^/SH.Y4G|@P/C4RQ|HQP?>J| M^YMARK2Z=2R7 3|<~<N1N8G+5\$|M^<D|JY M4S3,0%<H^<O^<Q8|/8;SV1,~<0,^<2@B0M^<DEY^7^UJS9J|8(8UNV%3FICA=
 M4E#N0=5;~39Y .9>2>YRZB&+39J|PW<~<^<F|G|>B2K2EJYL3K,ETID^<^<V^<M^<V MN 5R&Q5^<=3L1A^<Q%<XSB^>~<V^<W|Q3|H^<Q.E.XRJL9?>HIL2=219 M|Q|YZCR.SBZZ>=<~<DRH+1RM M=:
 (<3;R1&#^X^U^>?>IEM8KZXON05V\$F|DQ8 ^<F^<UJCG2^>921:30%<B^<J+Y19 MMYI^3.U(M2| P3^JN^>#2P,N^<N^<L^<V1,~<90=<ES<|<70P>T;S|<Q=<=<2/976[P M1^<Q4|Z<1LC,LT08K&|+4A)<
 (JAS;3#78LMA>="8ZY8&?>OU2L|^<4DEL^M.VE<\$(4D24B^<B^<J-S^<X>+>X>U.LD7F45-7.H,T|T|>P4A\$<=UQT^C2Z;=< M^R35Q^D N3N1^<+> [<3;R1&4C|L.U.SD^<H^< UKT1LC|U^<H>V>#| H559+< M^#U+GYSYU|D7L^<VCS1B^>~<V\$W\$8^>3;1\$G|P|LNQ@<^<H^<B82:6U^<F=Z;D M6X%<G43C^<H^<T^<|UA85^>77%<28&|>
 :IPQ\$C44E=W^5,IP@<UQNDRL^<+>QV3(2Y|G)@<R83X4^<Q^<Y|LZO>=R8X|)*6(XS1^<J, M2@Q^<^<V4J|>~<M^<#6\$B-N^<?>=>+>@<S|>7DG+V^<AV<K^<8^<V^<7E+2^<M^<Q4^<J^<78Z,9Y|N3^<MP
 ^<12UFC>~<~<292PL|WSN2:RAV\$#>?>H#Q B5T6Z4&BX^XUX^<^<YX N,Q| M^<N^<^<K=:~<R^<B18SK^<Q|B&1^<X^<KH^<C<60,(7-ZA,BZ^<SYB^<B^<^<F8HXRN<~<@ M^<W^<H^<GOON^<C^<^<
 ~<N|L^<AHU|N^<H^<OLC^<^<GN+Y8<QZ\$4~<~<EBBZ; QEQ WO M|L\$A3N;Q&7^<V^<N^<X^K^<KAG..\$<A(KR10^<U^<|<2773>2|,0\$<H60^<MOZT@<C91,0\$<S|SYZ(TGD;V|~<R^<X^<
 Q8&M|<O^<X^<F73G6GYW&K(SVRS58^<M^<=6)Y1P9^>|,B|F5^<F^<3DEJV;4+1|66N+<^<IDP4IDE?>X|2|J|93%A^<H^<P^<MX>9>74F^<V.122&+<T|<EOML|^<LJBRZ<33R^<MPD
 BAU|<ZS|QXK^<J^<N^<

[IFK-A*8<5A@;+>]>J%G;C"/Q=.5Q@/75 M*7-L*LL' L ZZOI2[B20WMNSD#U!+ P04 # #C@PU9H'Q! 90\$!8!0 M* 'AL+W=OO'=>49E1!=?;F\^L^! BHTJ?BJ4KUP)H M4AAE1J1MXWM-# #N-Z;BXBJ'F8YI*];6E(1ED\$QSDT3\$Q0YES M M6^~P6j OT,4^~!+!+!KGQV'!(O@&+9Y6QCB!>?E+ MOU6) #((@E<~@LH>@&'0U/UQZ&@&?>Z2%&? <?<~#J#8NAN.7B8<2%5=#H6 M? \$->=5K3S&1<.)!XYOE9I*(O'.FVJGZY%2ZRB0) JZ.LAI/LAW 96K*TS5Z3GGY' KDRU/(GW7%MT2L+>?)JNLEU6-Z;845V3 CQ4QENR!\$&S4 WE& M;K9:4!/TNXZ YYJQ? <31N1.P69 *=Z- #0J#W*?7P-ZNP-KL6-LYE+>BZ7,OMW&XZ22*0D.BE@N+D M\O'U!>=J]ZM'6)6Q5F'9NT(=U!E2+&'H'-A1;N9Q?7BNB8:\$Q.3N]YIE , MYT711W+>2=5G-XK;JL5%Z1C5D2;V!);60G? [4KKP^H/F\$S;&@>RRTMO)U MEB+!&FGSO4(CX6D33P)*~<5,*R1\$4L7C23S65U6P?&6S5TX43J).POKNNM< M?2/0'LF*AJ-MAJ(&S&F'1FHH*8*SU M%&J&D71WJ ?P7DQ 5881%:R8!.'0[L\$]_P6. 1)*%&XIDIRQ07NC-7IE(FYGEUB6)GJ]M?Z5F64H1%&VRZ&J].S=VLN((L_GJ,?M7E*186H MM+B-UED3T?&Z_0J? /NH72J7+42E15BTBIE?MFW-!R= %YVJ7F=E!B<ST&J; M;8;H;B,L6C/IA^>[8MW9U+37KCCUO339J\$XQ*~U%1!-MJK\$.*@W4Z?_ U!+ P04 # #C@PU9 M4UGS7JL"!_!0 &0 ' 'AL+W=O&!,1\$Jc?&2+M^~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~12# '434MJE' !J^<=0*537H/K! &T5G5I(7ATDS'X@;JFA/LO/ MRZFO7?>K5;J42W4') C1 +&L(WKJR)>[Y-7^'6U'KUVKJ M7>CAJ]>?>IG3^?>A4P8[!_ 5P@G]JMG6+>CQ.X.OY%Y%#KE;V@OFCU,1^M1*MTJ=E'~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~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~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~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~^U\$R+AUV;@<U2A4Z\$J[2Q4>7X>?>Y=I^!1FAKAN[GQ! M?_?J]FY5YKQDC69SW6_P12>#>#^EO+HJ]%;B%48U^ M056ITLS+&D?>J]7HJW6H)U^H0K4J E&H%6D(U1MAX5I;H\$8QV70K18>UP#%>1* <M5 LYV\$F=F^8^AW4J^Z8:@VHW\$&(FHY VT2H%D U^M?7ZL[C3G<0R25 [5!\$HS USWB?7\$Q_T9 M; %5(<[U1EM]7>GOQRD3?>I>1^4295F4?+8F%J]HNPC5 JA&H5K>U!>[<=<^E(03*&3WFX^5ZH(9^&O+&A8J>U2W^H\$S,DE7B>;+>7<3M^TFF9N4U MNVYN'EG? >=IBJHROGL9KH;W\$HS1+>J<_V4V2;(DR4-;H& >5< MR:C&ROHG 2MBJ4J2J_@HJL99=>JHP%?; B055 MVRIUY O2JH(+&73)FU^95TOIEHVS8Y[L.C6j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i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~>T^&G@&TR2A8;[.D\$H(GK5?>P9^M^U+Y&OE5+G9(#@<=>9O\$05/39!E!&V02=L/AM6/SO7^QDQT\$T21.8-LD76^ M.&V&#_#5>3&K&8RDQ;_&J]B?74Y2Z;3&NE4D;N+&@>^>U^>VS0\$5>N<K M=KO-MNM<WNC%JLYKRK]=NSWJ@6GK=-7ZBK_V>?>Y/L7_+>=&N5<3K!&K% MKB>2EJ^W^?>?>D>JDCX,H G^!8DX3M41?R&RUI^ P04 # #C@PU9 MH>[86]0 H#&@&_O&^&AL+W=O)M;W=Z2B2R-XG<C^2+&+&J;_J M^ODFU2IEE[JVU6=&I!E!M! 16QD(P^&N!&OAAAD9^&CR-HA@J?>25?>B7G(H MS))IN^B.T_>=AJ,I+^F17^,CJ[W T;#&Q5E)HJTOVQ!U10%&E-C(!B.# MC.75/WLZ.N)\$S(YT^,1^@=CQKA0YEA^R8BV0JGJ!&-%BCH.EY\$9F>_J;_7]=D 6&0%H^&(-9AK/K; +FGRU>XTD M^&_0DY C/&N&R&B1_2R6<=<^/(&RC N?>3U1?>[RRR<=< M9G.^Z9QJ!AN;YV6IRFZ^0 E<^<1^!MKT^<R^>Q^>Q^>?>N^1^?021Q!&C^?>#U M^U^V5Z_V^Q90HMBJ;5-H 8PE@U9^LCIOGMV<.<S/5,I^> M/ZPOIC+1 M3YN^&M9?>7K^M_>W6150!>_>J+D M^&(\$A^>_&HJ(UUEWUEWZT);KAIOU@& M1R^&OABAG&B.(29V76QK=<!)&#&M^&EA2TJ]#?>_J] QJ^H;SJ;G+&Bj# MMU9\$9UE2&7BJW3P6F&G\$G11XV+ODMH.#MNVN^H MAU^&B?16FJV1J0?>Y5C[VJ;3P0&M9&D1M^&K7C^WQJ? M^F49J;H3<3 G M?>3&R-XR^*ZULP6E030H?XD<5.O^KON^+&GIDH;- PPBj]Y\$1X_&H-F&#>M<C-M<~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
 M_(F9P^&Z^LP4 \$T9 9>=&P=O=VJR-W-H965TW9ZTVJILNQJ)]\$SD UA-8M8V MA[JV4E J0& (O@&B^>Y>6; &X&R=!(7%NNY^?01^>L569\$>S^!=[H\$^B^MY;J7V,(J9;P%&Y&E^9;3D70U^&!)>4JNUG(J^&L+O1F/HM EA^&6\$S^Q^DHL@ M&H+&@ #?>Y2J]XLA&E8>=>_&OSNG4Q&B!>IT^>WVG1H^&H D&H0^!&@F0;L^&W M?>J(T M&_-P8KF;M&L;JH&W-S]J756K&(&_1548U7U7+&+&O&TWCU^>T]D]J MTPCFK\$>S: XS :S!C^F(9_4!->10Y^DSHPE^&OCH+&G\$&QJFB M^* @*3^>S.746BP&8V&A2;-(R7T4Z;E5!_IUXJ14!&4& MDCJQ)(6HM>0\$G5@& KZQXOP) TjV764=MX&B;PJ^Q^035UOH&P 53^*K M^&_O0Y^HE?> \$HL#1<4N#1S;+>R6G^T^LPEM&4U1J9%&D4_V4=PM3B_Q.L6 M=^!+N100HG^!+1L%\$4VFP4^YI6<2_GU(5>1?<=>60E!&[O0^&6B!85&=&2 MMH6Q0&L^V+3W1V5%Z8BDE2XC&DZK; Q3%\$H&Z\$LU1^Y*4+&=7!71<4+&(30C M^Z;+7518-LL.LL2J?>5\$V4Y1^! T5 32W -2VP&A5,21^L^T^*# M>H>X3(AU^T^&#?>PVB^F)XBY>=<6=H3>+&?>_&CDG&W^!_F.@5L2R^V2B)IITC; M)R!>B?>J7M^ 76#6YW.^L2^65NK;AOW3N1Y]A:HF_8#EUCO+2^JYD(J M MVV15SCAO(\$%Z2P@&^AKJ!&-O\$#+=>7P7J+Y\$&ZJ V4!YE@&M^FY%R/Z!>L M8 E^TT&4-H-GP5H? (&N4>=>2JLV14J!&8\$?>666YJ&E.2AFY\$5&L<?>_D@^&[K13^"4 M^&Q+&Q^&G/!>T^>P!>?>77SHEYQ^&[CJY1+Z2)]>=R84C@&OX.Q5(*Z&K_?>V) M^J210 37Q!&AG7(G;NM4=>9>L<_>YD;_>1A% (2%CLX\$& &Z6H.NH<+&#^&E@2)1 MA&L&H& 92_Y?>=WT-CX!H^N92&1856V(F-Q,I,N^G09D<=&S<5&Z2=&4QL1N MZK287(*PDB8R3&3MA.ZK^H)JAL1L^+4R7H^HDHW&X304&ZTF^56 OFK<+&3J, M16 47^>@>K#8G>+&1P;J] QZ CZY1M^;1XZB<7&UTY]IYECJ_>T7.GR85-EM ME4V1N;(&G^!E#^&P^PD\$OSR<=> MJV;_9!>0>G_#U!+ P04 # #C@PU9 V2Z2& QDP#>?>P^&^&O^&AL+W=O MZ+TLW+&ERM@&QVOZ1+&N37J;Q7_>9+>MS@&HOFDE!&^PFWC2GH6?>J^!AEL]=286%F4C1R;=>XV66^&ADQJ@&-K M#?>N^2^!J]UJ]UT@OOC^?>V?>G?>H\$QJ)N^B>5F?>?> %&LEA04MN[N3V^>0 M;J^V^3+&MGF1J^PTD7I.R*(61H^&B^1-?>J2J!V.(HR,42T0;_!&D^2A U^& M^QTINB;449L^>=&_&Q84 EWBC&RE#&_I)^&E(S)QRA&8SFYD06>Mj8N17?D M^J] 7G(@10_Y ?>1^>J;5R.7ER>19T^_RE^M MC3J!Q?&44+>+&

`P=VJR;W-H965T&U4$L! A0#%< @ XX.-65UF2'GB<@<8 ID ('H'9 'AL+W=O&U4$L! A0#%< @ XX.-61#'[$$ M @ B@8 ID ("=H 'AL+W=OX'NN4'#K'0 &0 M@('QD0>&P=VJR;W-
H965T&U4$L! A0#%< @ XX.-65'R&P=VJR;M-W-H965T'SHW/IP,($$ M'H'9 'JW;WK&U4$L M4$L! A0#%< @ XX.-6'B>?F @&P=VJR;W-H965T&U4$L! A0#%< @ MX.-62UH7YB(<
AP8 ID ('I'Z'L'AL+W=O&P=VJR;W-H965T&U4$L! A0#%< @ XX.-67D,<'<. @ O@< ID M('I,'AL+W=O&P=VJR;W-H965TJP('V'9 M '@&U4$L! M A0#%< @ XX.-60.$<'<8<p'.PL ID
("IKLT'AL'M+W=O&P=VJR;W-H965T&U4$L! A0#%< @ XX.-M6S'AL+W=O&P=VJR;W-H965T&U4$L! A0#%< @ XX.-6>65UA'T @,0 M A0#%< @ XX.-6>65UA'T @,0 M A0#%< @ XX.-62*,A+>L @ V@< ID M('I'Z X'AL+W=O&P=VJR;W-H965T M&X$6@,+H-9-M' @=<%<0%;'JW;WK&U4$L! A0# M%< @ XX.-61\;(IQI0 PB< ID('I< D'AL+W=O M&P=VJR;W-
H965T&U4$L! A0#%< @ XX.-63/O,M,NB,W @ X 0 ID('IC1,'AL+W=OS;SH# #R$P#@ M @ I'%$>>&P=O&P=O7W/E';O=VJR;V(O;VLN>+UL+GJE';02P$,% 4 '#C M@PU9C^<W=;! V(0 $P @
$(X(0 6T-O;G1E) G17$'EP -97=-+GAM;'+108 !<'<1 (P$! end XML 68 Show.js IDEA: XBRL DOCUMENT / Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange
Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show=
{};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e.nodeName=='TABLE'){var ref=
(window.w?.document?.document).getElementById(r);if(ref){e=ref.cloneNode(0);e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e.style.display='block',Show.LastAR=e);Show.hideAR=function(){(Show.LastAR.style.display='none');Show.toggleNext=function(a){var
e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(e.style){}else if(e.style.display){}else{var d,p;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerHTML=p+a.innerHTML.substring(1)}}} XML 69 report.css IDEA: XBRL DOCUMENT / Updated 2009-
11-04 %*/ %v2.2.0.24 %*/ DefRef Styles %*/ .report table.authRefData { background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a {
display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; }
.report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table { font-
size: 1em; } /* Report Styles %*.pl.a,.pl.a:visited { color: black; text-decoration: none; } /* table %*/ .report { background-color: white; border: 2px solid #afcf; clear: both; color: black; font:
normal Bt Helvetica, Arial, sans-serif; margin-bottom: 2em; } .report hr { border: 1px solid #afcf; } /* Top labels %*/ .report th { background-color: #afcf; color: black; font-weight: bold; text-align:
center; } .report th.oiv { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, sans-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space:
normal; width: 200px; white-space: normal; } /* word-wrap: break-word; */ .report td.pl.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl.div.a { width: 200px;
.report td.pl.a:hover { background-color: #ffcf; } /* Header rows... %*/ .report tr.rh { background-color: #afcf; color: black; font-weight: bold; } /* Calendars... %*/ .report .rc { background-color:
#f0f0f0; } /* Even rows... %*/ .report .re .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... %*/ .report .ro .report .rou { background-color:
white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td .report .rou table td { border-bottom: 0px solid black; } /* styles for footnote marker %*/ .report .fn { white-space:
nowrap; } /* styles for numeric types %*/ .report .num .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 4em 0px 2em;
} /* styles for text types %*/ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .txt .note {
font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 71 FilingSummary.xml IDEA: XBRL
DOCUMENT 3.24.2.u1 html 141 263 1 false 48 0 false 8 false false R1.htm 00000001 - Document - Cover Page Sheet http://www.exicuretx.com/role/CoverPage Cover Page Cover 1 false false
R2.htm 9952151 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS Sheet
http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm
9952152 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet
http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)
Statements 3 false false R4.htm 9952153 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet
http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
Statements 4 false false R5.htm 9952154 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS??? EQUITY Sheet
http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet
http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
Statements 6 false false R7.htm 9952156 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) Sheet
http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH
FLOWS (Parenthetical) Statements 7 false false R8.htm 9952157 - Disclosure - Description of Business, Basis of Presentation and Going Concern Sheet
http://www.exicuretx.com/role/DescriptionofBusinessBasisofPresentationandGoingConcern Description of Business, Basis of Presentation and Going Concern Notes 8 false false R9.htm 9952158
- Disclosure - Significant Accounting Policies Sheet http://www.exicuretx.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 9 false false R10.htm 9952159 - Disclosure
- Supplemental Balance Sheet Information Sheet http://www.exicuretx.com/role/SupplementalBalanceSheetInformation Supplemental Balance Sheet Information Notes 10 false false R11.htm
9952160 - Disclosure - Leases Sheet http://www.exicuretx.com/role/Leases Leases Notes 11 false false R12.htm 9952161 - Disclosure - Investment in Convertible Notes Receivable Notes
http://www.exicuretx.com/role/InvestmentinConvertibleNotesReceivable Investment in Convertible Notes Receivable Notes 12 false false R13.htm 9952162 - Disclosure - Debt Sheet
http://www.exicuretx.com/role/Debt Debt Notes 13 false false R14.htm 9952163 - Disclosure - Stockholders' Equity Sheet http://www.exicuretx.com/role/StockholdersEquity Stockholders' Equity
Notes 14 false false R15.htm 9952164 - Disclosure - Equity-Based Compensation Sheet http://www.exicuretx.com/role/EquityBasedCompensation Equity-Based Compensation Notes 15 false
false R16.htm 9952165 - Disclosure - Income Taxes Sheet http://www.exicuretx.com/role/IncomeTaxes Income Taxes Notes 16 false false R17.htm 9952166 - Disclosure - Loss Per Common
Share Sheet http://www.exicuretx.com/role/LossPerCommonShare Loss Per Common Share Notes 17 false false R18.htm 9952167 - Disclosure - Fair Value Measurements Sheet
http://www.exicuretx.com/role/FairValueMeasurements Fair Value Measurements Notes 18 false false R19.htm 9952168 - Disclosure - Commitment and Contingencies Sheet
http://www.exicuretx.com/role/CommitmentandContingencies Commitment and Contingencies Notes 19 false false R20.htm 9952169 - Disclosure - Related-Party Transactions Sheet
http://www.exicuretx.com/role/RelatedPartyTransactions Related-Party Transactions Notes 20 false false R21.htm 9952170 - Disclosure - License Agreement Sheet
http://www.exicuretx.com/role/LicenseAgreement License Agreement Notes 21 false false R22.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet
http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 22 false false R23.htm 995445 - Disclosure - Insider Trading Arrangements Sheet
http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 23 false false R24.htm 9954471 - Disclosure - Significant Accounting Policies (Policies) Sheet
http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://www.exicuretx.com/role/SignificantAccountingPolicies 24 false false
R25.htm 9954472 - Disclosure - Supplemental Balance Sheet Information (Tables) Sheet http://www.exicuretx.com/role/SupplementalBalanceSheetInformationTables Supplemental Balance
Sheet Information (Tables) Tables http://www.exicuretx.com/role/SupplementalBalanceSheetInformation 25 false false R26.htm 9954473 - Disclosure - Leases (Tables) Sheet
http://www.exicuretx.com/role/LeasesTables Leases (Tables) Tables http://www.exicuretx.com/role/Leases 26 false false R27.htm 9954474 - Disclosure - Equity-Based Compensation (Tables)
Sheet http://www.exicuretx.com/role/EquityBasedCompensationTables Equity-Based Compensation (Tables) Tables http://www.exicuretx.com/role/EquityBasedCompensation 27 false false
R28.htm 9954475 - Disclosure - Loss Per Common Share (Tables) Sheet http://www.exicuretx.com/role/LossPerCommonShareTables Loss Per Common Share (Tables) Tables
http://www.exicuretx.com/role/LossPerCommonShare 28 false false R29.htm 9954476 - Disclosure - Fair Value Measurements (Tables) Sheet
http://www.exicuretx.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.exicuretx.com/role/FairValueMeasurements 29 false false R30.htm 9954477
- Disclosure - Description of Business, Basis of Presentation and Going Concern (Details) Sheet http://www.exicuretx.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetails
Description of Business, Basis of Presentation and Going Concern (Details) Details http://www.exicuretx.com/role/DescriptionofBusinessBasisofPresentationandGoingConcern 30 false false
R31.htm 9954478 - Disclosure - Supplemental Balance Sheet Information - Schedule of Prepaid and Other Current Assets (Details) Sheet
http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidandOtherCurrentAssetsDetails Supplemental Balance Sheet Information - Schedule of Prepaid and
Other Current Assets (Details) Details 31 false false R32.htm 9954479 - Disclosure - Supplemental Balance Sheet Information - Schedule of Other Noncurrent Assets (Details) Sheet
http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofOtherNoncurrentAssetsDetails Supplemental Balance Sheet Information - Schedule of Other Noncurrent Assets
(Details) Details 32 false false R33.htm 9954480 - Disclosure - Supplemental Balance Sheet Information - Schedule of Property and Equipment, Net (Details) Sheet
http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofPropertyandEquipmentNetDetails Supplemental Balance Sheet Information - Schedule of Property and
Equipment, Net (Details) Details 33 false false R34.htm 9954481 - Disclosure - Supplemental Balance Sheet Information - Narrative (Details) Sheet
http://www.exicuretx.com/role/SupplementalBalanceSheetInformationNarrativeDetails Supplemental Balance Sheet Information - Narrative (Details) Details 34 false false R35.htm 9954482 -
Disclosure - Supplemental Balance Sheet Information - Schedule of Accrued expenses and other current liabilities (Details) Sheet
http://www.exicure`

Stockholders' Equity - Preferred and Common Stock (Details) Details 41 false false R42.htm 9954491 - Disclosure - Stockholders' Equity - Securities Purchase Agreement (Details) Sheet
http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails Stockholders' Equity - Securities Purchase Agreement (Details) Details 42 false false R43.htm 9954490 - Disclosure - Stockholders' Equity - Common Stock Warrants (Details) Sheet http://www.exicuretx.com/role/StockholdersEquityCommonStockWarrantsDetails Stockholders' Equity - Common Stock Warrants (Details) Details 43 false false R44.htm 9954491 - Disclosure - Equity-Based Compensation - Narrative (Details) Sheet
http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails Equity-Based Compensation - Narrative (Details) Details 44 false false R45.htm 9954492 - Disclosure - Equity-Based Compensation - Schedule of Equity-Based Compensation Expense Classification in Statement of Operations (Details) Sheet
http://www.exicuretx.com/role/EquityBasedCompensationScheduleEquityBasedCompensationExpenseClassificationInStatementOfOperationsDetails Equity-Based Compensation - Schedule of Equity-Based Compensation Expense Classification in Statement of Operations (Details) Details 45 false false R46.htm 9954493 - Disclosure - Equity-Based Compensation - Schedule of Assumptions Used to Determine Fair Value of Common Stock Option Grants (Details) Sheet
http://www.exicuretx.com/role/EquityBasedCompensationScheduleOfAssumptionsUsedtoDetermineFairValueOfCommonStockOptionGrantsDetails Equity-Based Compensation - Schedule of Assumptions Used to Determine Fair Value of Common Stock Option Grants (Details) Details 46 false false R47.htm 9954494 - Disclosure - Equity-Based Compensation - Schedule of Fair Value of Underlying Common Stock and Exercise Price of Stock Options (Details) Sheet
http://www.exicuretx.com/role/EquityBasedCompensationScheduleOfFairValueOfUnderlyingCommonStockAndExercisePriceOfStockOptionsDetails Equity-Based Compensation - Schedule of Fair Value of Underlying Common Stock and Exercise Price of Stock Options (Details) Details 47 false false R48.htm 9954495 - Disclosure - Equity-Based Compensation - Schedule of Stock Options Rollforward (Details) Sheet http://www.exicuretx.com/role/EquityBasedCompensationScheduleOfStockOptionsRollforwardDetails Equity-Based Compensation - Schedule of Stock Options Rollforward (Details) Details 48 false false R49.htm 9954496 - Disclosure - Equity-Based Compensation - Schedule of Restricted Stock Unit Awards Activity (Details) Sheet
http://www.exicuretx.com/role/EquityBasedCompensationScheduleOfRestrictedStockUnitAwardsActivityDetails Equity-Based Compensation - Schedule of Restricted Stock Unit Awards Activity (Details) Details 49 false false R50.htm 9954497 - Disclosure - Income Taxes - Narrative (Details) Sheet http://www.exicuretx.com/role/IncomeTaxNarrativeDetails Income Taxes - Narrative (Details) Details 50 false false R51.htm 9954498 - Disclosure - Loss Per Common Share - Schedule of Computation of loss per common share (Details) Sheet
http://www.exicuretx.com/role/LossPerCommonShareScheduleOfComputationOfLossPerCommonShareDetails Loss Per Common Share - Schedule of Computation of loss per common share (Details) Details 51 false false R52.htm 9954499 - Disclosure - Loss Per Common Share - Schedule of Antidilutive Securities (Details) Sheet
http://www.exicuretx.com/role/LossPerCommonShareScheduleOfAntidilutiveSecuritiesDetails Loss Per Common Share - Schedule of Antidilutive Securities (Details) Details 52 false false R53.htm 9954500 - Disclosure - Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) Sheet
http://www.exicuretx.com/role/FairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredonRecurringBasisDetails Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) Details 53 false false R54.htm 9954501 - Disclosure - Commitment and Contingencies - Narrative (Details) Sheet
http://www.exicuretx.com/role/CommitmentAndContingenciesNarrativeDetails Commitment and Contingencies - Narrative (Details) Details 54 false false R55.htm 9954502 - Disclosure - Related-Party Transactions - Narrative (Details) Sheet http://www.exicuretx.com/role/RelatedPartyTransactionsNarrativeDetails Related-Party Transactions - Narrative (Details) Details 55 false false R56.htm 9954503 - Disclosure - License Agreement (Details) Sheet http://www.exicuretx.com/role/LicenseAgreementDetails License Agreement (Details) Details
http://www.exicuretx.com/role/LicenseAgreement56 false false All Reports Book All Reports xcur-20240630.htm xcur-20240630.sxd xcur-20240630 cal.xml xcur-20240630 def.xml xcur-20240630 lab.xml xcur-20240630 pre.xml http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 74 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "xcur-20240630.htm": { "nsPrefix": "xcur", "nsUri": "http://www.exicuretx.com/20240630", "dts": { "inline": { "local": ["xcur-20240630.htm"] }, "schema": { "local": ["xcur-20240630.sxd"] }, "remote": { "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.sxd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.sxd", "http://www.xbrl.org/2003/xl-2003-12-31.sxd", "http://www.xbrl.org/2003/xlink-2003-12-31.sxd", "http://www.xbrl.org/2005/xbrldt-2005.sxd", "http://www.xbrl.org/2006/ref-2006-02-27.sxd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.sxd", "http://www.xbrl.org/lrr/role/net-2009-12-16.sxd", "http://www.xbrl.org/lrr/reference-2009-12-16.sxd", "https://www.xbrl.org/2020/extendable-enumerations-2.0.sxd", "https://www.xbrl.org/dtr/type/2020-01-21/types.sxd", "https://www.xbrl.org/dtr/type/2022-03-31/types.sxd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.sxd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.sxd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.sxd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.sxd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.sxd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.sxd", "https://xbrl.sec.gov/country/2024/country-2024.sxd", "https://xbrl.sec.gov/dei/2024/dei-2024.sxd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.sxd", "https://xbrl.sec.gov/sptr/2024/sptr-2024.sxd" } }, "calculationLink": { "local": ["xcur-20240630 cal.xml"] }, "definitionLink": { "local": ["xcur-20240630 def.xml"] }, "labelLink": { "local": ["xcur-20240630 lab.xml"] }, "presentationLink": { "local": ["xcur-20240630 pre.xml"] } }, "keyStandard": 217, "keyCustom": 46, "axisStandard": 21, "axisCustom": 0, "memberStandard": 23, "memberCustom": 19, "hidden": { "total": 9, "http://xbrl.sec.gov/dei/2024": 5, "http://www.exicuretx.com/20240630": 4 }, "contextCount": 141, "entityCount": 1, "segmentCount": 48, "elementCount": 508, "unitCount": 8, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 502, "http://xbrl.sec.gov/ecd/2024": 29, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://www.exicuretx.com/role/CoverPage", "longName": "00000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"] }, "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"] }, "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true, "unique": true }, "R2": { "role": "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS", "longName": "9952151 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS", "shortName": "UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "div", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:OtherReceivablesGrossCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"] }, "reportCount": 1, "baseRef": "xcur-20240630.htm", "unique": true }, "R3": { "role": "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS", "longName": "9952152 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true, "unique": true }, "R4": { "role": "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "longName": "9952153 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"] }, "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"] }, "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true, "unique": true }, "R5": { "role": "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY", "longName": "9952154 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-25", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"] }, "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-30", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"] }, "reportCount": 1, "baseRef": "xcur-20240630.htm", "unique": true }, "R6": { "role": "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY", "longName": "9952155 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "is

"shortName": "Income Taxes", "isDefault": false, "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.exicuretx.com/role/LossPerCommonShare", "longName": "9952166 - Disclosure - Loss Per Common Share", "shortName": "Loss Per Common Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.exicuretx.com/role/FairValueMeasurements", "longName": "9952167 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.exicuretx.com/role/CommitmentAndContingencies", "longName": "9952168 - Disclosure - Commitment and Contingencies", "shortName": "Commitment and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.exicuretx.com/role/RelatedPartyTransactions", "longName": "9952169 - Disclosure - Related-Party Transactions", "shortName": "Related-Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.exicuretx.com/role/LicenseAgreement", "longName": "9952170 - Disclosure - License Agreement", "shortName": "License Agreement", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true, "unique": true } }, "R22": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true }, "uniqueAnchor": null }, "R23": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-5", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies", "longName": "9954471 - Disclosure - Significant Accounting Policies (Policies)", "shortName": "Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationTables", "longName": "9954472 - Disclosure - Supplemental Balance Sheet Information (Tables)", "shortName": "Supplemental Balance Sheet Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.exicuretx.com/role/LeasesTables", "longName": "9954473 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.exicuretx.com/role/EquityBasedCompensationTables", "longName": "9954474 - Disclosure - Equity-Based Compensation (Tables)", "shortName": "Equity-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.exicuretx.com/role/LossPerCommonShareTables", "longName": "9954475 - Disclosure - Loss Per Common Share (Tables)", "shortName": "Loss Per Common Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.exicuretx

"xcur:NumberOfSubscriptionAgreementsEntered", "unitRef": "agreement", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xcur-20240630.htm", "unique": true } } }, "R40": { "role": "http://www.exicuretx.com/role/DebtNarrativeDetails", "longName": "9954487 - Disclosure - Debt - Narrative (Details)", "shortName": "Debt - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-58", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-58", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.exicuretx.com/role/StockholdersEquityPreferredandCommonStockDetails", "longName": "9954488 - Disclosure - Stockholders' Equity - Preferred and Common Stock (Details)", "shortName": "Stockholders' Equity - Preferred and Common Stock (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["us-gaap:PreferredStockSharesAuthorized", "span", "div", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "xcur:CommonStockVotingRightsForEachShare", "unitRef": "vote", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "div", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "xcur-20240630.htm", "unique": true } }, "R42": { "role": "http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails", "longName": "9954489 - Disclosure - Stockholders' Equity - Securities Purchase Agreement (Details)", "shortName": "Stockholders' Equity - Securities Purchase Agreement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-67", "name": "xcur:RegistrationRightsAgreementRequiredFilingTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-67", "name": "xcur:RegistrationRightsAgreementRequiredFilingTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.exicuretx.com/role/StockholdersEquityCommonStockWarrantsDetails", "longName": "9954490 - Disclosure - Stockholders' Equity - Common Stock Warrants (Details)", "shortName": "Stockholders' Equity - Common Stock Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails", "longName": "9954491 - Disclosure - Equity-Based Compensation - Narrative (Details)", "shortName": "Equity-Based Compensation - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofEquityBasedCompensationExpenseClassificationinStatementofOperationsDetails", "longName": "9954492 - Disclosure - Equity-Based Compensation - Schedule of Equity-Based Compensation Expense Classification in Statement of Operations (Details)", "shortName": "Equity-Based Compensation - Schedule of Equity-Based Compensation Expense Classification in Statement of Operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofCommonStockOptionGrantsDetails", "longName": "9954493 - Disclosure - Equity-Based Compensation - Schedule of Assumptions Used to Determine Fair Value of Common Stock Option Grants (Details)", "shortName": "Equity-Based Compensation - Schedule of Assumptions Used to Determine Fair Value of Common Stock Option Grants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": ["span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": ["span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails", "longName": "9954494 - Disclosure - Equity-Based Compensation - Schedule of Fair Value of Underlying Common Stock and Exercise Price of Stock Options (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-43", "name": "us-gaap:SharePrice", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": ["span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-43", "name": "us-gaap:SharePrice", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": ["span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails", "longName": "9954495 - Disclosure - Equity-Based Compensation - Schedule of Stock Options Rollforward (Details)", "shortName": "Equity-Based Compensation - Schedule of Stock Options Rollforward (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofRestrictedStockUnitAwardsActivityDetails", "longName": "9954496 - Disclosure - Equity-Based Compensation - Schedule of Restricted Stock Unit Awards Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-111", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-111", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.exicuretx.com/role/IncomeTaxesNarrativeDetails", "longName": "9954497 - Disclosure - Income Taxes - Narrative (Details)", "shortName": "Income Taxes - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": ["ix:continuation", "span", "div", "body", "html"], "reportCount": 1, "baseRef": "xcur-20240630.htm", "unique": true } }, "R51": { "role": "http://www.exicuretx.com/role/LossPerCommonShareScheduleofComputationoflosspercommonshareDetails", "longName": "9954498 - Disclosure - Loss Per Common Share - Schedule of Computation of loss per common share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true }, "uniqueAnchor": null }, "R52": { "role": "http://www.exicuretx.com/role/LossPerCommonShareScheduleofAntidilutiveSecuritiesDetails", "longName": "9954499 - Disclosure - Loss Per Common Share - Schedule of Antidilutive Securities (Details)", "shortName": "Loss Per Common Share - Schedule of Antidilutive Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-114", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-114", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.exicuretx.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails", "longName": "9954500 - Disclosure - Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)", "shortName": "Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["ix:continuation", "span", "div", "body", "html"], "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-124", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredonRecurringBasisTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xcur-20240630.htm", "unique": true } }, "R54": { "role": "http://www.exicuretx.com/role/CommitmentandContingenciesNarrativeDetails", "longName": "9954501 - Disclosure - Commitment and Contingencies - Narrative (Details)", "shortName": "Commitment and Contingencies - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-3", "name": "xcur:AggregatePaymentsMadeToDateForLicenseAgreements", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "xcur:AggregatePaymentsMadeToDateForLicenseAgreements", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.exicuretx.com/role/RelatedPartyTransactionsNarrativeDetails", "longName": "9954502 - Disclosure - Related-Party Transactions - Narrative (Details)", "shortName": "Related-Party Transactions - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-140", "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-140", "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.exicuretx.com/role/LicenseAgreementDetails", "longName": "9954503 - Disclosure - License Agreement (Details)", "shortName": "License Agreement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-141", "name": "xcur:ProceedsFromPatentLicenseAgreement", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-141", "name": "xcur:ProceedsFromPatentLicenseAgreement", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "xcur-20240630.htm", "first": true, "unique": true } }, "tag": { "us-gaap:AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": "en-us", "role": { "terselabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } }, "auth ref": [] }, "us-gaap:AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap:LiabilitiesCurrent", "weight": 1.0, "order": 3.0 }, "presentation": ["http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "lang": "en-us", "role": { "terselabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth ref": "r30", "r696" } }, "us-gaap:AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap:LiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, "presentation": ["http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofAccruedexpensesandothercurrentliabilitiesDetails": { "parentTag": "null", "weight": null, "order": null, "root":

true } } , "presentation": [{ "http://www.xcuretx.com/role/SupplementalBalanceSheetInformationScheduleofAccruedexpensesandothercurrentliabilitiesDetails", "http://www.xcuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other current liabilities", "totalLabel": "Accrued expenses and other current liabilities", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r32"] }, "us-gaap AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment", "crdr": "credit", "calculation": { "http://www.xcuretx.com/role/SupplementalBalanceSheetInformationScheduleofPropertyandEquipmentNetDetails": { "parentTag": "us-gaap PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [{ "http://www.xcuretx.com/role/SupplementalBalanceSheetInformationScheduleofPropertyandEquipmentNetDetails", "lang": { "role": { "negatedTerseLabel": "Less: accumulated depreciation and amortization", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": ["r17", "r97", "r519"] }, "ecd Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [{ "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": ["r755"] }, "us-gaap AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.xcuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [{ "http://www.xcuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS", "lang": { "en-us": { "role": { "terseLabel": "Additional paid in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": ["r41", "r696", "r938"] }, "us-gaap AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [{ "http://www.xcuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCANGESINSTOCKHOLDERSEQUITY": { "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r547", "r825", "r826", "r827", "r828", "r882", "r939"] }, "ecd AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [{ "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": ["r768"] }, "ecd AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [{ "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": ["r768"] }, "ecd AdjToNonPeeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeeoCompFnTextBlock", "presentation": [{ "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": ["r768"] }, "ecd AdjToPeeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeeoCompFnTextBlock", "presentation": [{ "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Adjustment to PEO Compensation, Footnote", "label": "Adjustment to PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": ["r768"] }, "xcur AdjustmentsToAdditionalPaidInCapitalDecreaseRelatedToReclassification": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xcuretx.com/20240630", "localname": "AdjustmentsToAdditionalPaidInCapitalDecreaseRelatedToReclassification", "crdr": "debit", "presentation": [{ "http://www.xcuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCANGESINSTOCKHOLDERSEQUITY": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Reclassification of common stock warrants to liability", "label": "Adjustments To Additional Paid in Capital, Decrease Related To Reclassification", "documentation": "Adjustments To Additional Paid in Capital, Decrease Related To Reclassification" } } }, "auth_ref": [] }, "us-gaap AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [{ "http://www.xcuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCANGESINSTOCKHOLDERSEQUITY": { "lang": { "en-us": { "role": { "terseLabel": "Equity-based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": ["r23", "r24", "r311"] }, "us-gaap AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [{ "http://www.xcuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to cash used in operating activities", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "xcur AggregatePaymentsMadeToDateForLicenseAgreements": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xcuretx.com/20240630", "localname": "AggregatePaymentsMadeToDateForLicenseAgreements", "crdr": "credit", "presentation": [{ "http://www.xcuretx.com/role/CommitmentandContingenciesNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Aggregate consideration paid to NU for agreement obligations", "label": "Aggregate Payments Made To Date For License Agreements", "documentation": "Aggregate Payments Made To Date For License Agreements" } } }, "auth_ref": [] }, "ecd AggtChngPnsnValInSummryCompstnTblForApblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForApblYrMember", "presentation": [{ "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table", "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]" } } }, "auth_ref": ["r801"] }, "ecd AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [{ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r727", "r737", "r747", "r779"] }, "ecd AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [{ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": ["r730", "r740", "r750", "r782"] }, "ecd AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [{ "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Aggregate Pension Adjustments Service Cost", "label": "Aggregate Pension Adjustments Service Cost [Member]" } } }, "auth_ref": ["r802"] }, "ecd AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [{ "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": ["r768"] }, "ecd AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [{ "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": ["r775"] }, "ecd AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [{ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": ["r731", "r741", "r751", "r775", "r783", "r787", "r795"] }, "ecd AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": [{ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": ["r793"] }, "us-gaap AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [{ "http://www.xcuretx.com/role/EquityBasedCompensationScheduleofEquityBasedCompensationExpenseClassificationinStatementofOperationsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": ["r340", "r345"] }, "dei AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [{ "http://www.xcuretx.com/role/CoverPage", "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [{ "http://www.xcuretx.com/role/LossPerCommonShareScheduleofAntidilutiveSecuritiesDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Potentially dilutive shares excluded from computation of weighted-average diluted common shares outstanding (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r151"] }, "us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [{ "http://www.xcuretx.com/role/LossPerCommonShareScheduleofAntidilutiveSecuritiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": ["r12"] }, "us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [{ "http://www.xcuretx.com/role/LossPerCommonShareScheduleofAntidilutiveSecuritiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [{ "http://www.xcuretx.com/role/LossPerCommonShareScheduleofAntidilutiveSecuritiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": ["r12"] }, "us-gaap Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.xcuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [{ "http://www.xcuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS", "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r70", "r81", "r99", "r121", "r156", "r160", "r167", "r168", "r207", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r370", "r372", "r407", "r510", "r584", "r663", "r664", "r696", "r718", "r851", "r852", "r898"] }, "us-gaap AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [{ "http://www.xcuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.xcuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [{ "http://www.xcuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS", "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r93", "r105", "r121", "r207", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r370", "r372", "r407", "r696", "r851", "r852", "r898"] }, "us-gaap AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [{ "http://www.xcuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS", "lang": { "en-us": { "role": { "terseLabel": "Current assets", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.xcuretx.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [{ "http://www.xcuretx.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails", "lang": { "en-us": { "role": { "totalLabel": "Total financial assets", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r386", "r387", "r684"] }, "us-gaap AssetsFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosureAbstract", "presentation": [{ "http://www.xcuretx.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails", "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "calculation": { "http://www.xcuretx.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails": { "parentTag": "us-gaap AssetsFairValueDisclosure", "weight": 1.0, "order": 2.0 } }, "presentation": [{ "http://www.xcuretx.com/role/InvestmentinConvertibleNotesReceivableNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Available-for-sale securities", "verboseLabel": "Investment in convertible notes receivable", "label": "Debt Securities, Available-for-Sale", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r179", "r215", "r386", "r505", "r684", "r687", "r837", "r886", "r887", "r888"] }, "ecd AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [{ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-

us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": ["r790"] }, "ecd AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": ["r791"] }, "ecd AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": ["r786"] }, "ecd AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": ["r786"] }, "ecd AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": ["r786"] }, "ecd AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": ["r786"] }, "ecd AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": ["r786"] }, "ecd AwardTmgPredtrmdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": ["r786"] }, "us-gaap AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://www.xcuretx.com/role/EquityBasedCompensationNarrativeDetails", "http://www.xcuretx.com/role/EquityBasedCompensationScheduleofRestrictedStockUnitAwardsActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339"] }, "ecd AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": ["r789"] }, "ecd AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": ["r788"] }, "ecd AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": ["r787"] }, "ecd AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": ["r787"] }, "us-gaap BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": ["http://www.xcuretx.com/role/SignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "xcur BiopharmaceuticalCompanyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xcuretx.com/20240630", "localname": "BiopharmaceuticalCompanyMember", "presentation": ["http://www.xcuretx.com/role/LicenseAgreementDetails"], "lang": { "en-us": { "role": { "terseLabel": "Biopharmaceutical Company", "label": "Biopharmaceutical Company [Member]", "documentation": "Biopharmaceutical Company" } } }, "auth_ref": [] }, "us-gaap BusinessDescriptionAndBasisOfPresentationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "presentation": ["http://www.xcuretx.com/role/DescriptionOfBusinessBasisOfPresentationandGoingConcern"], "lang": { "en-us": { "role": { "terseLabel": "Description of Business, Basis of Presentation and Going Concern", "label": "Business Description and Basis of Presentation [Text Block]", "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": ["r29", "r56", "r57"] }, "xcur CBIUSADGPGCoLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xcuretx.com/20240630", "localname": "CBIUSADGPGCoLtdMember", "presentation": ["http://www.xcuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails"], "lang": { "en-us": { "role": { "terseLabel": "CBI USA & DGP Co. Ltd", "label": "CBI USA & DGP Co. Ltd [Member]", "documentation": "CBI USA & DGP Co. Ltd" } } }, "auth_ref": [] }, "xcur CBIUSAIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xcuretx.com/20240630", "localname": "CBIUSAIncMember", "presentation": ["http://www.xcuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails"], "lang": { "en-us": { "role": { "terseLabel": "CBI USA, Inc", "label": "CBI USA, Inc [Member]", "documentation": "CBI USA, Inc" } } }, "auth_ref": [] }, "us-gaap CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": ["http://www.xcuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap AssetsCurrent", "weight": 1.0, "order": 2.0 }, "http://www.xcuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical": { "parentTag": "us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 2.0 }, "presentation": ["http://www.xcuretx.com/role/DescriptionOfBusinessBasisOfPresentationandGoingConcernDetails", "http://www.xcuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.xcuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r11", "r95", "r654"] }, "us-gaap CashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAxis", "presentation": ["http://www.xcuretx.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents [Axis]", "label": "Cash and Cash Equivalents [Axis]", "documentation": "Information by type of cash and cash equivalent balance." } } }, "auth_ref": ["r95"] }, "us-gaap CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "calculation": ["http://www.xcuretx.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails": { "parentTag": "us-gaap AssetsFairValueDisclosure", "weight": 1.0, "order": 1.0 }, "presentation": ["http://www.xcuretx.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash equivalents", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r884", "r885"] }, "us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": ["http://www.xcuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.xcuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.xcuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical"], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, cash equivalents, and restricted cash - beginning of period", "periodEndLabel": "Cash, cash equivalents, and restricted cash - end of period", "totalLabel": "Total cash, cash equivalents, and restricted cash shown in the unaudited condensed consolidated statements of cash flows", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r11", "r53", "r117"] }, "us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": ["http://www.xcuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": ["http://www.xcuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "totalLabel": "Net (decrease) in cash, cash equivalents, and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r0", "r53"] }, "ecd ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": ["r766"] }, "xcur ChicagoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xcuretx.com/20240630", "localname": "ChicagoMember", "presentation": ["http://www.xcuretx.com/role/LeasesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Chicago", "label": "Chicago [Member]", "documentation": "Chicago" } } }, "auth_ref": [] }, "ecd ChnglnFrValAsOfVstngDtOfPrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChnglnFrValAsOfVstngDtOfPrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]" } } }, "auth_ref": ["r763"] }, "ecd ChnglnFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChnglnFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrYrsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested", "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]" } } }, "auth_ref": ["r761"] }, "dei CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://www.xcuretx.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": ["http://www.xcuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails"], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Domain]", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": ["r89", "r101", "r102", "r103", "r121", "r145", "r146", "r148", "r150", "r158", "r159", "r207", "r244", "r246", "r247", "r248", "r251", "r252", "r281", "r282", "r285", "r288", "r295", "r407", "r538", "r539", "r540", "r541", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r572", "r593", "r615", "r632", "r633", "r634", "r635", "r636", "r605", "r822", "r829"] }, "us-gaap ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": ["http://www.xcuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails"], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Axis]", "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": ["r20"] }, "us-gaap ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": ["http://www.xcuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails"], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Domain]", "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": ["http://www.xcuretx.com/role/StockholdersEquityCommonStockWarrantsDetails", "http://www.xcuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails"], "lang": { "en-us": { "role": { "terseLabel": "Exercise price (in dollars per share)", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": ["r296"] }, "us-gaap ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "presentation": ["http://www.xcuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares." } } }, "auth_ref": [] }, "us-gaap ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": ["http://www.xcuretx.com/role/StockholdersEquityCommonStockWarrantsDetails"], "lang": { "en-

us": { "role": { "terseLabel": "Number of shares called by warrants (in shares)", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": ["r296"] } }, "xcur_ClassOfWarrantOrRightNumberOfSecuritiesSettledInPeriod": { "xbrltype": "sharesItem", "nsuri": "http://www.exicuretx.com/20240630", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesSettledInPeriod", "presentation": ["http://www.exicuretx.com/role/StockholdersEquityCommonStockWarrantsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Warrants settled (in shares)", "label": "Class Of Warrant Or Right, Number Of Securities Settled In Period", "documentation": "Class Of Warrant Or Right, Number Of Securities Settled In Period" } } }, "auth_ref": [] }, "xcur_ClassOfWarrantOrRightOwnershipPercentageLimitation": { "xbrltype": "percentItem", "nsuri": "http://www.exicuretx.com/20240630", "localname": "ClassOfWarrantOrRightOwnershipPercentageLimitation", "presentation": ["http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails"], "lang": { "en-us": { "role": { "terseLabel": "Ownership percentage limitation (as a percent)", "label": "Class Of Warrant Or Right, Ownership Percentage Limitation", "documentation": "Class Of Warrant Or Right, Ownership Percentage Limitation" } } }, "auth_ref": [] }, "xcur_ClassOfWarrantOrRightOwnershipPercentageLimitationAtElectionOfPurchaser": { "xbrltype": "percentItem", "nsuri": "http://www.exicuretx.com/20240630", "localname": "ClassOfWarrantOrRightOwnershipPercentageLimitationAtElectionOfPurchaser", "presentation": ["http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails"], "lang": { "en-us": { "role": { "terseLabel": "Ownership percentage limitation at election of purchaser (as a percent)", "label": "Class Of Warrant Or Right, Ownership Percentage Limitation At Election Of Purchaser", "documentation": "Class Of Warrant Or Right, Ownership Percentage Limitation At Election Of Purchaser" } } }, "auth_ref": [] }, "xcur_ClassOfWarrantOrRightPaymentForLiability": { "xbrltype": "monetaryItem", "nsuri": "http://www.exicuretx.com/20240630", "localname": "ClassOfWarrantOrRightPaymentForLiability", "crdr": "credit", "presentation": ["http://www.exicuretx.com/role/StockholdersEquityCommonStockWarrantsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Payment for warrant liability", "label": "Class Of Warrant Or Right, Payment For Liability", "documentation": "Class Of Warrant Or Right, Payment For Liability" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": ["r767"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": ["r767"] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies (Note 12)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r37", "r73", "r512", "r571"] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://www.exicuretx.com/role/CommitmentandContingencies"], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r60", "r236", "r237", "r639", "r845", "r850"] }, "xcur_CommonStockAndAccompanyingWarrantMember": { "xbrltype": "domainItem", "nsuri": "http://www.exicuretx.com/20240630", "localname": "CommonStockAndAccompanyingWarrantMember", "presentation": ["http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common Stock And Accompanying Warrant", "label": "Common Stock And Accompanying Warrant [Member]", "documentation": "Common Stock And Accompanying Warrant" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r40"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://www.exicuretx.com/role/StockholdersEquityPreferredandCommonStockDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r40", "r572"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://www.exicuretx.com/role/StockholdersEquityPreferredandCommonStockDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r40"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://www.exicuretx.com/role/StockholdersEquityPreferredandCommonStockDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding (in shares)", "label": "Common stock, shares outstanding (in shares)", "documentation": "Beginning balance (in shares)", "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r5", "r40", "r572", "r590", "r939", "r940"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, \$0.0001 par value per share; 200,000,000 shares authorized, 8,651,148 issued and outstanding, June30u00a02024; 8,650,753 issued and outstanding, December30u00a02023", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r40", "r515", "r696"] }, "xcur_CommonStockVotingRightsForEachShare": { "xbrltype": "integerItem", "nsuri": "http://www.exicuretx.com/20240630", "localname": "CommonStockVotingRightsForEachShare", "presentation": ["http://www.exicuretx.com/role/StockholdersEquityPreferredandCommonStockDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, voting rights for each share", "label": "Common Stock, Voting Rights For Each Share", "documentation": "Common Stock, Voting Rights For Each Share" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": ["r772"] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": ["r771"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": ["r773"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": ["r770"] }, "xcur_ComputersandSoftwareMember": { "xbrltype": "domainItem", "nsuri": "http://www.exicuretx.com/20240630", "localname": "ComputersandSoftwareMember", "presentation": ["http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofPropertyandEquipmentNetDetails"], "lang": { "en-us": { "role": { "terseLabel": "Computers and software", "label": "Computers and Software [Member]", "documentation": "Computers and Software [Member]" } } }, "auth_ref": [] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": ["http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Principles of Consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": ["r25", "r659"] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": ["http://www.exicuretx.com/role/DebtNarrativeDetails"], "http://www.exicuretx.com/role/LicenseAgreementDetails", "http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails"], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]" } } }, "auth_ref": ["r125", "r126", "r257", "r283", "r437", "r455", "r509", "r656", "r658"] }, "dei_CoverAbstract": { "xbrltype": "stringItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://www.exicuretx.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "xcur_DGPGCoLtdMember": { "xbrltype": "domainItem", "nsuri": "http://www.exicuretx.com/20240630", "localname": "DGPGCoLtdMember", "presentation": ["http://www.exicuretx.com/role/DebtNarrativeDetails"], "http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails"], "lang": { "en-us": { "role": { "terseLabel": "DGP Co. Ltd.", "label": "DGP Co. Ltd. [Member]", "documentation": "DGP Co. Ltd." } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": ["http://www.exicuretx.com/role/Debt"], "lang": { "en-us": { "role": { "terseLabel": "Debt", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": ["r61", "r119", "r229", "r230", "r231", "r232", "r233", "r242", "r243", "r253", "r259", "r260", "r261", "r262", "r263", "r264", "r269", "r276", "r277", "r279", "r414"] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": ["http://www.exicuretx.com/role/DebtNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": ["r8", "r31", "r32", "r71", "r72", "r127", "r254", "r255", "r256", "r257", "r258", "r260", "r265", "r266", "r267", "r268", "r270", "r271", "r272", "r273", "r274", "r275", "r669", "r670", "r671", "r672", "r673", "r694", "r823", "r846", "r847", "r848", "r892", "r893"] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": ["http://www.exicuretx.com/role/DebtNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, face amount", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": ["r254", "r414", "r415", "r670", "r671", "r694"] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": ["http://www.exicuretx.com/role/DebtNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Interest rate", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": ["r34", "r255"] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": ["http://www.exicuretx.com/role/DebtNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r127", "r254", "r255", "r256", "r257", "r258", "r260", "r265", "r266", "r267", "r268", "r270", "r271", "r272", "r273", "r274", "r275", "r278", "r669", "r670", "r671", "r672", "r673", "r694", "r823", "r892", "r893"] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": [

"http://www.exicuretx.com/role/DebtNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth ref": ["r8", "r127", "r254", "r255", "r256", "r257", "r258", "r260", "r265", "r266", "r267", "r268", "r270", "r271", "r272", "r273", "r274", "r275", "r669", "r670", "r671", "r672", "r673", "r694", "r823", "r846", "r847", "r848", "r892", "r893"] }, "us-gaap DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": ["http://www.exicuretx.com/role/DebtNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-term Debt Instruments [Table]", "documentation": "Schedule of information about long-term debt instrument or arrangement." } } }, "auth ref": ["r8", "r18", "r19", "r28", "r63", "r64", "r127", "r254", "r255", "r256", "r257", "r258", "r260", "r265", "r266", "r267", "r268", "r270", "r271", "r272", "r273", "r274", "r275", "r278", "r669", "r670", "r671", "r672", "r673", "r694", "r823", "r892", "r893"] }, "xcur DebtSecuritiesAvailableForSalePeriodInBetweenReoccurringPutOption": { "xbrltype": "durationItemType", "nsuri": "http://www.exicuretx.com/20240630", "localname": "DebtSecuritiesAvailableForSalePeriodInBetweenReoccurringPutOption", "presentation": ["http://www.exicuretx.com/role/InvestmentInConvertibleNotesReceivableNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Period in between reoccurring put option", "label": "Debt Securities, Available-for-Sale, Period In Between Reoccurring Put Option" } } }, "auth ref": [] }, "xcur DebtSecuritiesAvailableForSaleRedemptionPricePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.exicuretx.com/20240630", "localname": "DebtSecuritiesAvailableForSaleRedemptionPricePercentage", "presentation": ["http://www.exicuretx.com/role/InvestmentInConvertibleNotesReceivableNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Redemption price percentage", "label": "Debt Securities, Available-for-Sale, Redemption Price, Percentage", "documentation": "Debt Securities, Available-for-Sale, Redemption Price, Percentage" } } }, "auth ref": [] }, "xcur DebtSecuritiesAvailableForSaleStatedYield": { "xbrltype": "percentItemType", "nsuri": "http://www.exicuretx.com/20240630", "localname": "DebtSecuritiesAvailableForSaleStatedYield", "presentation": ["http://www.exicuretx.com/role/InvestmentInConvertibleNotesReceivableNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Stated yield", "label": "Debt Securities, Available-for-Sale, Stated Yield", "documentation": "Debt Securities, Available-for-Sale, Stated Yield" } } }, "auth ref": [] }, "us-gaap DebtSecuritiesAvailableForSaleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleTable", "presentation": ["http://www.exicuretx.com/role/InvestmentInConvertibleNotesReceivableNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-sale [Table]", "label": "Debt Securities, Available-for-Sale [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth ref": ["r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188"] }, "us-gaap DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "presentation": ["http://www.exicuretx.com/role/SupplementalBalanceSheetInformationTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Prepaid and Other Current Assets", "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]", "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs." } } }, "auth ref": [] }, "us-gaap DepreciationAmortizationAndAccretionNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationAmortizationAndAccretionNet", "crdr": "debit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.exicuretx.com/role/SupplementalBalanceSheetInformationNarrativeDetails", "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Amortization and Accretion, Net", "documentation": "The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth ref": ["r3"] }, "us-gaap DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": ["http://www.exicuretx.com/role/EquityBasedCompensation"], "lang": { "en-us": { "role": { "terseLabel": "Equity-Based Compensation", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth ref": ["r309", "r313", "r341", "r342", "r344", "r680"] }, "us-gaap DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth ref": [] }, "dei DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://www.exicuretx.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth ref": [] }, "dei DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://www.exicuretx.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth ref": [] }, "dei DocumentPeriodEndDate": { "xbrltype": "dateTimeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://www.exicuretx.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth ref": [] }, "dei DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://www.exicuretx.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth ref": ["r722"] }, "dei DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://www.exicuretx.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth ref": ["r754"] }, "dei DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://www.exicuretx.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other.'" } } }, "auth ref": [] }, "ecd DvdsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvdsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year", "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]" } } }, "auth ref": ["r765"] }, "us-gaap EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]" } } }, "auth ref": [] }, "us-gaap EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://www.exicuretx.com/role/LossPerCommonShareScheduleOfComputationOflosspercommonshareDetails", "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"], "lang": { "en-us": { "role": { "terseLabel": "Basic loss per common share (in dollars per share)", "verboseLabel": "Loss per share - basic (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth ref": ["r111", "r133", "r134", "r135", "r136", "r137", "r138", "r143", "r145", "r148", "r149", "r150", "r155", "r366", "r369", "r383", "r384", "r506", "r525", "r660"] }, "us-gaap EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://www.exicuretx.com/role/LossPerCommonShareScheduleOfComputationOflosspercommonshareDetails", "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"], "lang": { "en-us": { "role": { "terseLabel": "Diluted loss per common share (in dollars per share)", "verboseLabel": "Loss per share - diluted (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth ref": ["r111", "r133", "r134", "r135", "r136", "r137", "r138", "r145", "r148", "r149", "r150", "r155", "r366", "r369", "r383", "r384", "r506", "r525", "r660"] }, "us-gaap EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": ["http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Loss Per Common Share", "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth ref": ["r12", "r13", "r152"] }, "us-gaap EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": ["http://www.exicuretx.com/role/LossPerCommonShare"], "lang": { "en-us": { "role": { "terseLabel": "Loss Per Common Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth ref": ["r142", "r151", "r153", "r154"] }, "us-gaap EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": ["http://www.exicuretx.com/role/IncomeTaxesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Effective tax rate (as a percent)", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth ref": ["r350", "r683"] }, "us-gaap EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleOfAccruedexpensesandothercurrentliabilitiesDetails": { "parentTag": "us-gaap AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleOfAccruedexpensesandothercurrentliabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accrued payroll-related expenses", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth ref": ["r32"] }, "us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": ["http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Compensation cost not yet recognized", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth ref": ["r343"] }, "us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": ["http://www.exicuretx.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth ref": [] }, "dei EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://www.exicuretx.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth ref": [] }, "dei EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://www.exicuretx.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth ref": [] }, "dei EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://www.exicuretx.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth ref": [] }, "dei EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://www.exicuretx.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth ref": ["r720"] }, "dei EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://www.exicuretx.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares

(in shares), "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://www.exicuretx.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": ["http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails"], "lang": { "en-us": { "role": { "terseLabel": "Entity [Domain]", "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://www.exicuretx.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r720"] }, "dei EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://www.exicuretx.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei EntityFileCategory": { "xbrltype": "fileCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileCategory", "presentation": ["http://www.exicuretx.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity File Category", "label": "Entity File Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r720"] }, "dei EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://www.exicuretx.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://www.exicuretx.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r804"] }, "dei EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://www.exicuretx.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r720"] }, "dei EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://www.exicuretx.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r720"] }, "dei EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://www.exicuretx.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r720"] }, "dei EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://www.exicuretx.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r720"] }, "ecd EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Footnote [Text Block]", "label": "Equity Awards Adjustments, Footnote [Text Block]" } } }, "auth_ref": ["r759"] }, "ecd EqtyAwrdsAdjExclgValPrtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjExclgValPrtdInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]" } } }, "auth_ref": ["r800"] }, "ecd EqtyAwrdsAdjExclgValPrtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjExclgValPrtdInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]" } } }, "auth_ref": ["r800"] }, "ecd EqtyAwrdsAdjExclgValPrtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjExclgValPrtdInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]" } } }, "auth_ref": ["r800"] }, "ecd EqtyAwrdsAdjExclgValPrtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjExclgValPrtdInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]" } } }, "auth_ref": ["r800"] }, "ecd EqtyAwrdsAdjExclgValPrtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjExclgValPrtdInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]" } } }, "auth_ref": ["r800"] }, "ecd EqtyAwrdsAdjExclgValPrtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjExclgValPrtdInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]" } } }, "auth_ref": ["r800"] }, "ecd EqtyAwrdsAdjExclgValPrtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjExclgValPrtdInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]" } } }, "auth_ref": ["r800"] }, "ecd EqtyAwrdsAdjExclgValPrtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjExclgValPrtdInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]" } } }, "auth_ref": ["r800"] }, "ecd EqtyAwrdsAdjExclgValPrtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjExclgValPrtdInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]" } } }, "auth_ref": ["r800"] }, "ecd EqtyAwrdsAdjExclgValPrtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjExclgValPrtdInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]" } } }, "auth_ref": ["r800"] }, "ecd EqtyAwrdsAdjExclgValPrtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjExclgValPrtdInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]" } } }, "auth_ref": ["r800"] }, "ecd EqtyAwrdsAdjExclgValPrtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjExclgValPrtdInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us":

"FairValueMeasurementsFairValueHierarchyDomain", "presentation": ["http://www.exicuretx.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": ["r267", "r301", "r302", "r303", "r304", "r305", "r306", "r385", "r387", "r388", "r389", "r390", "r396", "r397", "r399", "r422", "r443", "r444", "r670", "r671", "r676", "r677", "r678", "r684", "r687"] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": ["http://www.exicuretx.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": ["r684", "r884", "r885", "r886", "r887", "r888", "r890"] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": ["http://www.exicuretx.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails", "http://www.exicuretx.com/role/InvestmentInConvertibleNotesReceivableNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": ["r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r210", "r211", "r212", "r213", "r214", "r216", "r217", "r218", "r278", "r293", "r380", "r404", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r524", "r666", "r684", "r685", "r687", "r688", "r690", "r691", "r692", "r693", "r697", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r839", "r840", "r841", "r842", "r883", "r886", "r887", "r888", "r889", "r890"] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": ["http://www.exicuretx.com/role/LicenseAgreementDetails"], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets [Line Items]", "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r220", "r221", "r222", "r223", "r225", "r473", "r652", "r668"] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": ["r731", "r741", "r751", "r783"] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": ["r731", "r741", "r751", "r783"] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": ["r731", "r741", "r751", "r783"] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlock", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": ["r731", "r741", "r751", "r783"] }, "ecd_FrValAsOfPrYrEndOfEqtyAwrdGrntdInPrYrYsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrYrEndOfEqtyAwrdGrntdInPrYrYsFldVstngCondsDrngCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year", "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]" } } }, "auth_ref": ["r764"] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FurnitureAndFixturesMember", "presentation": ["http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofPropertyandEquipmentNetDetails"], "lang": { "en-us": { "role": { "terseLabel": "Furniture and fixtures", "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnSaleOfPropertyPlantEquipment", "crdr": "credit", "calculation": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10 }, "presentation": ["http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Gain (Loss) on Disposition of Property Plant Equipment", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property." } } }, "auth_ref": ["r3"] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 20 }, "presentation": ["http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOF OPERATIONS"], "lang": { "en-us": { "role": { "terseLabel": "General and administrative expense", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": ["r48", "r595"] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": ["http://www.exicuretx.com/role/EquityBasedCompensationScheduleofEquityBasedCompensationExpenseClassificationinStatementofOperationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "General and administrative expense", "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": ["r48"] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 10 }, "presentation": ["http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOF OPERATIONS"], "lang": { "en-us": { "role": { "totalLabel": "Net loss before provision for income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r46", "r75", "r80", "r507", "r521", "r622", "r663", "r831", "r832", "r833", "r834", "r835"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": ["http://www.exicuretx.com/role/EquityBasedCompensationScheduleofEquityBasedCompensationExpenseClassificationinStatementofOperationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r228", "r234", "r235", "r391", "r393", "r398", "r528", "r530", "r600", "r652", "r686", "r909"] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": ["http://www.exicuretx.com/role/EquityBasedCompensationScheduleofEquityBasedCompensationExpenseClassificationinStatementofOperationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r234", "r235", "r391", "r393", "r398", "r528", "r530", "r600", "r652", "r686", "r909"] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlock", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": ["http://www.exicuretx.com/role/IncomeTaxes"], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": ["r122", "r348", "r350", "r351", "r352", "r353", "r354", "r355", "r358", "r360", "r361", "r362", "r543", "r683"] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 20 }, "presentation": ["http://www.exicuretx.com/role/IncomeTaxesNarrativeDetails", "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOF OPERATIONS"], "lang": { "en-us": { "role": { "terseLabel": "Provision for income taxes", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r82", "r88", "r140", "r141", "r156", "r165", "r168", "r349", "r350", "r359", "r526", "r683"] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 70 }, "presentation": ["http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses", "label": "Increase (Decrease) in Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": ["r2"] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": ["http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "crdr": "credit", "calculation": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 110 }, "presentation": ["http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other noncurrent assets", "label": "Increase (Decrease) in Other Noncurrent Assets", "documentation": "Amount of increase (decrease) in noncurrent assets classified as other." } } }, "auth_ref": ["r819"] }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "crdr": "debit", "calculation": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 80 }, "presentation": ["http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Other liabilities", "label": "Increase (Decrease) in Other Operating Liabilities", "documentation": "Amount of increase (decrease) in operating liabilities classified as other." } } }, "auth_ref": ["r2"] }, "us-gaap_IncreaseDecreaseInOtherReceivables": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherReceivables", "crdr": "credit", "calculation": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 110 }, "presentation": ["http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other receivable", "label": "Increase (Decrease) in Other Receivables", "documentation": "Amount of increase (decrease) in receivables classified as other." } } }, "auth_ref": ["r2"] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 110 }, "presentation": ["http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Prepaid expenses and other current assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": ["r2"] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from

the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "ecd_individualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [{ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Individual", "label": "Individual [Axis]" } } } }, "auth_ref": ["r731", "r741", "r751", "r775", "r783", "r787", "r795"] }, "xcur_initialEmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exicuretx.com/20240630", "localname": "InitialEmployeeStockOptionMember", "presentation": [{ "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Initial Employee Stock Option", "label": "Initial Employee Stock Option [Member]", "documentation": "Initial Employee Stock Option [Member]" } } } }, "auth_ref": [] }, "ecd_insiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } } }, "auth_ref": ["r793"] }, "ecd_insiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": ["r723", "r799"] }, "ecd_insiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [{ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc", "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } } }, "auth_ref": ["r723", "r799"] }, "ecd_insiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [{ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc", "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } } }, "auth_ref": ["r723", "r799"] }, "us-gaap_intangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsDisclosureTextBlock", "presentation": [{ "http://www.exicuretx.com/role/LicenseAgreement", "lang": { "en-us": { "role": { "terseLabel": "License Agreement", "label": "Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for all or part of the information related to intangible assets." } } } }, "auth_ref": ["r219", "r224", "r226", "r651", "r652"] }, "us-gaap_interestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "calculation": [{ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 5.0 } }, "presentation": [{ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest expense", "label": "Interest Expense, Nonoperating", "documentation": "Amount of interest expense classified as nonoperating." } } } }, "auth_ref": ["r164", "r818"] }, "us-gaap_investmentIncomeDividend": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeDividend", "crdr": "credit", "calculation": [{ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } } }, "presentation": [{ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "lang": { "en-us": { "role": { "terseLabel": "Dividend income", "label": "Investment Income, Dividend", "documentation": "Amount of dividend income on nonoperating securities." } } } }, "auth_ref": ["r49"] }, "us-gaap_investmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": [{ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 4.0 } } }, "presentation": [{ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Investment Income, Interest", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } } }, "auth_ref": ["r156", "r163", "r168", "r663", "r817"] }, "us-gaap_investmentsDebtAndEquitySecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } } }, "auth_ref": [] }, "us-gaap_investmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "presentation": [{ "http://www.exicuretx.com/role/InvestmentInConvertibleNotesReceivable", "lang": { "en-us": { "role": { "terseLabel": "Investment in Convertible Notes Receivable", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "documentation": "The entire disclosure for investments in certain debt and equity securities." } } } }, "auth_ref": ["r77", "r90", "r174", "r176", "r405", "r406", "r907"] }, "us-gaap_leaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCost", "crdr": "debit", "calculation": [{ "http://www.exicuretx.com/role/LeasesLeaseCostsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [{ "http://www.exicuretx.com/role/LeasesLeaseCostsDetails", "lang": { "en-us": { "role": { "totalLabel": "Total lease costs", "label": "Lease, Cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } } }, "auth_ref": ["r423", "r695"] }, "xcur_leaseCostCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exicuretx.com/20240630", "localname": "LeaseCostCurrent", "crdr": "debit", "calculation": [{ "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleOfPrepaidandOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [{ "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleOfPrepaidandOtherCurrentAssetsDetails", "lang": { "en-us": { "role": { "terseLabel": "Lease costs", "label": "Lease, Cost, Current", "documentation": "Lease, Cost, Current" } } } }, "auth_ref": [] }, "us-gaap_leaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": [{ "http://www.exicuretx.com/role/LeasesTables", "lang": { "en-us": { "role": { "terseLabel": "Schedule of Lease Costs", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } } }, "auth_ref": ["r895"] }, "us-gaap_leasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Leases [Abstract]", "label": "Leases [Abstract]" } } } }, "auth_ref": [] }, "dei_legalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": [{ "http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails", "lang": { "en-us": { "role": { "terseLabel": "Legal Entity [Axis]", "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } } }, "auth_ref": [] }, "us-gaap_lesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionLineItems", "presentation": [{ "http://www.exicuretx.com/role/LeasesNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Line Items]", "label": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } }, "auth_ref": ["r422", "r429"] }, "us-gaap_lesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionTable", "presentation": [{ "http://www.exicuretx.com/role/LeasesNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Table]", "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } } }, "auth_ref": ["r422", "r429"] }, "xcur_lesseeOperatingLeaseAnnualRentPaymentInitialTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exicuretx.com/20240630", "localname": "LesseeOperatingLeaseAnnualRentPaymentInitialTwelveMonths", "crdr": "credit", "presentation": [{ "http://www.exicuretx.com/role/LeasesNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Operating lease, annual rent payment", "label": "Lessee, Operating Lease, Annual Rent Payment Initial Twelve Months", "documentation": "Lessee, Operating Lease, Annual Rent Payment Initial Twelve Months" } } } }, "auth_ref": [] }, "xcur_lesseeOperatingLeaseBaseRentAnnualPercentageIncrease": { "xbrltype": "percentItemType", "nsuri": "http://www.exicuretx.com/20240630", "localname": "LesseeOperatingLeaseBaseRentAnnualPercentageIncrease", "presentation": [{ "http://www.exicuretx.com/role/LeasesNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Operating lease, base rent annual percentage increase (as a percent)", "label": "Lessee, Operating Lease, Base Rent Annual Percentage Increase", "documentation": "Lessee, Operating Lease, Base Rent Annual Percentage Increase" } } } }, "auth_ref": [] }, "xcur_lesseeOperatingLeaseEstimatedRentalPaymentOverOriginalTerm": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exicuretx.com/20240630", "localname": "LesseeOperatingLeaseEstimatedRentalPaymentOverOriginalTerm", "crdr": "credit", "presentation": [{ "http://www.exicuretx.com/role/LeasesNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Operating lease, estimated rental payment over lease term", "label": "Lessee, Operating Lease, Estimated Rental Payment Over Original Term", "documentation": "Lessee, Operating Lease, Estimated Rental Payment Over Original Term" } } } }, "auth_ref": [] }, "xcur_lesseeOperatingLeaseLeaseArea": { "xbrltype": "areaItemType", "nsuri": "http://www.exicuretx.com/20240630", "localname": "LesseeOperatingLeaseLeaseArea", "presentation": [{ "http://www.exicuretx.com/role/LeasesNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Operating lease area", "label": "Lessee, Operating Lease, Lease Area", "documentation": "Lessee, Operating Lease, Lease Area" } } } }, "auth_ref": [] }, "xcur_lesseeOperatingLeaseNumberOfExtensions": { "xbrltype": "integerItemType", "nsuri": "http://www.exicuretx.com/20240630", "localname": "LesseeOperatingLeaseNumberOfExtensions", "presentation": [{ "http://www.exicuretx.com/role/LeasesNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Operating lease, number of extensions", "label": "Lessee, Operating Lease, Number of Extensions", "documentation": "Lessee, Operating Lease, Number of Extensions" } } } }, "auth_ref": [] }, "us-gaap_lesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": [{ "http://www.exicuretx.com/role/LeasesNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Operating lease, renewal term", "label": "Lessee, Operating Lease, Renewal Term", "documentation": "Term of lessee's operating lease renewal, in PnYmNdThHnMnS format, for example, P1Y5M13D represents reported fact of one year, five months, and thirteen days." } } } }, "auth_ref": ["r894"] }, "us-gaap_lesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": [{ "http://www.exicuretx.com/role/LeasesNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Operating lease, contract term", "label": "Lessee, Operating Lease, Term of Contract", "documentation": "Term of lessee's operating lease, in PnYmNdThHnMnS format, for example, P1Y5M13D represents reported fact of one year, five months, and thirteen days." } } } }, "auth_ref": ["r894"] }, "us-gaap_lesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [{ "http://www.exicuretx.com/role/Leases", "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } } }, "auth_ref": ["r417"] }, "xcur_lesseeOperatingSubleasePercentageOfOfficeSpaceSubleased": { "xbrltype": "percentItemType", "nsuri": "http://www.exicuretx.com/20240630", "localname": "LesseeOperatingSubleasePercentageOfOfficeSpaceSubleased", "presentation": [{ "http://www.exicuretx.com/role/LeasesNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Lessee, Operating Sublease, Percentage Of Office Space Subleased", "label": "Lessee, Operating Sublease, Percentage Of Office Space Subleased", "documentation": "Lessee, Operating Sublease, Percentage Of Office Space Subleased" } } } }, "auth_ref": [] }, "xcur_lesseeOperatingSubleasePeriodOfNoRentCost": { "xbrltype": "durationItemType", "nsuri": "http://www.exicuretx.com/20240630", "localname": "LesseeOperatingSubleasePeriodOfNoRentCost", "presentation": [{ "http://www.exicuretx.com/role/LeasesNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Period of no rental cost", "label": "Lessee, Operating Sublease, Period Of No Rent Cost", "documentation": "Lessee, Operating Sublease, Period Of No Rent Cost" } } } }, "auth_ref": [] }, "us-gaap_liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": [{ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [{ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS", "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } } }, "auth_ref": ["r33", "r94", "r121", "r207", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r371", "r372", "r373", "r407", "r570", "r661", "r718", "r851", "r898", "r899"] }, "us-gaap_liabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": [{ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [{ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS", "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } } }, "auth_ref": ["r45", "r74", "r517", "r696", "r824", "r843", "r891"] }, "us-gaap_liabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [{ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS", "lang": { "en-us": { "role": { "terseLabel": "Current liabilities", "label": "Liabilities, Current [Abstract]" } } } }, "auth_ref": [] }, "dei_localPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [{ "http://www.exicuretx.com/role/CoverPage", "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } } }, "auth_ref": [] }, "us-gaap_longTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtCurrent", "crdr": "credit", "calculation": [{ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [{ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS", "lang": { "en-us": { "role": { "terseLabel": "Short-term debt", "label": "Long-Term Debt, Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } } }, "auth_ref": ["r100"] }, "srt_maximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/irt/2024", "localname": "MaximumMember", "presentation": [{ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofCommonStockOptionGrantsDetails", "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } } }, "auth_ref": ["r238", "r239", "r240", "r241", "r308", "r346", "r390", "r471", "r527", "r529", "r536", "r562", "r563", "r623", "r625", "r627", "r628", "r630", "r649", "r650", "r665", "r674", "r679", "r687", "r688", "r692", "r693", "r706", "r853", "r900", "r901", "r902", "r903", "r904", "r905"] }, "ecd_measureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [{ "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Measure", "label": "Measure [Axis]" } } } }, "auth_ref": ["r767"] }, "ecd_measureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [{ "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } } }, "auth_ref": ["r767"] },

"srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": ["http://www.xicuretx.com/role/EquityBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueOfCommonStockOptionGrantsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": ["r238", "r239", "r240", "r241", "r308", "r346", "r390", "r471", "r527", "r529", "r536", "r562", "r563", "r623", "r625", "r627", "r628", "r630", "r649", "r650", "r665", "r674", "r679", "r687", "r688", "r692", "r706", "r853", "r900", "r901", "r902", "r903", "r904", "r905"] }, "ecd_MnpDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpDiscTimedForCompValFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": ["r786"] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": ["http://www.xicuretx.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"], "lang": { "en-us": { "role": { "terseLabel": "Money market funds", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": ["r855"] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": ["r794"] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } } }, "auth_ref": ["r768"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.xicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 }, "presentation": ["http://www.xicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r116"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://www.xicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.xicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 }, "presentation": ["http://www.xicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r116"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://www.xicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.xicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 }, "presentation": ["http://www.xicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r53", "r54", "r55"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.xicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.xicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://www.xicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.xicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "label": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r47", "r55", "r76", "r92", "r106", "r107", "r110", "r121", "r131", "r133", "r134", "r135", "r136", "r137", "r140", "r141", "r147", "r207", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r366", "r369", "r384", "r407", "r522", "r592", "r613", "r614", "r716", "r851"] }, "ecd_NonGAAPMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGAAPMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": ["r767"] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": ["r731", "r741", "r751", "r775", "r783"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r758"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r757"] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": ["r775"] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": ["r794"] }, "ecd_NonRule10b51ArrTrmtdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmtdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": ["r794"] }, "xcu_NonemployeeDirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xicuretx.com/20240630", "localname": "NonemployeeDirectorMember", "presentation": ["http://www.xicuretx.com/role/EquityBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Non-employee Director", "label": "Non-employee Director [Member]", "documentation": "Non-employee Director [Member]" } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.xicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 }, "presentation": ["http://www.xicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "totalLabel": "Total other (expense) income, net", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": ["r50"] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": ["http://www.xicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Other (expense) income, net", "label": "Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NotesReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesReceivableMember", "presentation": ["http://www.xicuretx.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails", "http://www.xicuretx.com/role/InvestmentInConvertibleNotesReceivableNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Notes Receivable", "label": "Notes Receivable [Member]", "documentation": "An amount representing an agreement for an unconditional promise by the maker to pay the Entity (holder) a definite sum of money at a future date(s) within one year of the balance sheet date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics." } } }, "auth_ref": [] }, "xcu_NotesReceivableOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xicuretx.com/20240630", "localname": "NotesReceivableOneMember", "presentation": ["http://www.xicuretx.com/role/InvestmentInConvertibleNotesReceivableNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Notes Receivable, One", "label": "Notes Receivable, One [Member]", "documentation": "Notes Receivable, One" } } }, "auth_ref": [] }, "xcu_NotesReceivableTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xicuretx.com/20240630", "localname": "NotesReceivableTwoMember", "presentation": ["http://www.xicuretx.com/role/InvestmentInConvertibleNotesReceivableNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Notes Receivable, Two", "label": "Notes Receivable, Two [Member]", "documentation": "Notes Receivable, Two" } } }, "auth_ref": [] }, "xcu_NumberOfSubscriptionAgreementsEntered": { "xbrltype": "integerItemType", "nsuri": "http://www.xicuretx.com/20240630", "localname": "NumberOfSubscriptionAgreementsEntered", "presentation": ["http://www.xicuretx.com/role/InvestmentInConvertibleNotesReceivableNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of subscription agreements entered into", "label": "Number Of Subscription Agreements Entered", "documentation": "Number Of Subscription Agreements Entered" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.xicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 }, "presentation": ["http://www.xicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": ["http://www.xicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "debit", "calculation": { "http://www.xicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 }, "presentation": ["http://www.xicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "totalLabel": "Operating loss", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r80", "r662", "r831", "r832", "r833", "r834", "r835"] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": { "http://www.xicuretx.com/role/LeasesLeaseCostsDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 1.0 }, "presentation": ["http://www.xicuretx.com/role/LeasesLeaseCostsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease costs", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": ["r424", "r695"] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.xicuretx.com/role/SupplementalBalanceSheetInformationScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 }, "presentation": ["http://www.xicuretx.com/role/SupplementalBalanceSheetInformationScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Current lease liability", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r420"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.xicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 }, "presentation": ["http://www.xicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "verboseLabel": "Lease liability, noncurrent", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r420"] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": ["http://www.xicuretx.com/role/LeasesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, cash payments", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": ["r421", "r427"] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-

gaap/2024", "localname": "OperatingLeaseRightOfUseAssets", "crdr": "debit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap Assets", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use asset", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r419"] }, "us-gaap OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": ["http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Amortization of right-of-use asset", "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": ["r820"] }, "us-gaap OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofAccruedexpensesandothercurrentliabilitiesDetails": { "parentTag": "us-gaap AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofAccruedexpensesandothercurrentliabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accrued other expenses", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r32"] }, "us-gaap OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap Assets", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofOtherNoncurrentAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofOtherNoncurrentAssetsDetails", "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Other noncurrent assets", "label": "Other noncurrent assets", "totalLabel": "Other noncurrent assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": ["r98"] }, "us-gaap OtherNonoperatingIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncome", "crdr": "credit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"], "lang": { "en-us": { "role": { "terseLabel": "Other income", "label": "Other Nonoperating Income", "documentation": "Amount of income related to nonoperating activities, classified as other." } } }, "auth_ref": ["r112"] }, "us-gaap OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap NonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"], "lang": { "en-us": { "role": { "terseLabel": "Other expense", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": ["r51"] }, "ecd OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": ["r767"] }, "us-gaap OtherPrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherPrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidandOtherCurrentAssetsDetails": { "parentTag": "us-gaap PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidandOtherCurrentAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Prepaid Expense, Current", "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r815", "r844"] }, "us-gaap OtherReceivablesGrossCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherReceivablesGrossCurrent", "crdr": "debit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Other receivable", "label": "Other Receivables, Gross, Current", "documentation": "Amount, before allowance, of receivables classified as other, due within one year or the operating cycle, if longer." } } }, "auth_ref": ["r104"] }, "ecd OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r729", "r739", "r749", "r781"] }, "ecd OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": ["r732", "r742", "r752", "r784"] }, "ecd OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": ["r732", "r742", "r752", "r784"] }, "ecd PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": ["r756"] }, "xcur PaymentForExerciseOfCommonStockWarrant": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exicuretx.com/20240630", "localname": "PaymentForExerciseOfCommonStockWarrant", "crdr": "credit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payment of exercise of common stock warrants", "label": "Payment For Exercise Of Common Stock Warrant", "documentation": "Payment For Exercise Of Common Stock Warrant" } } }, "auth_ref": [] }, "xcur PaymentsOfCommonStockFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exicuretx.com/20240630", "localname": "PaymentsOfCommonStockFinancingCosts", "crdr": "credit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": ["http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedLabel": "Payment of common stock financing costs", "label": "Payments Of Common Stock Financing Costs", "documentation": "Payments Of Common Stock Financing Costs" } } }, "auth_ref": [] }, "us-gaap PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments for minimum statutory tax withholding related to net share settlement of equity awards", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": ["r115"] }, "us-gaap PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "crdr": "credit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchase of available-for-sale securities", "label": "Payments to Acquire Debt Securities, Available-for-Sale", "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r9", "r113", "r175"] }, "ecd PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": ["r766"] }, "ecd PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": ["r766"] }, "ecd PEOActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PEOActuallyPaidCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": ["r758"] }, "ecd PEOMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PEOMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": ["r775"] }, "ecd PEOName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PEOName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": ["r768"] }, "ecd PEOTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PEOTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": ["r757"] }, "us-gaap PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": ["http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Axis]", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": ["r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881"] }, "us-gaap PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": ["http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Domain]", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": ["r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881"] }, "ecd PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Prior Service Cost", "label": "Pension Adjustments Prior Service Cost [Member]" } } }, "auth_ref": ["r759"] }, "ecd PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Service Cost", "label": "Pension Adjustments Service Cost [Member]" } } }, "auth_ref": ["r803"] }, "ecd PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Pension Benefits Adjustments, Footnote", "label": "Pension Benefits Adjustments, Footnote [Text Block]" } } }, "auth_ref": ["r758"] }, "xcur PrefundedWarrantsAndAccompanyingWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exicuretx.com/20240630", "localname": "PrefundedWarrantsAndAccompanyingWarrantMember", "presentation": ["http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails"], "lang": { "en-us": { "role": { "terseLabel": "Pre-Funded Warrants And Accompanying Warrant", "label": "Pre-Funded Warrants And Accompanying Warrant [Member]", "documentation": "Pre-Funded Warrants And Accompanying Warrant" } } }, "auth_ref": [] }, "xcur PrefundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exicuretx.com/20240630", "localname": "PrefundedWarrantsMember", "presentation": ["http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails"], "lang": { "en-us": { "role": { "terseLabel": "Pre-Funded Warrants", "label": "Pre-Funded Warrants [Member]", "documentation": "Pre-Funded Warrants" } } }, "auth_ref": [] }, "us-gaap PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": ["http://www.exicuretx.com/role/StockholdersEquityPreferredandCommonStockDetails", "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r39", "r281"] }, "us-gaap PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": ["http://www.exicuretx.com/role/StockholdersEquityPreferredandCommonStockDetails", "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r39", "r572"] }, "us-gaap PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": ["http://www.exicuretx.com/role/StockholdersEquityPreferredandCommonStockDetails", "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": ["r39", "r281"] }, "us-gaap PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://www.exicuretx.com/role/StockholdersEquityPreferredandCommonStockDetails", "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares outstanding (in shares)", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r39", "r572", "r590", "r939", "r940"] }, "us-gaap PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, \$0.0001 par value per share; 10,000,000 shares authorized, no shares issued and outstanding, Juneu00a030, 2024 and Decemberu00a031, 2023", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par

or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r39", "r514", "r696"] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleOfPrepaidandOtherCurrentAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleOfPrepaidandOtherCurrentAssetsDetails", "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "totalLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r816"] }, "xcur_PrepaidFranchiseTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exicuretx.com/20240630", "localname": "PrepaidFranchiseTax", "crdr": "debit", "calculation": { "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleOfPrepaidandOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleOfPrepaidandOtherCurrentAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Prepaid franchise tax", "label": "Prepaid Franchise Tax", "documentation": "Prepaid Franchise Tax" } } }, "auth_ref": [] }, "us-gaap_PrepaidInsurance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidInsurance", "crdr": "debit", "calculation": { "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleOfPrepaidandOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleOfPrepaidandOtherCurrentAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Prepaid insurance", "label": "Prepaid Insurance", "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r655", "r667", "r844"] }, "xcur_PrepaidInsuranceNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exicuretx.com/20240630", "localname": "PrepaidInsuranceNoncurrent", "crdr": "debit", "calculation": { "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleOfOtherNoncurrentAssetsDetails": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleOfOtherNoncurrentAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Prepaid insurance", "label": "Prepaid Insurance, Noncurrent", "documentation": "Prepaid Insurance, Noncurrent" } } }, "auth_ref": [] }, "xcur_PrepaidProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exicuretx.com/20240630", "localname": "PrepaidProfessionalFeesCurrent", "crdr": "debit", "calculation": { "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleOfPrepaidandOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleOfPrepaidandOtherCurrentAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Prepaid professional fees", "label": "Prepaid Professional Fees, Current", "documentation": "Prepaid Professional Fees, Current" } } }, "auth_ref": [] }, "xcur_PrepaidSoftwareCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exicuretx.com/20240630", "localname": "PrepaidSoftwareCurrent", "crdr": "debit", "calculation": { "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleOfPrepaidandOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleOfPrepaidandOtherCurrentAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Prepaid software", "label": "Prepaid Software, Current", "documentation": "Prepaid Software, Current" } } }, "auth_ref": [] }, "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrivatePlacementMember", "presentation": ["http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails"], "lang": { "en-us": { "role": { "terseLabel": "Private Placement [Member]", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from common stock offering", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": ["r1"] }, "xcur_ProceedsFromIssuanceOfCommonStockAndWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exicuretx.com/20240630", "localname": "ProceedsFromIssuanceOfCommonStockAndWarrants", "crdr": "credit", "presentation": ["http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails"], "lang": { "en-us": { "role": { "terseLabel": "Gross proceeds", "label": "Proceeds From Issuance Of Common Stock And Warrants", "documentation": "Proceeds From Issuance Of Common Stock And Warrants" } } }, "auth_ref": [] }, "xcur_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfPlacementAgentFeeAndOtherOfferingExpensesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exicuretx.com/20240630", "localname": "ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfPlacementAgentFeeAndOtherOfferingExpensesPayable", "crdr": "credit", "presentation": ["http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails"], "lang": { "en-us": { "role": { "terseLabel": "Net proceeds", "label": "Proceeds from Issuance of Common Stock And Warrants Net of Placement Agent Fee and Other Offering Expenses Payable", "documentation": "Proceeds from Issuance of Common Stock And Warrants Net of Placement Agent Fee and Other Offering Expenses Payable" } } }, "auth_ref": [] }, "xcur_ProceedsFromPatentLicenseAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exicuretx.com/20240630", "localname": "ProceedsFromPatentLicenseAgreement", "crdr": "debit", "presentation": ["http://www.exicuretx.com/role/LicenseAgreementDetails"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from patent license agreement", "label": "Proceeds From Patent License Agreement", "documentation": "Proceeds From Patent License Agreement" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities", "crdr": "debit", "presentation": ["http://www.exicuretx.com/role/InvestmentInConvertibleNotesReceivableNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale or maturity of available-for-sale securities", "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale", "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r113", "r114", "r838"] }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of property and equipment", "label": "Proceeds from Sale of Property, Plant, and Equipment", "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale." } } }, "auth_ref": ["r52"] }, "us-gaap_ProceedsFromShortTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromShortTermDebt", "crdr": "debit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from short-term borrowing", "label": "Proceeds from Short-Term Debt", "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r10"] }, "xcur_PromissoryNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exicuretx.com/20240630", "localname": "PromissoryNoteMember", "presentation": ["http://www.exicuretx.com/role/DebtNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Promissory Note", "label": "Promissory Note [Member]", "documentation": "Promissory Note" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": ["http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleOfPropertyandEquipmentNetDetails"], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": ["r4", "r428"] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleOfPropertyandEquipmentNetDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleOfPropertyandEquipmentNetDetails"], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, gross", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r59", "r96", "r520"] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": ["http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleOfPropertyandEquipmentNetDetails"], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r428"] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 }, "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleOfPropertyandEquipmentNetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleOfPropertyandEquipmentNetDetails"], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r4", "r428", "r508", "r520", "r696"] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": ["http://www.exicuretx.com/role/SupplementalBalanceSheetInformationTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Property and Equipment, Net", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation." } } }, "auth_ref": ["r4"] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": ["http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleOfPropertyandEquipmentNetDetails"], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": ["r59", "r428"] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]", "documentation": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": ["r756"] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": ["r756"] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": ["http://www.exicuretx.com/role/EquityBasedCompensationScheduleOfAssumptionsUsedtoDetermineFairValueOfCommonStockOptionGrantsDetails", "http://www.exicuretx.com/role/EquityBasedCompensationScheduleOfFairValueOfUnderlyingCommonStockandExercisePriceOfStockOptionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": ["r238", "r239", "r240", "r241", "r300", "r308", "r336", "r337", "r338", "r346", "r390", "r445", "r454", "r471", "r527", "r529", "r536", "r562", "r563", "r623", "r625", "r627", "r628", "r630", "r649", "r650", "r665", "r674", "r679", "r687", "r688", "r692", "r693", "r706", "r710", "r849", "r853", "r887", "r901", "r902", "r903", "r904", "r905"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": ["http://www.exicuretx.com/role/EquityBasedCompensationScheduleOfAssumptionsUsedtoDetermineFairValueOfCommonStockOptionGrantsDetails", "http://www.exicuretx.com/role/EquityBasedCompensationScheduleOfFairValueOfUnderlyingCommonStockandExercisePriceOfStockOptionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": ["r238", "r239", "r240", "r241", "r300", "r308", "r336", "r337", "r338", "r346", "r390", "r445", "r454", "r471", "r527", "r529", "r536", "r562", "r563", "r623", "r625", "r627", "r628", "r630", "r649", "r650", "r665", "r674", "r679", "r687", "r688", "r692", "r693", "r706", "r710", "r849", "r853", "r887", "r901", "r902", "r903", "r904", "r905"] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": ["r724", "r734", "r744", "r776"] }, "xcur_RegistrationRightsAgreementLiquidationDamagesPayableAsAPercentOfAmountInvestedIfFiledLate": { "xbrltype": "percentItemType", "nsuri": "http://www.exicuretx.com/20240630", "localname": "RegistrationRightsAgreementLiquidationDamagesPayableAsAPercentOfAmountInvestedIfFiledLate", "presentation": ["http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails"], "lang": { "en-us": { "role": { "terseLabel": "Registration rights agreement, liquidation damages payable as a percent of amount invested, if filed late (as a percent)", "label": "Registration Rights Agreement, Liquidation Damages Payable As A Percent Of Amount Invested, If Filed Late", "documentation": "Registration Rights Agreement, Liquidation Damages Payable If Filed Late, As A Percent Of Amount Invested" } } }, "auth_ref": [] }, "xcur_RegistrationRightsAgreementLiquidationDamagesPayableIfFiledLateMeasurementTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.exicuretx.com/20240630", "localname": "RegistrationRightsAgreementLiquidationDamagesPayableIfFiledLateMeasurementTerm", "presentation": ["http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails"], "lang": { "en-us": { "role": { "terseLabel": "Registration rights agreement, liquidation damages" } } } }

payable if filed late, measurement term", "label": "Registration Rights Agreement, Liquidation Damages Payable If Filed Late, Measurement Term", "documentation": "Registration Rights Agreement, Liquidation Damages Payable If Filed Late, Measurement Term" } } }, "auth_ref": [] }, "xcur.RegistrationRightsAgreementProRataAccrual": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xcuretx.com/20240630", "localname": "RegistrationRightsAgreementProRataAccrual", "crdr": "credit", "presentation": ["http://www.xcuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails"], "lang": { "en-us": { "role": { "terseLabel": "Pro rata accrual", "label": "Registration Rights Agreement, Pro Rata Accrual", "documentation": "Registration Rights Agreement, Pro Rata Accrual" } } }, "auth_ref": [] }, "xcur.RegistrationRightsAgreementProRataPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xcuretx.com/20240630", "localname": "RegistrationRightsAgreementProRataPayment", "crdr": "credit", "presentation": ["http://www.xcuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails"], "lang": { "en-us": { "role": { "terseLabel": "Pro rata payment", "label": "Registration Rights Agreement, Pro Rata Payment", "documentation": "Registration Rights Agreement, Pro Rata Payment" } } }, "auth_ref": [] }, "xcur.RegistrationRightsAgreementRequiredFilingTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.xcuretx.com/20240630", "localname": "RegistrationRightsAgreementRequiredFilingTerm", "presentation": ["http://www.xcuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails"], "lang": { "en-us": { "role": { "terseLabel": "Registration rights agreement, required filing term", "label": "Registration Rights Agreement, Required Filing Term", "documentation": "Registration Rights Agreement, Required Filing Term" } } }, "auth_ref": [] }, "us-gaap.RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": ["http://www.xcuretx.com/role/DebtNarrativeDetails", "http://www.xcuretx.com/role/RelatedPartyTransactionsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Related Party [Domain]", "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r173", "r307", "r434", "r435", "r511", "r518", "r565", "r566", "r567", "r568", "r569", "r589", "r591", "r622"] }, "us-gaap.RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyMember", "presentation": ["http://www.xcuretx.com/role/DebtNarrativeDetails", "http://www.xcuretx.com/role/RelatedPartyTransactionsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": ["r123", "r124", "r434", "r435", "r436", "r437", "r511", "r518", "r565", "r566", "r567", "r568", "r569", "r589", "r591", "r622"] }, "us-gaap.RelatedPartyTransactionAmountsOfTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAmountsOfTransaction", "crdr": "debit", "presentation": ["http://www.xcuretx.com/role/RelatedPartyTransactionsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Amount of transaction", "label": "Related Party Transaction, Amounts of Transaction", "documentation": "Amount of transactions with related party during the financial reporting period." } } }, "auth_ref": ["r27", "r434"] }, "us-gaap.RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionLineItems", "presentation": ["http://www.xcuretx.com/role/RelatedPartyTransactionsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Line Items]", "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r173", "r596", "r597", "r600"] }, "us-gaap.RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Related Party Transactions [Abstract]", "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap.RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": ["http://www.xcuretx.com/role/DebtNarrativeDetails", "http://www.xcuretx.com/role/RelatedPartyTransactionsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Related Party [Axis]", "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r173", "r307", "r434", "r435", "r511", "r518", "r565", "r566", "r567", "r568", "r569", "r589", "r591", "r622", "r897"] }, "us-gaap.RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": ["http://www.xcuretx.com/role/RelatedPartyTransactions"], "lang": { "en-us": { "role": { "terseLabel": "Related-Party Transactions", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": ["r431", "r432", "r433", "r435", "r438", "r544", "r545", "r546", "r598", "r599", "r600", "r619", "r621"] }, "srt.RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": ["http://www.xcuretx.com/role/DebtNarrativeDetails", "http://www.xcuretx.com/role/LicenseAgreementDetails", "http://www.xcuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails"], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]" } } }, "auth_ref": ["r125", "r126", "r257", "r283", "r437", "r455", "r509", "r657", "r658"] }, "us-gaap.ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.xcuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap.OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.xcuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"], "lang": { "en-us": { "role": { "terseLabel": "Research and development expense", "label": "Research and Development Expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": ["r347", "r652", "r663", "r906"] }, "us-gaap.ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": ["http://www.xcuretx.com/role/EquityBasedCompensationScheduleofEquityBasedCompensationExpenseClassificationinStatementofOperationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Research and development expense", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "ecd.RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": ["r725", "r735", "r745", "r777"] }, "ecd.RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": ["r726", "r736", "r746", "r778"] }, "ecd.RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": ["r733", "r743", "r753", "r785"] }, "us-gaap.RestrictedCashAndCashEquivalents": { "xbrltype": "monetaryItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.xcuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS Parentetical": { "parentTag": "us-gaap.CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.xcuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS Parentetical"], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash included in other noncurrent assets", "label": "Restricted Cash and Cash Equivalents", "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r11", "r69", "r95", "r117", "r513"] }, "us-gaap.RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": ["http://www.xcuretx.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents [Domain]", "label": "Cash and Cash Equivalents [Domain]", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r95"] }, "us-gaap.RestrictedCashNoncurrent": { "xbrltype": "monetaryItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashNoncurrent", "crdr": "debit", "calculation": { "http://www.xcuretx.com/role/SupplementalBalanceSheetInformationScheduleofOtherNoncurrentAssetsDetails": { "parentTag": "us-gaap.OtherAssetsNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.xcuretx.com/role/SupplementalBalanceSheetInformationScheduleofOtherNoncurrentAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "label": "Restricted Cash, Noncurrent", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": ["r83", "r814", "r821"] }, "us-gaap.RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": ["http://www.xcuretx.com/role/EquityBasedCompensationNarrativeDetails", "http://www.xcuretx.com/role/EquityBasedCompensationScheduleofRestrictedStockUnitAwardsActivityDetails", "http://www.xcuretx.com/role/LossPerCommonShareScheduleofAntidilutiveSecuritiesDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock units", "label": "Restricted Stock Units [RSUs] [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap.RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.xcuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap.StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.xcuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r42", "r65", "r516", "r534", "r535", "r542", "r573", "r696"] }, "us-gaap.RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://www.xcuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r91", "r128", "r129", "r130", "r132", "r137", "r139", "r141", "r208", "r209", "r227", "r356", "r357", "r363", "r364", "r365", "r367", "r368", "r369", "r374", "r376", "r377", "r379", "r382", "r416", "r418", "r531", "r533", "r547", "r939"] }, "us-gaap.RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.xcuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap.OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.xcuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": ["r78", "r79", "r156", "r161", "r162", "r166", "r168", "r169", "r170", "r172", "r298", "r299", "r472"] }, "us-gaap.RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesAbstract", "presentation": ["http://www.xcuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenues [Abstract]" } } }, "auth_ref": [] }, "ecd.Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": ["r794"] }, "ecd.Rule10b51ArrTrmtdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmtdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": ["r794"] }, "xcur.SaleOfStockAndWarrantsPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.xcuretx.com/20240630", "localname": "SaleOfStockAndWarrantsPricePerShare", "presentation": ["http://www.xcuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails"], "lang": { "en-us": { "role": { "terseLabel": "Purchase price (in dollars per share)", "label": "Sale Of Stock And Warrants, Price Per Share", "documentation": "Sale Of Stock And Warrants, Price Per Share" } } }, "auth_ref": [] }, "us-gaap.SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": ["http://www.xcuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails"], "lang": { "en-us": { "role": { "terseLabel": "Consideration for stock transaction", "label": "Sale Of Stock, Consideration Received on Transaction", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": [] }, "xcur.SaleOfStockConsiderationReceivedOnTransactionGross": { "xbrltype": "monetaryItemtype", "nsuri": "http://www.xcuretx.com/20240630", "localname": "SaleOfStockConsiderationReceivedOnTransactionGross", "crdr": "debit", "presentation": ["http://www.xcuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails"], "lang": { "en-us": { "role": { "terseLabel": "Consideration received, gross", "label": "Sale Of Stock, Consideration Received On Transaction, Gross", "documentation": "Sale Of Stock, Consideration Received On Transaction, Gross" } } }, "auth_ref": [] }, "us-gaap.SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": ["http://www.xcuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails"], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Domain]", "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap.SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "shareSpaceItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": ["http://www.xcuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of shares issued in transaction (in shares)", "label": "Sale Of Stock, Number of Shares Issued in Transaction", "documentation": "The number of shares issued or sold by

the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "xcurl_SaleOfStockNumberOfSharesIssuedInTransactionPercentageSubsequentlySold": { "xbrltype": "percentItemType", "nsuri": "http://www.exicuretx.com/20240630", "localname": "SaleOfStockNumberOfSharesIssuedInTransactionPercentageSubsequentlySold", "presentation": ["http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails"], "lang": { "en-us": { "role": { "terseLabel": "Percentage of shares subsequently sold at closing", "label": "Sale Of Stock, Number Of Shares Issued In Transaction, Percentage Subsequently Sold", "documentation": "Sale Of Stock, Number Of Shares Issued In Transaction, Percentage Subsequently Sold" } } }, "auth_ref": [] }, "xcurl_SaleOfStockNumberOfWarrantsIssuedInTransaction": { "xbrltype": "sharesItemtype", "nsuri": "http://www.exicuretx.com/20240630", "localname": "SaleOfStockNumberOfWarrantsIssuedInTransaction", "presentation": ["http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails"], "lang": { "en-us": { "role": { "terseLabel": "Warrants issued in sale of stock (in shares)", "label": "Sale Of Stock, Number Of Warrants Issued In Transaction", "documentation": "Sale Of Stock, Number Of Warrants Issued In Transaction" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction": { "xbrltype": "percentItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockPercentageOfOwnershipAfterTransaction", "presentation": ["http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails"], "lang": { "en-us": { "role": { "terseLabel": "Percentage of ownership after transaction (as a percent)", "label": "Sale of Stock, Percentage of Ownership after Transaction", "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockPricePerShare", "presentation": ["http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails"], "lang": { "en-us": { "role": { "terseLabel": "Sales price of shares issued in transaction (in dollars per share)", "label": "Sale of Stock, Price Per Share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": ["http://www.exicuretx.com/role/SupplementalBalanceSheetInformationTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accrued expenses and other current liabilities", "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": ["http://www.exicuretx.com/role/LossPerCommonShareScheduleOfAntidilutiveSecuritiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": ["r12"] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTableTextBlock": { "xbrltype": "textBlockItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTableTextBlock", "presentation": ["http://www.exicuretx.com/role/LossPerCommonShareTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": ["r12"] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "presentation": ["http://www.exicuretx.com/role/InvestmentNotesReceivableNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-sale [Line Items]", "label": "Debt Securities, Available-for-Sale [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188"] }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "xbrltype": "textBlockItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "presentation": ["http://www.exicuretx.com/role/EquityBasedCompensationTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Equity-Based Compensation Expense Classification in Statement of Operations", "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]", "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit." } } }, "auth_ref": ["r22"] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": ["http://www.exicuretx.com/role/LossPerCommonShareTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Computation of Loss per Common Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": ["r830"] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": ["http://www.exicuretx.com/role/FairValueMeasurementsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": ["r884", "r885"] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": ["http://www.exicuretx.com/role/LicenseAgreementDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]", "label": "Intangible Asset, Finite-Lived [Table]", "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset." } } }, "auth_ref": ["r220", "r221", "r222", "r223", "r225", "r473", "r652", "r668"] }, "us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock": { "xbrltype": "textBlockItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfOtherAssetsNoncurrentTextBlock", "presentation": ["http://www.exicuretx.com/role/SupplementalBalanceSheetInformationTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Noncurrent Assets", "label": "Schedule of Other Assets, Noncurrent [Table Text Block]", "documentation": "Tabular disclosure of noncurrent assets." } } }, "auth_ref": ["r814"] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": ["http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentNetDetails"], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation." } } }, "auth_ref": ["r4", "r428"] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": ["http://www.exicuretx.com/role/RelatedPartyTransactionsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]", "label": "Related Party Transaction [Table]", "documentation": "Disclosure of information about related party transaction." } } }, "auth_ref": ["r26", "r27", "r596", "r597", "r600"] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": ["http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails", "http://www.exicuretx.com/role/EquityBasedCompensationScheduleOfAssumptionsUsedtoDetermineFairValueOfCommonStockOptionGrantsDetails", "http://www.exicuretx.com/role/EquityBasedCompensationScheduleOfEquityBasedCompensationExpenseClassificationInStatementOfOperationsDetails", "http://www.exicuretx.com/role/EquityBasedCompensationScheduleOfFairValueOfUnderlyingCommonStockandExercisePriceofStockOptionsDetails", "http://www.exicuretx.com/role/EquityBasedCompensationScheduleOfRestrictedStockUnitAwardsActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": ["r310", "r312", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339"] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": ["http://www.exicuretx.com/role/EquityBasedCompensationTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Common Stock Option Activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": ["r6", "r7", "r66"] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": ["http://www.exicuretx.com/role/EquityBasedCompensationTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Assumptions Used to Determine Fair Value of Common Stock Option Grants", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": ["r68"] }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "presentation": ["http://www.exicuretx.com/role/EquityBasedCompensationTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restricted Stock Unit Awards Activity", "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://www.exicuretx.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r719"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://www.exicuretx.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r721"] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemtype", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": ["http://www.exicuretx.com/role/LeasesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]" } } }, "auth_ref": ["r170", "r171", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r559", "r560", "r561", "r624", "r626", "r629", "r631", "r638", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r653", "r675", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r707", "r710", "r854", "r908", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936"] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": ["http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 }], "presentation": ["http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Equity-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r2"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": ["http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Vesting period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMndTnHnMns' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": ["r680"] }, "xcurl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMonthlyPercentage": { "xbrltype": "percentItemtype", "nsuri": "http://www.exicuretx.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMonthlyPercentage", "presentation": ["http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Monthly vesting percentage (as a percent)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Monthly Percentage", "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Monthly Percentage" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": ["http://www.exicuretx.com/role/EquityBasedCompensationScheduleOfRestrictedStockUnitAwardsActivityDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": ["r330"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": ["http://www.exicuretx.com/role/EquityBasedCompensationScheduleOfRestrictedStockUnitAwardsActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Forfeited (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",

"documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": ["r330"] } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": ["http://www.xicuretx.com/role/EquityBasedCompensationScheduleofRestrictedStockUnitAwardsActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other Than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r328"] } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.xicuretx.com/role/EquityBasedCompensationScheduleofRestrictedStockUnitAwardsActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other Than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r328"] } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": ["http://www.xicuretx.com/role/EquityBasedCompensationScheduleofRestrictedStockUnitAwardsActivityDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Unvested balance - beginning of period (in shares)", "periodEndLabel": "Unvested balance - end of period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other Than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": ["r325", "r326"] } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": ["http://www.xicuretx.com/role/EquityBasedCompensationScheduleofRestrictedStockUnitAwardsActivityDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Unvested balance - beginning of period (in dollars per share)", "periodEndLabel": "Unvested balance - end of period (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other Than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": ["r325", "r326"] } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": ["http://www.xicuretx.com/role/EquityBasedCompensationScheduleofRestrictedStockUnitAwardsActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Grant Date Fair Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other Than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "auth_ref": [] } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": ["http://www.xicuretx.com/role/EquityBasedCompensationScheduleofRestrictedStockUnitAwardsActivityDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Vested (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other Than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": ["r329"] } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.xicuretx.com/role/EquityBasedCompensationScheduleofRestrictedStockUnitAwardsActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Vested (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other Than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": ["r329"] } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "presentation": ["http://www.xicuretx.com/role/EquityBasedCompensationScheduleofFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Exercise price of common stock option (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price", "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award." } } }, "auth_ref": [] } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": ["http://www.xicuretx.com/role/EquityBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofCommonStockOptionGrantsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Expected dividend yield", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": ["r337"] } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "presentation": ["http://www.xicuretx.com/role/EquityBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofCommonStockOptionGrantsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility, maximum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "presentation": ["http://www.xicuretx.com/role/EquityBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofCommonStockOptionGrantsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility, minimum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": ["http://www.xicuretx.com/role/EquityBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofCommonStockOptionGrantsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": ["r338"] } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "presentation": ["http://www.xicuretx.com/role/EquityBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofCommonStockOptionGrantsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate, maximum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "presentation": ["http://www.xicuretx.com/role/EquityBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofCommonStockOptionGrantsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate, minimum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "presentation": ["http://www.xicuretx.com/role/EquityBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofCommonStockOptionGrantsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate", "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement." } } }, "auth_ref": ["r336"] } }, "xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://www.xicuretx.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant", "presentation": ["http://www.xicuretx.com/role/EquityBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Increase in number of shares available for grant (in shares)", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Available for Grant", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Available for Grant" } } }, "auth_ref": [] } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": ["http://www.xicuretx.com/role/EquityBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Maximum contribution amount", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount" } } }, "auth_ref": [] } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate", "presentation": ["http://www.xicuretx.com/role/EquityBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Maximum ESPP contribution rate as a percentage of compensation (as a percent)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate", "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan." } } }, "auth_ref": ["r21"] } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee", "presentation": ["http://www.xicuretx.com/role/EquityBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Maximum number of shares per employee in purchase period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Shares Per Employee", "documentation": "The highest quantity of shares an employee can purchase under the plan per period." } } }, "auth_ref": ["r21"] } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward", "presentation": [

```

http://www.exicuretx.com/role/EquityBasedCompensationScheduleofRestrictedStockUnitAwardsActivityDetails", "lang": { "en-us": { "role": { "verboseLabel": "Restricted Stock Units", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] },
"xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan": { "xbrltype": "sharesItemType", "nsuri": "http://www.exicuretx.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of additional shares allowable annually under the plan (in shares)", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Allowable Under The Plan", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Allowable Under The Plan" } } }, "auth_ref": [] },
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares authorized (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r682" ] },
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares available for grant (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r21" ] },
"xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockIssuableUponVesting": { "xbrltype": "sharesItemType", "nsuri": "http://www.exicuretx.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockIssuableUponVesting", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares issued for each vested restricted stock unit (in shares)", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Of Common Stock Issuable Upon Vesting", "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Of Common Stock Issuable Upon Vesting" } } }, "auth_ref": [] },
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]" } } }, "auth_ref": [] },
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r319" ] },
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable, weighted-average exercise price (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r319" ] },
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r323" ] },
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails", "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r321" ] },
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average grant date fair value (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r331" ] },
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Shares outstanding, beginning period (in shares)", "periodEndLabel": "Shares outstanding, ending period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r317", "r318" ] },
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] },
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding beginning balance (in dollars per share)", "periodEndLabel": "Outstanding ending balance (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r317", "r318" ] },
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested and expected to vest, aggregate intrinsic value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r334" ] },
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested and expected to vest, aggregate intrinsic value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r333" ] },
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested and expected to vest (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r333" ] },
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested and expected to vest, weighted-average exercise price (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r333" ] },
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of outstanding shares allowable as annual increase (as a percent)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award,
```

"Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": ["r323"] } } }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.xicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"], "lang": { "en-us": { "role": { "terseLabel": "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": ["r321"] } }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheOneMember", "presentation": ["http://www.xicuretx.com/role/EquityBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Period One", "label": "Share-Based Payment Arrangement, Tranche One [Member]", "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] } }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharePrice", "presentation": ["http://www.xicuretx.com/role/EquityBasedCompensationScheduleofFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair value of underlying common stock (in dollars per share)", "label": "Share Price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] } }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": ["http://www.xicuretx.com/role/EquityBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Vesting percentage (as a percent)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": ["r856"] } }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": ["http://www.xicuretx.com/role/EquityBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Expiration period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r681"] } }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": ["http://www.xicuretx.com/role/EquityBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofCommonStockOptionGrantsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Expected term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r335"] } }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": ["http://www.xicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"], "lang": { "en-us": { "role": { "terseLabel": "Exercisable, aggregate intrinsic value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": ["r21"] } }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": ["http://www.xicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"], "lang": { "en-us": { "role": { "terseLabel": "Exercisable, weighted-average remaining contractual term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r21"] } }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": ["http://www.xicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"], "lang": { "en-us": { "role": { "terseLabel": "Outstanding, weighted-average remaining contractual term (years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r67"] } }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "presentation": ["http://www.xicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"], "lang": { "en-us": { "role": { "terseLabel": "Vested and expected to vest, weighted average remaining contractual term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r334"] } }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "presentation": ["http://www.xicuretx.com/role/EquityBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "ESP purchase price as a percentage of market price (as a percent)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent", "documentation": "Purchase price of common stock expressed as a percentage of its fair value." } } }, "auth_ref": [] } }, "xcxr_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsForfeitureRate": { "xbrltype": "percentItemType", "nsuri": "http://www.xicuretx.com/20240630", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsForfeitureRate", "presentation": ["http://www.xicuretx.com/role/EquityBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofCommonStockOptionGrantsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Forfeiture rate", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate" } } }, "auth_ref": [] } }, "xcxr_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding": { "xbrltype": "percentItemType", "nsuri": "http://www.xicuretx.com/20240630", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding", "presentation": ["http://www.xicuretx.com/role/EquityBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of additional shares authorized, percentage of common stock outstanding (as a percent)", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Percentage of Common Stock Outstanding", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Percentage of Common Stock Outstanding" } } }, "auth_ref": [] } }, "xcxr_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.xicuretx.com/20240630", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares", "presentation": ["http://www.xicuretx.com/role/EquityBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of additional shares authorized, potential maximum additional shares (in shares)", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Potential Maximum Additional Shares", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Potential Maximum Additional Shares" } } }, "auth_ref": [] } }, "us-gaap_ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermLeaseCost", "crdr": "debit", "calculation": { "http://www.xicuretx.com/role/LeasesLeaseCostsDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.xicuretx.com/role/LeasesLeaseCostsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Short term lease costs", "label": "Short-Term Lease, Cost", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } }, "auth_ref": ["r425", "r695"] } }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": ["http://www.xicuretx.com/role/SignificantAccountingPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Significant Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r56", "r118"] } }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": ["http://www.xicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails"], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": ["r89", "r101", "r102", "r103", "r121", "r145", "r146", "r148", "r150", "r158", "r159", "r207", "r244", "r246", "r247", "r248", "r251", "r252", "r281", "r282", "r285", "r288", "r295", "r407", "r538", "r539", "r540", "r541", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r572", "r593", "r632", "r633", "r634", "r635", "r636", "r637", "r805", "r822", "r829"] } }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://www.xicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r5", "r40", "r43", "r44", "r91", "r108", "r109", "r110", "r128", "r129", "r130", "r132", "r137", "r139", "r141", "r157", "r208", "r209", "r227", "r297", "r356", "r357", "r363", "r364", "r365", "r367", "r368", "r369", "r374", "r375", "r376", "r377", "r378", "r379", "r382", "r408", "r409", "r413", "r410", "r411", "r412", "r413", "r416", "r418", "r430", "r523", "r531", "r532", "r533", "r547", "r615"] } }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": ["http://www.xicuretx.com/role/LeasesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]", "auth_ref": ["r170", "r171", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r559", "r560", "r561", "r624", "r626", "r629", "r631", "r638", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r653", "r675", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r707", "r710", "r854", "r908", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936"] } } }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://www.xicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r128", "r129", "r130", "r157", "r418", "r472", "r537", "r558", "r564", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r615", "r711"] } }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "presentation": ["http://www.xicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]", "auth_ref": [] } } }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]", "auth_ref": [] } } }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]", "auth_ref": [] } } }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://www.xicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r128", "r129", "r130", "r157", "r173", "r418", "r472", "r537", "r558", "r564", "r565", "r566", "r567", "r568", "r569", "r572", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r585", "r586", "r587", "r588", "r589", "r591", "r594", "r595", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r615"] } }, "ecd_StkPrCOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrCOrTsrEstimationMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]", "auth_ref": ["r728", "r738", "r748", "r780"] } } }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] } }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": ["http://www.xicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock, net (in shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": ["r5", "r39",

"r40", "r65", "r538", "r615", "r633" } }, "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOffForfeitures": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOffForfeitures", "presentation": ["http://www.xicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY", "lang": { "en-us": { "role": { "terseLabel": "Vesting of restricted stock units and related repurchases (in shares)", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth_ref": ["r5", "r39", "r40", "r65"] }, "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": ["http://www.xicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails", "lang": { "en-us": { "role": { "negatedTerseLabel": "Exercise (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": ["r5", "r39", "r40", "r65", "r322"] }, "us-gaap:StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": ["http://www.xicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY", "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock, net", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": ["r5", "r39", "r40", "r65", "r547", "r615", "r633", "r717"] }, "us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOffForfeitures": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOffForfeitures", "crdr": "credit", "presentation": ["http://www.xicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY", "lang": { "en-us": { "role": { "terseLabel": "Vesting of restricted stock units and related repurchases", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited." } } }, "auth_ref": ["r5", "r65"] }, "us-gaap:StockholdersEquity": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": ["http://www.xicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS", { "parentTag": "us-gaap:LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }], "presentation": ["http://www.xicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.xicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY", "lang": { "en-us": { "role": { "totalLabel": "Total stockholders u2019 equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r40", "r43", "r44", "r58", "r574", "r590", "r616", "r617", "r696", "r718", "r824", "r843", "r891", "r939"] }, "us-gaap:StockholdersEquityAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": ["http://www.xicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS", "lang": { "en-us": { "role": { "terseLabel": "Stockholders u2019 equity", "label": "Equity, Attributable to Parent [Abstract]", "auth_ref": [] }, "us-gaap:StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": ["http://www.xicuretx.com/role/StockholdersEquity", "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Equity", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": ["r62", "r120", "r280", "r282", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r294", "r297", "r381", "r618", "r620", "r637"] }, "us-gaap:SubleaseIncome": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubleaseIncome", "crdr": "credit", "presentation": ["http://www.xicuretx.com/role/LeasesSubleaseReceiptsDetails", "lang": { "en-us": { "role": { "terseLabel": "Sublease amounts paid to landlord", "label": "Sublease Income", "documentation": "Amount of sublease income excluding finance and operating lease expense." } } }, "auth_ref": ["r426", "r695"] }, "xcur:SubsequentEmployeeStockOptionMember": { "xbrltype": "domainItem", "nsuri": "http://www.xicuretx.com/20240630", "localname": "SubsequentEmployeeStockOptionMember", "presentation": ["http://www.xicuretx.com/role/EquityBasedCompensationNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Subsequent Employee Stock Option", "label": "Subsequent Employee Stock Option [Member]", "documentation": "Subsequent Employee Stock Option [Member]" } } }, "auth_ref": [] }, "us-gaap:SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "presentation": ["http://www.xicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails", "lang": { "en-us": { "role": { "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]", "label": "Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]", "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group by type of sale. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity." } } }, "auth_ref": [] }, "us-gaap:SubsidiarySaleOfStockAxis": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": ["http://www.xicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails", "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Axis]", "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap:SubsidiarySaleOfStockLineItems": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockLineItems", "presentation": ["http://www.xicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails", "lang": { "en-us": { "role": { "terseLabel": "Subsidiary, Sale of Stock [Line Items]", "label": "Subsidiary, Sale of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "presentation": ["http://www.xicuretx.com/role/SupplementalBalanceSheetInformation", "lang": { "en-us": { "role": { "terseLabel": "Supplemental Balance Sheet Information", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity." } } }, "auth_ref": ["r813"] }, "xcur:SupplementalBalanceSheetInformationAbstract": { "xbrltype": "stringItem", "nsuri": "http://www.xicuretx.com/20240630", "localname": "SupplementalBalanceSheetInformationAbstract", "lang": { "en-us": { "role": { "terseLabel": "Supplemental Balance Sheet Information [Abstract]", "label": "Supplemental Balance Sheet Information [Abstract]", "documentation": "Supplemental Balance Sheet Information [Abstract]" } } }, "auth_ref": [] }, "ecd:TabularListTableTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Tabular List Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": ["r774"] }, "xcur:ThirdPartyMember": { "xbrltype": "domainItem", "nsuri": "http://www.xicuretx.com/20240630", "localname": "ThirdPartyMember", "presentation": ["http://www.xicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails", "lang": { "en-us": { "role": { "terseLabel": "Third Party [Member]", "label": "Third Party [Member]", "documentation": "Third Party Sale Of Company Stock [Member]" } } }, "auth_ref": [] }, "xcur:ThirdPartySaleOfCompanyStockMember": { "xbrltype": "domainItem", "nsuri": "http://www.xicuretx.com/20240630", "localname": "ThirdPartySaleOfCompanyStockMember", "presentation": ["http://www.xicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails", "lang": { "en-us": { "role": { "terseLabel": "Third Party Sale of Company Stock", "label": "Third Party Sale Of Company Stock [Member]", "documentation": "Third Party Sale Of Company Stock" } } }, "auth_ref": [] }, "srt:TitleOfIndividualAxis": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": ["http://www.xicuretx.com/role/EquityBasedCompensationNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Title of Individual [Axis]", "label": "Title and Position [Axis]" } } }, "auth_ref": ["r836", "r896"] }, "srt:TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": ["http://www.xicuretx.com/role/EquityBasedCompensationNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Title of Individual [Domain]", "label": "Title and Position [Domain]", "auth_ref": [] }, "ecd:TotalShareholderRtnAmt": { "xbrltype": "monetaryItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount", "auth_ref": ["r766"] }, "ecd:TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": ["r773"] }, "ecd:TradingArrAxis": { "xbrltype": "stringItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": ["r793"] }, "ecd:TradingArrByIndTable": { "xbrltype": "stringItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": ["r795"] }, "dei:TradingSymbol": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://www.xicuretx.com/role/CoverPage", "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap:TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": ["http://www.xicuretx.com/role/FairValueMeasurementsScheduleofFairValueAssetsAndLiabilitiesMeasuredonRecurringBasisDetails", "http://www.xicuretx.com/role/InvestmentInConvertibleNotesReceivableNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": ["r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r278", "r293", "r380", "r404", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r524", "r684", "r685", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r697", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r839", "r840", "r841", "r842", "r883", "r886", "r887", "r888", "r889", "r890"] }, "ecd:TrdArrAdoptionDate": { "xbrltype": "stringItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": ["r796"] }, "ecd:TrdArrDuration": { "xbrltype": "durationItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": ["r797"] }, "ecd:TrdArrExpirationDate": { "xbrltype": "stringItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "terseLabel": "Expiration Date", "label": "Trading Arrangement Expiration Date" } } }, "auth_ref": ["r797"] }, "ecd:TrdArrIndName": { "xbrltype": "stringItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": ["r795"] }, "ecd:TrdArrIndTitle": { "xbrltype": "stringItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": ["r795"] }, "ecd:TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": ["r798"] }, "ecd:TrdArrTerminationDate": { "xbrltype": "stringItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": ["r796"] }, "ecd:UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": ["r792"] }, "us-gaap:UseOfEstimates": { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": ["http://www.xicuretx.com/role/SignificantAccountingPolicies", "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": ["r14", "r15", "r16", "r84", "r85", "r86", "r87"] }, "xcur:VariableLeaseCostNet": { "xbrltype": "monetaryItem", "nsuri": "http://www.xicuretx.com/20240630", "localname": "VariableLeaseCostNet", "crdr": "debit", "calculation": ["http://www.xicuretx.com/role/LeasesLeaseCostsDetails", { "parentTag": "us-gaap:LeaseCost", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.xicuretx.com/role/LeasesLeaseCostsDetails", "lang": { "en-us": { "role": { "terseLabel": "Variable lease costs", "label": "Variable Lease, Cost, Net", "documentation": "Variable Lease, Cost, Net" } } }, "auth_ref": [] }, "us-gaap:VestingAxis": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingAxis", "presentation": ["http://www.xicuretx.com/role/EquityBasedCompensationNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Vesting [Axis]", "label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": ["r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881"] }, "us-gaap:VestingDomain": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingDomain", "presentation": ["http://www.xicuretx.com/role/EquityBasedCompensationNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Vesting [Domain]", "label": "Vesting [Domain]", "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": ["r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881"] }, "ecd:VstgDftrFValOfEqtyAwrdGrntdAndVstdlnCvrdYrMember": { "xbrltype": "domainItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstgDftrFValOfEqtyAwrdGrntdAndVstdlnCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year", "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]" } } }, "auth_ref": ["r762"] }, "us-gaap:WarrantMember": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": ["http://www.xicuretx.com/role/LossPerCommonShareScheduleofAntidilutiveSecuritiesDetails", "http://www.xicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails", "lang": { "en-us": { "role": { "terseLabel": "Warrant", "label": "Warrant to purchase common stock", "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": ["r708", "r709", "r712", "r713", "r714", "r715"] }, "us-gaap:WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItem", "nsuri":

```

{"url": "http://www.sec.gov/edgar/data/1591267/000159126724000001/159126724000001.htm", "text": "
    \"http://www.sec.gov/edgar/data/1591267/000159126724000001/159126724000001.htm\", \"lang\": { \"en-us\": { \"role\": { \"terseLabel\": \"Warrant liability, measurement input, term\", \"label\": \"Warrants and Rights Outstanding, Term\", \"documentation\": \"Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYmMnDnHhMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. \" } }, \"auth_ref\": [ \"r886\", \"r887\", \"r888\" ] }, \"srt_WeightedAverageMember\": { \"xbrltype\": \"domainItem\", \"nsuri\": \"http://fasb.org/srt/2024\", \"localname\": \"WeightedAverageMember\", \"presentation\": [ \"http://www.xcuretx.com/role/EquityBasedCompensationScheduleOfAssumptionsUsedtoDetermineFairValueOfCommonStockOptionGrantsDetails\", \"http://www.xcuretx.com/role/EquityBasedCompensationScheduleOfFairValueUnderlyingCommonStockAndExercisePriceOfStockOptionsDetails\", \"lang\": { \"en-us\": { \"role\": { \"terseLabel\": \"Weighted Average\", \"label\": \"Weighted Average [Member]\" } } }, \"auth_ref\": [ \"r390\", \"r454\", \"r649\", \"r650\", \"r687\", \"r900\", \"r902\", \"r905\" ] }, \"us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding\": { \"xbrltype\": \"sharesItem\", \"nsuri\": \"http://fasb.org/us-gaap/2024\", \"localname\": \"WeightedAverageNumberOfDilutedSharesOutstanding\", \"presentation\": [ \"http://www.xcuretx.com/role/LossPerCommonShareScheduleOfComputationOfLossPerCommonShareDetails\", \"http://www.xcuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS\", \"lang\": { \"en-us\": { \"role\": { \"terseLabel\": \"Weighted-average diluted common shares outstanding (in shares)\", \"label\": \"Weighted Average Number of Shares Outstanding, Diluted\", \"documentation\": \"The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. \" } } }, \"auth_ref\": [ \"r144\", \"r150\" ] }, \"us-gaap_WeightedAverageNumberOfSharesOutstandingBasic\": { \"xbrltype\": \"sharesItem\", \"nsuri\": \"http://fasb.org/us-gaap/2024\", \"localname\": \"WeightedAverageNumberOfSharesOutstandingBasic\", \"presentation\": [ \"http://www.xcuretx.com/role/LossPerCommonShareScheduleOfComputationOfLossPerCommonShareDetails\", \"http://www.xcuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS\", \"lang\": { \"en-us\": { \"role\": { \"terseLabel\": \"Weighted-average basic common shares outstanding (in shares)\", \"label\": \"Weighted Average Number of Shares Outstanding, Basic\", \"documentation\": \"Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time during which common shares or units have been outstanding to the total time in that period. \" } } }, \"auth_ref\": [ \"r143\", \"r150\" ] }, \"ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrYrOutsdngAndUnvstdMember\": { \"xbrltype\": \"domainItem\", \"nsuri\": \"http://xbrl.sec.gov/ecd/2024\", \"localname\": \"YrEndFrValOfEqtyAwrdsGrntdInCvrdYrYrOutsdngAndUnvstdMember\", \"presentation\": [ \"http://xbrl.sec.gov/ecd/role/PvpDisclosure\", \"lang\": { \"en-us\": { \"role\": { \"terseLabel\": \"Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested\", \"label\": \"Year End Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]\" } } }, \"auth_ref\": [ \"r760\" ] } } }, \"std_ref\": { \"r0\": { \"role\": \"http://fasb.org/us-gaap/role/ref/legacyRef\", \"Name\": \"Accounting Standards Codification\", \"Section\": \"45\", \"Paragraph\": \"1\", \"SubTopic\": \"230\", \"Topic\": \"830\", \"Publisher\": \"FASB\", \"URI\": \"https://asc.fasb.org/1943274/2147477401/830-20-45-1\" }, \"r1\": { \"role\": \"http://fasb.org/us-gaap/role/ref/legacyRef\", \"Name\": \"Accounting Standards Codification\", \"Section\": \"45\", \"Paragraph\": \"14\", \"Subparagraph\": \"(a)\", \"SubTopic\": \"10\", \"Topic\": \"230\", \"Publisher\": \"FASB\", \"URI\": \"https://asc.fasb.org/1943274/2147482740/230-10-45-14\" }, \"r2\": { \"role\": \"http://fasb.org/us-gaap/role/ref/legacyRef\", \"Name\": \"Accounting Standards Codification\", \"Section\": \"45\", \"Paragraph\": \"28\", \"Subparagraph\": \"(a)\", \"SubTopic\": \"10\", \"Topic\": \"230\", \"Publisher\": \"FASB\", \"URI\": \"https://asc.fasb.org/1943274/2147482740/230-10-45-28\" }, \"r3\": { \"role\": \"http://fasb.org/us-gaap/role/ref/legacyRef\", \"Name\": \"Accounting Standards Codification\", \"Section\": \"45\", \"Paragraph\": \"28\", \"Subparagraph\": \"(b)\", \"SubTopic\": \"10\", \"Topic\": \"230\", \"Publisher\": \"FASB\", \"URI\": \"https://asc.fasb.org/1943274/2147482740/230-10-45-28\" }, \"r4\": { \"role\": \"http://fasb.org/us-gaap/role/ref/legacyRef\", \"Name\": \"Accounting Standards Codification\", \"Section\": \"50\", \"Paragraph\": \"1\", \"SubTopic\": \"10\", \"Topic\": \"360\", \"Publisher\": \"FASB\", \"URI\": \"https://asc.fasb.org/1943274/2147482099/360-10-50-1\" }, \"r5\": { \"role\": \"http://fasb.org/us-gaap/role/ref/legacyRef\", \"Name\": \"Accounting Standards Codification\", \"Section\": \"50\", \"Paragraph\": \"2\", \"SubTopic\": \"10\", \"Topic\": \"505\", \"Publisher\": \"FASB\", \"URI\": \"https://asc.fasb.org/1943274/2147481112/505-10-50-2\" }, \"r6\": { \"role\": \"http://fasb.org/us-gaap/role/ref/legacyRef\", \"Name\": \"Accounting Standards Codification\", \"Section\": \"50\", \"Paragraph\": \"2\", \"Subparagraph\": \"(d)\", \"SubTopic\": \"10\", \"Topic\": \"718\", \"Publisher\": \"FASB\", \"URI\": \"https://asc.fasb.org/1943274/2147480429/718-10-50-2\" }, \"r7\": { \"role\": \"http://fasb.org/us-gaap/role/ref/legacyRef\", \"Name\": \"Accounting Standards Codification\", \"Section\": \"50\", \"Paragraph\": \"2\", \"Subparagraph\": \"(e)\", \"SubTopic\": \"10\", \"Topic\": \"718\", \"Publisher\": \"FASB\", \"URI\": \"https://asc.fasb.org/1943274/2147480429/718-10-50-2\" }, \"r8\": { \"role\": \"http://fasb.org/us-gaap/role/ref/legacyRef\", \"Name\": \"Accounting Standards Codification\", \"Section\": \"50\", \"Paragraph\": \"2\", \"Subparagraph\": \"(f)\", \"SubTopic\": \"10\", \"Topic\": \"718\", \"Publisher\": \"FASB\", \"URI\": \"https://asc.fasb.org/1943274/2147480429/718-10-50-2\" }, \"r9\": { \"role\": \"http://fasb.org/us-gaap/role/ref/legacyRef\", \"Name\": \"Accounting Standards Codification\", \"Section\": \"50\", \"Paragraph\": \"2\", \"Subparagraph\": \"(g)\", \"SubTopic\": \"10\", \"Topic\": \"718\", \"Publisher\": \"FASB\", \"URI\": \"https://asc.fasb.org/1943274/2147480429/718-10-50-2\" }, \"r10\": { \"role\": \"http://fasb.org/us-gaap/role/ref/legacyRef\", \"Name\": \"Accounting Standards Codification\", \"Section\": \"50\", \"Paragraph\": \"2\", \"Subparagraph\": \"(h)\", \"SubTopic\": \"10\", \"Topic\": \"718\", \"Publisher\": \"FASB\", \"URI\": \"https://asc.fasb.org/1943274/2147480429/718-10-50-2\" }, \"r11\": { \"role\": \"http://fasb.org/us-gaap/role/ref/legacyRef\", \"Name\": \"Accounting Standards Codification\", \"Section\": \"50\", \"Paragraph\": \"2\", \"Subparagraph\": \"(i)\", \"SubTopic\": \"10\", \"Topic\": \"718\", \"Publisher\": \"FASB\", \"URI\": \"https://asc.fasb.org/1943274/2147480429/718-10-50-2\" }, \"r12\": { \"role\": \"http://fasb.org/us-gaap/role/ref/legacyRef\", \"Name\": \"Accounting Standards Codification\", \"Section\": \"50\", \"Paragraph\": \"2\", \"Subparagraph\": \"(j)\", \"SubTopic\": \"10\", \"Topic\": \"718\", \"Publisher\": \"FASB\", \"URI\": \"https://asc.fasb.org/1943274/2147480429/718-10-50-2\" }, \"r13\": { \"role\": \"http://fasb.org/us-gaap/role/ref/legacyRef\", \"Name\": \"Accounting Standards Codification\", \"Section\": \"50\", \"Paragraph\": \"2\", \"Subparagraph\": \"(k)\", \"SubTopic\": \"10\", \"Topic\": \"718\", \"Publisher\": \"FASB\", \"URI\": \"https://asc.fasb.org/1943274/2147480429/718-10-50-2\" }, \"r14\": { \"role\": \"http://fasb.org/us-gaap/role/ref/legacyRef\", \"Name\": \"Accounting Standards Codification\", \"Section\": \"50\", \"Paragraph\": \"2\", \"Subparagraph\": \"(l)\", \"SubTopic\": \"10\", \"Topic\": \"718\", \"Publisher\": \"FASB\", \"URI\": \"https://asc.fasb.org/1943274/2147480429/718-10-50-2\" }, \"r15\": { \"role\": \"http://fasb.org/us-gaap/role/ref/legacyRef\", \"Name\": \"Accounting Standards Codification\", \"Section\": \"50\", \"Paragraph\": \"2\", \"Subparagraph\": \"(m)\", \"SubTopic\": \"10\", \"Topic\": \"718\", \"Publisher\": \"FASB\", \"URI\": \"https://asc.fasb.org/1943274/2147480429/718-10-50-2\" }, \"r16\": { \"role\": \"http://fasb.org/us-gaap/role/ref/legacyRef\", \"Name\": \"Accounting Standards Codification\", \"Section\": \"50\", \"Paragraph\": \"2\", \"Subparagraph\": \"(n)\", \"SubTopic\": \"10\", \"Topic\": \"718\", \"Publisher\": \"FASB\", \"URI\": \"https://asc.fasb.org/1943274/2147480429/718-10-50-2\" }, \"r17\": { \"role\": \"http://fasb.org/us-gaap/role/ref/legacyRef\", \"Name\": \"Accounting Standards Codification\", \"Section\": \"50\", \"Paragraph\": \"2\", \"Subparagraph\": \"(o)\", \"SubTopic\": \"10\", \"Topic\": \"718\", \"Publisher\": \"FASB\", \"URI\": \"https://asc.fasb.org/1943274/2147480429/718-10-50-2\" }, \"r18\": { \"role\": \"http://fasb.org/us-gaap/role/ref/legacyRef\", \"Name\": \"Accounting Standards Codification\", \"Section\": \"50\", \"Paragraph\": \"2\", \"Subparagraph\": \"(p)\", \"SubTopic\": \"10\", \"Topic\": \"718\", \"Publisher\": \"FASB\", \"URI\": \"https://asc.fasb.org/1943274/2147480429/718-10-50-2\" }, \"r19\": { \"role\": \"http://fasb.org/us-gaap/role/ref/legacyRef\", \"Name\": \"Accounting Standards Codification\", \"Section\": \"50\", \"Paragraph\": \"2\", \"Subparagraph\": \"(q)\", \"SubTopic\": \"10\", \"Topic\": \"718\", \"Publisher\": \"FASB\", \"URI\": \"https://asc.fasb.org/1943274/2147480429/718-10-50-2\" }, \"r20\": { \"role\": \"http://fasb.org/us-gaap/role/ref/legacyRef\", \"Name\": \"Accounting Standards Codification\", \"Section\": \"50\", \"Paragraph\": \"2\", \"Subparagraph\": \"(r)\", \"SubTopic\": \"10\", \"Topic\": \"718\", \"Publisher\": \"FASB\", \"URI\": \"https://asc.fasb.org/1943274/2147480429/718-10-50-2\" }, \"r21\": { \"role\": \"http://fasb.org/us-gaap/role/ref/legacyRef\", \"Name\": \"Accounting Standards Codification\", \"Section\": \"50\", \"Paragraph\": \"2\", \"Subparagraph\": \"(s)\", \"SubTopic\": \"10\", \"Topic\": \"718\", \"Publisher\": \"FASB\", \"URI\": \"https://asc.fasb.org/1943274/2147480429/718-10-50-2\" }, \"r22\": { \"role\": \"http://fasb.org/us-gaap/role/ref/legacyRef\", \"Name\": \"Accounting Standards Codification\", \"Section\": \"50\", \"Paragraph\": \"2\", \"Subparagraph\": \"(t)\", \"SubTopic\": \"10\", \"Topic\": \"718\", \"Publisher\": \"FASB\", \"URI\": \"https://asc.fasb.org/1943274/2147480429/718-10-50-2\" }, \"r23\": { \"role\": \"http://fasb.org/us-gaap/role/ref/legacyRef\", \"Name\": \"Accounting Standards Codification\", \"Section\": \"50\", \"Paragraph\": \"2\", \"Subparagraph\":
```

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

8'P:9~JUT?2ESPS9_CVG80@246CSH M1%R570J)BK82I+5G:.090Q/\$LB5GV3Z\$VSP0PUL M8<:5*2Y~N@T3W~H:(4*R= M)@%-IMQ7BVJ6Q.FGRI+R238J6C:J1=:@@/*<IY/P0J446FECI0R~K~4 M_F7MMP~P*ATP6I\$K3CF2FEF?>E8GZ.3KCQ*EBL~MR~A~CC~.~#H#PQL M~U2T+J~M7+6G0?ZEG~:A\$~K'V8KP4U!F~M~+MR%JZ\$?E5 L.5~HY~V8S@CI#9+&GQ+5MGO~.T3K4R6I'MRGD2+8JLJUL M.'0I'1C185LE?>SQQWY=BNMR#?2'SOO?H%>11J'JL72'116=6UAJ#E ID&I#V=I<&<~?Y MBI A[K.'1' H8 L:62GZ<EG~C5A+&SR'UW46GH8D:IZ@M5+&ZW:L' M_ M6Y2TH:~<YM=WS>L>LJLB0635H16XGHPA1#HSOK~CQEWER2>1IH6D3CP97P2S MVIT~XSL~L'6'4' (U/EIRL)1TS:(MM>E~M%G1%G. I907?2GIZ3@Z AD.MT.EDIT5 20:M<1?>H:~Y3HGKH6A1?<~M2Z?7H6U?>O98I# M 3ZSIAVABVC7M%=%C.LP/O HZ0S4K1E~L.1&X9 OT2Y+V!#P'':

[illegible]

26687SFI/04#5MKT# X174:2#TKI:K2%<...>

#C@PU9%N:EI15 "F0Q %0 'AC'=7(M,C,R-R # V,S;?8V%L M+GAM;,5=6U;N;9^GU IR7DI&G2 3,W,+@)D=JJB?/P-O-IP@/IT;M;J,??WMO,IV>_*[^+7+EY0O0C/Z>=)\\VN64
MBCMU%TR_FCU_<>_Z+?#W-GL;JLJ>/JH,ESV(KV6L JSZB>P*DGFW\$J|I>-8 M&F&B?O2\$&XFT4IGH_XHKIV53Y2R,(O4CXBCL//ZKYHTXO?Z?K9N1J,9C*** MIYVWRO?<
W1^U1C^>_Y L+G^/D+=+L 2Q00S=?@JF,W#XWV>GXXAO4-61A>GL%O+IKAZ=Q?%L^>=, J W&L M;R=%1%0+6GJL>U>Q_NUSI&/XOEH-F9'^^J,D0^XL J
Q13&^Z&4L^>7JVV&M;F+;JTYV>E=-85DA20Y278FCTAI M^AC1I^&ADU^S^XO:VONDMP3Q,F3AI=#+2)C+C\$@;^?7SR?IT&NPI^#TR MRGU< J;MGM_@TUX3=R9-@>:7P1<I7Z
L5_5J JC:<^HIMV>B?G=MOSTI/9 M,1EP^I>+OJ_-Y+06JZ;3:N50Q00/LSZ9\$V?7M<^I OW^JSDN^B.S.TNY-IWW3 M7***^9O
Z=C_9Q_E01FU535M810?O(ZAC)^J_89F+@+0+@&6&^S^?1=?>?D22^ETI# M^79FWJBZJ4I^4&B3;2X?5APGB93^R^K,(A=JAO>U9?^U0910^?^F66?17G4&# MO1U_@)TO
Z7<7N;ZFU15>_-=>=SWJS/L159\$3-ZA(4I+52+@40(B&N1LIP9&DM>2,B) M6&K1M@J>ZU^JL^CD?Z=9X6XUF^#?+I84.UH;I&A#V1^<#J\$O\$&3<R?QIV?M^>U+=BFEF/
Y/U;U>Y>TM 2= M/OQJXO,PA4^J^?006 U4J?>S3?Z,F^A/N\$O^YUOZ-YTOXZ27BUM-S^+ ME3^EO,9208K%:CHE83^HG^< JI_6W.F4 1L^H%Z@9W)Z,IR>SBOIX0_&1?F
M#-8F,^EYI0Q6;3>8/P+78IR809)IKA&^YH1;11D^, #4#N:L51_1j63A@XCLD0LJ1<1=9\$4)U8S_M13B@30+1IT_#NNM0^M^Z;SVYV
SKN.6/=D;^W0^5YI(O@MOIONUJJWY^@75476X\$2/J2)+6PAM,A&YSPOX^#TIZK8G+CA^*(2EO4 MR8QI2A??;N^Z^)>)/>JZTI&G&I6XJPC ETV%W41IX^2I+&
-9+7J8T+WWHW=^F%ZJ_ W9<+I^ TK1?H#2 W#V,9 M-689G, %VZ8R4I+BNMK MAD1I^AX9;KISZ^853ZNZ0I^&GRSYR@58=^<K22I3/U4P^,G0-V4N,U>C>G M99@A^4
>Q>N^TH^*03 1.4BZ1_YJ^T^4\$<3B)YF&6Z+O=6(PEN^74\$4),/D_ Q MM^WG+TN^S^5J3) A9FI^%06I+>YR^DAAEL=^@TD^S^;Z99%I3^47F^>^KT
M=VCPZ^I=43K^GSM^FCJ^@%_ /\$SXZ?CMJ?JW0P%1_0?7B-OIV-K\$;V1(DVMJL^ MO4X^?>53OX?ZS^@)J-VPX^<V5PSN\$V>2^*IQ(TV1#R0_0BB5=6QW? K#1
MHO+U3;IP\$EVELZL_1MM1M;CBT2D072W0WPM1>7DP;C_-Y;J_Y6N H-M-1J064\$HPXIV^CISD6I&F^H^W^2>1^UO;5.NQ.GTR>
MYW/PJLK6% E7TY+70.6%)A/YKIBTV<#7WS^YT3FI=:=&^L^J+D5<(1/K,B4Y9A=:=I^@MDNX ML^;F89^;#Z06QM7)S^<-9R>J^>W4VRA;.R(H_-20%>2F_1?0H\$C J:2>Z(M2&5?
7DE-OJ_X\$X_9@)H&N;B_<V_<:=<^W^<^<:=<^NU^A-G/HO/>?7AZ 2 M@>18R5Y3Q&?2B&\$<^J1 Z3+ZSO<4%B^XME:6YL=F05YJ^0)J1-10PL-3PE
M\$PC391GW(B+I06#X)DEXRGZ0+5MW^5@<C-SBN@J^G(UO;TCLB:TL^L^@G125\$SKQJL MKZFL2CJ1/L_@_#:=<CJ684/(I3Y&VKI^B_1^IZFK^7L6N_-IJHE H230IN
M2K5B)SX95\$;:=+I30>22U\$KJ>4K08EN;D=M1<^>20D5.7+4^JIG+>@J9J& M2 D7^*2^*DTI@XBJ&@GBOTTI4J5L1+_.L006XMM^=\$2-1^H^OJ)MBS&I+/_ M7^O^&^ 1-M
\$\$S;5^224L,MHJ5\$86;6^WIS^?8;-H82;D\$>+>_<: MRR90X?ZL7>+>1G1J6H?7IAY>O+U7D62G045ADG0 C I^C^>#8^CO+(MUR ME.TYL>D6<^#&2^I&E&DUDJI&^*9@Y1I1&
(HZAW90ZOU1Q80FF228D\$2M;V MPOX\$U^?5=S_<W^WVUY)^#-<+ 6/LX0@1L:73X7C83DM_/UOYED+K2UX B+A M^+>I>D>@%#<I^<)S3U=

))3BWRO,U&G3H<:HXQMIST5D*PXU,2V9\$NXWM06+6FSR&@)IV0QHWT M9A9A7_..JL/%6UX1QI_.*%97?5Q@0H:
(FWGJ6?UJNGTP-1@NM04I_2EVU="IW&A+BZ2E0:=T05E5Y0U^4IG9KS>%MI/FJA?2IDC!)
T@)DI8X)C\$D'HM@E'B4QM1+?_-(3M-9FHSVA(%CPU50)-Y M&AE-
FW>QO(CFA.U)7@%6H(+6=2*Z,S&DB:JF04&/5'OXZ8NT4MJ_F_4R MITK5NS)7"/G\$IPF"1&?
(A&D(19!@/L"X1X\$OK4*(2A)*EYM%-=<>HHZY3+ M,L7+2%O1L.%*9TTL%7<=G<*NI0L^AP_-"GU'BH3?L%/DS_H7FI
IG2'B M\$A\$D,&9^K)H?(8BI^IU-L(B%HRGU"CI9# U > #;E?S-3S" 4H;Q\$-C-5 MI^A-HG-GQ"D=4?
#SZIKYX0IU+"SSUFF?-HSC9U4I.39X6IG.;RQ.9F>:O6 MZMV^>RI"G\$AS%)/8AH&L%,J^O/N=0&08@R)LSR.YRR-
I%.=|RJ_>#^IW_ME2U0K<\$;KNZGJV;1O5P!^>SK)F5P+UW_UP)+7|@P#13M7.K9EN>:(3/+U)^<M@2R_ B2H"WF
M@|L<=%R|Z;\$W*IPA#S.(C*QH6W) M=EV8%&\$@*8,WVJES@P@-&SY7L;\$ZM?N6_T M6=O89:FN^M_@HGKJH8N!
JCW_9ZR"XB#V5>2@F,XA1!)*(&NPQZ DOB_., MTR U*CYN0^OJ;8J;1%I^JQU-
T_!"TC=R&@2>\$R/HH)4;.!>B3KRUWU;J1\$ M!58-8N0REA^9I&6/N69_S%C2(YC-/A|S\$+!|4U5G4#760\P"" .12)8!!Q
M#T.L0AF#I7I)HU/RQ*QJ?3#-#W#1L1W9R"QLQI?^>O!>|NZKS&5Y_QCGAT M>@IO)9:9.MKKD0F0SU=H!
W)JVUI?>MSH?%|HE",8T425>|=>M-/Y1J45:ZB MLM^DT=H4S64ADQ2C?12&E<I-
L/M,CNQC"X0'(EQP>6!W5BS71PX8K|_>#X MEQ85X/GZ(WI0.L7J/3IQIWISIA-09 OJN+=B#'_7EA*8?
=6CS)I57MIGUZI0 M>CO&?(75IYG>*Z1^"OS+_ ;C>O5YL^2^1R+_NBANBX=5Q=XM\9WN-WQV@ (F_ M;DD7*L)
48;^WK7IV_K01@5T^M_|>2#&M<_)IF9ZH2<^>^%-QX>C2R:B45NIT M?M39%&Q4L+
I*C3IL&_8HY^S#NBR;G\$B5DK)5W>?'GE1'SF4KIA8%IQYIA9_
M5TF458\$E#3G7Q=|IBC^4DKFV9Z*2G==3=#%YBPQ",<OT.3#*(4!3 E(8"20"P? (TY.T?TS_%.G#, MAI^U|M4_6.IT?
4^#TZ24.#8ASQ_8HBDXP13#V;8J&?>L)48Q=J|H8T^L MEBTEJVM?
03T2!+NL5NY%RKK8PW;14@8Y\$%L.6(ACY20^EF@E(L9AF*91XF>I3Y'6 M/O.43\$Z=C.\$(USTIP9)-04,IGF1B|S"<+
M9EE,D9?^>^L"*_8JHV7#XLNJ_M'4!R.9%O2ZA91XW?-I49857.C2Y^|SI6KJ?3^I7S.14XOP(4)<.1H<4 X*,
M!P5N9#0S*SV;H" Z!219=2"K6IRY.^<8%|J(!@8=K:08%RT?E"@V;1%)Y;/_
MO"PY_<'5G=UYLO^C;HQ|DF_5XU;87+1>9|(DP1A4&02J>%4@+3- D@"A\$-
MXS#|F>10MY^)"LV)-71+ODG_N@*KF@.5L;BW|BT1| \$!A&4%WD5ZEI"20XY9!SD@HOI#%B
M6CGT&K2F3K9HB*N#I2UU(+CN>9(.6!K6T!T\$9E;PD|V/&"C*XT4YC&\$P_!GN MX+ S=1?_8F;?I_0=M&LC0\QGS_1DV_-
CFJ|<>N_ZPD)N_NZ0>1^<9"F,\$X# M'R(FD#1H40)Y\$..4D"0+8Z_."Y9G A:|MV_/EUVS/9"M_;"TMSA>E;HS:RT
M|NJ@X|<I<-JR7ME+<<^JVES_7NF"!NL75^R=H9@|HT=HUP.W)306=F""U1FZ#(MPT>5MMZ1H1FV^BS\$;^_16?U
M_@5Y;F5;M/TG/DJ<@_8SI!;3R RKD1-Y592I\$555KKI9EWF|HKF_ S8HS07W MQTZ;|M=LD&Q^O?
*AA^T+)+*6#U1>*E6MO>KU_@OK_"R-=2!+U|2/H>Q8 (B MCA#\$6<)>APE#(0HXX5NG^!G52AZA-G?6RI5W|H8#!?
0=#2-ZR3.@B97I#0# @S M!3W&H(-@A836C*ZJH22&O>PJDZ8A_53M5ZR>*XY TG5_6^5><+|7VRKMU
M04ON;KIRIG_Y'S)%HPFOE3W3"ZL1/5UQ@P2P0ED_0YID/AQ@@+MDQ-MLE-Q
M"!4P).B97!@H(^.QA*)%B8Z;UBH;74/=S<%9U7QL#*Z MSWSRY;F=G";A_-'H"Z)+PEW968/IRZ>%H_9+Y;7F)
8XWT'6L0(:7NH" M(Y.A9A!O3(:>73K4P#F"<&IG^DCE*(THS!%,M_ B_PLEB;8H2;IFC/4IHZR4"1JSLT
MU&T8;X7GP=)SX-R(KJ90323VCSA:4PB5WE+9^C,FWXT)NY1%M'H"W;J>IAD M|E;E)W&VP-
3\$A1(CRG\$_.18>=>BEJ@M#QLH3C+?L/5&H3H3VI+L.E.L_@+ M0)LN-F6=P=CO@)L05SBHOEE_=.?S#3Y"Y)
(GCL>0\$D(@L@XIS#E&\$_.@S3T M>(ICWT^SQ5=>D/6_"/L:6/XH<.N 0T"UH(Z)7QZ9M!)&9&\#@+5-7VK8FZ
M,X4C4CDRA.>HS&H&1T0I-OCSSO(YA|7MW7E?519_|/_%V_795Y=53>_RE_
YJ|H#F%1&IP_RD_F'I=|&U6I5F6N>/&H M>FOT^H=0G_ _81I2WZ?2>I8I@G)(.9)&F#"?H6P|MJE-'0SVB|75^"ZNA
MC^"XO9@%\$!_0R1P2LY+DIB)>4K)6|LEU1GU/C5<"|@IY_*J>#(+ (SQU8LHID3-S(@K79E^T MZH39^_JUX6'5I^XK?
X.KO*V5@\$_.Y9(88XC24JV@49#I#00I!4AR&/(VS*3M M(#M\$:&+%;\$B#_FW5316;U988!6M8B5Q"8+C?
9BF144I9=|A^LH.#CQ;UD= M?K19;6>-UJ^5-)(>X3O9LW+C^ONZ+\$K4F9|UA_Q|ERJ5I&).<@-6ZZM(N
MMF70I%&2^LX3""V%QVJP76@.QLZZ^YZ/WE MV>+M"PHGDXX" HFT=47)81I1K3B|9Y>QZ91HK)+;M?
JIV^|X+FI6Z;A0=EX#NV#3(27MY M)K4@WX1\$|GZ&L!8%WT|Z#00Z15%WD">=>44\$M|RJ-6\$M|7I?U=O>9_5'
M_5GUI+X"G=S;QA_+R4%/= \$>Y9R|W.EU6PGX9@LU?/ MER^TN!>CE<3CSJE_ MT;9M;/(8;R30*FGUCB_16%?R8
_C#V57L@IQ!'R(241B:(HR8BG57YA4BYG M6(N5W70<\$@0_XA+@|>@>V3G33-3\$Z4K^&=?^H|8MT4-
JS76_PMR|@|=+! MIKG7H4\$>_QI+B@LSE8+6)VAOY&?@J!*BKL5K|N7|LMQPM|D|92_1-|BI MNHWG|1DD2T=|
MP\$|@+!I.Q.P*|L#XTH#1D_4-77<&.%PV1U9H@_"LIFT^O&P3ZO/ZNY|(:V+7/7RLBZ;NMO!9+^GIR(A MD*B;0B3_*;H-
^10/I_JR&*2UB^I-P_|IZ!>E5=R^FMVKYG" K\$/?LM=|
MV44&U%6KCFM0LVU;=C%#&JZ<|U+X9NG+;IF;D|L\$TG5<&=L';_Q4%=@CK M^7K+HE<>%E/;LO(KF>-EE-
U^3L@|Z%W%?24\$_.0Q83*TSF*84EJ_1/5 MPR+&3)J_!#=&K+NSV/4GK>_=\$O!MCR87NO:PA/38/I&"5#.W@Y0/97
#4D-M=GT;<(CD|UP_U_#A!|U!G7==CI=!"E1%=EBZ"FOQ3% 2111.4?F&8)(S|! MYH=G1V2F3K7YUR;OGF=|
(*N+@ENZ+GJ.7M0U=)YMJ^UVU&|/H"F4@LMT.8? M3MT4=(I-I&.B+Z QY^ VSOFG;?>AUI1S5JH6_ZKFV""LU)&
M_/8?U8PO/"^CF!|AF%4.;""&(J_PA9\$H>>"W!8E3?R(#VY#LU#2=-?X|2 M-U|^8|M_|F|_|T@+6,7(%E:NFB/4> L|GB,
M(7^VZ;->>9=(&-CK>?S(>P.SKO5W(Y;?X>|MTQ.(K+O)J\$;SL\$X(GD.((M-768.H&_..HB.>9ADW"B?TIG>F\$S-
5;M(-8%R&L>0(6_FW9O.H>2GIEP M(+N926@(-DFQ|PC CRW1_ O;QJH (I8C-3I'95:5'A^U4"W"K>HHG9I=U?P
M.ODY%_NWK0Y;EQ)%/TKC)@;<|LCA GNRYO|MGNT;VVI6>K^T3?_E"!5:YS M2BR=8DENS;|_V;YFK>DBSF|TU%.;
Y&3CPIK-1JA^F+P@X3 M3Z'BW2U5YCFW)#9>B|ZV4A+Y@>M?ZJSEDHEEW-4 MQI&({=KHQ=j^>|3>^G|B#=""?
6ZOKPBOY^CIA5MM^QQD515IM82_9;Q)+35MO=M-O7S12|ZB|_7ZEWHIRP2080(Y4S;G&(2\$Q3)
((DOY+|J>@.T^.;>|H0/M239K M%A(L\$|/*_AA"DP|U+,@MDA<>|L&*3PV8R!<)|?"R;D+P")U4<<(L:Q"#
M%0R|03X|+I8OG'_EJV=IKAP|1DM|HMRDDJO.P>INN<+ N^OEM7Z|W+|U^K M>;E\$V_F
MIS>%2JK7W|53M9;VJH9KRYM;Y5E)?^?W>&_9JD|8IC(|\$J("F(2:1(76;.* M?P;2Q5\$A2_JZA## P?'QF6(\$>P"9Z6>CG?,
QBB;I%HC4|=+SO\$A^O0TC5 ME+8H>1U.ZMK#YK@88XY8FR0#QV#B(3/&+ #I%L58OHL.E7=N@#2Q>_Z7<(V;"V-
R8"+? M@AF?CM&\$N^P9@TL|N" LH3 AB91R-3(AIRD*(HJE)"B2((QG;V4EG1EN!PG|H|V=U0;T9RGN721@BY MI
YB+GQ\$>J@0@/B)SXOI^T_AFT03NV(20B|5Q9|TGY\$?-2_G^+@H%ZA^RTV-TWIV-KAXE^<@|L?8_8;DCT 4|K MH8
936PSG_C0XXB>(CB33HC\$WQPX%@J>1;|B@|K;K?E|I\$%ZG^_XA MB2<;|JYU\$SR>C7;EV737>|;?(4JW;?Q30)\$_9YB\$!
MIX+S.(AID;B_9PD'+#K=3UO/3I5#XU_S=)B)LDT"

?ZXQYCWPTP BLN999D>Q3!6(4%!_AZB_RSG!69=I#_!!#*00\$)%35@00XN(\$Y^MBC\$;EP-6R(5)
I1%*3;X&3I\$;N"2P0+K9=0%DLV%7!R,D#5XBG^IWNNN\$>QW M+A;&GC48D_"TX(%DN!RM;L/91KIF&|
H5'(AQ|VW6F@>J7I" B8*?;I6H5 M.R_QT&Q<77*58@=RF\$*9)OHI^@%:U1!H/DF8TM_|+D="_*!DG:&4>1
M"Y.H\$4K^CV>00)VFS\$B8CBPWF2"=)J40I-/F?G;F^YEO|QI_OI?<^EMK^BW MEY_16=+|U|R:X2Q-
<8X9PJH;YSZ2?Y=(EIQOT(S|H999#/K6"JWK0&I M#>S_<M^I;OWIT(V#A.DXEZSK|H%L\$D^1SN@/UC&+&60&1
H)/ZRC!&|O_ MP+?/*R^IQW#S?K?#;A=5VW#1".L*DPJ0DY" M='U|4H2;_2!8M<8H%6#1Y=/0S;_/%22&&IDVY5
MA>NQOC_2:F(?&13/X1Y|Y N_ ^ (B)@S*1M^W CJ7PEAT6 M'E9H>.LM^N?_X|R74^=N.0E3+MT/UW>KKCJ?"2N;_?
U7.7K&Y1T;1SG@D_M9%F2P.U_ _ILMF2L;F3O_1)3 MKGLE=>9_?4WF<2T.3<17*#;D|F|@%ZVLLA/TU;K-
5X>#IU&*GD;ZIC;==V M37&V;8AR.W\$M)U M>84?YVN|F.SHY3YC%.5IPM1EID-D+E)STZ+
(8YJG\$;P^|@0IC^&4JWAJS.\$\$% M3D+D|SPKXI#&GX")1!TOT+=PZ4^!>P;_H&-IQ@+%;3P"177|_4%Q)1&+/"IP+E19;@
M_..LCA;|DWID85K0@HJ(Z"B:(V|I5B,U-*!|J|R.<:&825P)G\$P\$8?0I2W" M Q0,7)?*MOK9E'_9BN2QM281N

\$B.G\$:>L0D5;#M WHCE'PNRSIBT8YF45.5 M*^FD1C\$5"8XHX@++HUH\$!^B!,,RI O2(!O C *TO8^6
M0HU1D4@TV<=>Z-"0/ZY@J84:CIR60:O,,4LYI%KXW@BO=^\$*:T- G4I*-ML M@:0BVF6/85KBN6P"YBKJTSR8S
MXSC:6J2JBFC:\$JR.B: M&2+E04A\A#E3@W^+ M*^0QCQF%38MSB*QC==&?-IM%JCWQ%I-IABJJ-1%5EFV\$9:
M>1YLE@JG'-W\B\W>3302VIV7K4I(=H#J*PT=L?TT-.#'<*>YI3-5K+5XN7^ MJQ16+?JH- UK83)KIZ5I
I=TK9M2?JR*8V4L@7:)7:D8'0+>JISZ)UJ-I-> MU3>E /ISID=XJO L:(#IOXT:6&Q8T^M4:Y^2+3Y:KKT=B\VI?
|PVXP%Z7 M3&H IH2;U)- =UIR\DSU0'3G.IRA*YQ(3.G">HL=7"LO65/HV\D)7M+3285-MQTGH2I&))POBLL(/DA??
8H>D1-'@>>?ZG>=G^53-7IK5YJO/"_D&V MWL3E:J:OIQ3^I\$W\IKM+>0.IL-'Q;P.0PJH^C#=#54I M?
K)Z7MISGTFK*\$:4|0C\$O4D1\$ MCA%.29\$(PF.6Q:# |9D(,,:#?FII/TJ5M-I&%INH)"<5Q*F#CETAW8H_RG6^
M87I5X=G;HAD(GI#90.NCYFB#FM?@U@Y@NFC*F(^\$>IM#@I=I#CTI+49T+3', M5M3V7'2FC>ONU!
(ND^@QSZ65BS-L4 MYQ%&.0U2Q+(P):E\N.AB0-T1+1!9I!)D=\$VO8BWR!RD>W:%^FQUT-I\PB-ML\I)-
*K'@W<8"33M%C89Q |X<@BH|*3J/849Y1YJDZ?>C2TU>?;1)FW' M\$H!T7S6T0X^..L^M9T-40+JMG^B;TS6/=
(+ZGSZ+Y@#X.Y 2?U.SI)IY" M_S M#OLZ5C_S?9_Y)(HIA(C8Q58Y;BHXI')QCCGP1%#K);R: L9W;8B-M*Q6M M8!O%
IJ5>+>I.Z@1>Y3I|ZZF^?N&|P\^)4K*7:EM^..19L:6FZZ%O.=95K M-W9WE'DM:5NU7I-GD)QQO@U%B'XY\$2':
M='ZZE-L.OX.ZJCJFC:'^\$\$.PP\$U&(B4!)2'(4.Y6UQ\.(12&A\$>=!%L:PU#UG MJ#H^LSI8GGG\$WP>"
EZ^%|XFZV\&H*LY/%*9=M MGB%N\$)W^M'#*|*G@EN(A!+-MG2,-2E-U5?I"?..53V/1C)QEN9I&(M3-MFTR-4-
S^D\$EGSK\$&=5 #BX\63&H#GGIRE"MYIU-KE.I?7-I=REFI>7)5-C M*AZ5NO@X+ GUFCI4LS",8I4#/#15%\$*
X%\$S\$JHCQ!Q.#4*F^DI-L+>GPH-K\8#V+I!@Y=Z=D)=#@%CN.XI @-O9T\^"4^1 M?H:*.402-
)E3IWOVC|>K98E7SY5>YYRBX9^*OU) ^H=%S!;I M0)MXF&K03ZME=SHT&N7@GUQTFLS\.,+Z>?
FCSYXGW;3M>5AMVFWQC*0B&*)I M *L *M,M0GA) @C1(AXC&F.>@-@\$G(3F6T>T8T*Y7JF:)RSB+I,X_*X3#)'1+
M:JX6OGU: *6Y 'HL;Z>I8U;7AIO\$8-6;<<3(U@>" MFLP#.&-
!WRIP7,'|*@G/0@IK6K6.U\ISU6SLAO1IBW#B^M2VC=U6FAU)R%4 MQW_U;OF Y^6.QSY/DH C1F*.XE@-(AY@5C*_
RG\$8X+K1LR%\BYSL/K 'LI MR-Z?#6Q@7.IJGNA9.Z_%:9BB,V0RV
IRP0U+ID)5U":UK%PP==I&.^RR1O/P9A@X'U#1^OU!1E(HRB!!(%R0& 4DXD7!\$H\$ MH-
OIG=4=BU97IVIF*>SR04^0C*F#R9\$V86!;D.J)3G:77M2,3I*UKX4'7-(
M42G/J<1L%=E8O-0.S'JFTMTW7+8IVY^7=6=5OI^H-.LJ0'J'UWR3PS?+ROSOK^NL:KM>I^ 9(@XC6/H':409;
MBXU'L/PYI1R"++?EV5;^JXL/\$UMT"22"'.Q'R812L*?R-MRI.?-6R(-K%TY)WSJ7 U8?I- WD>B:5" ^ 50=FK'GY_PW=.ZX
MYLVW0Q+4D=5N%MJ'V2.593;&G2.Y5\$Q8@#;A#DY5E#8%26^K4W'3007KTV) MXYF5UOL_KH(BJA*12)7#8Z;U(>
<9CC+&R& R4R5-|0^RHFTR0K*LCB@6>0G MH."M+F#*#M;Z'M2KCI>WUV- ^I=?GIG?;VIN?
J- W7S| =W\+U- = R..C^ MYKW- WZIOOL#=#M)I\U7O-'!+!+=B)T<-@<^%WS?HGO-
%^A1JE;I'NM)7U>7IBK>YHA(*JW_S#CI(#59):/:@2%*I%_A_E"
MC:I\TJVL:6POVZ%|YBBI#&HRIOP9E;RXIH9#V5.NR" ^JABS>@CM:%;@XK MN%?>(Y@.W-F>I'E'OQWIX>RL.ULH
YY-2Q!K>58JA- =/TERB6;E- = M.^T9+0(A@B!'41(4**,<1Z3(8TIYXN.LC7F64*N\ 2PA/D%..@+L,51"&;UHE
M+3T5+X3/Y)A4QW?OCC^ M)H&B-6-FWWG\$ MP13?W0JKK=S1WSX|UF:"N='3/
M.Y8)J32IJTJU4Y+U4.=AO)N7M'4@56I&5D0IYX9)@0IL'.09K::DU+I57I MQ\A)PF:1R;I-?;3I7-W\AQ\EB-
)=;0%J-U%4-F'2N8;MEDE+(X1TD< M4I3I683R1D^M4IAC%/I.2@I2PR@W!#;IFFAN U\$="YL35CH9YE;Y,QT"C\$
M.3P|FZZA%HR>4?I36HZA*..V)JOV<8NM@.^#Y=CET?"Y6A+Q@&?)%4: X M47G')&3(9W\$@PBQ(>
@+/6@="GV^:G0.@8)TV6IIN/O@%' |HL'L\$|.'#!.MMCQD7;#3>KA-9AQXJ-#W7R<"VO-X!|=?.+|H(CIJ\$".B:7+N<%
(0Y\$=9RKB? MXI %\$U8_P+""2*AO@4/EUYE0Y?" JHIZ"|I#DGD\UA@Q'QI=L9Q&B(LCQDD M!;&.%461)?
EDI0NN=OI#KF2IB3@7E*"M\G&*" M4Z2&HZ\$&<9S+GZ>.@=H9#TDS'=E0T-I2H"25<\$!-&SN>)13>@K:&OTPM;IM
MEC#O? VO)"POARBT7:IOZ.P7J?EXQ#9)IL^#KYDW"3Y"Z=+J3>-M0I'I8^I Z%LU-F^#%2W..IQ- '3+@-
LFI!B/ZH+/|\$PNM>FV&^T?(O*^ LBI M"TI=&-DH.4Z2(A_|M7I^3;+)2EXD>7\$1U%>Q"CV18:((-*1+I(XIPS| O-7
MJ=SAZ2-/GJ-4N4M^X;UE?O59>-2N+2X=XQ(3C/(^E-\$R\W3B0;7F4(YIE
M)\\SEI#NOZ(G;KIS8) |V+ZUOO?;V13)>L?7 L3:>(O?
5UL;+B^8P/ZZIOBM1K6W\NHB2O5A*7KEU4WRZ@|HL^7*^VCE==)7;I M%U67*RK7N0%+VD?
RK>@C0:MF4I>-6^11V IO+;?WE*3R=Q\$OI25\$5WX).P#U31X@ M\$M\$,<^.<.ZX"VQW,1C(YH>&X,4>|M MY)>WLY&
UA%O9\$/-^DB|@8V%I968@-N#329Y#|6+U^7"58C;<1H M1"D*LS|;"<13%J"!)..E.! =I&G*>?I'LA6<7"?;:@
K |&)DWI5#P>ODDAX M>.VI8A#I:T+4NIU-T3F*)VM=E/^/ PNM M3A173R\$| 3Y
3M+)|/PT)QP7X"GHU4.#A^\$=D!->.99Y7Z=-FZ5;J|P)KUI M&B5W-Q9I-73HOYW3TUG-EA!?->68ZGK>X(=2&A-X;
+6"1.6TPL3I6RSJ* MGD\$9_SXE9Y3P;Y:N'Q- GX3#TOV#)PR3E4|WDA8IB?TBS!'S4WF&\$9\$CPK(\$ M)5E BBP6+\$A \$IQ?
K2MW-W#7A907" 'I'N9-=>L/U6FTW<"ZIR-5Z-2=ZJHC MZ7H"IT?KSD0'Q3>655!SQMM>-ISR^3-G- TOLX1?
M5;.P""*..T0BQ"22XB4<%9DOS=[4CR+?)R)B6KWU#>+ISB?N8^&M6C0NO'L%
MV^R62Y>QL)M%|^PZZO9QEW\$=0M|WF75K^IY:8SZ("75FXIK?#5^+8/R!7= MFSW=95_E%@|
(ZD;.^@R<"/JTWJU4&-3JAO1A\$O!-M3I%1RKV4_2CES+:(> M#507#QR)F^O;4@.<&#>EI#
JICRUZ'=@4HW3:F11#2PIF4\$U3EK?GM)XVJ X M8;&X+MG|>|**"U5<=>?I?U#=-QBX25@
BH5CM\$Y+FCGD@3L3WJ|+%<7#=%B M5KIP;.'TJA@&R-FI91AZSL#->| 77/Z'WSQ>+4..2+H(AEZD38?EU^ M6-14J+
(YVFQOY)(G\$HG1":9<(725%\$^EZ+^E3\ M>BX2D\/(7(-N;9HE+W MTP18RJKL U/ U7#
)>*FG0YIQR3Z#40!GP@7?#S%P<XR#^OU0!@QZ"JH+3>KGG5>!OJ#KSI BCF+IJQ@*
HO5V.A&"K")\$)UVP-TNSXT0>4.L'2H? VLY?V62#X91@FJ>1M;.:##.69R!F289P*A)Y MNO@DS1GD4IF
Y5@B&LB>+!TS9I9PZL<0S-0.'\$N<@ (F6,1/ IX|&>9;.H"(% MDYY\$&B3OGT9)\$- T\ (Z<12*F!8+!T)YE|T M@E'>O)\$&R>!
I)VI'I'ZM-'J^!X!AYG@^P8IGQ6"2^?E^6RZSI")D:KEA6-M?
\$83OXAS@A\$.DQC%A">H2*20%&9YB)-OY#3.0\$V?I\Y%J0F68XWL(-GX?9 MI'>(V2,>)GL-W7W
7GNT-3"AU>"F YK\$6DK9I/P'F:2JL1A!UV>|MTRK M-/KIW>T%I/\$:AESXA11DC'C*3-44@G5.P?2%"2895(D-B+96*
(#<^+;\$0:#LM(("^; M*8^3PZ|>F3*UI^-.JFOE\4@B8,\$1 |*!9%(V#E"* HD0F!0^ITVXTX#I M.A0T+CMPE-82*F0>
#5A@XWJ92&91I!5;..97F/M;Y5G?RYW,5C*P+M%(PQ M!:PF&1:4A(Z\$)=5\$0-6I'L(R*O&<."5&E3QCC?_O2XI4X8^K52)8?
U95#6.M")C-(<9RF*TRR@/(L(PHRD*P+DHMD5O)I;S'A0:TP&Q)0E%(PD'2- MI'(#NQDIHYD^
F6H=L#&GL@V;I M=F?6GJ8IKOZQ|UUY-5IS2&R3)@GEG4?)?ZJ9?>W;P138-AVHF19LK7;HN MN/O,5<_L!::UDW-
Y+ _XP+EH-9-T+PU;R;X.DU2U^J4'NIAFY# MW5,BZ77(JP!+UTI+X>D)+R.
DIME1H.T'AU51XDHS: 6Q.IHX2KR/%.VEY M4YL+2 Y4YMLEE7XAC8;EI'\$QK=8S%=)N1D'-U)H9P.JEF0H/\$0-N7Q
M1I(|CG/69@))&(UL;Q@ N41BU"4Y!\$F61R'-(=\$\$H90.GLW9 PRJ?@*_ MRX@:
(36BL\$MKZ(#NM(" ^\$5Z#EUW@"IH9N<I8#+-9S^3/ MH"5JNO9TIN69U.I8C>>N!0 T:@:B-7/0LTI-L/O?
EV5:AI-9QJPX+5.I.N MEB6KWJWD7PP&.J|YORB>3L*4/I/(<-)G@JPP&ISH#S4KJ2+_TA@NMO>*U>
M7=3I5"Y=RIO'Q6B=[2;7>;GY@;.=2TB>.AZNGSW#QKC>1M; M9IGNPRI;C<+HEE"8+
)NEV7I8+SEE^2GB/D@A!;G/29K ?2=IXDSG2:S" MU;2+DJG JTF&2I4MHHC7OPL3F60D((@FOD9BGTN\$&&
<(Y\$QG(4TRO(*.M^N M# =FOW"H\$ZO:M+0; 'NIZ#-239"=L@0EXS1\$EW75?>EB<"/9DW0PI984@#I< M2?
4"F\WIZ@*^@&\$NS?W| ^OUJH1KD7CZLM=-J=MYR'3N_OU-5.7B>+!DL^?I MVFN5;A@C1\VZ-
YW\;P)Q<8+C^34ECNRU&BS-) <=I>+;J/E* DIR2O'GX#) M">(SV4?)R\7M-IDIS8"Q6<*3(B-
!CH*0JCY++\$R>"4H\$HE(.0GB)-(|&SVV MN&_JL%Y-.QV=IZ>I|SEPI#TG\$E=,/*K3YBVJ Q1." L\K5&6.1?ML)R=+%)
MQ&6(C\$Y@H\YZVCYO\$S_P=2ON/Q8'^:E2J;&YG%|K/7:QY!\$S).8>5O4C(ZD-MTIP""516V&3Y^#KDD(/.G1

>G'O:G0:P&F?@*+DG3L:QIPR+R+NKA"YI9):' MC/(PD)&?1@6*8U\$@>83F*&L7: MUDNW1>/
Q(Y#ON@YEV=1"O/EI:7>^S\$2X:7@BP5?UJL/ZT!=^GR#NH\3IY MX,2SOH[->ARK_IY8<7Y=2FU_J_6:M+
D)_S7_'I898'3_0I#I'(\$X)B&B0(M:I+^S2(5_JG?TLO/3C=RW:7G1%1?O'&(F
MNIG6YEN9PI_X7I;5VRYK(+WHE89LMDPEU\$4T5IXZIN,VXP"=NY5XIOUIG'X\$GL\PVUL[^<%E
M85>G.ZH@WPI\MTD+UQ_C4(*PW=I!)J)K2_0YWA=X<>Y=,BW9PDNTC1G,6(A M+E",I4-
Y2#C"11Y3GD51KC>Q#0I:12WY-141I?#7:?"BZ4917Q4OYIC,%W.5 M_0*10 =P5T)N^\$93...>:E*Q85V+B:NFKT
&N&M6<0KP: >K&&&(1LN*L16, MVIC7X4'@5?K>:XX5@6H+W@0QS\H\WZ=U_&B##)ALFM&(&03^C%:3/NA\ZPU
M95?T8T3L148_<L@9:B_9MQ'(OHUP*W?ZFR1\$6,WWREC;TH19&)\$H)86/L\$12 M%,KPX\Y5Q^+I_NOMK?28(N\$1*BR'?
LE86UWV@%?_ MK/M_J_<^;U)I_1-L^<E^I5=VIR?Z\#WJO1W^LL*F_LNS...>6S34_#:+3NW%:
M&7\4AW,+T7+4=6RL,VSSW/_'R(IMUS_''7=:=;0\6UT'3UD@7:7T2.O M&MJ6\!MG3VJB\!6EJR?/FX#&GLM:
(B#K,08Y2D_9&V8L1YCGV/LC\B:(<^M@):'5M0&13KXWR*BK(\$6E4U+2JTIEG4/H:1I9B_D_13Y\!FM:<,YX2#0)CO"
MO\X:3AH0FM-ORU:2\SRM\O-ER(\$M_U_AG+?%F\HK*GNYMH4W^XX8MA/14.Q MSJ2FB8(4D5SZ_R2* D&CC(412-
_P*!L6MJQ(-O\!ULHY\G0SS3CA:X 10 M1?3'(K0+ @1=WDS7: 5I7:WDHS\O\O /Y 3?US#-2X7O^_B_I_U_:VH6L(3E
M4FN@V"=2D:0\13G+^R1IFZ ("IZD_J39#>>1XUA--"#>(R4<:S+HPV+STV/*QP*M*!<_12K'!)!SV>A_+-%D0TWT"KY^I-
K+ZE'Z877T>JUQ'H=M4UH\NVD4\IC9MC>2;W\$F,3\40H:=C:L6\$) M^<.(X*: Z5>14_U*/^UTVJ^?I\$6_S.>+Y2-
_V&Y4K \RJGSZ5R5GP0)S8(@ M4G:1(H3@5%,Y=1XD'8\IC=*\$@>>2F>#A/G+8:S\<8>75KKR"%C%EO>(-226
M*U0_46VP_P<3C:9'_.#HFL' V^4=WB\JH\2'Q\4KGR-G_N M&X+6,\$9'1G*8BH57I'FB)!4C:\$G&6=I\$'.2@H^@,'13FK;
(M/T.^FC VP# M_V.KGO)RQRR8SAKDTTX_9B?A33,VV&H-P_<7\8\8<-(DQ6\5_>BS\4@? M_>M2F\!T0*Q=15V
G&C=7.W<^,I.E.A\O\O\I?>S79UQV-7?)(L@R'O,48954<>C MUHJ3'T5\FE1Q(C@JX#T>IK@.\$JFOTG\NVVT^E\!QHFIV:.*
KJUK76K0M=^1 M3'\$+XN3NP=DIP&O%Y,2CXW9BU5SPU8J\$T0BIEZTNG\2EJOX?W,V"WC"6,1C
M%,54NDY)X*!\S2AB,8ZS*.,%"DL)#T\$SGGDN07>2-E%(U:5AS<(U(+7_10H_M:2_1U(TGV^(-&S<.:9-T&I>UO8-
D/'_C1:B_P_ILXP*M#^&\$<5^LM@^\$F MDHYER:1PJF8SO+Q\XG?+MM/3C7A?BN6J';FG7RL(6-
+U*=M@XG6H>_RIGMS< M8E-/O-CB-T\ISL@_@I<-MS6^E@=2\3LZ:L2ZW?#5?LD8G?>:ZU\5,U*\$TC(@%,'CU%,@@
1+B@*VDX MH:GS_OR_3',ML(X52G)*,MI2O_!OC:W&C19JFF_6V<4T+O79<&@6\P3X-" M9U!<>!*Y@F+ #1MA=-
MR#?2 3NLV@!A0X%+ WCY_SN9'U>N@_N_RQ?S\L)GZ< M\FF"PCR1+GW:6=,IBQ;<%RR+TU
O\$CP.RK&NV/:A:\$9G2OYA\Z&->UP:5@5V M:8>)_ ^ Q8_-M,7Z\JZE32Z8#Z@TYX:M,93Z7#EKTN1Q0B'S)/=6>+6ID<>
(-&B%J^<5ZOGY\+7JW+97U?+1^MO*B\$1ER^SD&68AU2:..#G)4)PE M,2(DBQ"/1)2QV/= #KI6\,@+L)J(L=:*^!;7
10847UR7C?_U2KH0S('D6\2BF MOH_B_"L0H92C%*OY,V #
M#6T6@T\PE.>J>86JCL,A"CG\$4:YP)/:))%20:Q_16@.A:'%H.@&BVY\KP9S4X0>Q8= ?A\ULX.Y? M_7+IV\?+=
1_>7BT_KEG\34<1BV,18"1RFJ(X95Q:S7&"J_3G).\$EBKZOPD M\,>:0(+T)\$SOW_'#X\H\5K:B_A2>@
W_8H8S0<^W\A0GV24K\Y5F39(7 M2RH9LXI?+A+OL058.>^M\$7IW/OA_#>1<@JX>1F Y5C=-V*%-O6@M\U>
M@%G?0US3,S_L1<(LIFC_!K\H4&@)4MB".*D\H.&R?M6@1XK\&2\$S\OR5\EZ MFRK87Q@ZB7%)<>2*Q%
OUY>WGI=GF@/I_T\$ PV&#(NM?5\I')>(#0ZF*NJ3 M:10XH+19/D'^J3VTP0:QF)IRU?2N;+R^?
(NAL573_AQ>+E%L\9('H9D) M\%>UY_XL_1=URJAMU+BXREI'P'E#8SS2\$F=:1('LCW.0.5:AV93H1Y<>TJ)
MUBR3RYU7GD#HQH\#AR_>Q=RF<5\ 5+1/HJ7I7@_@5F>"AX(SE6\1)DMJA'TO M(PH22F6G.2P;*)4'=1\1UJGG>
+ P'AK0KSB\<7@W\5R)M\I',WH<%SC M9N>W)'7S&D>V_W7G_6KMQ&MW:(C F-
T8S+>\$*=3&_4P.",=1=MR(=^H5,OF M\I"Z"@_LDTEB@F/(4D2RE\HSAF)\$P8"EAX(Q4'Z%VF,\$3*Y>>
@J1\JY'S.+T9+ZG'HE\U\U/S#;-#05\$"RO)8EM*P M.,=1(2G(8D2Q\$/:49Q&*<GZ_16\$0^VE."A)R%\$HKOVYYES:
#6KNILYJPW^M6\ZJ78*9GS%17.<8%2+1%*Y(+A6,13'69_6(N1YP8E+1E=9J=5Z56?EU.U\BC0\IPP%18'2<(Y(PCC\!
MENP1F-(3K%)3Q%8(1XF^29T@15A'I+1(Q\$B:J\8P(4\1P1@HHL\5&&21\$S M(LE\$!,NQ.H3A.FSV;E:(_GB@VJB@U?V^+
1P6 M8-<)?*@#_3QOZC1AMA*FCD'8-E'J-(D''5(#CYD)X8T:C/>4SY_5FE6U: ^K
M955UWQXN<_9X\$*,HKTWN+5\$Y@C"21H\$G 1)SD\$S X_:9;+&K2WVL"&">8@
ME_0DU\;M,%MR.Z\O?JPI\NAM2>1.@1:\$ME\4\)*K@1\1^T*L18Y\!*)JON:H7 MPX08#Y^/7:H1\)%G(=D-I
1R0"/SW_W&O2#(A%CD)#(QOMDO/ B/O \$UP\$ MHW4I-8M'CZX^74A:E\|=1+3V2V:1^7\OU/5\1+&_6VZ\17RKZ_(*\17>1%!
M1/D7_J^G>35?Z\13RGO&FKHOHUW9?U*K5S/2.XR,B"E""(Q_%)\$>11\$ M*,_B5*3\$5\1^\$.2N\$9XD7(YJY%3'I0UV,*O
^;16190:3_2N\IV^NKB>1;3 M-B7D0@T<7=4_3<1RY5TMJ\770\&> 3,5'RT90<11G=20FHKY^1,89'1_FTH
M_<87BZ\9B4_R/\$IQ@8HH5VVL:"UN @19IF06CT\IPS8>:.*_O&NMVW1C\J"&: M\H#9X<:P>CR?1N"-)
(0\@T83QZ@XH\O\$SG(3MY@X1LIA?XFC3YF*D9J2O'I<
MKFK1K>1=KE0AP>KE:LE4;2>C112EB(>JHTOF\Z@H(H\$R@0L_REF JVXHR:1
M:01M\X6+YK\JT_0&A%80*5OY\$VZ@JD->882>A9?#07"UJSY#DX?4G%FTM
M8@1E7>1U@SX17Y>1'Q>U'8D7\9OZJ5?X^EHUKWUHTH^1,55)5N2DH*JODSQB MXS#B'"?(<D:2!&\$
<&15M,U*KQ(13+P6%:_&Q>LA Y\Y\6;OL'9PR328 MFG@K_)TL'#\$-
1/&%O;X\VMX8<"\$P3X8D/6F:X\A0.5.UPR3\1^1Z+L5DR\1 M=O\$?1>/#8G\B8NKI;835R?#1DPN;1<_8D)7"8
M3E"4^#A)1B'AO:4FB_1>)Z\$?1#WQA&D=D31EU)8TW5\X""4T\4T\0#;H" ME<(&1S\XG09R2_TJ\W=
1O*N\8@.F\$F7F#U6Z,4VS0D\$GOG:M\I4\PCP5KM MSLIB\$Q?H"/LL
KGZ%&Z7U=&6#;:D*M^V%_ 7\$2_K2JN3,1/4\$S'(4Q2Q& M*H%?^O)\C\PPYRQF>92&H+G?&C="UX/L+>1;)CBK\1
1/=&TS1>8O\JR\X4 MJ\$^DK01'1#8C3)@OJL_@<@1#P*DA\$*OUK(X0\4C7JU?/N_9HZG=--QDH8\$
M\8PQ%>=YCD@0\$3RV(B&J8\UD19.@7 L:CW07H*)BBHR17AB7:1JTP\063
MJ2VX8\0,2:E\MR>A\E\Z3RY\1'2B.\$94)W>CSQD:L2\I?_1\$FG%1B3\!(\$3*7H)\$*A(B8_1B"68L\$S@L\O\1;"NC=XM\$MX6
M"Z\# V@ "ZS%2TS2VSAZ@R3S,&5=%B'J:5G9>D"GM;Y\!C#BPRF%OPV_>KN;K M%\$S4?
1X7*A+LQPG)\$L*TFS'*,1SS*421^7YJF@TQ+,^PO\HP5K=%"A;P MJFR\IF%A\HK\W);"V+S)EH7+*1/BF/ITZ"HAJCB;?
+1 MP13V"U5.WR*ZW#56VZ117\1^K7N8 <7!O/H+HW:G\$VH<:H2>#U2?YAO\DH*1.X:Y'S_>P3,C7@+ MVS:<.;?
&J&\$Z8O_\$6=F(W(^1-8&1JEYET\$^T*2J\+AH0:T2+^C.<+=4WY8;GZ
M5:ZRG413S)I@*\$\CPH4YTF\$BJR9+144022\LOR0\$N@<7\<6UJ809UYZY4:-
M=296AQ>IG.OT(^KHJ7W6MI#>S6Y.;0IN\OBY\1U\WCNWL=4W,VH?J\$7S M9Q;YUK=BW2W'\6H
M/R_7EVSYN;PGKW:"SH_DVL\O"X=~/IF:F*10X>U(B+#'S6M3TDU\UN39\
MH#1C&.Q8-."5@UX+8\$88)=CJ0YDL\Q9>#1M%_1RF2F&U^6C=%,^1F>^"-J9 MHD7\1BCR0^D(C%3%?
1"B7\$C&JZ+4HN&KF8TV_@^G1&B3:SA0\ NEU.@1\DWPR,W#@%<>*E7% MUYO>7%F19V&(\$O3Q6/KO6>8C\1
<^BB_1L2(1+1_TMEZN4\8G=6\GH\H;V M=WNG7O%H>Z:(C\B4\O_346.*84+9@'"0ANPH_K9;NRL\6U_C&-D'32S
M_/K0F94K-^(\$5\1+);2\UM/(T%CXA?1RF\$8IC*O^&X*H+1*\$" ^C\$1/ M_-B8ZP2_3>6BL\+X%X-
'5S>J<4W\1&TQ0\I@S.B<\$>8U,0,4VJZ0.0:J=>IE M:H@^63TS\1Y\Z+R9M'SSR%7%7E?CUQ6?OD7Y9.7Y1-
>X;W67L^1U,IQ1S\!M*(MR>9C2)\$8XSD,4"2J2(1+1A\IG(A@X%&5;)#Q%LU(12IT>DGIZHFS7@;= M+,SSP\$13@CB7?
&X+5_1XACQ0\1;5(\$6\$'L\IV@CE5\1#C?ZD_1\1^OXMK M>C;>15Y Z=X=7_UG=Z7;#X&S)IM,".D-
"&"OBT(>C?BV=PW MW4A6J;CFE;JS:YR9D\$1TBA)0L2HREX-A4\Y\O(9RFC092G0\^SFC,'2N< M'COX-
H2\;=%T1%<3V4#O\?R1V32;&=D;M+MTOC.1\NOLIT1D%59@UICG%,3R^>R0>@9MMGP9T1\!"M:M:H\1(2ZKF&(1)E<4
B?OB/O2HI?A;X^HHZ15%1>JCS1>W'WGBV?^5FNOU4S MGO0%9WZ<&1)1Z9.Q'5A+O\9QCC,>)1SIN63G87%U^&X-
O161^(>Z&S.C Q\I M\=HPUF;@Y;B:6TS3'3GBE0SY>Z^X;+UM+1O'R?>7F\1?O\1-M_0?
R6=)VS^N4RG=XS3?)&%^6B\6'Y4JM.I/N.LM4-_0@SAF*HR\!1-?

X".M002TN3"WEE10XQ.PB^\\CG10\\#MS\$7%&6UMB^F#!%PS@19?G I !?QR:T^A&O MOV\\A'E&\\XE2H.&?
(D0AC/XA\$5L1Z'8K5U)QU IFD_4>9@D. MI%6)N_@3%"!:#U0;K/JNX>JR!"!:#;T!:-=5L \$M/(M M;0!+G J;:>?&
#@Z!Q5':26\$NBK %P40'69!^R />-%, #5PM<53>B;G27CE7R
MBYQ'/'N:QZ'*.9!)*16J(T(%F&Q^87:0(1^T,0CL6\\EAWA;JH5)H-H#K" M&#W1/HH!)@\\2Z5\\LUK\\YPRN?/*D?O
MIONR;5-BW4X2XX*CK) B&\$>=%0\$0-B&-^&K XGX*YMD@;: &JRW A7OA M287+;P8Z*)U#*IC)=2"IVKX7@\\!\\T^%@E?
C #0*1GFH: W; MXP54IC^+*0.FOOZEU@S_ \$7 3F_ UZO!; 9KOF2F"7WG)5WAQ6;)+IC OYRJ<ML)X _|=K2%;!K#
(\$Y@^Z+-C%\\3W?H0=8.'7)*2I(\\!FU3T-4G?EWS= MU^\\!99MA5^Y-# #J NS+^_NZ;>WEPUJWD^S \$HC=O?
W*WZO4E4VK7;U>\\; M43XLK!;A@EIU_>UEPQOX6UQ\\(PPIM4_1H71^U2#;J-?KT+J3=7?5(*I?
MSU7G<;@X00_7^N7R^XI5E^P25>OE;8KAD5>GN;VJDV_DQ!2^\\!52MZW14?2\$! M1N^XU)U)*DSH3E)IL?
GJ"%%&0G5LOVO^\\Z%#R! 8GF+4+8+>X>N>><" MG>1;W3CRML>KGQ0BWKSV=O@XEV.U^02&V3?;C98-7YB
MU^"?;R5;+5N>J: OOE!<@"I<=<R25;13UOP>J?W*?I^C^_K9_D^T;I">4 M9JLFBAH1F?YZ54G.J%">N?
Z^/FV9;J!FVOJZ+E5+^\\D12!K?_#UG4_ M2ZT'KV172^ANREO!>DO?2P*&8=T;WK&QB08#9BZZF&L=J+NEJ-"
MQNF6PM=TIFA.GSKMEJF;O6-XJJD2 M; >+%WI&*AJUO5E1414L;\$/IAN>JZ2KL&LB(4*&DCSD* Y\$@7"6"<2#)"VH
M5&E;X'O9X7(HIRF%\$5I* XS5-4Q&DF_Q"\$!U&4)GK#@@I6 M=GT-U.'R%# IF3ZD?
EC!G443T%75(T=;TDZB/N"*RG<;8TK^96M#;XTB2B= M)*
3EI/P\$7B?;F6.O6%W!>7K.7Z.WI@LR2ETAU_4JRO>2P0M4_)BAHL@ M2#+*TD!;HX!<'U14X/TMC I!51?
4(IR9%Q>SJ44>\$!#(O(D/D.4&\$G1T04G M\$Z8AZ M9P\\POTB/>7!\$8N;LX4E&*GQ0&WO+4L4G'I25O.XY7 JOP!;KT?
\$V^%C_ M0@+!;RL920_HM#E)(\$8-KUX"*N MS=-RH"W7JKF=^CV_8WW6?YOIYW/A^5R72I7@_RF8>
[K&A!=""=QNMR%TPG<SJHEEZ#N'TI?V\$59+!WG.&DB!";!\$3&4<9I9@D4_VBPXO_3?I4P^*H(ITY(3M3D/5-
I#;=Q73V_184)S(L=""=RVU1!#30\$*IS MHAPU_2@R#P5ZK5;96H0=9&9;WE9'TH/6)5/Q?3_*8>?_PN%B<^%Z?ZDWO
MRI9FS' :AT+;UZ)! M G")J;_184%UP1.@P3W"*L_ SI_ =OK6^/V97V^7R"W64#B;Z\\QM999IH; M;_15.Y?
7D/<_U*!>0>KE&W75;A^6*Q6%;%K_7I>_\\5WSLLO?GEHZMY>7_ J MM&Y0F_ \$L29,HQ2K/Y_*DF!;\$"&8HB9-
""Q+@T@_*>AL=%QG"\\48J\$Q"TN#@_ MK;9(<(\\:V)5;7G\\X"&HIV4KS_U7*=D;G&\\V)9<(K%<(87?I=MEW;LNO19'
MKX>D)H&\$'VGIQV@R"?EOYF;GV8?8>+!;-8_A3G0YGN&+&D9U#QMZJ1B_P M<<6OEM7Z2Bf;W%W'D'4<%(8^0-\$
Q4S4\$))1^F#*&(D8+_1/E/W570>Q%#B/ M2GBP\\8E!+_!0Z><0!M/0I3!#!40^V4 [ASC0S\$=S(DUG.0*(A4YG/\$L R-3%
MO9>FG*9X^_!^*8DG^C(+?6)!^M26E/51_!;V%G.&\$!:(2%*;) \$/ZX CG M)\$_Q(D0*8YP" J;_0#+N9:0H+P0%N
>8HU>8-L2P3#ML8V%77@_W NOI= _! ME98&B99B\$G.0)HU=;Y"\\!6>>5UAI?I7D\\NRR9ZLA#54+84OWH1F*YQF5=
M M/U9KDNUI(&J>;TB0LSA(B32E*\\JQ<+LAG_X1B)*6"ZU*Q53N48.V_*M7&?I_K;;"VL2?J2UM+63Y7\$#7S_FJ;KJ?W?
HBM! 8O+0XS;BKRR(I E5" MD?JQ?&I+Y(5WMMY.W/ SMZK-S+AS)R.'VK6V=C;97OJV?D(&1Z<==)G'=O!
M_*0.8OD/A6=U755/JMM&KU'E+;HCFH8V""KFN>JU4U;S-Y@'H607AL^;QXHAIP!-!8K'I M5'_A;?
G8X.)=;_C80!>BWC9@@BU5"P\$IK78T8,J\\OC_9PTP'J3#@L;2IG/*0 M!R!_G*6I=+RC".6)IR;HXSZ*M?;JR'JY@0"4
M"A%FB>>-0K7M4)P6_<)SD'8J(2_+\\GRJ5JTI9_W@Y9IH_6C MS3\$I4#X895)K
9@LK1I';C_&O2>N7IY75;K57TO_P%3WG0.G=^Z FJM(CPN71;=SZ_@)O<^AX@IYGX/GI&U7\$3;WKW5"=JU>E@M>GY
MF7^O?U/-DHE6&EJ"APA_+0SQ&_>8?S2>^SZ) ") \$:T%U+X")9;I8XP_MNGQXD
=5U0172PZ49STE.H;;;&&&>N4_ ;*#0)L6>M&E>4@LF@&0H=SO MDJTPW7";8WKZP_H?
8#I@EP4U4*2@>H_Q=K#;CU)F2;OZ+(3 M_-L;(NVPY= _@TV8'I_6RK);+;LC)H?R;_1E>S-)4^(3U08DXDRZSRRAJ%"C
M11.I18G(<_>"UYW\$A!";^#C);XBU00;8P.Y 5?J MX'I MOJUOUCLFH5^I*_;U!8 J=#YU\\S2;?5Q MY%7\$MJ#*
T_90+\\RS;>*W_IG JM/HY1K1?/HM@;#A\\B%;O3P7=6KSZ)%V& MX>G#12;1HD9C?X?/HQN_W;EC*^!"&YFZ!7?I;&
<28"1E'&"VFTYC! A(4^ MXHE/(YIS\\H9.6Z=GD.B3*R@U(C^L MT5-D&%F@\\XM_9G>>(J-O;9Y\\QM3&5-
_ES4U%E(&1%4BA_B5(5W\$\\%0D<5" MRI;HBM0/_8R_2N_V 3@6HJN=Z.W_\\O_#I_W>\\0K\\HE.D^GDJR;^&^>A^/A M-
_K;I#QTUHZ/_YNS"RR_2)+@<(XKS+2U89-2KY0_I;D/I_B_P+M3WU#?ZO?B^R)#KYUCM.Z_*KJLV@?
C."&KHNZ9KW)KO!=2@K>;AS5#N;@)K MCM@T88^38\\ULW5M^8E/U;'&YNF)YPP0;C=7P3>B?
W' A214TW95_EO52.8>Z.F"Z3@+O'0Z5L8&8RK\\LMD*+VQ=29^S+07UU88
M=W"\\;6=56_/O;KZ74C=\\FS_>P&.'EO<3EG97IY)FB9?5S1K6EZ^U!4\\IZ_0PNNW&;/'TMHAZ
MEVNO0U4ML\$'V%7;BW#F;G?\$_IA_ZSMC89*@.00A@P8-8+WR'\$)S\\HR/*3QC M;4/7'U??U-
A9^\\!U=\$;ZQ_4QNKZ2_*EY\\XUG&1\$>YHRD2_\\0\$N;ZL\$1R) M/;(B+P(C_PA@4#I"!ZCI((C7CCE5?^%>_-
(!>N!8#-5USVVP!GA!=1^J_!#"X M4=WAX3M#A_@HFUYI5HPW7U(6PX\\!\\+\\VQ;Z^E??7Y0=5@'0C5&\\\$5MY+
M>+^5SI6;O?_7^N7R^XI5OZ\\!^;LN;U>K/U;5_HB;LP_X5A)_<+Q"*D!>J;IY
M5\\^4"ZJ?ZGOE=JKBH9DI7Q<\\5\$UG^*;V_G8U7ZX\\J6\\EW7V34B0=EGZ/E5K< M?JN'A_\\\$Q2SNQ_@IVR1;_5-
D^Z"Q2YE5MAI= EH#G6R\\J*\$S&=;_4#Q_L3?5
M_^SI7I+\\FU>J*>N15EA%F\$0%)3E*^L;H5OD_11@D2)HJ21#@/'V\$UFC=5Z?S ML0;O=;OBO6Y7SW6W*\\QI<#7?-
+AZ^C1OWMA7H&=7_A!;QXA=MH0K4?DC\\P0_M37^OWG9#- TZ_B9RD";_10/*T8S'S
Q\$DH'Q7';.SZ<^!53CX\\U;@I.JCS9GJ\\Y M89M_%;5O@T/P_B8_DFU=-\$;.6TW\$P_3#H80-Z=V/AN';5M\\6Q5SY27GF'9
M*L\$RY7@_63_"K_SE5<5FI\$Z7IB>WYD0AV);\\ISJ\$!E*&>X_>"Z^CV&M)=C6@\\6UNXVM;I7;)^C%> "<;=X.=
MV4GIF;_5W<3M;ODI9YS\\O);IRW0I\\VZ&(\$74);)SS(QYH*9_M^"@.5&=#OQ_H\$#@8I\$5;\\@ADZL-
1F.+^42R6W\\NR;M%AXN\$*H%-6>P6>_(MQN5^R/U?\\I_NRJTW3)*6XZ>V=
\\5IS\\QF\\T\\I;\\PL>F;Z99O;LIEG!%IC^0R>XQSV5+_QKS\\+5_F AP_MP5?RP^H5\$T515^0%(PCCE*8C^3?
0N;C*!5\$11Q5&2@_\\4C;IQKM_U\$K4*P_M8+_K%SNS;20J_KG!%1Z^5L>_3LMC_9#E_F6WZ\\K?@;(G;I@Z!#"!;W!C\\I)
MXF%3H_-/FFD#59R\\FINKG^_I9<=VII";@X37;."AI(WRT;"I(Q!#+<2+" M*\$I'O?@-
I"9*H%T/UW2L#G\\67S7TP=3<1.F_Y@)%AYV.")2US\$BJ3JB;_ M3-O76U;6?)VDK9Z_66Y6^Q8KM009T7JRR(!
(\\HBRF@*+<%SD*..98\\GX;_M9J"(E1LT^20%QO;T^5.G_F2;Y*CSV?QZF4HS_%A;W7HF\\I\\X\\KE\\VO?>PPC
M^6/<8V@QVG;>T0@T;W^_N%QL7SAO+;%6\\LHS+(B^Z;"I0&)4(RQND@0_@F6_M2Q(6SU7<"C_\\UWCQCM;5E\\J@
MK=^_6W\\A5%5_SL64S_M="=TT/NUMZ6P0IA6\$=9FIPK-LTU5AZ+9KJ^7U\$)\\!\\0(\\Y#MA5AX_U8_M2N.M.F^P_-
X.L.G*JXUR9J2\\DF2\$AY%L8AGSWQ%EI\\QK@_FWL2;\\XU#\$;>J=GI_MCG&=OJYS_!;ZBTXU;ZDB3%
<>#5(B\\Z\$6VK/6C;*.UUX?(/+8#Q\\V4W37.MO-(X5Z75Y2JD9(5)=25Y4^LX""\$8D%1F' "8H34B"AS>I*#N3?
Z^0.N_+;A_OGP^*3\$Y2LZU*LI6?)VIA0ENI\\I.YO@RC%*(Y(MAGG^BC#&#;_D^\\M8I91N\\XOIKM_-27BE4+&M+;
I#2^!Q@.W0#+U^W2.Z@_MCD?20+1#>K-9X8%ANS5#7@!;IXU2_P-I?3K\$S8X&Z5AMV?9^/GCY'KYC#6 M?
3^\\ML8S(G_61^Z_DBO3?UQ@8H01XC2(L2EH=\\D9F.DSL*T7EV6G^FVDZ@
M;RD\$7YTU5^XX" _6L\$ZN;@>FP79\\TYW^V6XFI&3@W2*J#P7/X;W;_+\\H\\H<& MT0V_*8;_J0?
+35^>2\\IF3Y=;H94J0L25B_?!(C*!;J'R^N%O^Y.8A(F_M6@UUA\\\$X3Y\\H@7H+!26B;3_XV_*B?P)\\NG)^?
G4PX1I2_CAO#;_9K\\CQ;_MDB4A/@D4LD=)G1?7\$>>A?2(7+)_W"UO^5*9_Q_*\\70US0J8\$Z^\\HOTWH65U_M9W#
_\\F8G>T85R_7Y7*MZ24.L6%8_BQOP3;YAXIT^K<^8T;_6J"CFUYF1%_M'R-\$16LZOAXU\$#^5*7/W-9?;RA%
MAXW_U^\\U4R\\K>@PSV\\I;=(1"@I<(CBC;C^%&6\$!#;_QNO6;_!M L;@U^V9A&>0*FOE
_2LY%=A*TS\\V.BWLMV4V^%;_4Q_MN&U<"WZ_M_Z.TV8H\\G_8T;1Q@E."#6;#X&P8.R?W\\^K.L2NGJ5%^?
Z56UAK7\$/_6^\\W=D MT\\WW5O^A/C%\\B8A?^>IY3KFG)HT\\G)-3K-#P32QP>B;.#/
_AC#UK_*5#_MB7=V\$%XL7E3^Y>\\RZO\\RM<\$1PDTEYO@*G\\K MT;_H^G;S\\5_M&T'6YP_S0T634NM0ZX!!-B"(C^6<
M1"MVOT.B5R@@PE^VQU/?=1+ZD)ONQ;GN9X_G*2IFS4_C' MMMAOSJMM""3FG!<^HF'DHYAEL_&B((C\$?8S'IsHE?
IZN<8+01#((0B02MXLSA;_6*1QM8FW)&"1X6#CG"&KTPR'D\$PW\\H#Y;#H;=I2BP%.XX F#3(<9K_M_>#&P)-

P: ^KW:EW>OUL?I<9W64JH:=N4#Q:M " LV#I2XUW4W>1>I 33C2A5 M4FTLVFO)Z6^
P:G(K<KYI2Q.)&WR%/+H1=C)AEY:G!HD_EPOHSH>W/FBYB9 M LT E1D.TI#Z/D:4T!2I X8CAUXFJHX"\$9Q00B.\$L:&-
+6,%3PE<4HGZ>8&1MU! D...7AKP^AJ#Z&ZIO+6DB@CB<!"Q+4A7!2.5)\$* @SP*2
M)KG(HVD.)B#BCH^ESI?2!3B:5NUO9H MG' 770L\@J+J8YQ&AHLQW2BV\$ G/HFV5Q>M6D2B?^:/SPIS"! \$L\$
MB/S85S68<8@ (BP7'89I&+ ,DI+ ,89=J!K.,3IW<IMQ3I82"- 2*Q?2*IZM7A MJ?OELGS"HN-
U^ ^CLB:M.NQN4E+@KI+P6*T^B=>%=/JA_MZ=H@:DY?NWEDI\$PI>J&AZ#K+5-F&-UN@8%-
=KEERH; ^W9:Q&F9FJVH?,F12 MS!7>\FD4Y#HJ\$"I07@DBKTZ>H\+,\$B8!RD2=%)")0YX\!6.13 MF3O(SV#.@-
&BS9A.09K4?- \$@ M>= ZT'GE#5S:29E7_RPXORZE,+JH6*W'Z:E!7GDL09XU'&4)(PI25P@O+0 M%Z@(@,6%)
(2)*02V:IT+ ,1E:NX4/9XBR.LHJB L+KQ/(SO_NC=W&MOPV@XK%.T?PWDUW RG=W8Z!.%
M! =V*27SN^\$KJP!H!E:BGZID>?
=FQ\$N!JY,*J3W.XZ2.NY5G4PE3@W'S%R9R!08+Z'MWP@X9NV!JB&9LZRST:> !S+%"!")4&
M&0UO'OD\$T9S?4F3+0/!5L8+EVY^IZG>6V7F?9UNL8SOH=XJFQV:%T"/MS9P<+=MG\$!;MI
I&G=MG&2#JPVC5?>@-06)0WNIMQT5TX)YCR*>(1XJK.MDUA(/4\$CE,1<.,K3YUI*MVWDANFU= ,5'#=K>_1F7+?_
SN!E M6UZHOM&XYUXBH!.,(KO^FM2%./3@!#P.J5^>JGG)J^H=K^AJ7L.1+)D: MCB0/Q5LINKRMS-
ZV!*"4I"RA:K@)DT:FPF\$.@+SN J<>-^2EE 0M#1 B3^JS(8Y07@8!\$S>.,D9@6802RFTVP<*S-
M.IR4D'4S7VO@7A^O^V5F!2ZSQHHH%INM@^:)%JIKL)TVDEFCGG(.F&>0IDM
M8!\$(AVGMOG/8=&#"C:68Q5C@^!XBLXK?KN:JRDQ!2^KIK=5.,L+\$H4T(TBD MHD OQQ21/&
(HS8."J\$(Q^44FR\$A7^O@O'2KX5F&FC!C."B319:"CLJ M/EE:(U5!YEJY#-5))S^.(R6CF*P^O',779I!7AU%
L3)UW5A>!)3T6LNT MK?K83?F%JP9&TG62#WQ>EJONGI6A^%=:D=K_E#-8D99DJH)PBK&&:((S# M"-
&.\$R\$57RR**+@K&+G.JUY!1^Z!HT!^IAW#7FY)YTO38X%P_U<>Z=:7^ M5(A!>9 TJINGNKIT5?.*9A^295-
BM?)RTD)3MXC:ILC;"UGTE!@:(F7+? MCM^I9Q9NPINM.:S:75<'TS!^5:RO\$E8 (KK:ID7V!6=IOOY8R07&HLPE"6A=+
!MHE >4@3%*#.X2(A!4Y!6TV.,UAJJA>BW8"TI!5LZ? JVG!C:X,ZOX+%- M4R9&:&LK#PV2!+DY-N+!_V:J
H34G\$6L-HCI1U7G4H"G!H!>"H99YVO M^DV<2TJE#L#EBS1QVA^WS2X9X!O%RGRXS!%,*"&F2V@1J)CM?I L-
H!CXC+O#.NV69S!1A!K0%HV5^E?M-U9 PS MZ! =NY.:#=5@WXL!@B=*>ENMD*ANX?)^MM*Y;+O^:5+\$MX(!&
M\$*_1@N(D+U A%2WB@H@8YIS(LQ#DT1V<!)R0=:J+DG>GPHE,#YVA"^:3M=9 MU,+T(9!0N,=TDA9:3M
A@&G!FL\$K@JHY\!>A?>T9W:^B:8AT2=>SYWE! M\$!F-I L%7%.(L0\$SU#,:8R*F*8H"6B2AX0\$!?-?
W:4UMXTG?_?I%7WPLU7 M%B@:!?NP59!\$:.96J3.P3>W9K:QY4N#K:(TLI4O: _T!2\$J6+!%I0\$A!SLLF
MDR71%ZH:C4:WUS)S*WAP96G&Z@?3H:M9MS.S#5!ICBG7*@?2G+V'G&N:5K!>4
MS\$6KXHN!CMNZB&"25(T_37FOEW!FZ(V*)Y58!EQ=DK.X*^K^K?CQ3=I LQ MGHN"1B*A%*.08JZ=8!H1"^-./9@5V-J
@.50^2V!>401W1>:"N08HX@<*O>WF+Y*!,UI MBY%?E6UB'A!AK@UP ?&Z\$IA6L M-!F8J1 +CLL%UQ+<'<6"^!C4-
G> G M0^GGX*!+92L<5Q^F-N J\$=0KFR4)HJ1EA M(+!\$.,9_Z\$S" +<#XO'Z2!AXDRJZ7+F:*>NZIEDU:;DW'8DH_V"TW-
M#GBX".IDHREQ-V'H7QC1/4V6%8!+C!GKPW@/"LKA VND=^WV&%B<2JKZ:
MV4X\$%^>#2HZJG1>8"B:8RA!C!62J-\$>D2"@J6!H&A)D.:% Y!8R!3!SW"18LXO:IE,29_?
R3UITO>94(U)O3_>B8577<'S(C:(+ CS\$7:H)SM7 M:(+ 3P+&39B !?@IYN:IOZO; ,N#S,F+4Q<+T>?@J3+&K3;E
I6_@N'E@/(B MJFO/INYOTIFE3 M*KG4!K^?2.99+PKAB4KR5"&I- OGNYS =OI9!05!W^E=SX%IN4W!*<:!-?
!+=X:!)7!G>H?=(=>QXO409&LNYZ<0ET!E 7H=)E\$:6Y=+AZ5!^MU>M@L_%?K7Y M>ES \$A!UM\#?
AD=Y^Y^\$!Y+4B65^7ZOKH1U^N!_ ^Z? ^G^J:6G^CRN^V M*^/'=93YX:D4_RIA89!4A-
!UH +IZ60:U&C0#6^Q2M:KK7N*WVZ7-8P)L=Q MS7JS:1!C!DM^.,5JL%?UT,G:E9.XYEE%IV@QF+IY_XEZ2E?;CHXS-
QXIS M2R&8CY !XWB..3WJUBD(14% MJC4HI!C.PU2?RSK\$K;AL-S_TNZZ!
^FAWQW"J!IEBL^AO5D>YP!4WJG!H>PX8:M75W:J! _(:-^!A+@!E6P2H+L#,F!(=W8+Z:ZF7SKSP2F/BGB JC;
!@9K>OZG: ^F**=.UD^&/#^=7.L4Y*E:12)))\$ M&W!>I^A0!4\$YCGC:.*8(T%2CI.<>!--*1YK*=X2S?
0BP&GSEOHS!ZT_6H% M9N.G575?&L48!A!SH8%?_9N+XZGP!<@.*L!L%?_U<>-/
!1U2)>5)"AEBB3XZBR27F(!F@!Z3F!@7M?2# M35VDU4(N G?U\$7W9V!+ "O M# =WR+7@A!2M)?K:LGKR#Y:R#!-
DSB)\$*>)WEDS%!!N(ZW"R5"08LP M9E:5JH9G=>L!@OABX#>WY=UWRPW#\$1/!DN"K@I EN=OO!^ @.: "EH<-I
MW!-^!%W\$C29!<-!)JV6?O^C2,SM^J!JG".SO3IZ7H7H#3!#U=K<5!;\$6 M<8)93GF(1,X9PCB2B\$C!D,HXQ43@-
!2:/G-\$86YBF:_%CM-3!DX:4WQWH9 MOT8!6UK@#0544*>BFTYASBJY.5YQH*3H&ZRFVZ'W2,P!Y9M11+6C!F!TGIF
MA1E245=@4A%RS\$*,&,"YPF8N?8&9-KPBI*FBM& "!(7>2VEBLS/43:MFB8?C M4!;KR/+8.6Y.!8
R(T"X8\$!C7MMY+9!Y=>4S=,!>[G]= M_UA^6%>B%)!6!XV!#!JM1904.TN%L^F%SXKU!O/IL,N%:,:BTST+T"#Z>
MA3A?9N=WX"XP>^&MJ?&TF!G/(0/4O.EH<8%NDP#S'RYN#ZONZJ:&EI=BU M4BD2DU"K7Q S8"13:.(AR_762HJ.\$?
Q>?^TPUY%2FL8HY@:6T7QR2D." MJ#_*""^PQ""IO!8.Y !TWWHGPSE?6H!%G^L_Q)6!^VKS9Z_LD1HW(MTX.VU
MASS\$?E?_#0_W3!Y.92FR7,O/6_E@,WBG ^7!M:\$5+ ,^@8QE,%OOL&@IH#3_PN(A,?'
LK/%Q>_B'<,&%D^!9HE^_%C5WX^N M?FFVZMOO4FY?"NB!%!1T&G)&<*\$0C!(889&&B&11BE*E%,FDCGXQJ+
(%0GSJ M7-(!*T+2U SH_>T&H!F#XTNP30K6W":1J->.%?F4=,!+V/LV<9<5>,M: M
4C/G,B""^4TM^6P!GS/NW!<5ENZKOW8_?WVJBS_GSYL+7>4N,+&+*,M7.YOVS7YS5IN!M7D?/#YG&@-R@E?%
P(M"8!H IRY \$<&HK\$X!0?^JL!4# MHX(=A@/C#SM_FOV#EDMSVUL7S!HHRJIRJZEQBL8H#"3"<)2Q8CD>8YX&!8J
MSPC/!9!>BE,;+0!DDTI>XVM:UFIVJ^388OT(BG,&O="MF7IAJ^8\$LC_FZG MI!(LG,E=@,B@TL_RCFDH0?JSSQ?E
QX:X/H&WS08;"4W%SR!2=K9X_MCB=P9^!>V(!<7-U>RH-N'C9VW4/1H8W!7%Q!F_Z3&S9M:E TMY?3W4O. M-
W=J4^2CX5!3SHLU\$W:Z5!9RVA>+NNDU^6.P9HTS-5Z: ^XE%U&>"AJ%!H!@EETJZ!K!1PR\$+QP\$+0L>-<:
(\$!PKB.WP.%!7<\$""9#8@Y&%W4KS MA1H@R8YB#!B;#H4UXMIWF!K?FHHNVWJ:PY>F+J/93!O MINCI?>O@!"J:(RG'
MXPQG_6'J!V:T5KO=*X%_!KAVSR)D,!8N0BEB(<\$9UW* P1C\$/4YSD25\$D I+DMZ Y=83?<+ #O M7J!TQ/IN&5MXPX
168:/,!,<,RRQ," 3J:&VY#^QT5P7!YO:I:Z7MLJ MW!7=NX:V!%I9S:6WTGF/=S^\$07P9U>=20IG-
^X\$!AWGL?/+ #V!NT2_I3: MWV^AD89!H^)=2=25TAQ:FLFFBI"@>=VPI06#S!S!_!R4US"Y",S4N-
@GT5FIBR>+SMZ^V"=6 M5P=C!H/N)O@_CI34O_+5<L+BX3"5""0A9)A#DF!JP_U!98*"P+07ED#4+< M0V,N
!R3=:_U!JQ-!S1:T/FMIG8R0!YZS: _UFK:7H!079:7!ZC#!=-
MN>=2BNJ3YNES53V:4C"#GO:PLD&8JK!4J2G^WU8+DK""*4L1B21\$.58:(
M#!F*\$!83R6)9&Q!SP2A+&L G>Y!K@!1L0X,H\$!#V+6Z61= +;#1^N4!L&E/7)J78,2,5#H#W#9-
I3NW2R>?H1=JGH8?_6"K3@?)=1+G(> MW4DY+>"6&J#U3:9)KWP_8C=KY*:BEMQK>,H DU-!\$Y: OPI&YP+L>
!CPE>-!0APZRZ5^6^ (G2EPI@WLA5>H=I-L.BG3^0IF?AF6?:.(MW.M9FY'FW M.:B;W-
+E6HHK6AHTB^H=BIWS))%I&".2U=.Q1(1H7IBZA(2R(DM83D"A33>9
MJ>MN#XM/*ZHP4/X*62+RTS/2*!8LLSA<99I@!>L&.X/BL="!C"R3L_VI MA!BLF_6PH*!WWT&G72VSVI9+KG^!W3-
9%Q\$IN\$RE 9!3RB#?%(C2+\$4*)S(6 M6&62@69/C1&KOCJ4=1EQ6VARUI_NS-J7485:FO7_M0\$M?"I
MAGIC)ONT=3LYO5G!+F9!<I.%-/8F>0X_NEI?BG!7MT_!0!5MMR+;#I^_ M=Z>N_IKJB!MWA>D5L&M+)^67-
M8H#6GB!AVW5A!S!V(N!XWXS!AW!H MNA:6!L!_O.DU_2<\$%T!6K3=9:20#72,:2R
M3!6!&EI<#8!@!#"12:V!5H3GGD3ABKD=#L&K^#F1?XIE_??!7!73!PDIW+? M8E,C!1W
H@D&U_D111%1!%4&%0?*:9@:ND*" =A@E.E2,Q!@!<=!"U"?V)3M> M\$&V8"9@A&O#F!JV!"PV!S@6SHB\$.)W:N9W)-
GS/#LV@I:X/4)LV\$E..#E M(JBY!>>(G)3@R1?!,_JCIS4MHCN2T"/RW<;O_WIN37Y5U57E7:98.CU91T MOH!69X>:-
::Y^!LT_0WI0FG-V5P= LM>&&EK76V/U%8*6?A.%;+S 28:,2 MSUA@4*&=3B)6!&8IF4#5!3RI@-
!S:&GBRQD).F:2RB+2%2 I\$68L0E0?5%"> MA:D2(:!I)U6ALE-:2!XJH3:S0+UWT9QN84)R(N!^NJ4= MSQ&

<+2C.R\$IEI KLRB-TVf_>179CO># AV>YXR92ZL><=>BZO-ECJ/_OVR?1AU&^M0S/(@
M)DPGI*YSCC!&."D8H(4A)I!%2..D9"\$)%^MZH:X UQI<?&25RK9(8ULG#%O; M5TM8OL5\$QX/9'FHD9.?ZLIC?LYC
>,FY"R8?T=S&(&BE-D'+M/RT7.ER=P1>9'R.9I:?.OIM.AEKDOMT";1H@AP^I/@YC 14DH4.'9J<<9S1FJWI&GDK
WZBU&Y-MV/FP>Z7""IE."0XYR0?21\$ZO1H0Q163.@>NK&3_Z84>QUL5-#J M94?H8C_7<50M+IYH5\$LK+M)
H<<>_%06.;FUI1J5>CTD4I56.Z>9PL.W&12RSI!>P M31FB02FETRI!>H-"H NLI0#1%)>_WO?IGIB_X?
H/_O _E_P!02P.\$ M% @ Y(-607=-Z(>0 A72 EC")! M4"7YUTDP)T\$!0+YDWU<9LED10REB? ^>WSI>ON%Q_-
^00_ M* O++SA/BSR=? R7O_SQX26XO_S/? T? ^.? R^ _/N!>_/%^DLH X7_R M;(EAC?F7/Z?K3I^L/^\$O?UL_W/Z-?
SR=A.69;1#/"OFW_V/_E^W+Z!/=Z M%&\$NOBUBY\N_PFM,B8*#H\$K1%5" 8I_ F:6N4LN*ZW_GX_AJ4:&.&PX.
M)8P"YI"15 [KYZ>60KJ;W_2H M+/ _U_SMI?OT"3I_EY7ZS!/=8'5D)16FV^<7J2PWDCIAW3ILO.WZM_@XM>@ M?@NX
G ^FV5_*O_ ^77L:B6"YF^ [++ 6_?I0I=6-) #9-9TMJJ M_?5/_UBH_O2UP1:C8.OZ9OG1&7>U_8O#;&N<9MUQ>+#+
I:N>LR7BPO_M_N4LI)QMOCO()UL/ODDKM;+D_+3P+)),49(F A@TA1PTG(2IHC*L*AD_#Y MKW2OB/"_2E:8_OIQ!?
57<N1?JSSJ!S:"V0CESG)XMOQJH4>_ \$"_0Q&B+9_M@72&28F'(R!<'S46BXO>)>* #JHN H"7:A_72X<5J%_%^"9")
MIK&BM2!_MNA<*3_I.H.\$*272#A*87U2S)A M&1&_ GCL1792+W1 FR1<5(R:BLU!Q6Y(=E\$#R%J#8%\$0P&Z5MJV.
T/\$K\$7 M3FSO.&DGYRY@1R%1>Y5)?_RW=Y7G%M"7IT@1HR48#UY1ZS4I&_M_ID_#N6WPLJKG>HM)!M%R
YR9E4L#K_S^OI/G\$>)%RD0H0"R\$IF_C.9P<^ M>R9DDE'U@_@IRRI%SAI/^ X5J8I>_9_?%T^6'QYWS">=12^
"&&P445_5P ML00(A5GFZ0MWOATLKA>1^J*_22H.%"/6%B+M1N%U^G1X03Bj>_C4*" M""M%?C?
92!H%&AH')8*_5N84'RRNLKZ>SMH71 MX@:&.\$2NB/;(3_E10#/C_?T1%!:Z.B+IBBUWUYO/15W?)5YE A'50H3&=+
M@BZQ^&&ZGN&\$^1P5.@_H'1UER2OP@24PL6BAHV1&'7<(W%YO/_5W?=(YF A' M5O^'9:B9*_^?XZ+V00E*B5%
HHBW(A@2L1(>8HL^>T'F3PN=+BQW_Z*1_C_ MGA#A;+I7WQ+G1+I
(V1N61W6(GF4X+V)=&9I1L\$)"GBB)1#43143J_1R65CCQ17R^T1D18E_#SU72.JJ6\$
M*9=TD)+B(^KE;HE2V#@OQ6=+SU_"/N\$.Y53J1D>HJ:CF^P@.BZ1G.3L?.'22H
#_#C_2>*L0L0\$.&?>QK'(OWG^T1DM17IV;K6L*%01..1_2;)55;HZSN1 M(D@7%D1.0@7?)!Y@(-10+Q161C.?S3-^<U_X?
2)C<5P!1_S MS>?P D(6&1RK9Z_F+HL69JIM9?>#1L).!":A""8C2;U*>&XL_1^N.CXBK.-4\$=&Q@EQD#=#/OO_MJ>
MO/CP_B8O^Y5O/^;CVQ1X1S0D27@9ROX&.*7R29;KF+DM+RG7)1>TOR+M'
JO#"/B%)YK*4\$;IFSVC\$SNAVK@#^'R M)@7C%)@/AH0+4I1 W".>0C>I/_?+YE@/K'@E &C-Q4MCDRS8@%"D\$EZM(HA
MOR?2X9BY1"Y!@Q=X"59V'UZ62>ZW1>_?9J&N8\$3.KD_6SL%Q^
MG1X_>N8G>?D'.6BLA*0NRHF8""Y,\$\$18757N4'O9E#L1_783U@Z2@+ (6 M1@<0.UU_PN413\$C1Q1FN?
E)N5A_>2FPAN71.06\$Y@(-DK6BQ@'(Q1^YEP>8G MV4TC_P8SA_9!1SAZN10089I?2?N")Q72-MDP=T-
FDUB2ECPJ2%E1O.@0 MP3'A(4L=G^>1021*!P"ISW(&J?OQG"H;JV)#L!UDWCFK2;/0_7^91842@_. M9@&S.X@LNU1_?
S@*)8YIK MR?RE1A1OD!Q(EX(HY#;&4-^1.(O@3(X4=
(ADG/_Z=#1VU">CBOYTF#F#%W@)4M_1.ZK+432=8B\$@V*+9X'2K54IJ@O\$SI MH3T-<3J;KJ>XHH-
SDZOS:3\$CH;_JGK^?BF_ M1*XX>IO!>B5_L?K.PH(%+O&1NVB=;^VH\$O;N'LX/?+@ZBH\MSC;-X8-\$ MDHNP#HQPQ
D:#5YY1X(K%+U)UJ.G@IGU178O)=V_Z2@1WS1Z MCA=Z'19GM&J=V0T4817ZI<_1I<"2EJRWLP;\$+ZX*%7V-
C1_#M%S+B'W7 M:B#Z#C#T>C_ ^&7GYIC7%PH_OG6&H3?T?F6.7Z_L,Q),L<'(*4>2'V^>
M=)C)6/<2?T/W1PK1AX0YV XJ6_#ERCAR\$3DB11J6_6 MJ1.G3("W6(N1>J8/#_W1&O1<I
K125#5214=@.KMQ;H;EK8Y M@R@^@U+@6>U\$"\$7;LG61BA:9W#<0;8=)M-'PW^>^ F&MES%OZC41O-M-\$4@/H
W1YQ'(-=0\$FI&(L9(I9.0IQ_PIA/'H_@Y2A!>P"4DYPWKSya1C9_MZOYL_!E2C16)+J_1')K@E-BR%F-
YPB@-8D3G(\$&5H7H!Q/RGC^M\$#P;.% MV#M_SSMSSV:S.8WV.99JFZXD5/O-0(OBL:U8=KU)R M1C*)08L7F/K-1@?
4S6N3ST0IAHKHP-XW144F5>1L@P45WI!)2D.V= H(E
M)Q+M%1<>ZJ/7OHD>UWD>"#Y""KN#F/Y4<7\$1Q"#M*6.LPF@"/H01%097/CV@:9R396+= \$QZNE&CIPRFYRM6V2=C
(0<81%&O_@YH1H2U%L51^U!" MJ>/_=INBL1=GA1D1ZFC4W""16JW.B!_A1*T\$)A=\$UXZ--GH*3T'6511."Q
MI&MV'5JOKZ4&_4ZBA4T!>_&FHO5\$HL:6('C%U<Y L><=>T_-"TOF?>0H M0U7QDW>?>^1OO1MQ9L/ITJ?GKYH>
1DPROZ?MIUAWK14=ZSXL_KI?234G MFO_2M%<C930D\$^H_9W+652X1?+UGD%\$&\$B%W2K>N3MM!RO&N%IQ?
H97%=7_M3HB'WD&4N6Q>_W*9AW)O1%CI_ ^S1A)0I..#.Z7I)
MPJH)JH6%OT_7GYZ=K=8DJ^6+;VEV5BUL+FG_ ^4/X=ND""1%=A%\$#"00'AA\$ MKNA(3I4'4'2X4.3H81 TF/('=KQ^B?
I-HJ0.<'A9LW">G.Q*<-ZX*%RM MU6"Q3E.N<_!LA>Z(I:=2M7?>=O(QIZ3Z\$_6HC1PX1(YT0034-IS1;O_M%INN4^=
<35B43BB>0.AD0.4F5.0300@+ #18LJ MEBASZ1>Z'Q(UHOP\$%1J1X<_C1Q7Z^XVM2P;MEY/OTZS3C/\$^8BM179012R
M-@-."3Q*#BRBIM.7)9Y1S;811-/BZ"#Y=X&C+=WGLKDNM(D4F)) HQ6 MJ8V;DV(M09;2#
IOU":QV0D#N.NGS0TFMIHX?&1EM_S2%CS7OYT+9AUA_M331ZJ9W.D)F-M#UX B<+
ZX"4TZ1X\$K5%CIWDS*NLS0LGEH(OP/CM(-B1L*M:RA1+8&1J=6N0GY1B1D1).ZR9TK+UK;IX0JGQ M"G"C-"B?
\$0+;VME329&_IUAR>*ZW M((OYZC.0UO.1Z+Z;4 LGF_CWW)". M91J>.'3T?YJ#1#4QC;8V!
16D#CB,>2(#XX#/QS"=T@9UYH.11_C9-1#88SK M:S?%@AD=,X4Z;-
"27L#OD@+F=#09+;^19>W0T"QD1D'N0216#Y=F17+MJ4 M7%1C_!96TS3)0EB7C8?B-(E#DZ,0(?
@P8LM7F)QL8@N9>0<7.SAP#1?+N MP*+<9N+Y=;VQCS)+@_73^CG5 &N:3K^3"?
<0W9Y1C+D_+G13Y1Y0DB>3;JSBK0_58P&7.0\$O M/FGGO(BQ=7KSHPC<IRF_4PX&TY!_+O?"=K=/
J&V)AD^V\$D\$9+2&*>K+; M7)R3QLO0.H7AD23NA1"?*D=12"71_Q33//NWDS>_OWC_ZLW1#Z?/_M>_G;Y^M_N+=^Q?
^X17'_C)H>MJVL>60BIRVWV+D+1_D817.122.8C\$=0*4@GQ_1@KY M_M;#%)S'2"&C\$ZV#1;T1;
1X#X/DB'1J0H1+WEAT'C%D.2M9O)6 Y> P4F1 MHDN14" FO1TT1&H\$1N:@\$16;
X=1+*7U&1E1FSO^H\$2P=H>A=HCA91!QBZQPG1!#/*_IVC'FTU#N SK7"Z1IA M=1TGP0IMH^+6*I%_ %F1DUJ
B(PS3YXHCP.60F^)&1+9L_@W%.2FS=3QB1@12-"XN71MX=-.AU_Z7;+ M1W,N>-#"V-KA.1\$JG1#
Z431L(NZ!&6S8.V+^_ZC9-S400;@:2#0#E1S>8Q3 MD(R;E^D)P11?3M"F3QQ4'MB194A1H0^<C1LW17_+A6==.1LZ!?)N
-(J) MG19U)N1SW1WU?QNP1EN.9N17"S_#L1T0:311S1H;\$7JR=U(RH&=+96R=D M2J9U/5(\$COQG 1\$Q-
W1@_4TP'Z'NO@Y*0220M^1>\$Q?J<=HY6"\$?<'E=)%I+RW70IT713YC_5D1J0(0B7E
MP1I@1\$7QCA#\$FM_27304(@ANV<1&...U_ W2#K)_19MFIHJ6&Q(138;1(C_M LW5)<7Y;J1=TALKZ9K?
(+K14FY,29>1P+3I_Y^R22LF2"8^<=>F#U2HY MYR4X10)!K6(JY\$RU;J5T_1C5X?_60HJPH=(Y1O10UP+V%<*.4=;L97?
5@0 MQL_P6DW+&WD_K\$VZHW1N:O/ X(9B1Q2+SP01Z\$6Y=DIQ1&O?Q_SNCUV8_# M>235151WMA1MC?K1
LEN3S;K;CUA-1A:KV//_3V1)1-O!T'6#H8W M1H>_-(^Y=AM-LOFK?; MIPW^N?G1:A)M8#PR12@K^V/_50V;1J?
0L_=A1AJA1'1=X2>.@#? MS3H@S_:9+ QDCPJ4S;6:0V;0D1M9N!?:M+9QCZ^S&K("XLG_+=C<_P#-@1>Y M)3OE%
8PT14K%\$DGO21J>BBNB9Z.^2?7 MKT_/O_DD*MEGKPRX7X&V1OY4_"H1R8\$X%D'WN&#J1L#7^VFHTDF
MFLN\$15Z@EQH09W"E%B)L82A% I=1G?PAVL.C.K"V" 3Q'R/Z@W"S%9=QT2S9_M^J337TWG*?
I#&1P16'Q6'F;))T.4OIM981@2G.P?T*)7+LLC2.EMP"#Y& M;F/ZM#@>0@=F_G2"NGZ5.%GQ?+1?2_MW^>YY-\$?
GC1TED8BS7>B>LM>4: ME*Y^_J/#*7ABYX;W+K23HDC:NZ1T'9XOA%=H13B_ZL1S;19D(35&^19UO M#1
1W;"">TD.#1 MK+3U1.FF4'U\$%5 MW &\$?P_3>97JZ?Q1E.%1G1D2Q^OO_V=A61_Z&O1U<8QYFP0%U"Q4N&\$Q1
M9(H6.F@78O.15'M1-FX:67=P'4"=->23W;T_OA3C>2;=53=>%_SG\$,"4B?" M;891*X1_QXN2\$DWP12>
(1\$O=N1EBW6%V(+5V8%SOX:QV#B>AX_1K+9E;353@_MCDENP'E:C.BJ?>W*(T46MNM6_>A>_5'56H-
&#S^&W3*Z=E.OEWBES#_MS1_NFA=/L1;CC>NS&KBM?60P(KR.-65F9P@DZ'@-D1KZWP=;^Z6&4E1J MAT3H;*
1\$GA%1.6\$AG2YK4BZX1S1&1\$1KT7C2:A:8&S1X+S(4Y+9N1;OX'N2 MUEMASE:S*/4U#;
(3U):G)&1#91W12WHRO,%&XA%4->18U731&-1US.B8QKB=+;QK2>RRB=Z X;75IF*(7C&_M_0CA-??*8TE/

K:=/56W_)TB#M&05V".F. ^KVZXXK\$6N:RX0 MI'20E<I6D8,A=>M>SH\@K|>:E*<I,8I65P=(WA==X).!:"(\$N.&53-W
RB M3FA KY007\$D|P 2,/:D;>0SCDV=U*#&T#L9H.L:1:T?D%:SH.HWV1=2"1 M2K3AO.!@R-
@VR<\$;#YN|%4=M(K' _BGBVK#X'-Z(HMGN I/8ET=96F@-@'Y|V>=5B;:H/K5M:/ M)+!+_+=FB%D|G?
KZB9=)F@DQ;:JW7/8=#+/5+!-70+@:<#3 I="=%#AD^T M LVGB,)H&.A-
4#W)Z _+!+:P#F0VGHPE M+G256R&@H=XX-5TAFV:D< DA:Y%MD'Q%:!"5P)%T6*3-PV:SLZWNVQ6)=.6VLH#2+Y
M8T/:9EBBZ/S%-URFZ>KFOOA|6"XI-)I8D3WM-).Y*8WEQKTA<3C3%>JY)5 M>0RN\$^(R"JI?
P|NBX"),=Z)71 _43Q@90@ MZB2-VG @UG|*5)"5P:-#6# M+9>J|.4B1\$U*%%S())4C^/2&|-R.*Z7,=AM3L:E9+
M1O",,":|+MI6|^6W04P>-Z)WU" _%%*I&9FQ*\$L|Z*5)Q#5#4+NH9Q/K MBVND@("99G/K6IOA<3N8Q|
(A^CQ^T-FQO-XK|A.MI"K.:3 I6D^WFFJ.U M:~N L:2HUN:P)E)*#4X"MTEL _=R37GG;(-|R7UV
ML:U2.G@7NF/9:I0SD (R8R.(7)N6(T6Y,48-V2NE6Y#X M:JJ*#J|UG|^AZ|^H#E87T2 V<1?GM:#6=XVKU6UA-
5XOR|MHB89Y_7VQ>V.8)E _# _+| MEVKC|C54M)DN=UY 6*<9+&;3=*(HN8\AN3!!"RUZA _!V6C!E.QD-J&XYG5W
MNZDYUDA>B/F:J&E:81^>D/H'TBPOUJ%@ 3R44DNX|I'483EZ1CPGDQ:7FB=
M\$T:8TCHX_%4CMS5KPUZ:AO#@975LQN:0'23S _\NYNN|BCW\$SCW|@6VL MV2.(MYFV222\$2G3Z8L)5+
(G\$P22O*6)<%.SY8;#B:I:DKZ!/?&UAY+B1D MER.HYR@2|M4#\$)PQ%1"#:#X382 _NK5-CT")G8Z-
I972KSTZ^T)IKJH8?9: MF-5\$N?>?L:(*HOEYVW&PR%6:8^/62;'LO D19JD|6SQZ*72.396/+<'11>
M.PV%|.I19BAUGD8V)>G:5TL4JD>L>C19FG'4L^GJS|:K.H(P*M|S _":J|MM
QUI+LO\$ "7M/&DHP(L.HK.MKS4>0|X)FI0F-PQ6\$.HJUNSM6E1>I" _=XO MVQB?^|AHY %M/_J|O0*(BF&)(+/U=)YY|ZX
)A%\$=|SH+ #U)KM)P:;FY34Y M^X@W>|Q>0V7!D%.NI3ZPU:WYR&W-R"!N-S.W5TIM"
MI?/:V'7WJ_KM2S|F'K4PN8#5R(\$&NSMVK?69TE%8&16%(D73Z M)|_!Q_(44N=N#F74_-87@9NV?J(\$B|VY.H R:T'W
WU8LW) _EN725>AYJ97#PXU)B4HA<#6Y3ZZ&GIU-R)R:ZYJZ M| MZ:F'W|GME.%Z
71#|AK9#6V'WV)%N:SD5H|S).XJR(T1+7C8=2"5F+0)3 MK3?330K:3^:M:NAI(/:15(*AU(JH4*TFG5(.0HN
LQ%|^:U:V)&|^>2'(&) M'T I:;&:FW*EL6|Q7<(&)9='I7&NNQ%:"O'Y%+;FYK1R|7.J _VYK08 MR.FHW;ORAD-
0.:8,+!@Z;('M5(XR09(F**>*,KU8_IQ%|_MZ.R|^F_75| _:M2:*HP@Q&2\$S\$R4((YABB U=H'WOCH _/!_T=1 _+
(CM/3X?..@_6\$JN|6:&ZG MVGP(WPZ|& _^SUO=9^T@J-FEU?GGW^>NHV>L|H.L,@50IB2((F1P1@HGN&2I M#-
!2?I:M8P|*N=&*&6 MF+BG1W4;#71K/NHXK+>X|.I&48WE0>|K=S^ET5O;#|AK%<>%Y7PZ_UB7VBQR M|I25Z7P22
=#:3RN'4;D)LM%UL2-I\$-G(E%RN="T/XZKEA6+1L|S J-KTCF4#/A0)Q6=N,X_2
MYM8AW@_1^SKZ?;>V&=CX#R3UL&"5S|4^AZW&?B0O,F 8|A|.BJN7T6N|8_BO2JWLP:
M8KZEPW@00:0PC+>O(<|ACBZ,I|8#>M.X5RP^FM6|MY2'E'U-BS7WS|LPWQ% MQJ3|/BJH?RL-
C9M/U(6:1=BU" S3.5.J8\$5HE(-VJ54&0> >&;>U87KK M5T_HNGX00+|/_|_|_VXY%S|A8YL2|RK'+
(417MF44N:F|72>1Y WKL5J MBIV|)>;#*E;_" 5ZFC93>#|N<1,S'70Y=/LS&ET-/4A:(TOT^V*1_YS.9G0D
MO:KNW>:FGD|S>L26M|J)2I7!"I#YU UX&_BO3NC+!_.1LM:3|UX%("7TCO M6N%ZP:9CP5@/3#()J*#&*T
B<%&_TUNG7?@3W(&MBNQ?6:374K6%Z ML%QOL+_!RRQ':O4EH=HZQ\$%2=56CU\$QD634*SAV|K"HF|MQ_9L#
|'M+|^U MP/?MUZLMX:S*J*2"FNX""D.=8UJ|AY&30&5*QY2X"J*.NVU/8Q*+G3|J"| M4G|HUT^(<(&0-JY58N'7W\$0:
(|+I6?&_40.R9>:7|YK'4S*)_0|T41W&*VTK0^QW| MTKBMN <"44LU|MM_|BF_4.MD#K,X|HPI^L>
<|HS"QU"PGGF666PCT|@IE9 M(Y7 _ITA|L.XY&EZ'DYJ=M(N?^)+2.U.MGXN:S6-I DE:33P&3G_3)QG=7:P;
|>+.8D|Z|3:UT?K3\$*>S38'IQ@VZXDSP%"3&-" Q8 MK*VY P1.W| 2VBA*B4&UCBCVIVZ|=45=U&^>=:PX.+&
|Y:|GP8(M#RYT?+L'D!:=Y.M#HVW7.L4/1IU6^|5#/'C:_.M43 C|OB@9/9YM|MT _+?0-Z3_MG\$5;^|)(RS2F7.HE(C.U
M40SM32U Y>RJ^VA*|FWHS#Z4UH555Y"78G|&99YT_WB=-,E M?E4+!+_ 6:W./F^ _=XMJR:
(T(5G(7M01E:42T|S\$Q%Z)%R7DV@:5:|&K+P:B/ MLEWLEB<0J?X+H"KG _/M:X^RV_*X3)|+B=5.H25\$B\$X*B,6*XA-
/KK2^M-3^>ZG&?E#N#^X *|P_B|3:'5P.0-KS?&(FT^#&:HPI7NN+U"S:9.M|N>3V=G MM!5N.T<6BX"K_?
\$>H3|+CZ|JMER+739\$>NDW:@:1VV0GA,1C:;=&4UI7 MQ_O)?#W-E:7I5|SJD_S|B6YJ=T39_25*0%OUL?
H@|NZ,X9WUBJ."XCT")\$R0 M (TIX|?#KLYJ|2C>??=2_CR/FV8D%|I"+6P5*\$B MWS()T9XCS'J;SK)
HARON" 1^LGX6ELOOM_YF6TZ<|&P\$&3L.U=O(4@ M98
D@@PA*|9=ZR2*00CKMKCO,1BY:~|Y6Y5T: ^ VR/NZ."4VEJ#F2H?S7.EG MVQ5S|Y3IPRU@K;B"-
\$|^33/PE|;EP|E9K6)6H\$H\$GD_|<659^69RC|2 MU%.78IP+|=6<: MA7\$ _%|/OPG|5\$X|_|Y#DV'BXS"LI-
|D0S2S3Z"#JS6,>.(0\$|2\$Z1VZ3 M_KV<(0=8+CI3D)Z<#|2#A*DF/#X|S&;Y>+0I%-C61F+Q%7%ZPHXD6)R\$56
M14*1S|"/*D _I23D*I>T'R@>7N\$() MG|G"/%<% H|(+!|D(XDM|OV&HM _^7L|I/_T #E&|AT%FU< _67GRKK_N7 MG
AEG*/_X|UY"KQ7(M6D@>_Z(U.TD07.H-O-S5|H->/LL370USMP3*+1/J=HH0B;Z%CW&D(F'G(AA=KK2BM
MVU3<2|A/<TYQ0MMBRP\$P92|3HV3-QZF+?:Q/MZ#*QVYV'9:64D=16H^9VX.L<=-=AL'#ONVA#E1.SWBK
M#U?2|3:;&D_-9Z|25L68Z|8FWOAT#<)*^+1%EFT.N:RIUGCXJTY%|N1:8 M7CJ_VB4+?
V/\$9=\$ODE9>0'DPQ+YM48@"EV'KJHZ(2-J*5O/9KM%0J<0.E3% MMUL7'R'OL>|EML4E|G|DUEZB)VSD8-
(C@>LCQ4D"\$7ACG.Y@TD'JU2BK>G M|.QP*G>O,6YESU"X:"G8#LS)R|/E?+JNDW7F^>7T6_W3ZIR3B.R@COHR.|R>
M9RDXP/HXK+"5#C%QZT+3G92.VXCA*&-3",M=("|GG9*BZ|U?K?S:A*\$R5H(
M"=9P|B|LGDW1@C|>QV(Y:MVZ' _/J|K76(WK=Q^F|H|HOMRL5I_7\$%19\$BT M(Y.MM|_6@L&|/?&::&UBT&M
U%G7I*|^1_7W@|7AD=0.LDL//9YM^L^1 MB\$C3C9IHSS/<*R>3SXOENOI?V|GZ>QB?N(C|H(@AV2Y(7I@TZ?2.S
EH4+3 MDN*M_2-6M?JP+6|ZR@?ZCRP_1:8<_Q8*?TPO.E|@^M)R355TC|/B@*N6,"
M+RVYM+H8EWT14:2>I00/9WZ?@;S<VEZ ME|G&?E\$EL5H"X<25&W^IPR\$FE?FK--HHA5;
H=C_13 _(.U^ (YXWAOS6M'7X:| M|S|9'R GI+/9@4NIP#)RRA_XNAN5|8= X#U(Z)^D|3*8V#65C\$=(&V;VW=G
MYL_EOM'1H'L6))>%N-&RMG9+P(M|I20Q.C4W90|2D).D6QYERMJH _/DDG\$*0ZO\$V5:"\$%&
<\$0@)\$RS"C7NCM7ZWE?JQ7B MYC.O|47:00#I\$|RCHQ4BTYE"8UWGD\$#BD#DLQ2KK7.MJ@ ?(Z6KNUV/T?G?N
M5QN1CW@.K9:KR7L2_L;" _HZ+C|OPY=,TA=DF32Z3;4L_UG&5;W?6B|X8<I M+W6.06NSEQM-JUS##/WM"B|/\$C
V4AJH=|%:UE#_#IC _>9N\$|7R72^8M*D+L5_MZFZ*(S(4"Q04HZ+@V=G"TLXN <0#34+&+UE(>|5VP\$OYQ<9YX)|/+
@VO M#>53I6 _(|RK9|9*3%KJ:C|D0-R|V-U'H:2V:"*R#<_9-DWG|UJ'E30.V# M_VZS(79.)%|=\$.11Q<6DLV:MZZ|_0-
*X^0BMCY@A|#"V|=GRK1 QV%K(|WT M:(C>G-5C^K2|J)<2M7?<:N(|I4Z3AQPSTK9!!RYF:|D8*Z.DN)+MY^/LM|JX
MB4Q|H.%:G-NH=SO?;_L:8Q%4LK|/#%J'6@<@D-D1>)R|B1.8CVKA?P|VZ M@:|&TKA3|9L:AY|BQY-T|E|2A9FQ_-Z?
%K@|J ET|27F.L395_P:6>|/JTG D M6B:_.GA67WD) (%C.8+3LKHZE|N|PEYA+;AX)Q>D>8KZ:ZT|U/VVW47K M+;
O<9FJ/C_BJWE:U|H|"D7=)% HJ/ 6&.&4!+>R?2#:+T5DN_7O.B0UDO5BMY|KFL&|S>|/@^9XZ_4H>PG+Z<3H-
^.*:YO1>>#3PVD8|H7D**@;0"D=N&TW>;P8OCM)P607D6RU"O5E MV%@@>04RV""P8;SCJO5MUOV4|_4P|S;|K*"D.I-
=|_B;/_+I44^+!>E3! _^M_Q+HR_FAR0KFUU_09Y MJ|T^#KXX%*)7E.6Z2H@P|?0G8"U3^9P+5DZFC M7|A-
_%FTO%E4ZUR'(DRX"W6|K06>"Q\$BDR0G0"E@5BD5E1(H|LOWGO)_Y2
MV3|0KHZ|>:>%"MLTBLOI&L>4&.SZJ)8I13|@=)BY|Y<@^8!>?H2_-><6I;S?>UNE\$MREH.7*F-56G:9B-
S.OX3|WQK4'B^MJG?B6|5QV M7"S2AQEN.S0EL>+4.T#^>:NB:K%QXBB4(PDR*SOK\$ |B|K7(V\$|N<-@5I
M|JY.0.67TFW8|V8O9J3@;Z|"?2U YKD\$=&1HYV@QD|7""06X_%F4E"Q672 MQ&7J_|.2.BZSF*K _=+|6|_#N
T8=EF*|HY15MO?>X_#I-T G'TW(=ZO:~9U M_X_JQB4|UT# 4:A:P0E60!S|@_7J0+1J'4V+H(N27|XP*V":.6G6BW_V3?
M|Y\$T+H(E9@1:<|OZ|M6&!=#"32W:"W&SK#P MX<^+NCQFHA>6%T 3"Z@<'7C4
3*7@2E75.#B\$ "QP6#A.C|V<0%.Z>O+5 *G=(_I9@B:FV+4Q!:=Y."%*@9EEM:V?OY|%(C0FQH=WXX M78UNE,|+8-Z?
QS&F9FJ_DRR8Q":0.N# "KX#FS:;HG=W*&3C%%(3<|R7-&Y:8_H\$0_UT= MG|RS;Z&MR|MO0S:&
H@^H:|V|\$&PZ:N1_V.*.H9C.3&HP\$M6_#%C03O_M8JKYOS(CPY(-^SG@>R|Y:C+|\$YFU8130-

ZRV:9FOYK A^D_\$^3MC5.240\$1H5E.T3F3^_.UBS(/@M@NWIOE(B^FU4N2|^D(=2\$!;I4^WZ=/%=)NE\TC M%3)?
ZG6!K(C_JRB"\$K#)8SP*SH6B^7_!2#^"R-T^C-5,^7N>+H14PH^S-/>W MSQ:OU_G<5_JHA8E6 6HE23AH:G?@0G!-
R)67EKNXUV^%S!W!/@! 6ENT\$6\$! MGNKY9*VW51J;G#^*!FHCS-^_7_)9N<@#X8IHH)Z4#5!6X4#4K@NGB1#":!
MK8=^!\$=^N JKK2^@;32&=XNO#V4\$K(Q^GH^A)^+5D\$5(0IS\$2=;D&=0=^E M8EQ/>"A!P^K X3?
&7PN)AI(50VNAE3*\$YLJ9@1.F@+1,Y<4\$XM-D")!>JEC MI2H 3 X0<@9N3, 0H52GQ M&+W7D&-,17NMVI?!
!4I=3Y<^0R"LF6:Z?A3?+GSY*(J628U,@Y0B@E*!3DZ9.12* MH5/+ ,KF+>QN4G!W LZ Y"#>2>^)-NKJY&S!;,&<-C?
F">.,^,^CY" 2T\$9S MX)*S8 4*E-8YV;SNY&&*QCT#C!#^W32;9H+OX "R0V%#Z?+K7WHIS JIVEM
M&P8G.209I40P/AF0FE-4XEV@/X5@445K1>MX2S_*QCWX!H-5\$T5T!Z_M9GCU M6IW11N'66X4&@?E-
+V6E("K+0"26DGL!^9W+NI&? MI&L>YIWCVC&*2+*7@#516P6*(@+F3#M#12V+ESRUOEUEZ@)QQ\$^L;(JB5R/M"
MS!Y36;H2&+97*D7_\$%)\$8AA,+0%"V20%UGVQ!)1_E&@R6^#X.F)BKH"U4W
M#FE5K&%;!PH=YE<%WS=#WHF)C*P7,I6K?)"W\$^*N,+AK1!;XBZ1\105RL7P1TJ>M"36.#N-P;1&K#-M4
/70!RR5!E.EQIOZU>RPV M!F(A!@91^H T?>WT50^9V!096DUOJ/=89ZA;ZL>R, Q-M94RN.@T;7MH#>9
M&_ID!FV\$LHI9CJYUZI^V-16U4!HT3/R^ER^E 0PH&!K9!++&(M1SPM&-' M!OWN+U \VO:%VYD2BY 4/&3^ZVA4
U\$5!5IFGWE4!C6GG9+^KNZ!7!LNYI M-#Z.4COPQ*!8N<;E)M'+*TQ!)R01*DM!B*C).W54A!HR25;;6 V^SEO\$C-R-
M;31\ 3J.GP/(&,%(G).NTC;^V!0-72NP0 _IO/B MH6T^>^>'5/6"PZ/4?QM4;771 ;K>+J=?POK?
SD+;.#CG.80^F^"10AP64@ (5 M;0>ON011BA*21R=C:X-V/R4CHZBQON_8F)OM8L;W,=I-MK"
(ZKZI+!7>/GCM4;N!3<,6H:0!XBP-MR3B=O_-/8?9BOIZ>)HKK9FV@>20;R%.G4GOM9&@DX@"\$+X8(N%0;.:?EQ!
M_94^>FMIZ !7!N:>!4?&R=@^TK\$J&!D!6ZK/=U0L.MB0Z!!WZ\$&B)!#K2T#. M*62NA;&V' 6=ZZN-
)^!Y/T 9ARMT5!B?;CIU3R=T^Y<!)\$K#L5" M"P3F M(DAFBN\$IE.3*
(!1)^<C^+J1CNJ^_#!!C.WL6S+@.C/A0QV.Z1DH3H(1B/C MZ!VQ%9S2F(7!3X#T+J!7UZ#PJYCRK0-W65\$8L
M1>=DLPM*3G\$F'-1T+N(F;D!L!C>XEME=4!ZJ!3?WZX&D!TDK<\$*H21M.XYNT0%R'<<=1!^P!L.%GW@):K-I
!+=A'9Q\$C^%S.N-B?R M-8&->TB47>^3U75A:+ MX!3&4L:EY%3\$5+)3VSK'D>X6YRNK!6QRH'Q@=(VQ
ZZW2WQY5M-6SCE9 M7;X^E\$+;C(+=79XY):V&,60@L K8(JWF>UW7;JC@0XQ<8CV%HU%V8%=.:?^
M!BB6F3.70=8QS2I80=*(!XY5!P6N4X:6Q):A P!AU!YP<+^Q!<4U9^UD MGD!2VKY 3>S) M\$*(>&SYW;.2#G
5CHL24@M1>Y<39UX&#T5G(YCDV>9TV""T-
)0&V^+6+!2=M0J<,36W)R\$\$(R+@\$Q;J8V>T5=0!7?6XV\$MA!5A.5_#1! M>TTT@2?K@?\$ZNC;R \$!6HC-
NM1=8HB!MJH1 M,1>5\$TG#&B)=6@V!JCDGH&KS(VR=J^CK8?7Z@&UJL!KUV\$.+;VKQ*W\$HDW M&FD
QN2L750G;:PD.@%ZWGDK!3!W!^!>U/B= @>B("\$7&L3%P^UW>HRQ2
M:@\$;Z^2ME&H?40FLF@=//E@R/9KW7U(D/S4.B)\$'"#\$NX7+DW(?WU9I&.3
M#I"RICDS"DEOQUG>CU^IEQ2R9EAZ"AWT9:=^S.%\$V1+H_R(\$X^M0&F-20 M@W)1*R.B;JU4IE\$H(H
J1%:ZRFCLS<#YV JY.85=3X7V?TEIGWIXM9KL6N M@8N<0=M-J7_Q\$+%;
(G19X7"ZCTCS3;T!))!A@Y?"I=I64BKY@Z+;=SFF) M3L O)X76NKHHHC8E&
(T@0ZS!_Y(EY2%I(2SF=OB5.O&KX^EL9>@=U#7K!FR MQK:5!_#CM+8VV5C^32.FRTNH=I3#ID3.RRG!RX!?
E=2)4YIM!AUCZO64,N:GSP/GVD?K=Z&L_6B MZ61UW*M) L!4.O((K%4?0.C M'5C'LF"&QY+VFQ
^0H=X_C.^<;36R=CVYZ!H8M.WGN? RF68K%0B&6=K1.Z-M.OUDR6
3!T4HD;+9KR*X!;=#T!_!SM':^%WA*N3^65R^*UG06!C!+1%;*^0 M->9UM(*2 IQQG-
E.D4UZ!7QKL7V0!#/!\$8QB)A!./7N*U-X!8W"Y.D*-YQ= M!9+SGZ!XQ&BA!4""8H!U?P?T;0?Y!&
M5X>FVACIQ*18)2^FU4N28#W!PSQM^W!>*!6f8"@B2HPY.IHG2C.@HY!BF6@\$
M.&ND93H9%'ZOH_Q!^X^D ND6\$PP2!B^J#Z!RV2CXY"!>8E(OW"Z_E3!M4J*>-
M6+;UIPOKJ!)O(8LCS=*I6%==Z/L?K5'8+;17)O!3%&_1NA!V M?H!A!Y4W.\$!?:\772117F16O!Y^G6_U.A!!%
M!A&!T8\$GDVY\$ K#8D+22>3C8SIO4SPX!>+Y^YIWN8&@)/Q_&3M8O9KBY
M@J+SX!P;SEIM^V<+@629E6^+;\$+T3-C.W.I9@%3G7>Q:9M2%HS3^=*;8ZCK
M)QH7=|W5N2!SFHZ>^#SAOH/MR!+PXR%2TZ+4.L>4TG5WTL&*%".D)@NS)28 M"<>-
W9^V8^>Z3'O\$>!#=#@L(22_7M>-(IFKX MVV/PHU5?GAC&A.R7&HENJ.ORF!&"Y-)3R%9)H!G*<.GP&>3F^!|
MGH""1F53-77I\$YGW!Q<+%/!OYS.2)P42_D0. O 5*D3S5R=.%\$SA,ASC#IY M!B0.L GN67'^<^K8&(I.OEV"YJZQ?
H_K!R^9).K.EWDB146I=\$!T"D*L0(MCF*G&B!57B(>^L0_6.@!UORU5&Q10;67?;0RPE>%O%-3D.J0.YZO-9!ZI
MLEA/O^(!HO^ ^!W&S^(!D49_-/!LT6-5UW.^KM80%W.*OY3!6J_5JDST0
M*WGGIFIU"5PG12JU+5!0)8%R7D+D28!DV5F72HRI=3>1XR@^NA@M?<!)MHGK MZQ!WE'92-^+'S<7ZZK?
O5H!S3L?)GV&9MU"9&#>)6\$AF)!&@!5L1VZ@!828O5/>-HKZ.PA1WL!"_+M7LR89-8UD2C4)J\$AU6%"
M!EIXZ+!WJ?4&+K7UQ^Y(9;R90)!EE M2JXU!AU0#H6F'H8"*)D)9_X0*QCAQ OMD!JWGWZJV#<7036JC?:Y!4QLY!
ML66K\$RNO\$FF1)!A.SBDN.C&D-GB7K\$;_!KM@^!@Y1Z6)H^78"FM.OSQ;\$ ME-I
%\$51R)7*4(H/H+@VX!/%2'HD&E!9GVBS3W77'<&Z_&H&DKWPZ.G^T)
M3+^!L;@F&*FQ3I22FKZ8F"#8Z@WZ(%/Q%'_!UL!<P@8N0E8%|X1KI \$Z' M""Z*
!7F^M6F9MS\$E!@RK(W2%,G5EZS!AA*ED2\$E!INC<@@^QCTICX#5L!O M;!UW@/7G!_%M1^_1HU^J
"ZF_V-0!W^*XI&4%D8DFQ L)OCB!8.-Z MWAY.8D:.#4?R6((I8WMZ;V.3!23_-O-3.K%9BTU%)-%?6.KX*Q@8#1G(4IK
MDMTO!>E*XU!60<"K_9&1MB5TW2=O.3B1GCM.CM,+K_R)(A!QVV(H!D;RH /)AP7+@K(C.B!A MC!\$>1E-U
!06BNH!^!PM5Y.TOKSAHD_R&ROWKW_XYP975(03B;PF9%PBB*W M6"#@+2!JZ9S6137J!B!HY.Z=O>&OG?
(Z0.*\$S/3^-1626)0NM; VO+3_R!<K%K;_!X?# 3+M!_!HM%FHI!>HOUV.L=SHXE<8)*N M4C+ZC#3DFL.C 0%?
6!1J^AX:|OS"/*Z_-A(CORNQHC8P!NO'#=%WMHJMY MCGZ=YK.PV^PI3"Q(3&2&62)!2#!N4 GO)6!Y%B4.FP?
2/U@3..JBX_LL(!Z ME+712&^0^OMT_6F3RT3RJH5='Q8OYNOI^ON%.UFD=(D)\$,E7I\BA#J44!1N
M>#&1C/T@8'N8K!&0C8 P\$-P;JB-L2^YWBSF>H//AN,=&O7EK@VC!;90H!MF*H%,PH"-
P(T4!K(&&SR^SV1!URB(WRTU.BBN7CH;N3!DN2 _JZLLP5BW") M_!AT_.WMMD.T5L05DB9HG7!-
!_I=C35(!I!=!\$5/K'N?V.TWYS!6ER^7<1ZLX58!R+BX-% MTXLCGX@P\$H=BD(CP8I797!Y?M"A.F2\$X;
!D!J;PLX03.7E!J.(< MZL*EQ3XHOG/OHWN5PA!#.->"@2!J^EY4C'L)!8H*%21CEAK6K73*5/* M/M+^U!BM3 ^UH.B6-
H!6A"@@;82V^X.M\$!0A08Z(!_8!J;FSD+ TAZF67;_M^M!6JW@2"@A^+4H09?C!V!V!%>+)E^QZ#8PB&C8MG^@N
BN!"IM#" R!>C ML.=.9!H WXP!_*Q#_DXM++>2A>+!+;1C/6?6MF=K)@%!"?YEFVV(M(A54 M=/^"M>D!D@&2" *
<|UA"Z"3!N>N0^!E!%#8"C2CM(!_D5YGB>/QN*!_.K MB;=6.^"BM0
4&02DQ!&#%:13%HRV*GOCJ+Z0*3W2!KQU)8^_G&ULO<-B+&:H M#XB6/KJ/ 3"M4N+&'U*:5+O540H==&O-'M! ?
8.8^E9O.<86.=E?"V'11=W M!J&M_!+!L!0VD6.88!L\$!" O@)&E"%")_H"0QUISJCVJ!L38BTWI<<(5-M!?
EI>1LSXN'X+%K\$!) M"!&_)&E 00\$ A48!H!CVOT-YFOIKRW!3ZEAT)7<*!4("EG>D!&-N)CS_!M_-Y7WF85P88B#R"U
E!27J@ (H"V3"/K^O1*RGWJ=(CUM(3JL_Q1.E\$!"HX M31YC+3^YBT!D9@)!L9W?
CKSBTN>Z54STZ!5WZ?_W)^V=J^=NEM5T;_M4(P@HP.P+LTBL^F@D!+).6(B,AE3SS4=(,J4G;)<H^J0D=>L+
(L!HVA# MEC!^X<&E!@M->.:9+ZT6^!L(4,6)!4LY*Q.GA\$+^+8>EYXZ!4K8Z7!@IT MK3-S%NW#IO/3>/HP&>?
W23.=#B!3ABN)@8\$FO1VV'DCH/OA!!*\$5\$S3T4K28 M%XW2D!/-
*C)!>O3C7^QZ<2MFA@!OPD1GSS7H!5_!>#R=_Z=&M'SBF">1
M/(B\$U(//4Z"04,!!95W!8+C//3#SQ"B6J_ ^FE0JKSR=>K@>9SX+#G_83J! MG6+@KMCYH&? M\$KQ>APKV3!Z!A-
B:"#D (D4I=_2T6.8!0"F-E.3=*YMRUY;E.% POA@ M@/68 _J! HKK#8Q33\$&\$.79W;A?@PD/E-
D>!Q;>P/X*@IP/XVCR_*Y^M@L M+9BY\$?@6 IA@0E(8H)! "KU""%>6<^!P9P!F;C:Q YQ7;L:P\$ %I^N%608*W

M:"+F6&#(&A Q@!H0Y2B0W+/HF3\$DO)"*HPIHTE16^:&OO)TX=>%"!0%U& MGD0 OE.VW5M_YT?-IX33TAI
&*&G!E+=+1V028.@.H<2*!F=51>->Q2 C*>K MXQ9@52E<783@9?/UK!RI0.A^!^/HO8B1A?N9C@>)M M14^\$(9D>I
H@<(".\$LH(\$5TTV@JPLBV7^A.T_%RI0-0RY%ZXAXA!R8\$5B*0F MKBHUAD: 2P>I=AS:>KJ%?3RHB^0Y3'0!PL
!>|KD|94,V13E+<9!4F#P+W M:1HK MWBQN;/Z.?S1KWOH(4SR6GJYFGO<|FO_MXG*GSQ1K#KA.F%O-
3L(ZDJH<#Z29 M!JYSP%&(D8QL!)K;W\$TC"9.SX6I*J2@:#!%& "0 38'4*(LD0.%!1JBC
M1OU*JO:15#U\$90M+JA! " L+C*"X32O/C\$5.\$F(Y\$-S&>_1GDXZ 2*!0A.? MHQ'8*H>U9!#\$XX:O)4%Z\$+.:3RE?@|@L
U1\$6&K>8P V7JY:~T&%H58";@4#E&\$#%&X M1HHX;ARH|3.&5UBI+,,.2T"!TFFJ M*0>\$&PXAAQ);DT\$-
FY>IG%X+D\$XGIX5Y+LR9&P<#U0!PT'TEE(^.J5W0L6 MP4P%P3\$SN)IXZ5>7W>WBH;B?2W2WJ7UQF.^9R4EE-
*);+SE9 \$TCE9\$H6Z.(J3D)'\$&)&F59VH!0-609B<_99Y(D.E= EKQ'4HNZ=&\$'M)DI<#J?_0!HX_V\$<?
336>H&N'2B!X0\$SISV(+T5B+7@T'AE)MGU#\$#8?PO M=SW\$J7|^_%"1ZM2;0+T4RC60H.QSV&U
%B>;K*BA12V,5H14DM'\$*0TG!V MBG5 LY>:R75K5@=!.AG4*P!:=M!'6B!@ (4R=SN<5CT0)10.3%L23#6/BMLB
M=2:CA:16I8-\$YK7IT/ ^U>3!C6!AK/U6!&8JIC_1PJ6DA*0@GZR*15!@A M3:SUT-
6L3#N0_ M90!5H53XA^DG4:WEX"VT4PI@ JW@:2H 0T\$&DK*2&G CJ
M:(VF|O)@L.Y^DE'MZM5!B%Z;>JVE^)|3:.*"4YCA2!40#%(/.E.67@D?*H/1< M6SNJ7"!IF4^"W=F/1:I&O?
0417=,79E1K<-XMQ\$EO?-)CA!;BYW0@-GK# MVC# 4:.*#_ 8H;@7PB\$O\$(\$>>K*4+S/D^ M:5BINI^W=!=#|?
7*_7W>NS>_? 3.US.2&C"2EE^KX!;DI VHF<_/9"QCH<-MB\$DHK'&I-Q'52 :2&L-\$);BXQ7@>5N9_I'C9
0!@V! =3%WL=#F*5GKU1 M0*Q/95\$8>|2JYO?7PX8>9:; APV'L+^&2O5YQ:;33E 1#SV\$;22=I@A(9 D(
M!DONH:|GB*G(D^A0":4P@<X3PX M0@B6.6I=^WO8(.I3&.;I(2>2B=S MV(KN9%^+M.|#MX&&D"II&? :1+=
IEA>1DYFK;7+9C0*\$221A!LY98M!3PE1^/3Q.O** M&-(T.YT!3H6) LDP,*F/EL&.=JMO@ "B M7HTY5E1H.%L>Y@-
Y! 9V\$FF!P&6.IG35=7Z(F R 080)E1PPE27H6IS(0!:=,5
M(B'>4N!T ">W.AP.Y9D^U^M1UOMEI&BK!;B//7>0%@(O1)OZ:E<|%&S!UR+ M8&%JNR.CI*!|UM<+R
M&.=28G&0V&C(21+)A(X1'S*/L4G3(A1GU/ZNI5F./\$Y.@OXIW85:\$KRP,V M730NB: |JEA@#HOEJ61"*&|2+W"D6?
62JA:;8FJ%TB4#2!..\$=UG#C4\$\$(< M28" %A/H4Q7PLGE1DW|TTE8X|RGDT7)OFFKBB8H4TM0#)K"QV@I/36!\$ |\$
MK6RX)V E.!^ IRZUMW<.*@B MG;RWQA)!H3AYLY.L&+Z:"ZJST.O^A.UJ:;&>XS=I%&4Z* I\$!\$!5DHM@ (P^
M1E0!IOA@9EV0QO.J9P'XOA!HLK.0CW!%!.S4-!KCZ3!DJ##= Z>A.T\$ D4 M\$QCX *F@ E-
*KYS.UH=S^\$FK@IU+!'NK^N;B=I'+>|4\$ 0<8'2B001F_ M0M""^A;SZL94G,8:F4U8P3J'V(SBLXV_9?X.RD5G0
L!)!H\$GR2@E%JG4 M+E0XR"WIE#M;35!+|B7!4-|QOIW0D%|6IYX=PP?="C)Y8_!3\$PR5T(5B* M521&_*2! " Q16!
P4E2S9R!@B5!3YIQD!53TO!FI!FSGOCF+ YTM_HX7C> M!EX!)VMJ4177C@<Z!6X0_2P-/I"22CDN-N8-
!|C.QY!1HGO?%8\$8A MSS7!H402!PJ4U.91Y!B"+CF-GX\$RF "O:6"1^43@7JHJL#^ MO"!1ZU7A0O)9BV;W&F5?
7%|YL^7/D1*#"14ZNZG M0WT"2Y%C|7=,E!93-D9V?.^7>Q9;ZN7OEK4-(^A!P0:."PH00I!#2.5BM^ M1
@I^*W6\$+ND:TEW*X7K Y!WO#>@_ (3)3BR;E-SDK!-IF=ZX'7E.I!^NAY>1&)-A(LR!Q<6? MX^&"2+.00>Q?
^WS_Z'K3< 422\$;L2HHR>B-YX:AS1@G!>Q0R*>+XS\$+Q#I M(*F64!_QO*US%IA!"IOH0""8A\$U/LE0-EMKI9
M*X>POP);_Y_Y.GA!"&_0B 5BL#*"SZD5(#S#G1E% 64.ILWC_7LL.MEH.H.G%D0K\$J3OAGM>NRIC/?
ZD;S;)J7YHN&\$578@B!8-01\$Q5;1\$X M8&WP4>7ER5-5? H*!Q'B%6V0_/*Y SC?X=M+/KWANOZ>88+S2B %AL 14
M*F4.A!X#Q7\$3E!K!9+8-3!^#>@H0!+EF8T^Q2! M(E 1#*##&.)<4I13!6OIKSLXV:;7.JWBW!SM!JOHL.S#8-
U&+Q6XUM.(@G7O:Z.F0J_P!R"RUN92F5Q!J MK%MW?F*.TMKUDB*S.WYR!4TO*3-.M+N.YTX?VD-!B@)V
7"MTJU%H\$!J"DE MM.)60L1_0IV#D7N3+6K7_!I82!2MKYI&|3)|G'3.&Q!#&. | (4AB""@ MD-Y&.EFK*!1*\$);
|4CD5;F=;_E*U/ (.3MG-W,0718WB(|T3%1BHT|MZG.9^0!>81.*>JP#<3038LE7HGI'R-DK:).^ESS+@A@K%\$+^4(\$;
M 5*EA%+JTZY02XTN!;..V:##^7BD+!|TPK(5Z*QTC;SZ"/+IUVJ0/B&FIA M4R.HQH!F G8- "J!K(R5L>G30^K!|
(!7HXC&2=NY=5=H39^V!Q=R;?QN- MR>-XWU5&"PRY!48"Y:4%E%('00&6 OPJ9*C"H%V"?.*K<(^?
D@&\$")CM2C5@#LB67:8.E?4J)*.IVAHA4IT(C<) 4_W2Y MWOWDLUY9P;T\$-MK^5!04PQ_ '(9#0:H@0LIZBLS\$"!R)_IB?
X3V4)^I3G5^T(C/M\$|&|B>=|@)9:@U@2K+4LX0#PQ "SC&M""5A3GE^U
M(5A!+R2;HXC|JR2AP/4)"58!DQ0&D!)#51<86I!|CC)B?;+!IS(!O4GR MJH; V(H(*6F)@B;>
^F@I%>319EHFJ&&_1N4I&^W/G!&H+SG_4^E^3U*<M_?N?^GUAW"!Z* T#S_H"-9!|2!1CZEW+Y7D>W1K@3^>'_=
|>D7Z^#)4 M:BR=,39E@^9#XBF0B\$F %1;2RBC)G'I=.30C&4_&CWT8S@: M!*F4Y\$!+H@%3J2>(%P9K6QFDDJW
)*V;I!+DE8-V@YZ%Z!=\$N!); M\$A'?ZCR4R-U;CV^X^G.T9W->300WW"!V:.\$*D!33B
M;N=_.SU>_3QEV'Z!*=D;00S";O! "I U5TR@S8%Z%&VMO:*2*& Q32G5*-I&
M0@J@#&@);/\$"SWV2;H/E6#OXR<|6.I9X.&#\$DY0=&T'E-&(*P\$DL1(P#977 M3BMF<|H/
.@|&9A= KHPI@2LX)= "BT6QT*UYVK!4XQ>AG8 H5)>604@ M8PQ0@7 J;R?6!^L"/1"<@=+!\$8-FSLA?IZH!|4K?
Y^H-KU:7! =QP!DQ==L4F\$>JHB9X(&G\$%&F\$@M8*95!\$MV!);J5CFE!&9A4@4RN\$ZSA2(1!2R M5\$974T;?
%A\$&%)\$04(H3#A@A17MV-LM-YR!+W(T \$K^<(13H:2WT8(X5 MHM "1SE/+7!5..P*
(%0_B'2#ENJ^)^6<)2MD<|TEDIPO1.TK*/;|BQ@:NX1N M#)J_ ^OA_#F=#/^T!_R!6?
!QX0'(IAT*VF#BP04=",@10'5RJ;C4@#*KG9)2 M>IV|ZKNO4!"IFMF^K|H84>WD93OHS*O1.6?PSI BY8N#EHN2-
1A'R"-!HW! M0'.8BJDI01(ABDSVN#PYBROPY8!\$^2!)IQZ M""^Y1>=NB0.2\$IT+!@3'9?
(HS2WB.ZM72@/+V4KK>AK\$1DJM6>E69T!C!B M+6;11W<:4!D.4(IK@+QAAL%NZI
MG<@65\$KGO1XYO=;L1KM7FE.Z"!JLSY\$>P?E!P^VMN(?IT3FGL<<71K3<&>LH_JN07+#7TM+V
MW&./L)0@;\$!\$N+^F^9V!M@2A02E@&\$&8V>AY! 4XKB^40\$T0:DGV(0P! M:W03^Y.YO(+?00
J3OH_5G' X76JKY07@C^EPA! 23&=^ME4CIW'H3; 4TQ0D MR_%I>?Q<=W)LA#@F&N!|L)+X\$6*E!1KO@.@54J
ME1M' U!H0"VUD.FA/#6!D688X\$O:~*SR=NZV2!#W HY^WP> V!9RL@30VQ_1#,< "1XT0Z MAU3(266T&9*R
G8Z26BRLZ4"X7H!6=|9N+AS5) MYJJVO<1OJ=>.420)2QU00M)K'X D@< NTY1TFBZ;>|L>M@&P\$LN844+&X!-
Y2B)/F=T!3B5R MEE(|MHG;D1RI5+CP\$A5N"37:.* #3@PIJ*0?&(1J="GC06\$#Y!W=%KT\$!Y+@ MMHAP=>%
(I<)%EJBP0(F.2@\$0M3:ZJC:B@0"FF!&49J0H4!\$BSJ9|HTN=:4V.M7" C;@GC.1.PV! M!92R#ZHK"1 R<*D"6W8UT>-
!W#F1!N?W UM:AP5-F WO8I+3C?_JG"GLC4 MFD"&*&'.TP"Z10!GBED(\$F&&*R&|^<|?VW((5%.)=RN0!\$-
S*=DA>M)65?G&8Z!A1!@E!|W2B.<C.?)Z2!\$**(|E|ECUVH V)6UB!0E21Y3B!P MZV7E6:E7@3AN+@09@._@ D!|=0
%8*B"@B\$@.7+ 6VX%#MBZ!M.M6@-7^,%# M7J!H56UH+
(YU!="T"4Y&%Q<7T_M9J|Y9B7Z1;^ME|JEF7P(Z8> "APC*85%8...!Q^GBB+))R/\$LI@V%JOG<>L=4,EDU';MOFC6*IX
J M24M(-?DXAJD(D0"YEEB0W)W0H&4KSODMIW>W#_!S355A(TV%!.!!(L!HUA M.M#26> "%-
P3BW7VBH1.@)9^_Y%1GK;W?R+<17\$H^U06W1.8^F\$| Y@<02@
M7L730@D&O!>6>T.TS)X+;0!+=8T7>Q.5%V_@>N%;91*YQ\$Z2&"K).0.\$IS%|
MAFJ@M\$N=S)%4T#&\$7)^G0@U7P7WQ>X=8=2!^9>*SO#LD@3K"HZ^K3>J+Q0.) MAX#1(V?)\$(9J6CN*IF74-
0C/EWXND..A"Y.C%9T;>G"Q-HA>T"ALQIP"U MW@.9E"IPYCPTP<)P(D_TL&O4\$S3X*GS&=>103*W:;+LT_1Q6?
C;PT5!5Q 6@ MA; "IRL\$!DW!T>D!4M*+0/I_P> 5X!Q.UXNV@G=T4RJ-K>QGK(Y903%EFJ4R M#;9H
YBF1.703>|^8Y&%VW(26_KX21F"WR!Q02:28X3)A40#=(HTPK8)0(C MI
\$VA&L@Q8N!VR:@P#E)X/OP/9_IC!Z_V'9A!P7#P:_.@3 61N=3&V!4 M-/!&H^E!
<2IW\$%B>^C*FJW^9&IYB(KOPH>H=)/;!!LL!^|CU9YM3U=OF6 MS@MI+071?
XTF&&\$5/W\$#)=6!^SB.= "J;BANL")K!;LG.=NV=RTIA|P!;C(2 MO+ # 7/KOMO/I3.^<&>LH/3PT04\$@S3!PA\$4*.86!9IH
)Y#WV!;I.XI:@U0 M&=^*P_.F:P84E*KY#>B:8?/FY!<:;MO9T.K1ZF!JAX!;+>*A>9K@\$+@@"* MD(PA\$W>=
(M=BGG(CTQ-6F'Q)7\$/?M;-!/.80BD H.\$<BQ2S> M<*PEX!

(A3PQ@O#L\$O+;P%5+SJ&70ZXW!I4V45\F30QZW32U?/X2P!GQ:#UX M&D 6""(DZ!S!J9#)\$*!@_ M?
*:TP_2@17%8"GEDRAVBWJ8_=/?L.LH)F#MX O:A.CPR\|C/5!O!3-' MRWV>(RM^A#5O/A5*XH4C'J?
P>=GWQJ7F5!KQ;)BG3CUF9J5,*K+W';MV>1F!Z4!463CU?L8C/WXE/&RE1'9>2QO!VGKI)/C:M+5G\$4^!L_5!2HA)&
M_:?Y!PF^O!9PR!)O.M.C-M.F!G(?#Q3AS?>O6!FR4!A2X^_5K==ZQ9QA@!B M70NJU*!XTH&S=12-8_@!@N)C-
JW9 TV2!3E5;=E:KE9THL>4!62GW*F*:MA!S;W@W=K5ZTJC^&46M+E0W*=M.V4> TJHT&CW!-=V;
!&FA1)L6+;A+3!O MVA&@@H\$!Z32!J7IU-!CV=IE@^566K23*F9=?>31N06B!;!3!65!<6!XV
MY:V"/@VJK!RT5(7\$5FOH?*)PQRVB^!Q>SN/UM-OUZ%FXC!JJWPI)S/+!&EQI8!^?834;WUT! MVRYN9L?
S;,>JK4PI+;^U722!@67Q?DSLE!G09M"OI25;,>"J!47R-? D= C M"3";-W=Z:%MW/&LVK-F*!Q5!?
6CCBUUMZ^F!P3WSW5W;YX!>O.V3/EU_#K!N @WGQ!Q!H!DX!ISU=27LR52!V>;GB!5K)*Q M*!^SO!Y,K&?)U?3R;OI
M;BC*U=+^@!3!WL;_!X4OM<!X!L!-RU/M;8!K)/LY?/N39/H C K?/GB_<!R%^ OSAYGO!0AH!F\$^MM
#!S!+V+;^!LF5!7KVD^CBFX% M&C^<=>E_^MQ+7PC!M!8VC;W!+9J!ZV9R?W3!R.85!R!%IG=Y-
2^!+!Y)!HW7PACY3\$Y!X%_V4*\$7!6* MISQ!M4G_JH/(PW!OI=-2_X_%CU>+Y2L3*J7=JQ\$=G2*!B-L*HQKKRY4!
MUC>2NVF#>VFF7%_YJ^6QM/Q7SHH!2:FYM%WFHZ&U^9T?MF*2KCT93+!)S!CU;2%(Z2S=?V?
W%_!W#2!F(%5F!8K MURJXE=G;08):F.S.W+(/N7R>#08M(F;9^.#/\$/LW0!N!HX>U.7WRLP
M&IVEY6AR%Q:7OR*"UV!G&^4!XA%_2CV&<3D!-V*.85YQ*,S>>NQ(A?3SV&) MQN,?NY;FY,'SO!VZ.VV-V\$W?
M3N*7)*3"8!B#TOSR%>A26JK=WSDT_3S!ODW>10BG7!SG!2.VGV;YX_!L
M+V!O!K2N9O.Y6E"12Z!RK%_L<>M>>0!PM*3W?Q.M7%7V5N;L!L4-GUT7F
M!D!+!WJ7T;IE7ZY6KEJB^/*+VM!=-O);!16/?!H8N92AHU^<,%ZQW/U_-W!M MI\$OAK!(BGN!O?
HZQ3S.KM9U/XV*ZV)SU=28R3!N6!-8FY_.C M#F!D)NYT-!V7==3;N'7!A3\$??FD*U8 MB)Q.W+1VN?8B&7BY@U@UF-
!4!;U*TKEVLHXG4!M!V9?2!HMB!E M#&JNB!D=&!7B>%6YHPYD+;SY#>8G8;Y.2N5A>ML!6O&
!HNS3@<2K3LD_S!Y2<_Z MO7F/5JRN*7%U(!%*.[4VMR,!^3B=6!2M!4!TIG!250:0^M"S!9D*V M+!F!6J&F9-
9NTA3/_#!8_P.W+=V*!T!6E;H2:R"!+V83_!HN"!L!IKO!M;J_M@7^<=BLFUI+ VDF>XM!FN=JK!M7+
5NVI*0.TB2^D.M1_-MCD/K57%_:9(*RU2;A>_1<5D"!M9!/60XOX!)5*>Z?_E63*PI =*>9,7!93=,M<_D!A?CN";M
Z!T^NO2*4!F!>LQ;J.TB!H!B%/KH(\$X^DP\$O-JHN>3)R>35#>=IBJL M90".\$6P8YLLR-7*GI=>C\$;,>E>=KE:E^X E!M
MZ)R!ER".J^7T!%??=A_6\$+*,UFXRN_!F^CE<35R4KSS>_(YEB^G083!" M?L(4!Q025#DF-SY?J=C!^4-IN
WHU*2J^L;/?ZV5+!%L)W9;HS A3FRN7M MR"-H&I>C6N^S!O!H+7!1!%GVYK%'KD?QJ<!)F?
SN^#9SN6+?J_3^V!2=,M%09P!F=EZ!*G.8S@L^6*06CO8@W\$;:(B8W@UN!GAMK"E26+067O;@!F?J!0N
M2YB)8=M7+?;_2@!6!W;@*&R3 MG*Q:6!F#Z5>1?FK%@"K9!H29V,IP_23B M^OKB3@!1!HOV+%NNZ?
B7!BVDS;G<1W!1D+43@RZ2Q/5X'/!NFA^O@!6AD MOPY>W>J%C&2X%!Z!_E&7)LOEW>K2N6+O_!M7?+!I
!7>D/U_)!WT*!B!H!1?IB!-3_W_U_P%02P\$"%_4_"#C M@PU9SA7)B"\$' #'*0 &P @ \$ 97AI8W5R965X:&EB
M:70S,3\$M-C.P.CO!N:1M4\$!L!A0#% @XX_69KOC=8C!P UAT !L M (!6@< &5X:6-U&AI8FET.S\$R+38S.#(T+FAT;5!+
M0(4 Q0 (-.#5F;!WA!+8 *L?;_";8_!E M>&EC=7)E97AH:6!)I=#.R.2TV.S.R-"YH=&U02P\$"%_4_"#C@PU9#E7/
M.&L_0 4!X \$0 @ \$:%0>&(-U+)?X0 #HL \$0 @ &U5 \$ M>&U&-U&UL4\$!L!A0# M% @ YC_66!WN^>_.P(\$"!4 (-!L!L!
^AC=7(M.M.C.R#V.S!29&5F+GAM;?!+ 0(4 Q0 (-.2##5E_4#SY-D /E" 5 M " 8&T 0!X8W5R+3(P,COP-
C.P7VQA8BYX;6Q02P\$"%_4 M "#D@PU9!>TWH@YY"%RP4%0_&8C@(> &U&UL4\$!L!@) D 90(-D'P \$! end
XML 76 xcur-20240630-htm.xml IDEA: XBRL DOCUMENT 0001698530 2024-01-01 2024-06-30 0001698530 2024-
08-06 0001698530 2024-06-30 0001698530 2023-12-31 0001698530 2024-04-01 2024-06-30 0001698530 2023-04-
01 2023-06-30 0001698530 2023-01-01 2023-06-30 0001698530 us-gaap:CommonStockMember 2023-12-31
0001698530 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001698530 us-gaap:RetainedEarningsMember
2023-12-31 0001698530 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001698530 2024-01-01
2024-03-31 0001698530 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001698530 us-
gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001698530 us-gaap:CommonStockMember 2024-03-31
0001698530 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001698530 us-gaap:RetainedEarningsMember
2024-03-31 0001698530 2024-03-31 0001698530 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30
0001698530 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001698530 us-gaap:RetainedEarningsMember
2024-04-01 2024-06-30 0001698530 us-gaap:CommonStockMember 2024-06-30 0001698530 us-
gaap:AdditionalPaidInCapitalMember 2024-06-30 0001698530 us-gaap:RetainedEarningsMember 2024-06-30
0001698530 us-gaap:CommonStockMember 2022-12-31 0001698530 us-gaap:AdditionalPaidInCapitalMember 2022-
12-31 0001698530 us-gaap:RetainedEarningsMember 2022-12-31 0001698530 2022-12-31 0001698530 us-
gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001698530 2023-01-01 2023-03-31 0001698530 us-
gaap:CommonStockMember 2023-01-01 2023-03-31 0001698530 us-gaap:RetainedEarningsMember 2023-01-01
2023-03-31 0001698530 us-gaap:CommonStockMember 2023-03-31 0001698530 us-
gaap:AdditionalPaidInCapitalMember 2023-03-31 0001698530 us-gaap:RetainedEarningsMember 2023-03-31
0001698530 2023-03-31 0001698530 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001698530
us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001698530 us-gaap:RetainedEarningsMember 2023-04-01
2023-06-30 0001698530 us-gaap:CommonStockMember 2023-06-30 0001698530 us-
gaap:AdditionalPaidInCapitalMember 2023-06-30 0001698530 us-gaap:RetainedEarningsMember 2023-06-30
0001698530 2023-06-30 0001698530 us-gaap:EquipmentMember 2024-06-30 0001698530 us-
gaap:EquipmentMember 2023-12-31 0001698530 xcur:ComputersandSoftwareMember 2024-06-30 0001698530
xcur:ComputersandSoftwareMember 2023-12-31 0001698530 us-gaap:FurnitureAndFixturesMember 2024-06-30
0001698530 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001698530 xcur:ChicagoMember 2020-07-01 2020-
07-01 0001698530 xcur:ChicagoMember 2020-07-01 0001698530 xcur:ChicagoMember 2023-05-04 2023-05-04
0001698530 us-gaap:NotesReceivableMember 2023-05-01 2023-05-31 0001698530
xcur:NotesReceivableOneMember 2023-05-31 0001698530 xcur:NotesReceivableTwoMember 2023-05-31
0001698530 us-gaap:NotesReceivableMember 2024-03-01 2024-03-31 0001698530 us-
gaap:NotesReceivableMember 2024-06-30 0001698530 xcur:PromissoryNoteMember 2024-05-03 0001698530
xcur:DGPCoLtdMember xcur:PromissoryNoteMember us-gaap:RelatedPartyMember 2024-06-03 0001698530 us-
gaap:PrivatePlacementMember 2022-09-26 2022-09-26 0001698530 us-gaap:PrivatePlacementMember 2022-09-26
0001698530 us-gaap:PrivatePlacementMember 2023-02-24 2023-02-24 0001698530 xcur:DGPCoLtdMember
xcur:ThirdPartySaleOfCompanyStockMember xcur:CBIUSAIncMember 2023-06-23 2023-06-23 0001698530
xcur:ThirdPartyMember xcur:ThirdPartySaleOfCompanyStockMember xcur:DGPCoLtdMember 2024-02-29
0001698530 xcur:ThirdPartyMember xcur:ThirdPartySaleOfCompanyStockMember xcur:DGPCoLtdMember 2024-02-
01 2024-02-29 0001698530 us-gaap:PrivatePlacementMember xcur:CBIUSADGPCoLtdMember 2024-01-01 2024-06-
30 0001698530 2022-09-26 2022-09-26 0001698530 xcur:CBIUSAIncMember 2024-01-01 2024-06-30 0001698530
xcur:DGPCoLtdMember 2024-06-30 0001698530 us-gaap:CommonStockMember 2021-12-16 2021-12-16
0001698530 us-gaap:CommonStockMember 2021-12-16 0001698530 xcur:PreFundedWarrantsMember 2021-12-16
2021-12-16 0001698530 us-gaap:WarrantMember 2021-12-16 2021-12-16 0001698530
xcur:CommonStockAndAccompanyingWarrantMember 2021-12-16 2021-12-16 0001698530

xcur:PreFundedWarrantsAndAccompanyingWarrantMember 2021-12-16 2021-12-16 0001698530
xcur:PreFundedWarrantsMember 2021-12-16 0001698530 us-gaap:WarrantMember 2021-12-16 0001698530 2021-
12-16 0001698530 2021-12-16 2021-12-16 0001698530 2021-12-31 0001698530 2023-06-23 2023-06-23
0001698530 xcur:ExcicureInc.2017EquityIncentivePlanMember 2017-09-22 0001698530
xcur:ExcicureOpCo2015EquityIncentivePlanMember 2017-09-22 0001698530
xcur:ExcicureInc.2017EquityIncentivePlanMember 2020-01-01 2020-01-01 0001698530
xcur:ExcicureInc.2017EquityIncentivePlanMember 2020-01-01 0001698530 us-gaap:EmployeeStockOptionMember
xcur:ExcicureInc.2017EquityIncentivePlanMember 2024-01-01 0001698530
xcur:ExcicureInc.2017EquityIncentivePlanMember 2024-06-30 0001698530 xcur:InitialEmployeeStockOptionMember
xcur:ExcicureInc.2017EquityIncentivePlanMember us-gaap:ShareBasedCompensationAwardTrancheOneMember
2024-01-01 2024-06-30 0001698530 xcur:InitialEmployeeStockOptionMember
xcur:ExcicureInc.2017EquityIncentivePlanMember 2024-01-01 2024-06-30 0001698530
xcur:SubsequentEmployeeStockOptionMember xcur:ExcicureInc.2017EquityIncentivePlanMember 2024-01-01 2024-
06-30 0001698530 xcur:NonemployeeDirectorMember xcur:InitialEmployeeStockOptionMember
xcur:ExcicureInc.2017EquityIncentivePlanMember 2024-01-01 2024-06-30 0001698530
xcur:NonemployeeDirectorMember xcur:SubsequentEmployeeStockOptionMember
xcur:ExcicureInc.2017EquityIncentivePlanMember 2024-01-01 2024-06-30 0001698530 us-
gaap:EmployeeStockOptionMember xcur:ExcicureInc.2017EquityIncentivePlanMember 2024-01-01 2024-06-30
0001698530 us-gaap:EmployeeStockMember 2017-09-30 0001698530 us-gaap:EmployeeStockMember 2017-09-01
2017-09-30 0001698530 us-gaap:EmployeeStockMember 2024-01-01 2024-01-01 0001698530 us-
gaap:EmployeeStockMember 2024-06-30 0001698530 us-gaap:ResearchAndDevelopmentExpenseMember 2024-04-
01 2024-06-30 0001698530 us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-01 2023-06-30 0001698530
us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-06-30 0001698530 us-
gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-06-30 0001698530 us-
gaap:GeneralAndAdministrativeExpenseMember 2024-04-01 2024-06-30 0001698530 us-
gaap:GeneralAndAdministrativeExpenseMember 2023-04-01 2023-06-30 0001698530 us-
gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-06-30 0001698530 us-
gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-06-30 0001698530 srt:MinimumMember 2023-01-
01 2023-06-30 0001698530 srt:MaximumMember 2023-01-01 2023-06-30 0001698530 srt:WeightedAverageMember
2023-01-01 2023-06-30 0001698530 srt:WeightedAverageMember 2023-06-30 0001698530 2023-01-01 2023-12-31
0001698530 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001698530 us-
gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-06-30 0001698530 us-
gaap:RestrictedStockUnitsRSUMember 2024-06-30 0001698530 us-gaap:EmployeeStockOptionMember 2024-01-01
2024-06-30 0001698530 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0001698530 us-
gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-06-30 0001698530 us-
gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-06-30 0001698530 us-gaap:WarrantMember 2024-01-01
2024-06-30 0001698530 us-gaap:WarrantMember 2023-01-01 2023-06-30 0001698530 us-
gaap:FairValueMeasurementsRecurringMember us-gaap:NotesReceivableMember 2024-06-30 0001698530 us-
gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-
gaap:NotesReceivableMember 2024-06-30 0001698530 us-gaap:FairValueInputsLevel2Member us-
gaap:FairValueMeasurementsRecurringMember us-gaap:NotesReceivableMember 2024-06-30 0001698530 us-
gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-
gaap:NotesReceivableMember 2024-06-30 0001698530 us-gaap:FairValueMeasurementsRecurringMember 2024-06-
30 0001698530 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-
30 0001698530 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-
30 0001698530 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-
30 0001698530 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31
0001698530 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-
gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001698530 us-gaap:MoneyMarketFundsMember us-
gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001698530 us-
gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-
gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001698530 us-
gaap:FairValueMeasurementsRecurringMember us-gaap:NotesReceivableMember 2023-12-31 0001698530 us-
gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-
gaap:NotesReceivableMember 2023-12-31 0001698530 us-gaap:FairValueInputsLevel2Member us-
gaap:FairValueMeasurementsRecurringMember us-gaap:NotesReceivableMember 2023-12-31 0001698530 us-
gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-
gaap:NotesReceivableMember 2023-12-31 0001698530 us-gaap:FairValueMeasurementsRecurringMember 2023-12-
31 0001698530 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-
31 0001698530 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-
31 0001698530 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-
31 0001698530 us-gaap:RelatedPartyMember 2023-02-27 2023-02-27 0001698530
xcur:BiopharmaceuticalCompanyMember 2024-02-05 2024-02-05 shares iso4217:USD iso4217:USD shares utr:sgft
xcur:extension period pure xcur:agreement xcur:vote 0001698530 --12-31 2024 Q2 false 0.0208 0.0208 0.0278
0.0833 10-Q true 2024-06-30 false 001-39011 EXICURE, INC. DE 81-5333008 2430 N. Halsted St. Chicago IL 60614
(847) 673-1700 Common Stock, par value \$0.0001 per share XCUR NASDAQ Yes Yes Non-accelerated Filer true false
false 8651204 528000 816000 559000 15000 992000 1193000 2079000 2024000 40000 54000 6126000 6517000
2443000 2985000 10688000 11580000 1585000 1631000 846000 879000 1000000 0 3431000 2510000 5644000
6039000 9075000 8549000 0.0001 0.0001 10000000 10000000 0 0 0 0 0 0.0001 0.0001 200000000 200000000
8651148 8651148 8650753 8650753 1000 1000 192604000 192593000 -190992000 -189563000 1613000 3031000
10688000 11580000 0 0 500000 0 0 0 500000 0 0 0 1423000 1235000 5642000 2571000 8758000 1235000
5642000 2571000 10181000 -1235000 -5642000 -2071000 -10181000 1000 15000 5000 32000 3000 13000 6000
24000 6000 0 6000 0 637000 637000 -150000 -46000 635000 -122000 642000 10000 -600000 -5764000 -1429000
-10171000 0 0 0 0 -600000 -5764000 -1429000 -10171000 -0.07 -0.07 -0.68 -0.68 -0.17 -0.17 -1.38 -1.38 8651078
8651078 8432394 8432394 8650878 8650878 7366594 7366594 8650753 1000 192593000 -189563000 3031000
5000 5000 197 -829000 -829000 8650950 1000 192598000 -190392000 2207000 6000 6000 198 -600000 -600000
8651148 1000 192604000 -190992000 1613000 4965901 0 187571000 -172649000 14922000 308000 308000
800000 800000 5561 1000 -2000 -1000 3400000 4597000 4597000 -4407000 -4407000 8371462 1000 191674000

-177056000 14619000 969000 969000 276845 -119000 -119000 -5764000 -5764000 8648307 1000 192524000
-182820000 9705000 -1429000 -10171000 14000 479000 11000 1277000 390000 364000 0 -44000 544000 0
-415000 -145000 0 -288000 -46000 -18000 -32000 -190000 -395000 -347000 -1616000 -8129000 0 2000000 0
211000 0 -1789000 1000000 0 0 5440000 0 843000 0 800000 0 121000 1000000 3676000 -616000 -6242000
2016000 9777000 1400000 3535000 528000 816000 872000 1200000 1400000 2016000 Description of Business;
Basis of Presentation and Going Concern<div style="margin-bottom:9pt;text-indent:18pt"><span
style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-
height:120%">Description of Business</div><div style="margin-bottom:9pt;text-indent:18pt"><span
style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">Excicure, Inc. has historically been an early-stage biotechnology company focused on developing
nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company
announced a significant reduction in force, suspension of preclinical activities and halting of all research and
development, and that the Company was exploring strategic alternatives to maximize stockholder value. The
Company is attempting to license its intellectual property to generate value for stockholders. In addition, the
Company is engaging in a broader exploration of strategic alternatives. This effort involves exploring growth
through transactions with potential partners that see opportunity in joining an existing, publicly-traded
organization. </div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout these unaudited
condensed consolidated financial statements, the terms the "Company," and "Excicure" refer to Excicure, Inc. and
where appropriate, its wholly owned subsidiary, Excicure Operating Company. Excicure Operating Company holds all
material assets and conducts all business activities and operations of Excicure, Inc. </div><div
style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</div><div
style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated
financial statements as of June 30, 2024 and December 31, 2023, and for the three and six months ended June 30,
2024 and 2023, have been presented in conformity with accounting principles generally accepted in the United
States of America ("GAAP") and with instructions to Form 10-Q and Article 10 of Regulation S-X under the
Securities Exchange Act of 1934, as amended. </div><div style="margin-bottom:9pt;text-indent:18pt">
<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-
weight:700;line-height:120%">Principles of Consolidation</div><div style="margin-bottom:9pt;text-
indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements include
the accounts of Excicure and its wholly owned subsidiary, Excicure Operating Company. All intercompany transactions
and accounts are eliminated in consolidation. </div><div style="margin-bottom:9pt;text-indent:18pt">
<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-
weight:700;line-height:120%">Unaudited Interim Financial Information</div><div style="margin-
bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-weight:400;line-height:120%">The accompanying interim condensed consolidated balance sheet as of
June 30, 2024, the interim condensed consolidated statements of operations for the three and six months ended
June 30, 2024 and 2023, the interim condensed consolidated statements of changes in stockholders' equity for the
three and six months ended June 30, 2024 and 2023, and the interim condensed consolidated statements of cash
flows for the six months ended June 30, 2024 and 2023 are unaudited. The interim unaudited condensed
consolidated financial statements have been prepared on the same basis as the annual audited financial statements
and with instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934, as
amended; and in the opinion of management, reflect all adjustments, which include only normal recurring
adjustments necessary for the fair statement of the Company's financial position as of June 30, 2024, the results of
its operations for the three and six months ended June 30, 2024 and 2023, and the results of its cash flows for the
six months ended June 30, 2024 and 2023. The financial data and other information disclosed in these notes related
to the three and six months ended June 30, 2024 and 2023 are unaudited. The results for the six months ended
June 30, 2024 are not necessarily indicative of results to be expected for the year ending December 31, 2024, or any
other interim periods, or any future year or period. These interim condensed consolidated financial statements
should be read in conjunction with the audited consolidated financial statements and accompanying notes for the
year ended December 31, 2023, included in the Company's Annual Report on Form 10-K filed with the Securities and
Exchange Commission ("SEC") on June 6, 2024. </div><div style="margin-bottom:9pt;text-indent:18pt">
<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-
weight:700;line-height:120%">Going Concern</div><div style="margin-bottom:9pt;text-indent:18pt">
<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">At each reporting period, the Company evaluates whether there are conditions or events that raise
substantial doubt about the Company's ability to continue as a going concern for a period of one year after the date
that the financial statements are issued. The Company is required to make certain additional disclosures if it
concludes substantial doubt exists and it is not alleviated by the Company's plans or when its plans alleviate
substantial doubt about the Company's ability to continue as a going concern. </div><div style="margin-
bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial
statements have been prepared assuming that the Company will continue as a going concern for a period of one year
after the date that the financial statements are issued. As of June 30, 2024, the Company expects to incur significant
expenses and negative cash flows for the foreseeable future. As of June 30, 2024, the Company's cash and cash
equivalents were \$528. Management believes that, given the Company's current cash position, operating plans and
forecasted negative cash flows from operating activities over the next twelve months, there is substantial doubt
about the Company's ability to continue as a going concern within one year after the date these financial statements
are issued. Substantial additional financing will be needed by the Company to fund its operations. </div>
<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:120%">Management believes that the Company's existing cash and
cash equivalents are insufficient to continue to fund its operating expenses and additional funding is needed in the
very near term. The Company has already engaged in significant cost reductions, so our ability to further cut costs
and extend the Company's operating runway is limited. As a result, substantial additional financing will be needed
by the Company in the very near term to pay expenses, fund the ongoing exploration of strategic alternatives and

any alternatives that may be identified. There can be no assurance that such additional financing will be available and, if available, can be obtained on acceptable terms.

The accompanying unaudited condensed consolidated financial statements have been prepared as though the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements as of June 30, 2024 and December 31, 2023, and for the three and six months ended June 30, 2024 and 2023, have been presented in conformity with accounting principles generally accepted in the United States of America ("GAAP") and with instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934, as amended.

Principles of Consolidation

The accompanying unaudited condensed consolidated financial statements include the accounts of Exicure and its wholly owned subsidiary, Exicure Operating Company. All intercompany transactions and accounts are eliminated in consolidation.

Significant Accounting Policies

The Company's significant accounting policies are disclosed in the audited consolidated financial statements and the notes thereto, which are included in the in the Company's Annual Report on Form 10-K (the "Annual Report") for the year ended December 31, 2023 filed with the SEC on June 6, 2024. Since the date of those audited consolidated financial statements, there have been no material changes to the Company's significant accounting policies.

Use of Estimates

The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases its estimates on certain assumptions which it believes are reasonable in the circumstances and while actual results could differ from those estimates, management does not believe that any change in those assumptions in the near term would have a significant effect on the Company's financial position, results of operations or cash flows. Actual results in future periods could differ from those estimates.

Use of Estimates

The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases its estimates on certain assumptions which it believes are reasonable in the circumstances and while actual results could differ from those estimates, management does not believe that any change in those assumptions in the near term would have a significant effect on the Company's financial position, results of operations or cash flows. Actual results in future periods could differ from those estimates.

Supplemental Balance Sheet Information

	June 30, 2024	December 31, 2023	June 30, 2024	December 31, 2023
Prepaid insurance	476	508		
Prepaid franchise tax	2			

61

Lease costs	255
Prepaid professional fees	70
Prepaid software	62
Other	68
Prepaid expenses and other current assets	72
Other noncurrent assets	24
\$	992
\$	1,193
June 30, 2024	
December 31, 2023	
Restricted cash	

[illegible]

3

Furniture and fixtures	30		
Property and equipment, gross	279		
Property and equipment, net	(239)		
Depreciation and amortization expense	40		
Accrued expenses and other current liabilities	54		
Current lease liability			

June 30, 2024

December 31, 2023			
Depreciation and amortization expense			
Accrued expenses and other current liabilities			
Current lease liability			

Times New Roman', sans-serif; font-size: 10pt; font-weight: 400; line-height: 100%;>			
671			
626			
Accrued payroll-related expenses			
		71	
—			
		182	
		846	
879			

Prepaid expenses and other current assets															
<table border="1"> <tr> <td colspan="4">Prepaid insurance</td> </tr> <tr> <td colspan="4">476</td> </tr> <tr> <td colspan="4">508</td> </tr> </table>				Prepaid insurance				476				508			
Prepaid insurance															
476															
508															

[illegible]

[illegible]

[illegible]

Current lease liability

671		
626		
71		
Accrued payroll-related expenses		
—		
71		
Accrued other expenses		
175		
182		
Accrued expenses and other current liabilities		
846		
879		

671000 626000 0 71000 175000 182000 846000 879000 Leases

The Company's lease arrangements at June 30, 2024 consist of (i) a lease for office space at its headquarters in Chicago, Illinois that commenced in July 2020 (the "Chicago Lease") and (ii) a lease for office equipment (the "Office Equipment Lease"). The Chicago Lease and the Office Equipment Lease are classified as operating leases.

Chicago Lease

The Company has approximately thirty thousand square feet of office space in Chicago, Illinois. The original term (the "Original Term") of the Chicago Lease is 10 years, commencing on July 1, 2020 (the "Commencement Date"), which is the date the premises were ready for occupancy under the terms of the Chicago Lease. The Company has options to extend the term of the Chicago Lease for two additional successive periods of five years each (the "Extension Periods") at the then prevailing effective market rental rate.

The initial annual base rent during the Original Term is approximately \$1,113 for the first 12-month period of the Original Term, payable in monthly installments beginning on the Commencement Date. Base rent thereafter is subject to annual increases of 3%, for an aggregate amount of \$12,761 over the Original Term. The Company must also pay its proportionate share of certain operating expenses and taxes for each calendar year during the term. During the first 12-month period of the Original Term, the base rent and the Company's proportionate share of operating expenses and taxes were subject to certain abatements.

The following table summarizes lease costs in the Company's unaudited condensed consolidated statement of operations:

width:40.726%"	width:0.1%"	width:1.0%"	width:1.0%"
width:12.842%"	width:0.1%"	width:0.1%"	width:0.601%"
width:0.601%"	width:0.1%"	width:1.0%"	width:12.842%"
width:0.601%"	width:0.1%"	width:0.1%"	width:0.601%"
width:12.842%"	width:0.1%"	width:0.1%"	width:12.842%"
width:0.601%"	width:0.1%"	width:0.1%"	width:12.845%"
width:12.845%"	width:0.1%"	width:1.0%"	width:1.0%"
Three Months Ended June 30,			
Six Months Ended June 30,			
2024			
2023			
Operating lease costs			
\$			
142			
326			
285			
652			
(117)			
3			
313			
9			
Short term lease costs			
313			
9			

—

Total lease costs	34	307	965
-------------------	----	-----	-----

The Company made cash payments for operating leases \$327 and \$860 during the six months ended June 30, 2024 and 2023, respectively. On June 11, 2024, the Company received a formal notice from its landlord indicating the landlord will draw on the restricted cash account designated for the lease as a result of past due rent for December 2023 through June 2024. The landlord also withdrew the July 2024 payment from the restricted cash account. These draws are within the terms and conditions of the lease and the related restricted cash account.

Sublease of Office Space

The Company entered into a sublease agreement with Cyclopure, Inc. (the “Subtenant”) to sublease approximately 57% of its office space pursuant to that certain sublease agreement (the “Sublease Agreement”), dated as of May 4, 2023. The term of the Sublease Agreement began on May 15, 2023 and ends on June 30, 2030, the expiration date of the Chicago Lease. The first three months under the Sublease Agreement are rent free. Beginning August 15, 2023, the Company began charging the Subtenant for 57% of the base rent under the Chicago Lease, and the subtenant is responsible for its pro rata share of operating expenses and taxes payable. In 2024, the Company does not receive payment from the Subtenant as the Subtenant pays the Company’s landlord directly.

	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998	1997	1996	1995	1994	1993	1992	1991	1990	1989	1988	1987	1986	1985	1984	1983	1982	1981	1980	1979	1978	1977	1976	1975	1974	1973	1972	1971	1970	1969	1968	1967	1966	1965	1964	1963	1962	1961	1960	1959	1958	1957	1956	1955	1954	1953	1952	1951	1950	1949	1948	1947	1946	1945	1944	1943	1942	1941	1940	1939	1938	1937	1936	1935	1934	1933	1932	1931	1930	1929	1928	1927	1926	1925	1924	1923	1922	1921	1920	1919	1918	1917	1916	1915	1914	1913	1912	1911	1910	1909	1908	1907	1906	1905	1904	1903	1902	1901	1900	1899	1898	1897	1896	1895	1894	1893	1892	1891	1890	1889	1888	1887	1886	1885	1884	1883	1882	1881	1880	1879	1878	1877	1876	1875	1874	1873	1872	1871	1870	1869	1868	1867	1866	1865	1864	1863	1862	1861	1860	1859	1858	1857	1856	1855	1854	1853	1852	1851	1850	1849	1848	1847	1846	1845	1844	1843	1842	1841	1840	1839	1838	1837	1836	1835	1834	1833	1832	1831	1830	1829	1828	1827	1826	1825	1824	1823	1822	1821	1820	1819	1818	1817	1816	1815	1814	1813	1812	1811	1810	1809	1808	1807	1806	1805	1804	1803	1802	1801	1800	1799	1798	1797	1796	1795	1794	1793	1792	1791	1790	1789	1788	1787	1786	1785	1784	1783	1782	1781	1780	1779	1778	1777	1776	1775	1774	1773	1772	1771	1770	1769	1768	1767	1766	1765	1764	1763	1762	1761	1760	1759	1758	1757	1756	1755	1754	1753	1752	1751	1750	1749	1748	1747	1746	1745	1744	1743	1742	1741	1740	1739	1738	1737	1736	1735	1734	1733	1732	1731	1730	1729	1728	1727	1726	1725	1724	1723	1722	1721	1720	1719	1718	1717	1716	1715	1714	1713	1712	1711	1710	1709	1708	1707	1706	1705	1704	1703	1702	1701	1700	1699	1698	1697	1696	1695	1694	1693	1692	1691	1690	1689	1688	1687	1686	1685	1684	1683	1682	1681	1680	1679	1678	1677	1676	1675	1674	1673	1672	1671	1670	1669	1668	1667	1666	1665	1664	1663	1662	1661	1660	1659	1658	1657	1656	1655	1654	1653	1652	1651	1650	1649	1648	1647	1646	1645	1644	1643	1642	1641	1640	1639	1638	1637	1636	1635	1634	1633	1632	1631	1630	1629	1628	1627	1626	1625	1624	1623	1622	1621	1620	1619	1618	1617	1616	1615	1614	1613	1612	1611	1610	1609	1608	1607	1606	1605	1604	1603	1602	1601	1600	1599	1598	1597	1596	1595	1594	1593	1592	1591	1590	1589	1588	1587	1586	1585	1584	1583	1582	1581	1580	1579	1578	1577	1576	1575	1574	1573	1572	1571	1570	1569	1568	1567	1566	1565	1564	1563	1562	1561	1560	1559	1558	1557	1556	1555	1554	1553	1552	1551	1550	1549	1548	1547	1546	1545	1544	1543	1542	1541	1540	1539	1538	1537	1536	1535	1534	1533	1532	1531	1530	1529	1528	1527	1526	1525	1524	1523	1522	1521	1520	1519	1518	1517	1516	1515	1514	1513	1512	1511	1510	1509	1508	1507	1506	1505	1504	1503	1502	1501	1500	1499	1498	1497	1496	1495	1494	1493	1492	1491	1490	1489	1488	1487	1486	1485	1484	1483	1482	1481	1480	1479	1478	1477	1476	1475	1474	1473	1472	1471	1470	1469	1468	1467	1466	1465	1464	1463	1462	1461	1460	1459	1458	1457	1456	1455	1454	1453	1452	1451	1450	1449	1448	1447	1446	1445	1444	1443	1442	1441	1440	1439	1438	1437	1436	1435	1434	1433	1432	1431	1430	1429	1428	1427	1426	1425	1424	1423	1422	1421	1420	1419	1418	1417	1416	1415	1414	1413	1412	1411	1410	1409	1408	1407	1406	1405	1404	1403	1402	1401	1400	1399	1398	1397	1396	1395	1394	1393	1392	1391	1390	1389	1388	1387	1386	1385	1384	1383	1382	1381	1380	1379	1378	1377	1376	1375	1374	1373	1372	1371	1370	1369	1368	1367	1366	1365	1364	1363	1362	1361	1360	1359	1358	1357	1356	1355	1354	1353	1352	1351	1350	1349	1348	1347	1346	1345	1344	1343	1342	1341	1340	1339	1338	1337	1336	1335	1334	1333	1332	1331	1330	1329	1328	1327	1326	1325	1324	1323	1322	1321	1320	1319	1318	1317	1316	1315	1314	1313	1312	1311	1310	1309	1308	1307	1306	1305	1304	1303	1302	1301	1300	1299	1298	1297	1296	1295	1294	1293	1292	1291	1290	1289	1288	1287	1286	1285	1284	1283	1282	1281	1280	1279	1278	1277	1276	1275	1274	1273	1272	1271	1270	1269	1268	1267	1266	1265	1264	1263	1262	1261	1260	1259	1258	1257	1256	1255	1254	1253	1252	1251	1250	1249	1248	1247	1246	1245	1244	1243	1242	1241	1240	1239	1238	1237	1236	1235	1234	1233	1232	1231	1230	1229	1228	1227	1226	1225	1224	1223	1222	1221	1220	1219	1218	1217	1216	1215	1214	1213	1212	1211	1210	1209	1208	1207	1206	1205	1204	1203	1202	1201	1200	1199	1198	1197	1196	1195	1194	1193	1192	1191	1190	1189	1188	1187	1186	1185	1184	1183	1182	1181	1180	1179	1178	1177	1176	1175	1174	1173	1172	1171	1170	1169	1168	1167	1166	1165	1164	1163	1162	1161	1160	1159	1158	1157	1156	1155	1154	1153	1152	1151	1150	1149	1148	1147	1146	1145	1144	1143	1142	1141	1140	1139	1138	1137	1136	1135	1134	1133	1132	1131	1130	1129	1128	1127	1126	1125	1124	1123	1122	1121	1120	1119	1118	1117	1116	1115	1114	1113	1112	1111	1110	1109	1108	1107	1106	1105	1104	1103	1102	1101	1100	1099	1098	1097	1096	1095	1094	1093	1092	1091	1090	1089	1088	1087	1086	1085	1084	1083	1082	1081	1080	1079	1078	1077	1076	1075	1074	1073	1072	1071	1070	1069	1068	1067	1066	1065	1064	1063	1062	1061	1060	1059	1058	1057	1056	1055	1054	1053	1052	1051	1050	1049	1048	1047	1046	1045	1044	1043	1042	1041	1040	1039	1038	1037	1036	1035	1034	1033	1032	1031	1030	1029	1028	1027	1026	1025	1024	1023	1022	1021	1020	1019	1018	1017	1016	1015	1014	1013	1012	1011	1010	1009	1008	1007	1006	1005	1004	1003	1002	1001	1000	999	998	997	996	995	994	993	992	991	990	989	988	987	986	985	984	983	982	981	980	979	978	977	976	975	974	973	972	971	970	969	968	967	966	965	964	963	962	961	960	959	958	957	956	955	954	953	952	951	950	949	948	947	946	945	944	943	942	941	940	939	938	937	936	935	934	933	932	931	930	929	928	927	926	925	924	923	922	921	920	919	918	917	916	915	914	913	912	911	910	909	908	907	906	905	904	903	902	901	900	899	898	897	896	895	894	893	892	891	890	889	888	887	886	885	884	883	882	881	880	879	878	877	876	875	874	873	872	871	870	869	868	867	866	865	864	863	862	861	860	859	858	857	856	855	854	853	852	851	850	849	848	847	846	845	844	843	842	841	840	839	838	837	836	835	834	833	832	831	830	829	828	827	826	825	824	823	822	821	820	819	818	817	816	815	814	813	812	811	810	809	808	807	806	805	804	803	802	801	800	799	798	797	796	795	794	793	792	791	790	789	788	787	786	785	784	783	782	781	780	779	778	777	776	775	774	773	772	771	770	769	768	767	766	765	764	763	762	761	760	759	758	757	756	755	754	753	752	751	750	749	748	747	746	745	744	743	742	741	740	739	738	737	736	735	734	733	732	731	730	729	728	727	726	725	724	723	722	721	720	719	718	717	716	715	714	713	712	711	710	709	708	707	706	705	704	703	702	701	700	699	698	697	696	695	694	693	692	691	690	689	688	687	686	685	684	683	682	681	680	679	678	677	676	675	674	673	672	671	670	669	668	667	666	665	664	663	662	661	660	659	6
--	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	---

[illegible]

[illegible]

Total lease costs

34	307	308	965	2024	2023	2024	2023
----	-----	-----	-----	------	------	------	------

Sublease amounts paid to landlord

173

[illegible]

earlier of (i) May 3, 2025 or (ii) upon an event of default, at such time, such amounts declared by the investor will become due and payable by Company. Interest will accrue on this Note at 6.0% and is payable at maturity.

On June 3, 2024, the Company executed another promissory note ("DGP Note") and subsequently received a loan in the amount of \$700 from DGP, a related party. All principal and accrued interest will be due and payable on the earlier of (i) March 25, 2025 or (ii) upon an event of default, at such time, such amounts declared by the investor will become due and payable by Company. Interest will accrue on this DGP Note at 6.0% and is payable at maturity.

300000 0.060 700000 0.060

Stockholders' Equity

Preferred Stock

As of June 30, 2024 and December 31, 2023, the Company had 10,000,000 shares of preferred stock, par value \$0.0001 authorized and no shares issued and outstanding.

Common Stock

As of June 30, 2024 and December 31, 2023, the Company had authorized 200,000,000 shares of common stock, par value \$0.0001. As of June 30, 2024 and December 31, 2023, the Company had 8,651,148 shares and 8,650,753 shares issued and outstanding, respectively.

The holders of shares of the Company's common stock are entitled to one vote per share on all matters to be voted upon by the Company's stockholders and there are no cumulative rights. Subject to preferences that may be applicable to any outstanding preferred stock, the holders of shares of the Company's common stock are entitled to receive ratably any dividends that may be declared from time to time by the Board of Directors (the "Board") out of

funds legally available for that purpose. In the event of the Company's liquidation, dissolution or winding up, the holders of shares of the Company's common stock are entitled to share ratably in all assets remaining after payment of liabilities, subject to prior distribution rights of preferred stock then outstanding. The Company's common stock has no preemptive or conversion rights or other subscription rights. There are no redemption or sinking fund provisions applicable to the Company's common stock. The outstanding shares of the Company's common stock are fully paid and non-assessable.

September 2022 PIPE (Private Investment in Public Equity)

Securities Purchase Agreement

On September 26, 2022, the Company entered into a securities purchase agreement (the "Securities Purchase Agreement") with CBI USA, Inc. ("CBI USA"), pursuant to which the Company agreed to issue and sell to CBI USA in a private placement an aggregate of 3,400,000 shares of Common Stock, at a purchase price of \$1.60 per share. The private placement closed on February 24, 2023 (the "Closing Date"). The Company received gross proceeds of \$5,440 from the September 2022 PIPE (or net proceeds of \$4,597 after transaction expenses).

CBI USA funded the acquisition pursuant to the Securities Purchase Agreement through a loan from its affiliate, DGP Co., Ltd. ("DGP"). On June 23, 2023, DGP exercised its the option pursuant to the loan and acquired the 3,400,000 shares of Common Stock initially acquired by CBI USA pursuant to the Securities Purchase Agreement. DGP subsequently agreed to sell its shares to a third party, with the closing of 10% (340,000 shares) occurring in February 2024 and the remainder to close by or on September 30, 2024.

The Securities Purchase Agreement, as confirmed and clarified by that certain letter agreement, dated October 31, 2022, between the Company and CBI USA, provided CBI USA together with its affiliates and any "group" of which it or they are a member with the right to designate directors to the Company's board of directors in proportion to the ownership of CBI USA and its affiliates and any such group. CBI USA and DGP have announced they expect to exercise such rights as a group. Together, they beneficially own 45% of the outstanding shares of Common Stock based on their most recent Schedule 13D amendment. As noted above, DGP has entered into an agreement to sell its remaining shares to a third party by or on September 30, 2024.

September 2022 Registration Rights Agreement

In connection with the Securities Purchase Agreement, the Company entered into a registration rights agreement with CBI USA (the "Registration Rights Agreement"). CBI USA assigned its rights under the Registration Rights Agreement to DGP when DGP acquired the 3,400,000 shares of Common Stock initially sold to CBI USA. Pursuant to the Registration Rights Agreement, the Company agreed to file a registration statement covering the resale of the shares of Common Stock sold pursuant to the Securities Purchase Agreement, to use reasonable best efforts to cause such registration statement to become effective as promptly as practicable, and to keep such registration statement continuously effective until the earlier of (i) the date the shares covered by such registration statement have been sold or may be resold pursuant to Rule 144 without restriction, or (ii) the date that is two (2) years following the Closing Date.

In the event the registration statement was not filed within 90 days following the Closing Date, subject to certain limited exceptions, the Company agreed to make payments as liquidated damages in an amount equal to 0.5% of the aggregate amount invested in the shares of Common Stock pursuant to the Securities Purchase Agreement per 30-day period or pro rata for any portion thereof for each such month during which such event continues, subject to certain caps set forth in the Registration Rights Agreement. We have paid \$27 to CBI USA and accrued \$191 to DGP pursuant to this provision.

Registered Direct Offering

On December 16, 2021, the Company completed a securities purchase agreement (the "Purchase Agreement") with certain institutional purchasers (the "Purchasers") entered into on December 14, 2021, pursuant to which the Company offered to the Purchasers, in a registered direct offering priced at the market consistent with the rules of Nasdaq (the "Registered Direct Offering"), (i) an aggregate of 433,553 shares (the "Shares") of the Company's common stock, \$0.0001 par value per share, (ii) pre-funded warrants to purchase up to an aggregate of 718,981 shares of Common Stock (the "Pre-Funded Warrants"), and (iii) warrants to purchase up to 576,261 shares of Common Stock (the "Warrants"). The combined purchase price of each share of Common Stock and accompanying Warrant is \$9.9780 per share. The combined purchase price of each Pre-Funded Warrant and accompanying Warrant is \$9.9480 (equal to the combined purchase price per share of Common Stock and accompanying Warrant, minus \$0.03). The per share exercise price for the Warrants is \$8.1031, the closing bid price of the Company's Common Stock on December 13, 2021 (and as adjusted for the reverse stock split referenced in Note 1). The Warrants will be exercisable immediately from the closing December 16, 2021, and will expire on the five-year anniversary of the date of issuance, or December 16, 2026. The Pre-Funded Warrants and Warrants, which met equity classification, were recognized as a component of permanent stockholders' equity within additional paid-in capital together with the net proceeds from the Registered Direct Offering. The gross proceeds to the Company from the Registered Direct Offering (excluding effect of subsequent exercises of pre-funded warrants) were \$11,478 and net proceeds after deducting the placement agent's fees and other offering expenses paid or payable by the Company were \$10,226. The securities were offered by the Company pursuant to an effective shelf registration statement on Form S-3 (File No. 333-251555) previously filed with the Securities and Exchange Commission (the "SEC") on December 21, 2020, and which was declared effective by the SEC on January 7, 2021 (the "Registration Statement").

Each Warrant is exercisable for one share of Common Stock at an exercise price of \$8.1031 per share. The Warrants are immediately exercisable as of the date of issuance of December 16, 2021 and will expire on the five-year anniversary of the date of issuance, or December 16, 2026. The Pre-Funded Warrants were offered in lieu of shares of Common Stock to one of the Purchasers whose purchase of shares of Common Stock in the Registered Direct Offering would otherwise result in said Purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the Purchaser, 9.99%) of the Company's outstanding Common Stock immediately following the consummation of the Registered Direct Offering. Each Pre-Funded Warrant is exercisable for one share of Common Stock at an exercise price of \$0.030 per share. The Pre-Funded Warrants are immediately exercisable and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full.

A holder (together with its affiliates) of the Warrant or Pre-Funded Warrant may not exercise any portion of the Warrant or Pre-Funded Warrant, as applicable, to the extent that the holder would own more than 4.99% (or, at the holder's option upon issuance, 9.99%) of the Company's outstanding Common Stock immediately after exercise, as such percentage ownership is determined in accordance with the terms of the Warrant or Pre-Funded Warrant, as applicable. In lieu of making the cash payment otherwise contemplated to be made to the Company upon exercise of a Warrant in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of Common Stock determined according to a formula set forth in the Warrants, provided that such cashless exercise shall only be permitted if the Registration Statement is not effective at the time of such exercise or if the prospectus to which the Registration Statement is a part is not available for the issuance of shares of Common Stock to the Warrant holder.

In lieu of making the cash payment otherwise contemplated to be made to the Company upon exercise of a Pre-Funded Warrant in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of Common Stock determined according to a formula set forth in the Pre-Funded Warrants.

Common Stock Warrants

Warrants to purchase 576,261 shares of common stock at a price of \$8.1031 per share were acquired in the December 2021 registered direct offering transaction. The warrants were classified as equity. As a result of the closing of the September 2022 PIPE, a warrant holder elected to exercise their option within 30 days of the closing of the September 2022 PIPE (February 24, 2023) to receive a cash payout for the outstanding warrants in the amount of the Black-Scholes value of each warrant as prescribed in the warrant agreement. The Company paid \$800 to this warrant holder on June 23, 2023 and 526,151 were settled as a result. As of June 30, 2024, warrants to purchase 50,110 shares of common stock at a price of \$8.1031 per share that were acquired in the December 2021 registered direct offering transaction remain outstanding.

10000000
10000000 0.0001 0.0001 0 0 0 0 200000000 200000000 0.0001 0.0001 8651148 8651148 8650753 8650753 1
3400000 1.60 5440000 4597000 3400000 0.10 340000 0.45 3400000 P90D 0.005 P30D 27000 191000 433553
0.0001 718981 576261 9.9780 9.9480 0.03 8.1031 P5Y 11478000 10226000 1 8.1031 P5Y 0.0499 0.0999 1 0.030
0.0499 0.0999 576261 8.1031 800000 526151 50110 8.1031 Equity-Based Compensation

2017 Equity Incentive Plan

On September 22, 2017, the Company's stockholders approved the Exicure, Inc. 2017 Equity Incentive Plan (the "2017 Plan"), which became effective on November 15, 2017. The 2017 Plan provides for the issuance of incentive awards of up to 194,750 shares of Exicure common stock, which includes 72,330 shares of Exicure common stock to be issued to officers, employees, consultants and directors, plus a number of shares not to exceed 122,793 that are subject to issued and outstanding awards under the Exicure OpCo 2015 Equity Incentive Plan (the "2015 Plan") and were assumed in the merger transaction on September 26, 2017. Awards that may be awarded under the 2017 Equity Incentive Plan include non-qualified and incentive stock options, stock appreciation rights, bonus shares, restricted stock, restricted stock units, performance units and cash-based awards. The number of shares of common stock reserved for issuance under the 2017 Equity Incentive Plan automatically increases on January 1 of each year, beginning on January 1, 2020, by the lesser of (i) 153,333 shares, (ii) 5% of the total number

of shares of its capital stock outstanding on December 31 of the preceding calendar year, or (iii) a lesser number of shares determined by the Compensation Committee of the Board (the "Compensation Committee"). No future awards will be made under the 2015 Plan upon the effectiveness of the 2017 Plan. On January 1, 2024, pursuant to the terms of the 2017 Plan, the number of awards that are reserved and may be awarded under the 2017 Plan was automatically increased by 153,333 awards.

As of June 30, 2024, the aggregate number of equity awards available for grant under the 2017 Equity Incentive Plan was 455,292.

Awards granted under the 2017 Plan are contingent on the participants' continued employment or provision of non-employee services and are subject to forfeiture if employment or continued service terminates for any reason. The initial award granted to an employee or consultant generally vests 25% on the first 12-month anniversary of the grant date and vests 1/48th monthly thereafter until fully vested at the end of 48 months. Subsequent awards granted to employees or consultants generally vest 1/48th monthly until fully vested at the end of 48 months. The initial stock option grant to a non-employee director vests 1/36th monthly until fully vested at the end of 36 months. Subsequent stock option grants to a non-employee director vests 1/12th monthly until fully vested at the end of 12 months. The term of common stock option grants is 10 years unless terminated earlier as described above.

Employee Stock Purchase Plan

The 2017 Employee Stock Purchase Plan (the "ESPP") was adopted by the Board in September 2017 and approved by the Company's stockholders in September 2017. Through the ESPP, eligible employees may authorize payroll deductions of up to 15% of their compensation to purchase common stock. The maximum number of shares that an employee may purchase on any exercise date in an offer period will be the smaller of (i) 250 shares or (ii) such number of shares as has a fair market value (determined as of the offering date for such offer period) equal to \$25,000 within one calendar year minus the fair market value of any other shares of common stock that are attributed to such calendar year. The purchase price per share at each purchase date is equal to 85% of the lower of (i) the closing market price per share of Exicure common stock on the employee's offering date or (ii) the closing market price per share of Exicure common stock on the exercise date.

The ESPP provides that the number of shares reserved and available for issuance will automatically increase each January 1, beginning on January 1, 2018 and each January 1 thereafter through January 1, 2027, by the least of (i) 10,000 shares; (ii) 0.3% of the outstanding shares of common stock on the last day of the immediately preceding calendar year; or (iii) a lesser number of shares determined by the Board. On January 1, 2024, the number of shares of common stock available for issuance under the ESPP increased by 10,000 shares. As of June 30, 2024, there were 61,971 shares available for issuance under the ESPP.

Equity-based compensation expense is classified in the statements of operations as follows:

Three Months Ended June 30,	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998	1997	1996	1995	1994	1993	1992	1991	1990	1989	1988	1987	1986	1985	1984	1983	1982	1981	1980	1979	1978	1977	1976	1975	1974	1973	1972	1971	1970	1969	1968	1967	1966	1965	1964	1963	1962	1961	1960	1959	1958	1957	1956	1955	1954	1953	1952	1951	1950	1949	1948	1947	1946	1945	1944	1943	1942	1941	1940	1939	1938	1937	1936	1935	1934	1933	1932	1931	1930	1929	1928	1927	1926	1925	1924	1923	1922	1921	1920	1919	1918	1917	1916	1915	1914	1913	1912	1911	1910	1909	1908	1907	1906	1905	1904	1903	1902	1901	1900	1899	1898	1897	1896	1895	1894	1893	1892	1891	1890	1889	1888	1887	1886	1885	1884	1883	1882	1881	1880	1879	1878	1877	1876	1875	1874	1873	1872	1871	1870	1869	1868	1867	1866	1865	1864	1863	1862	1861	1860	1859	1858	1857	1856	1855	1854	1853	1852	1851	1850	1849	1848	1847	1846	1845	1844	1843	1842	1841	1840	1839	1838	1837	1836	1835	1834	1833	1832	1831	1830	1829	1828	1827	1826	1825	1824	1823	1822	1821	1820	1819	1818	1817	1816	1815	1814	1813	1812	1811	1810	1809	1808	1807	1806	1805	1804	1803	1802	1801	1800	1799	1798	1797	1796	1795	1794	1793	1792	1791	1790	1789	1788	1787	1786	1785	1784	1783	1782	1781	1780	1779	1778	1777	1776	1775	1774	1773	1772	1771	1770	1769	1768	1767	1766	1765	1764	1763	1762	1761	1760	1759	1758	1757	1756	1755	1754	1753	1752	1751	1750	1749	1748	1747	1746	1745	1744	1743	1742	1741	1740	1739	1738	1737	1736	1735	1734	1733	1732	1731	1730	1729	1728	1727	1726	1725	1724	1723	1722	1721	1720	1719	1718	1717	1716	1715	1714	1713	1712	1711	1710	1709	1708	1707	1706	1705	1704	1703	1702	1701	1700	1699	1698	1697	1696	1695	1694	1693	1692	1691	1690	1689	1688	1687	1686	1685	1684	1683	1682	1681	1680	1679	1678	1677	1676	1675	1674	1673	1672	1671	1670	1669	1668	1667	1666	1665	1664	1663	1662	1661	1660	1659	1658	1657	1656	1655	1654	1653	1652	1651	1650	1649	1648	1647	1646	1645	1644	1643	1642	1641	1640	1639	1638	1637	1636	1635	1634	1633	1632	1631	1630	1629	1628	1627	1626	1625	1624	1623	1622	1621	1620	1619	1618	1617	1616	1615	1614	1613	1612	1611	1610	1609	1608	1607	1606	1605	1604	1603	1602	1601	1600	1599	1598	1597	1596	1595	1594	1593	1592	1591	1590	1589	1588	1587	1586	1585	1584	1583	1582	1581	1580	1579	1578	1577	1576	1575	1574	1573	1572	1571	1570	1569	1568	1567	1566	1565	1564	1563	1562	1561	1560	1559	1558	1557	1556	1555	1554	1553	1552	1551	1550	1549	1548	1547	1546	1545	1544	1543	1542	1541	1540	1539	1538	1537	1536	1535	1534	1533	1532	1531	1530	1529	1528	1527	1526	1525	1524	1523	1522	1521	1520	1519	1518	1517	1516	1515	1514	1513	1512	1511	1510	1509	1508	1507	1506	1505	1504	1503	1502	1501	1500	1499	1498	1497	1496	1495	1494	1493	1492	1491	1490	1489	1488	1487	1486	1485	1484	1483	1482	1481	1480	1479	1478	1477	1476	1475	1474	1473	1472	1471	1470	1469	1468	1467	1466	1465	1464	1463	1462	1461	1460	1459	1458	1457	1456	1455	1454	1453	1452	1451	1450	1449	1448	1447	1446	1445	1444	1443	1442	1441	1440	1439	1438	1437	1436	1435	1434	1433	1432	1431	1430	1429	1428	1427	1426	1425	1424	1423	1422	1421	1420	1419	1418	1417	1416	1415	1414	1413	1412	1411	1410	1409	1408	1407	1406	1405	1404	1403	1402	1401	1400	1399	1398	1397	1396	1395	1394	1393	1392	1391	1390	1389	1388	1387	1386	1385	1384	1383	1382	1381	1380	1379	1378	1377	1376	1375	1374	1373	1372	1371	1370	1369	1368	1367	1366	1365	1364	1363	1362	1361	1360	1359	1358	1357	1356	1355	1354	1353	1352	1351	1350	1349	1348	1347	1346	1345	1344	1343	1342	1341	1340	1339	1338	1337	1336	1335	1334	1333	1332	1331	1330	1329	1328	1327	1326	1325	1324	1323	1322	1321	1320	1319	1318	1317	1316	1315	1314	1313	1312	1311	1310	1309	1308	1307	1306	1305	1304	1303	1302	1301	1300	1299	1298	1297	1296	1295	1294	1293	1292	1291	1290	1289	1288	1287	1286	1285	1284	1283	1282	1281	1280	1279	1278	1277	1276	1275	1274	1273	1272	1271	1270	1269	1268	1267	1266	1265	1264	1263	1262	1261	1260	1259	1258	1257	1256	1255	1254	1253	1252	1251	1250	1249	1248	1247	1246	1245	1244	1243	1242	1241	1240	1239	1238	1237	1236	1235	1234	1233	1232	1231	1230	1229	1228	1227	1226	1225	1224	1223	1222	1221	1220	1219	1218	1217	1216	1215	1214	1213	1212	1211	1210	1209	1208	1207	1206	1205	1204	1203	1202	1201	1200	1199	1198	1197	1196	1195	1194	1193	1192	1191	1190	1189	1188	1187	1186	1185	1184	1183	1182	1181	1180	1179	1178	1177	1176	1175	1174	1173	1172	1171	1170	1169	1168	1167	1166	1165	1164	1163	1162	1161	1160	1159	1158	1157	1156	1155	1154	1153	1152	1151	1150	1149	1148	1147	1146	1145	1144	1143	1142	1141	1140	1139	1138	1137	1136	1135	1134	1133	1132	1131	1130	1129	1128	1127	1126	1125	1124	1123	1122	1121	1120	1119	1118	1117	1116	1115	1114	1113	1112	1111	1110	1109	1108	1107	1106	1105	1104	1103	1102	1101	1100	1099	1098	1097	1096	1095	1094	1093	1092	1091	1090	1089	1088	1087	1086	1085	1084	1083	1082	1081	1080	1079	1078	1077	1076	1075	1074	1073	1072	1071	1070	1069	1068	1067	1066	1065	1064	1063	1062	1061	1060	1059	1058	1057	1056	1055	1054	1053	1052	1051	1050	1049	1048	1047	1046	1045	1044	1043	1042	1041	1040	1039	1038	1037	1036	1035	1034	1033	1032	1031	1030	1029	1028	1027	1026	1025	1024	1023	1022	1021	1020	1019	1018	1017	1016	1015	1014	1013	1012	1011	1010	1009	1008	1007	1006	1005	1004	1003	1002	1001	1000	999	998	997	996	995	994	993	992	991	990	989	988	987	986	985	984	983	982	981	980	979	978	977	976	975	974	973	972	971	970	969	968	967	966	965	964	963	962	961	960	959	958	957	956	955	954	953	952	951	950	949	948	947	946	945	944	943	942	941	940	939	938	937	936	935	934	933	932	931	930	929	928	927	926	925	924	923	922	921	920	919	918	917	916	915	914	913	912	911	910	909	908	907	906	905	904	903	902	901	900	899	898	897	896	895	894	893	892	891	890	889	888	887	886	885	884	883	882	881	880	879	878	877	876	875	874	873	872	871	870	869	868	867	866	865	864	863	862	861	860	859	858	857	856	855	854	853	852	851	850	849	848	847	846	845	844	843	842	841	840	839	838	837	836	835	834	833	832	831	830	829	828	827	826	825	824	823	822	821	820	819	818	817	816	815	814	813	812	811	810	809	808	807	806	805	804	803	802	801	800	799	798	797	796	795	794	793	792	791	790	789	788	787	786	785	784	783	782	781	780	779	778	777	776	775	774	773	772	771	770	769	768	767	766	765	764	763	762	761	760	759	758	757	756	755	754	753	752	751	750	749	748	747	746	745	744	743	742	741	740	739	738	737	736	735	734	733	732	731	730	729	728	727	726	725	724	723	722	721	720	719	718	717	716	715	714	713	712	7
-----------------------------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	---

(c) General and administrative expense.

Year	2023	2022	2021
Total general and administrative expense	\$1.54	\$0.969	\$1.11

The following table presents the assumptions used in the Black-Scholes option-pricing model for stock options granted during the six months ended June 30, 2023:

Assumption	2023	2022	2021
Expected volatility	120%	120%	120%
Risk-free interest rate	1.0%	1.0%	1.0%
Dividend yield	-	-	-
Option term	71.342%	71.342%	71.342%

The Company utilizes the Black-Scholes option-pricing model to determine the fair value of common stock option grants. The Black-Scholes option-pricing model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable. The model also requires the input of highly subjective assumptions. No options were granted during the six months ended June 30, 2024. The following table presents the assumptions used in the Black-Scholes option-pricing model for stock options granted during the six months ended June 30, 2023:

Assumption	2023	2022	2021
Expected volatility	120%	120%	120%
Risk-free interest rate	1.0%	1.0%	1.0%
Dividend yield	-	-	-
Option term	71.342%	71.342%	71.342%

[illegible]

\$1.58

The weighted-average grant date fair value of common stock options granted in the six months ended June 30, 2023 was \$1.26 per common stock option.

A summary of common stock option activity as of the periods indicated is as follows:

	Outstanding – December 31, 2023
Weighted-Average Exercise Price	\$12.115
Weighted-Average Remaining Contractual Term (years)	4.28
Aggregate Intrinsic Value (thousands)	\$5.4
Granted	—
Exercised	—

[illegible]

Summary of Restricted Stock Unit activity of the periods indicated is as follows:

Unvested balance – December 31, 2023	3,043				
Granted	10.41				
Vested	(592)				
Forfeited	3.45				
Unvested balance – June 30, 2024	2,034				

The grant date fair value of restricted stock units is based on the Company's closing stock price at the date of grant. At vesting, each outstanding restricted stock unit will be exchanged for one share of the Company's common stock. Restricted stock units generally vest evenly on a quarterly basis over a period of 4 years in exchange for continued service provided by the restricted stock unit recipient during that vesting period.

194750 72330 122793 153333 0.05 153333 455292 0.25 P48M P48M P36M P12M P10Y 0.15 250
25000 0.85 10000 0.003 10000 61971

Equity-based compensation expense is classified in the statements of operations as follows:

	Three Months Ended June 30,	Six Months Ended June 30,	2024	2023
Research and development expense	\$—	\$—	\$—	\$—
General and administrative expense	\$6	\$6	\$154	\$969

General and administrative expense

	Three Months Ended June 30,	Six Months Ended June 30,	2024	2023
Total equity-based compensation expense	\$6	\$6	\$154	\$969

serif;font-size:10pt;font-weight:400;line-height:100%">11</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.123</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ceefff;padding:0 1pt"></td><td style="background-color:#ceefff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#ceefff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">6</td><td style="background-color:#ceefff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceefff;padding:0 1pt"></td><td style="background-color:#ceefff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#ceefff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">969</td><td style="background-color:#ceefff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceefff;padding:0 1pt"></td><td style="background-color:#ceefff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#ceefff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">11</td><td style="background-color:#ceefff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceefff;padding:0 1pt"></td><td style="background-color:#ceefff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#ceefff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1.277</td><td style="background-color:#ceefff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0 0 0 154000 6000 969000 11000 1123000 6000 969000 11000 1277000 21000 P1Y4M24D 0 The following table presents the assumptions used in the Black-Scholes option-pricing model for stock options granted during the six months ended June 30, 2023:<div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:bottom;width:76.762%"><tr><td style="width:1.0%"></td><td style="width:71.342%"></td><td style="width:0.1%"></td><td colspan="3" style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.843%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.415%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended
June 30,</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#ceefff;padding:2px 1pt;text-align:left;vertical-align:bottom">Expected term</td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ceefff;padding:0 1pt"></td><td colspan="3" style="background-color:#ceefff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right">5.8 to 5.8 years</div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Risk-free interest rate</td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right">101.0% to 101.0%; weighted avg. 101.0%</div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Expected volatility</td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ceefff;padding:0 1pt"></td><td colspan="3" style="background-color:#ceefff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right">101.0% to 101.0%; weighted avg. 101.0%</div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Forfeiture rate</td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5</td><td colspan="2" style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr></table></div></tr></table></div>

[illegible]

[illegible]

align:right;vertical-align:bottom">5.51 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">4.9</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">—</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ceceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Vested and Expected to Vest -
June 30, 2024</td><td colspan="2" style="background-color:#ceceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11.699</td><td style="background-color:#ceceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceceff;padding:0 1pt"></td><td style="background-color:#ceceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#ceceff;padding:2px 0;text-align:right;vertical-align:bottom">5.51</td><td style="background-color:#ceceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ceceff;padding:2px 1pt;text-align:right;vertical-align:bottom">4.9</td><td colspan="3" style="background-color:#ceceff;padding:0 1pt"></td><td style="background-color:#ceceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#ceceff;padding:2px 0;text-align:right;vertical-align:bottom">—</td><td style="background-color:#ceceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 12115 4.28 P5Y4M24D 0 0 0 0 416 5.51 11699 5.51 P4Y10M24D 0 11699 5.51 P4Y10M24D 0 11699 5.51 P4Y10M24D 0 <div style="text-indent:18pt">A summary of restricted stock unit activity of the periods indicated is as follows: </div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:bottom;width:70.512%"><tr><td style="width:1.0%"></td><td style="width:58.218%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.672%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.674%"></td><td style="width:0.1%"></td></tr></table></div><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Restricted Stock Units</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted-Average Grant Date Fair Value</td></tr><tr><td colspan="3" style="background-color:#ceceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Unvested balance - December 31, 2023</td><td colspan="2" style="background-color:#ceceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,043</td><td style="background-color:#ceceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceceff;padding:0 1pt"></td><td style="background-color:#ceceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#ceceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">10.41</td><td style="background-color:#ceceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Granted</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Vested</td><td colspan="2" style="background-color:#ceceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(592)</td><td style="background-color:#ceceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceceff;padding:0 1pt"></td></tr></table></div>

[illegible]

[illegible]

The outstanding securities presented below were excluded from the calculation of loss per common share, for the periods presented, because such securities would have been anti-dilutive due to the Company's loss per share during that period.

	2024	2023
Options to purchase common stock	11,699	166,906
Restricted stock units	2,034	7,700
Warrants to purchase common stock	50,110	50,110
	50,110	50,110

Basic loss per common share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per common share is calculated using the treasury share method by giving effect to all potentially dilutive securities that were outstanding. Potentially dilutive options, restricted stock units and warrants to purchase common stock that were outstanding during the periods presented were excluded from the diluted loss per share calculation for the periods presented because such shares had an anti-dilutive effect due to the net loss reported in those periods.

	June 30, 2024	June 30, 2023
Three Months Ended	13.645%	13.645%
Six Months Ended	13.650%	13.647%

[illegible]

align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td style="background-color:#cceeef;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#cceeef;padding:2px 0;text-align:right;vertical-align:bottom">(0.68)</td><td style="background-color:#cceeef;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td style="background-color:#cceeef;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#cceeef;padding:2px 0;text-align:right;vertical-align:bottom">(0.17)</td><td style="background-color:#cceeef;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td style="background-color:#cceeef;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#cceeef;padding:2px 0;text-align:right;vertical-align:bottom">(1.38)</td><td style="background-color:#cceeef;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div>-600000-5764000-1429000-10171000 8651078 8651078 8432394 8432394 8650878 8650878 7366594 7366594 -0.07 -0.07 -0.68 -0.68 -0.17 -0.17 -1.38 -1.38 <div style="margin-top:4pt;text-indent:18pt">The outstanding securities presented below were excluded from the calculation of loss per common share, for the periods presented, because such securities would have been anti-dilutive due to the Company's loss per share during that period:</div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.294%"><tr><td style="width:1.0%"></td><td style="width:64.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.439%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.442%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">As of June 30,</div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt;text-align:left;vertical-align:bottom">Options to purchase common stock</td><td colspan="2" style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11,699</td><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">166,906</td><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Restricted stock units</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,034</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,700</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt;text-align:left;vertical-align:bottom">Warrants to purchase common stock</td><td colspan="2" style="background-color:#cceeef;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">50,110</td><td colspan="3" style="background-color:#cceeef;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeef;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">50,110</td><td colspan="3" style="background-color:#cceeef;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>11699 166906 2034 7700 50110 50110 Fair Value Measurements<div style="margin-bottom:9pt;text-indent:18pt">ASC Topic 820,<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-

Fair Value Measurement, establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value, as follows: Level 1 Inputs – unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date; Level 2 Inputs – other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability; and Level 3 Inputs – unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.

Assets measured at fair value on a recurring basis as of June 30, 2024 are as follows:

	Level 1	Level 2	Level 3	Total
Assets	\$—	\$—	\$—	\$—
Investment in convertible notes receivable	\$—	\$—	\$—	\$—
Short-term investments	\$—	\$—	\$—	\$—
Background-color: #ffffff; padding: 2px 1pt; text-align: right; vertical-align: bottom;">Investment in convertible notes receivable				
Background-color: #ffffff; padding: 2px 1pt; text-align: right; vertical-align: bottom;">Short-term investments				

[illegible]

[illegible]

Total financial assets

\$	1,629
----	-------

The Company uses the market approach and Level 1 and Level 2 inputs to value its cash equivalents and Level 2 inputs to value its short-term investments. The Company uses the market approach and Level 3 inputs to value its liabilities. There were no liabilities measured at fair value on a recurring basis as of December 31, 2023 nor June 30, 2024.

There were no transfers between Level 1, 2, or 3, during the six months ended June 30, 2024, and 2023. Both observable and unobservable inputs were used to determine fair value of the positions that the Company classified within the Level 3 category. Unrealized gains and losses associated within the Level 3 category include changes in fair value that were attributable to both observable and unobservable inputs.

Assets measured at fair value on a recurring basis as of June 30, 2024 are as follows:

	Level 1	Level 2
Total	\$12.473%	\$0.487%
Cash equivalents	\$12.473%	\$0.487%
Short-term investments	\$0.000%	\$0.000%
Liabilities	\$0.000%	\$0.000%

Level 3		
Assets		
Short-term investments		
Investment in convertible notes receivable		
Total financial assets		

[illegible]

[illegible]

Legal Proceedings

On December 13, 2021, Mark Colwell filed a putative securities class action lawsuit against the Company, David A. Giljohann and Brian C. Bock in the United States District Court for the Northern District of Illinois, captioned *Colwell v. Exicure, Inc. et al.*, Case No. 1:21-cv-0663. On February 4, 2021, plaintiff filed an amended putative securities class action complaint. On March 20, 2023, the court entered an order appointing James Mathew as lead plaintiff and Bleichmar Fonti & Auld LLP as lead counsel in the action pursuant to the Private Securities Litigation Reform Act of 1995. On May 26, 2023, lead plaintiff filed a second amended complaint against the Company, Dr. Giljohann, Mr. Bock, and Grant Corbett. The second amended complaint alleges that Dr. Giljohann, Mr. Bock, and Dr. Corbett made materially false and/or misleading statements related to the Company's clinical programs purportedly causing losses to investors who acquired Company securities between January 7, 2021 and December 10, 2021. The second amended complaint does not quantify any alleged damages but, in addition to attorneys' fees and costs, lead plaintiff seeks to recover damages on behalf of himself and others who acquired the Company's stock during the putative class period at allegedly inflated prices and purportedly suffered financial harm as a result. On or around August 6, 2024, the parties reached an agreement in principle to settle the litigation, subject to executing a definitive settlement agreement and approval of the court. A status hearing with the court is set for August 30, 2024. The Company believes that any liability as a result of the settlement will be covered by insurance.

On March 1, 2022, Kapil Puri filed a shareholder derivative lawsuit on behalf of the Company in the United States District Court for the Northern District of Illinois, against Dr. Giljohann and Mr. Bock, Jeffrey L. Cleland, Elizabeth Garofalo, Bosun Hau, Bali Muralidhar, Andrew Sassine, Matthias Schroff, James Sulat and Timothy Walbert, captioned *Puri v. Giljohann, et al.*, Case No. 1:22-cv-01083. On March 8, 2022, Yixin Sim filed a similar shareholder derivative lawsuit in the same court against the same individuals, captioned *Sim v. Giljohann, et al.*, Case No. 1:22-cv-01217. On April 25, 2022, Stourbridge Investments LLC filed a similar shareholder derivative lawsuit against the same individuals in the United States District Court for the District of Delaware, captioned *Stourbridge Investments LLC v. Exicure, Inc. et al.*, Case No. 1:22-cv-00526. Based on similar factual allegations presented in the Colwell complaint, described above, the Puri, Sim, and Stourbridge complaints (collectively, the "Derivative Complaints") allege that the defendants caused the Company to issue false and/or misleading statements in the proxy statement for its 2021 Annual Meeting of Stockholders regarding risk oversight, code of conduct, clinical program and compensation matters, among other things, in violation of federal securities law, and committed breaches of fiduciary duties. The Derivative Complaints also assert that Dr. Giljohann and Mr. Bock are liable for contribution under the federal securities laws. The Puri and Stourbridge complaints further assert state law claims for unjust enrichment, and the Puri complaint additionally asserts state law claims for abuse of control, gross mismanagement and corporate waste. The plaintiffs do not quantify any alleged damages in the Derivative Complaints, but seek restitution for damages to the Company, attorneys' fees, costs, and expenses, as well as an order directing that certain proposals for strengthening board oversight be put to a vote of the Company's shareholders.

On March 18, 2022, James McNabb, through counsel, sent a written demand to the Company (the "Demand Letter") demanding that the Board of Directors investigate certain allegations and commence proceedings on the Company's behalf against certain of the Company's officers and directors for alleged breaches of fiduciary duties and corporate waste. All of the Derivative Cases have been stayed pending a decision on any motion to dismiss that may be filed in the Colwell case. Further, pursuant to agreement, the Demand Letter is being held in abeyance and any related statute of limitations tolled pending such motion and decision.

On October 3, 2023, a former employee filed a complaint against the Company and its executives related to the former employee's separation from the Company. The parties proceeded with paper discovery and this matter did not settle at an in-person settlement conference on July 17, 2024. As a result, we are entering the discovery phase of this litigation.

Northwestern University License Agreements

On December 12, 2011, (1) AuraSense, LLC, the Company's former parent, assigned to the Company all of its worldwide rights and interests under AuraSense, LLC's 2009 license agreement with Northwestern University ("NU") in the field of the use of nanoparticles, nanotechnology, microtechnology or

[The content of this block is extremely noisy and appears to be a corrupted or heavily redacted version of a document. It contains numerous non-printable characters, symbols, and fragments of text that are largely illegible. The visible fragments suggest it might have been related to a technical specification or a legal document, given words like "MACHINE", "SYSTEM", "UNIT", "ITEM", "PART", "SPECIFICATION", "REQUIREMENT", "FUNCTIONALITY", "PERFORMANCE", "CAPABILITY", "LIMITATION", "DEFINITION", "DESCRIPTION", "IDENTIFICATION", "CLASSIFICATION", "CATEGORIZATION", "SUBCATEGORIZATION", "HIERARCHY", "STRUCTURE", "ORGANIZATION", "PROCESSING", "ANALYSIS", "INTERPRETATION", "CONCLUSION", "SUMMARY", "DISCUSSION", "REMARKS", "NOTES", "OBSERVATIONS", "FINDINGS", "RECOMMENDATIONS", "ACTION ITEMS", "RESPONSIBILITIES", "ROLES", "TASKS", "DEADLINES", "PRIORITIES", "STATUS", "PROGRESS", "COMPLETION", "START DATE", "END DATE", "DURATION", "ESTIMATED COST", "ACTUAL COST", "BUDGET", "EXPENSES", "REVENUE", "PROFIT", "LOSS", "GROSS PROFIT", "NET PROFIT", "MARGIN", "ROI", "NPV", "IRR", "PAYBACK PERIOD", "BREAK-EVEN POINT", "SENSITIVITY ANALYSIS", "RISK ASSESSMENT", "MITIGATION STRATEGIES", "CONTINGENCY PLANS", "EMERGENCY PROCEDURES", "SAFETY PROTOCOLS", "SECURITY MEASURES", "ACCESS CONTROL", "AUTHENTICATION METHODS", "ENCRYPTION STANDARDS", "COMPLIANCE REQUIREMENTS", "REGULATORY FRAMEWORK", "STANDARDS COMPLIANCE", "CERTIFICATION STATUS", "ACCREDITATION BODY", "AUDIT RESULTS", "INCIDENT RESPONSE PLAN", "BUSINESS CONTINUITY PLAN", "DISASTER RECOVERY PLAN", "CHANGE MANAGEMENT PROCESS", "CONFIGURATION MANAGEMENT SYSTEM", "DOCUMENTATION STANDARDS", "VERSION CONTROL", "RELEASE CYCLE", "DEVELOPMENT LIFECYCLE", "TESTING STRATEGIES", "QUALITY ASSURANCE MEASURES", "PEER REVIEW PROCEDURE", "CODE REVIEW CHECKLIST", "UAT SCRIPTS", "UAT RESULTS", "UAT SIGNATURE", "UAT DATE", "UAT LOCATION", "UAT PARTICIPANTS", "UAT FACILITATOR", "UAT CHAIRMAN", "UAT SECRETARY", "UAT OBSERVERS", "UAT NOTES", "UAT COMMENTS", "UAT SUGGESTIONS", "UAT ACTION ITEMS", "UAT FOLLOW-UP", "UAT CLOSURE", "UAT REPORT", "UAT SUMMARY", "UAT CONCLUSIONS", "UAT RECOMMENDATIONS", "UAT NEXT STEPS".]

5,(R>3DD M3J)+=(#D1&JWM/("Z 2P0C?%S(OZ7:K%:Y\$;Z:%#TWM@XP8OT3&4+XO?1) M(MAIC"D-K:P?BK1947S1.*41+H8A9+KN:P#G<+RUGOOL+O6Q\$0K&PEDLS7 M&>
>D4TK3W%WO*T-425H/19Z9E>HV1Z CF9)RA7Z/1JX KP =T;L&+/3J ZO MW%J9;.#K0D>*1+3Q M\$21)YX8O*CK"NMV-.(S.L@DBS)I.C8="SPZ7PZV1"TG5U\$Z%N(f&HM/>Q8O M7&HQ%
F3\$RKYV.E0I #E#+/1 AYVMKJYD~R M28NMJ26L:380TB W3Z+OTG:PU/\$E/I"SOZ 5W MRAY+MV.;><~W1SC"1@/#JZPP0!%OXF4.7KOCM.(I4814GR>X 7AWNUEC< MJW?:"C<DOX,SC
ADNV%)WU\$USXO MD701Z "RUW9?S;+M*H(KRORECI)19VF6ZT"!3.~%U/ UAV?9X"O=3X MHV0..&76R3-283C~U173Y%I4ETDI8T>?>1=4C@V-R0."*YBF"+(1?1 ?8 MAYP0?P#~2WD-
60OWM15FNIOX089F#SN2EON/DR6N5R5&1OC7F"~W*#496 ABWJ(ON=NRJLAKZDIPW0."N1X7E296(%8VB6G+P6 M.83.2'IG =9GH85F.D50"&T./T1T'KBI>SJW9A@8#B.5WWJAX9%Y7:J)
K17HZK9PB1XE#>B/APOUGN?>T@5: M>X 'JZ >QB "DWOH--HHK<6-KI5>BXYZ/2.7PNIH"1X880*GI&PJXTC "C/J M MGIV4??:>~(U>C&N"W.09C,0M5A:B*
IX%IA3@~E="BORN16309:QM):H2?5 M<9%CZ31.C DOI+0WKK1VYZ@IX3&\$&X.C.'Y10-DHZIRH:E#N1+IJDJX13F:RK MJ<59@%OALIO &3#X?T" (R4?7KM=IP0<+<=KW9:
S?XJWCD2:=I8E16 @1 M #0A2FIW "P71&3@Z>MIA"~W*#225#SDBI(KSD= X@1T1V4>=>UC&F E#>19 MEFIME0S0U6O~\$1 R1E5TKI@I22>P>8VY%~OOLCASUEP7K0G13+P&0001&\$)
XJLHI@<:~@?BWL-F81)~.QMAJ1(4HM-98EBHBH+FTX'B0%ET~HID KJ(3D.61)KK"RU>[PBI].-Y.#1"Y29.4@MFJIKQ8%P7? Q30NY:WU?KE+&+I5+6 MID:~Q T@
6EO"X.M:2V1ZCC06X9V)/#1~5&1"Y0&K.#:#HSI)VZXFU4< M8.U+U1(C70D.6)M~ M79+FH "JV(+2CTI3=~%3Y-CA0951~I7I4U.-<@TW@86E,EF8120:CI:P5<%W:M.Y8NY".6@FQ9=K"UCVY=A.IP
E+CLIM@<+W+!\$2.O=8PD4+NRITD4?") M0CPIA>EUEUMR\$NXDV0 +RZ+MI0VJ .M7T>M+I3:K9DZ0!IAM~W74BIW%) MKP0A+P= M XI+ON*IV/O X87:ICC07D6Y6/PJ4! KC'I C-
~TW419RE8+QT44DWSR0.M-SESPR@VS.XQI>L8P3Z.0\$50>1<6B80.716CBZ~WP%HWTY.G8..1J): MIBRDV(MJTB^EW I8P3Z)#B.04SMUZ(SI#..P(\$A24=~&/O*H8R00+R3XT
VR4ZV>?%#03F1.O:83H&IR)H5K06%U MT.KXH9.6MAH+=@3@F6I%?T+~:~.3R&=IYD9. MCIF=:K4O?SI'>D?Z4X<4YX1+7DB@UIJWHTZ(N.(O?(IA5K)T>U?Z>J91FE MIO\$09=)IF 3/\$W/O?
V4ZTIP6#~84OBCITW+LA=:12 FXI(2TI M^GS'WY UNG.OI~O.O. FW25\I\H=~\$ZRI G\$~TADH.>I!>=KRU:8&+&:OM&G MR>~)KR*M#@1U7YU?CJO. \$ WR88HNAB@0T5D&=~.Y? MTTO\$5\$1
9(IA1FIE100KD72%@IE5B.INOZO.(GP&H~K.B.~>OCTCKF+Q(I)9.IW&~BRYI H1Y0"~5Z7PZU?P17. M18WDM.R.S<14.41NM"5SWRI3UW125C="6"9J8JK#0H8I18" MZ>".RET@-IX?
>08K@42B .1S&@I I V.IA.6X#E.K2\$S1.??@V#IIN%>ZPMJ.UJ3TP4)~1W"9@>3>=FZ8Y?0.CGS~.2F MY7@AI3F4CUBM0 #N"1ARD83'6=1)1I1*~380.ETA% ~I7%
M.M:2V1ZCC06X9V)/#1~5&1"Y0&K.#:#HSI)VZXFU4< M8.U+U1(C70D.6)M~ M79+FH "JV(+2CTI3=~%3Y-CA0951~I7I4U.-<@TW@86E,EF8120:CI:P5<%W:M.Y8NY".6@FQ9=K"UCVY=A.IP
M=8>Y7W.9NIG14N9W?>XWRVU5/GPTZYIY.5~IP<E?B2.XM@%#(RT056/ M*DKCH.C T#8:~. IJWVIR?RLN.R%AS2SJCJR8/ 9EDVIIDGL%CWJ@>2VTO%~X.CT.F:PI*EE IP.
~RCY4.9N0V6S3J3TV MRZAL3W/F3IRAPBC..M@>2PHS=2J8+OA"U*1UI%HFVIEW1H>.<OC@>~>W1MSI?FPII:GP4C&.@OG:T(G@5)BASNUJ.34C.9/!W%.~2XW"X<+AK#WM\$) M>:~.
H.F\$5JY0.77AM<6NKYBOKF?>B.MR&IANPR9%95(4Y# .!CC:2MDW1YF.6+R. M.C:51660ZK&1A3UL)9SRTH/=1.\$~\$U.O.XIUU3=D1CT.~".LBS2UF15H MCA5>6.V=&@VA-
ZFA5"316THW44I894&UJM25EC.Z=D.FA IOH%O=<1/K9A~UR. 7IIO~R.M.~\$U* 6.L.M.I2UYL2~>VJH+U+I4+R+2Y.50K.6S(F@UEX/F8IS3Y VV%ZO~+H.XOJA MV%[N/YG(L\$F-U?
286J3. \$9W=3L.JM "K1E7LIRYOC".Z.Z=%X.M.M# =R=5)=FS>+NOSS(IA?Y'=J2W<.&&@I1J!AOUBJ:~.IRI?C?YCK\$ G.KI X=1X:TYTS!>~.K? 4=XGBJ PYON*>V:Y3\$~OK KR+JDX&~ML~
6DO*3KX#BULX2PZW?~.I3@EHN\$U10/GY(MI'DAF&B1ROOV4.O~>M MS3?GIA~T&:~I'(U@8XPXC%Q N.)"ZCE"~X4~55I?@A.N.U)>1>MHRR.1 7H
MOLHKOB&JFHSDD?~ A4\$4:2?IBL0=J~E.@#&W8&J2&@V?NPUZOE?M"LI=CYLAM I9N<~*~<I?726? M=I#NFTIT7V+QJ/L@=E U<I@=I#>JNZGS=?IW.N.'+0QW8H%>L1LJ9G)IT.FAG
MNNXHG.O*CC&JTS'&GQCD'FVUHM\$+VP@.F7WJWHY.\$BJM=Y-38\$~?TXN*~<MRV?ZSBH.U29YX0R+7E1+OYE4I1+ON567YI?I(71EPIET*~@IO..~KZ10VFMQA-MQS.W.ZS150@O?
QO~SN. 6N\$MTC\$ "M658I=<+I@O(YN).O>TO>+35L\$Q M#UF7N@NP0\$~.2I~ 1M5P2ZB.U.D255\$41Q *+S8QB(O~O1>[UZAODB)I
~.9>@%WTDSDWS&3JL(41.IRW42I~#PU&I4V R<~M1K@9.YOA*~T=R~@BHJ.MYE@7.8Y+ZQ>~>~(4~I URA MRB@CIG7BBDT #SB"VAIOUQC&NNF+^=~:~I.
9.>@39CI4D.<KE#TOH1TL9L2TISF&ILIN72W% MJ.O4+BOA*TV=5I2.&+A@I.P12U1UEFWK.M30TVPN%YO>H\$<=< WZKN140I8B\$SCUJ?I7Z.F-F. J/IH=G23.V:SSZ6Z/XHEN+L 7>%K36?^+ MK>BHM\$=.
~43=L.NL<9DC?TO.GT+O=S.YAXP11W.6RZ9.K08IG(W/CG3J)I MK6I.~\$BCIF5.~*~&5W'M@YF154P.ZZHSIO:V4I\$*OP.~RH70PO/K.P.MT.E41F#F+~71L~H= *?+18RS:IK)
~KAOIE:THXC>1.&~9H.YU\$6(HD1X\$5 NPR2ZM210.OHF~8 DZA7N0SK MO6.T73GWYB~JGH@Q3DKI5W.S+2D1Y-B.7GLGHITTC>SZ6F9Z/OA:JO\$J1)M*.1R<~Q<7&70&."W>O:1X8?
XO.U+I JZ> >HY*H~L ROY?~*2~K.V. M9Z<.IB=8K.&DXIG?O F3~(W\$+AI)IHWHB6K~JH@M.NB.JE&\$#MMH/R06 MOVMI3@MV1.~.~.8535Z2.1AIW4Z6X4S:
@U6/OJ35S5H.R?+4F1"\$JOSN MN (OH1 TRK71VBMI19AFXITMYKIA2*%5D16R2P3@PN159\$0TTI?0/L=IKHAJD3UL) M9@DSP.PNH:(BKOH68@W<~*3NKLFXI# CXWKU"CN1X
MH="X".1YJB6I8AL@P4@6IMBKFM@C4G-VIGD:'8IS=BY9NO...6G M.GT1:VSL7+~ITIWNYN0I.N.~I@~*+@~I Q8>@IJOI@.TERT>~02F>~WCKV MWPW5(OW>@>Q5*N0*?
XIM=XOG\$R.I2 ?@G24 ~NZ6WIDT+C= C.M191D1DTS\$7R0I M7Y5P9BFU53>~?Z9Q6?WQ~1GNB58B98IW5?>INN-X>5&H=U/~%0>H4IK&A: M73>IYE.>S6E~H/W>=TH?2
~\$X:4&:7NOI~12: ?~1@IJ.PY3'OG:H.8GPJ7KAIMMNPV6.3UBCIIA.MQ~JH?Z3.ZO3ZU?I.X4D-8T(O8&GSWZN.ZSO1=VY.73SZIF3/CEI\$S?P2F6&2RIU-EBU*1HLPUXS2I8S IVP7I1O+7R?7
MZNAC9.4>S& 2.L\$FNH~"NFGI)&8&5Z9=LXC0U\$S@QRV'63<~K5UF@BK